force O
overflow O
and O
levodopa-induced O
dyskinesias B-NEG
in O
parkinson's B-NEG
disease I-NEG
. O

we O
assessed O
force O
coordination O
of O
the O
hand O
in O
parkinson's B-NEG
disease I-NEG
and O
its O
relationship O
to O
motor O
complications O
of O
levodopa O
therapy O
, O
particularly O
to O
levodopa-induced O
dyskinesias B-NEG
( O
lid B-NEG
). O

we O
studied O
two O
groups O
of O
parkinson's B-NEG
disease I-NEG
patients O
with O
( O
parkinson's B-NEG
disease I-NEG
+ O
lid B-NEG
, O
n O
= O
23 O
) O
and O
without O
levodopa-induced O
dyskinesias B-NEG
( O
parkinson's B-NEG
disease I-NEG
- O
lid B-NEG
, O
n O
= O
10) O
, O
and O
age-matched O
healthy O
controls O
. O

the O
motor O
score O
of O
the O
unified O
parkinson's B-NEG
disease I-NEG
rating O
scale O
, O
a O
dyskinesia B-NEG
score O
and O
force O
in O
a O
grip-lift O
paradigm O
were O
assessed O
on O
and O
off O
levodopa O
. O

a O
pathological O
increase O
of O
forces O
was O
seen O
in O
on-state O
in O
parkinson's B-NEG
disease I-NEG
+ O
lid B-NEG
only O
. O

in O
parkinson's B-NEG
disease I-NEG
+ O
lid B-NEG
, O
the O
force O
involved O
in O
pressing O
down O
the O
object O
before O
lifting O
was O
significantly O
increased O
by O
levodopa O
( O
by O
61% O
, O
p O
< O
0.05) O
. O

an O
overshooting O
of O
peak O
grip O
force O
by O
51% O
(p O
< O
0.05 O
) O
and O
of O
static O
grip O
force O
by O
45% O
(p O
< O
0.01 O
) O
was O
observed O
in O
the O
on- O
compared O
with O
the O
off-drug O
condition O
. O

in O
contrast O
, O
no O
excessive O
force O
was O
found O
in O
parkinson's B-NEG
disease I-NEG
- O
lid B-NEG
. O

peak O
grip O
force O
in O
on-state O
was O
140% O
(p O
< O
0.05 O
) O
higher O
in O
parkinson's B-NEG
disease I-NEG
+ O
lid B-NEG
than O
in O
parkinson's B-NEG
disease I-NEG
- O
lid B-NEG
, O
while O
static O
grip O
force O
was O
increased O
by O
138% O
(p O
< O
0.01 O
) O
between O
groups O
. O

severity O
of O
peak-dose O
dyskinesias B-NEG
was O
strongly O
correlated O
with O
grip O
force O
in O
on-state O
(r O
= O
0.79 O
with O
peak O
force O
, O
p O
< O
0.01) O
. O

no O
correlation O
was O
observed O
between O
forces O
and O
the O
motor O
score O
as O
well O
as O
with O
the O
daily O
dose O
of O
dopaminergic O
medication O
. O

force O
excess O
was O
only O
observed O
in O
patients O
with O
lid B-NEG
and O
motor O
fluctuations O
. O

a O
close O
relationship O
was O
seen O
between O
the O
overshooting O
of O
forces O
and O
dyskinesias B-NEG
in O
the O
on-drug O
condition O
. O

we O
postulate O
that O
both O
lid B-NEG
and O
grip O
force O
excess O
share O
common O
pathophysiological O
mechanisms O
related O
to O
motor O
fluctuations O
. O

-DOCSTART- O

postinfarction O
ventricular B-NEG
septal I-NEG
defect I-NEG
associated O
with O
long-term O
steroid O
therapy O
. O

two O
cases O
of O
postinfarction O
ventricular B-NEG
septal I-NEG
rupture I-NEG
in O
patients O
on O
long-term O
steroid O
therapy O
are O
presented O
and O
the O
favourable O
outcome O
in O
both O
cases O
described O
. O

a O
possible O
association O
between O
steroid O
therapy O
and O
subsequent O
postinfarction O
septal B-NEG
rupture I-NEG
is O
discussed O
. O

-DOCSTART- O

angioedema B-NEG
associated O
with O
droperidol O
administration O
. O
angioedema B-NEG
, O
also O
known O
as O
angioneurotic B-NEG
edema I-NEG
or O
quincke's B-NEG
disease I-NEG
, O
is O
a O
well-demarcated O
, O
localized O
edema B-NEG
involving O
the O
subcutaneous O
tissues O
that O
may O
cause O
upper-airway B-NEG
obstruction I-NEG
. O

we O
report O
the O
case O
of O
a O
previously O
healthy O
19-year-old O
man O
with O
no O
known O
drug B-NEG
allergies I-NEG
in O
whom O
angioedema B-NEG
with O
significant O
tongue B-NEG
swelling I-NEG
and O
protrusion O
developed O
within O
10 O
minutes O
of O
the O
administration O
of O
a O
single O
iv O
dose O
of O
droperidol O
. O

-DOCSTART- O

clarithromycin-associated O
visual B-NEG
hallucinations I-NEG
in O
a O
patient O
with O
chronic B-NEG
renal I-NEG
failure I-NEG
on O
continuous O
ambulatory O
peritoneal O
dialysis O
. O
visual B-NEG
hallucinations I-NEG
are O
a O
rare O
event O
in O
chronic B-NEG
renal I-NEG
failure I-NEG
and O
not O
related O
to O
uremia B-NEG
per O
se O
. O

unreported O
in O
the O
literature O
is O
visual B-NEG
hallucinations I-NEG
occurring O
in O
association O
with O
the O
new O
macrolide O
antibiotic O
, O
clarithromycin O
. O

we O
describe O
such O
a O
case O
in O
a O
patient O
with O
end-stage B-NEG
renal I-NEG
disease I-NEG
( O
esrd B-NEG
) O
maintained O
on O
continuous O
ambulatory O
peritoneal O
dialysis O
(capd) O
. O

the O
combination O
of O
a O
relatively O
high O
dose O
of O
clarithromycin O
in O
face O
of O
chronic B-NEG
renal I-NEG
failure I-NEG
in O
a O
functionally O
anephric O
patient O
, O
with O
underlying O
aluminum O
intoxication O
, O
may O
have O
facilitated O
the O
appearance O
of O
this O
neurotoxic B-NEG
side O
effect O
. O

it O
is O
important O
to O
understand O
the O
pharmacokinetics O
of O
medications O
in O
face O
of O
chronic B-NEG
renal I-NEG
failure I-NEG
, O
the O
possibility O
of O
drug O
interactions O
, O
and O
how O
these O
factors O
should O
help O
guide O
medication O
therapy O
in O
the O
esrd B-NEG
patient O
. O

-DOCSTART- O

acute O
renal B-NEG
toxicity I-NEG
of O
doxorubicin O
( O
adriamycin)-loaded O
cyanoacrylate O
nanoparticles O
. O

acute O
doxorubicin-loaded O
nanoparticle O
( O
dxnp O
) O
renal B-NEG
toxicity I-NEG
was O
explored O
in O
both O
normal O
rats O
and O
rats O
with O
experimental O
glomerulonephritis B-NEG
. O

in O
normal O
rats O
, O
2/6 O
rats O
given O
free O
doxorubicin O
( O
dx O
) O
(5 O
mg/kg O
) O
died O
within O
one O
week O
, O
whereas O
all O
control O
animals O
and O
all O
rats O
having O
received O
free O
np O
or O
dxnp O
survived O
. O

a O
3 O
times O
higher O
proteinuria B-NEG
appeared O
in O
animals O
treated O
with O
dxnp O
than O
in O
those O
treated O
with O
dx O
. O

free O
np O
did O
not O
provoke O
any O
proteinuria B-NEG
. O

two O
hr O
post-injection O
, O
dxnp O
was O
2.7 O
times O
more O
concentrated O
in O
kidneys O
than O
free O
dx O
(p O
< O
0.025) O
. O

in O
rats O
with O
immune O
experimental O
glomerulonephritis B-NEG
, O
5/6 O
rats O
given O
dx O
died O
within O
7 O
days O
, O
in O
contrast O
to O
animals O
treated O
by O
dxnp O
, O
np O
, O
or O
untreated O
, O
which O
all O
survived O
. O
proteinuria B-NEG
appeared O
in O
all O
series O
, O
but O
was O
2-5 O
times O
more O
intense O
(p O
> O
0.001 O
) O
and O
prolonged O
after O
doxorubicin O
treatment O
( O
400-700 O
mg/day) O
, O
without O
significant O
difference O
between O
dxnp O
and O
dx O
. O

rats O
treated O
by O
unloaded O
np O
behaved O
as O
controls O
. O

these O
results O
demonstrate O
that O
, O
in O
these O
experimental O
conditions O
, O
dxnp O
killed O
less O
animals O
than O
free O
dx O
, O
despite O
of O
an O
enhanced O
renal B-NEG
toxicity I-NEG
of O
the O
former O
. O

both O
effects O
( O
better O
survival O
and O
nephrosis B-NEG
) O
are O
most O
probably O
related O
to O
an O
enhanced O
capture O
of O
dxnp O
by O
cells O
of O
the O
mononuclear O
phagocyte O
system O
, O
including O
mesangial O
cells O
. O

-DOCSTART- O

etoposide-related O
myocardial B-NEG
infarction I-NEG
. O

the O
occurrence O
of O
a O
myocardial B-NEG
infarction I-NEG
is O
reported O
after O
chemotherapy O
containing O
etoposide O
, O
in O
a O
man O
with O
no O
risk O
factors O
for O
coronary B-NEG
heart I-NEG
disease I-NEG
. O

possible O
causal O
mechanisms O
are O
discussed O
. O

-DOCSTART- O

subjective O
assessment O
of O
sexual B-NEG
dysfunction I-NEG
of O
patients O
on O
long-term O
administration O
of O
digoxin O
. O

various O
data O
suggest O
that O
male O
patients O
who O
have O
received O
digoxin O
on O
a O
longterm O
basis O
have O
increased O
levels O
of O
serum O
estrogen O
and O
decreased O
levels O
of O
plasma O
testosterone O
and O
luteinizing O
hormone O
(lh) O
. O

this O
study O
was O
undertaken O
to O
investigate O
the O
links O
between O
the O
long-term O
administration O
of O
digoxin O
therapy O
and O
sexual O
behavior O
, O
and O
the O
effect O
of O
digoxin O
on O
plasma O
levels O
of O
estradiol O
, O
testosterone O
, O
and O
lh O
. O

the O
patients O
of O
the O
study O
and O
control O
group O
( O
without O
digoxin O
) O
were O
of O
similar O
cardiac O
functional O
capacity O
and O
age O
( O
25-40 O
years O
) O
and O
were O
randomly O
selected O
from O
the O
rheumatic B-NEG
heart I-NEG
disease I-NEG
patients O
. O

a O
subjective O
assessment O
of O
sexual O
behavior O
in O
the O
study O
and O
control O
groups O
was O
carried O
out O
, O
using O
parameters O
such O
as O
sexual O
desire O
, O
sexual O
excitement O
, O
and O
frequency O
of O
sexual O
relations O
. O

personal O
interviews O
and O
a O
questionnaire O
were O
also O
used O
for O
the O
evaluation O
of O
sexual O
behavior O
. O

the O
findings O
support O
the O
reports O
concerning O
digoxin O
effect O
on O
plasma O
estradiol O
, O
testosterone O
, O
and O
lh O
. O

the O
differences O
in O
the O
means O
were O
significant O
. O

tests O
used O
to O
evaluate O
the O
changes O
in O
sexual O
behavior O
showed O
a O
significant O
decrease B-NEG
in I-NEG
sexual I-NEG
desire I-NEG
, O
sexual O
excitement O
phase O
(erection) O
, O
and O
frequency O
of O
sexual O
relations O
in O
the O
study O
group O
. O

-DOCSTART- O

fatal O
aplastic B-NEG
anemia I-NEG
due O
to O
indomethacin--lymphocyte O
transformation O
tests O
in O
vitro O
. O

although O
indomethacin O
has O
been O
implicated O
as O
a O
possible O
cause O
of O
aplastic B-NEG
anemia I-NEG
on O
the O
basis O
of O
a O
few O
clinical O
observations O
, O
its O
role O
has O
not O
been O
definitely O
established O
. O

a O
case O
of O
fatal O
aplastic B-NEG
anemia I-NEG
is O
described O
in O
which O
no O
drugs O
other O
than O
allopurinol O
and O
indomethacin O
were O
given O
. O

indomethacin O
was O
first O
given O
four O
weeks O
prior O
to O
the O
onset O
of O
symptoms O
. O

a O
positive O
lymphocyte O
transformation O
test O
with O
indomethacin O
in O
vitro O
further O
substantiates O
the O
potential O
role O
of O
this O
drug O
in O
causing O
aplastic B-NEG
anemia I-NEG
in O
a O
susceptible O
patient O
. O

fortunately O
, O
this O
seems O
to O
be O
a O
very O
rare O
complication O
. O

-DOCSTART- O

plasma O
and O
urinary O
lipids O
and O
lipoproteins O
during O
the O
development O
of O
nephrotic B-NEG
syndrome I-NEG
induced O
in O
the O
rat O
by O
puromycin O
aminonucleoside O
. O

this O
study O
was O
undertaken O
to O
ascertain O
whether O
the O
alterations O
of O
plasma O
lipoproteins O
found O
in O
nephrotic B-NEG
syndrome I-NEG
induced O
by O
puromycin O
aminonucleoside O
were O
due O
to O
nephrotic B-NEG
syndrome I-NEG
per O
se O
, O
or O
, O
at O
least O
in O
part O
, O
to O
the O
aminonucleoside O
. O

the O
purpose O
of O
the O
present O
study O
was O
to O
investigate O
the O
changes O
in O
plasma O
and O
urinary O
lipoproteins O
during O
the O
administration O
of O
puromycin O
aminonucleoside O
( O
20 O
mg/kg O
for O
7 O
days O
) O
and O
the O
subsequent O
development O
of O
nephrotic B-NEG
syndrome I-NEG
. O

since O
massive O
albuminuria B-NEG
occurred O
after O
6 O
days O
of O
treatment O
, O
the O
time-course O
study O
was O
divided O
into O
two O
stages O
: O
pre- O
nephrotic B-NEG
stage O
( O
day O
1-5 O
) O
and O
nephrotic B-NEG
stage O
( O
day O
6-11) O
. O

in O
pre- O
nephrotic B-NEG
stage O
the O
plasma O
level O
of O
fatty O
acids O
, O
triacylglycerol O
and O
vldl O
decreased O
while O
that O
of O
phospholipid O
, O
cholesteryl O
esters O
and O
hdl O
remained O
constant O
. O

plasma O
apolipoprotein O
a-i O
tended O
to O
increase O
( O
40% O
increase O
at O
day O
5) O
. O

at O
the O
beginning O
of O
nephrotic B-NEG
stage O
( O
day O
6) O
the O
concentration O
of O
plasma O
albumin O
dropped O
to O
a O
very O
low O
level O
, O
while O
that O
of O
apolipoprotein O
a-i O
increased O
abruptly O
( O
4-fold O
increase O
) O
and O
continued O
to O
rise O
, O
although O
less O
steeply O
, O
in O
the O
following O
days O
. O

the O
plasma O
concentration O
of O
hdl O
followed O
the O
same O
pattern O
. O

plasma O
vldl O
and O
ldl O
increased O
at O
a O
later O
stage O
( O
day O
9) O
. O

plasma O
apolipoprotein O
a-i O
was O
found O
not O
only O
in O
hdl O
( O
1.063-1.210 O
g/ml O
) O
but O
also O
in O
the O
ldl O
density O
class O
( O
1.025-1.050 O
g/ml) O
. O

in O
the O
pre- O
nephrotic B-NEG
stage O
lipoproteinuria O
was O
negligible O
, O
while O
in O
the O
early O
nephrotic B-NEG
stage O
the O
urinary O
loss O
of O
plasma O
lipoproteins O
consisted O
mainly O
of O
hdl O
. O

these O
observations O
indicate O
that O
puromycin O
aminonucleoside O
alters O
plasma O
lipoproteins O
by O
lowering O
vldl O
and O
increasing O
hdl O
. O

it O
is O
likely O
that O
the O
early O
and O
striking O
increase O
of O
plasma O
hdl O
found O
in O
nephrotic B-NEG
rats O
is O
related O
to O
a O
direct O
effect O
of O
the O
drug O
on O
hdl O
metabolism O
. O

-DOCSTART- O

circulating O
lysosomal O
enzymes O
and O
acute B-NEG
hepatic I-NEG
necrosis I-NEG
. O

the O
activities O
of O
the O
lysosomal O
enzymes O
acid O
and O
neutral O
protease O
, O
n-acetylglucosaminidase O
, O
and O
acid O
phosphatase O
were O
measured O
in O
the O
serum O
of O
patients O
with O
fulminant B-NEG
hepatic I-NEG
failure I-NEG
. O

acid O
protease O
( O
cathepsin O
d) O
activity O
was O
increased O
about O
tenfold O
in O
patients O
who O
died O
and O
nearly O
fourfold O
in O
those O
who O
survived O
fulminant B-NEG
hepatic I-NEG
failure I-NEG
after O
paracetamol O
overdose B-NEG
, O
whereas O
activities O
were O
increased O
equally O
in O
patients O
with O
fulminant B-NEG
hepatic I-NEG
failure I-NEG
due O
to O
viral B-NEG
hepatitis I-NEG
whether O
or O
not O
they O
survived O
. O

a O
correlation O
was O
found O
between O
serum O
acid O
protease O
activity O
and O
prothrombin O
time O
, O
and O
the O
increase O
in O
cathepsin O
d O
activity O
was O
sustained O
over O
several O
days O
compared O
with O
aspartate O
aminotransferase O
, O
which O
showed O
a O
sharp O
early O
peak O
and O
then O
a O
fall O
. O

circulating O
lysosomal O
proteases O
can O
damage O
other O
organs O
, O
and O
measurement O
of O
their O
activity O
may O
therefore O
be O
of O
added O
value O
in O
assessing O
prognosis O
in O
this O
condition O
. O

-DOCSTART- O

transketolase O
abnormality O
in O
tolazamide-induced O
wernicke's B-NEG
encephalopathy I-NEG
. O

we O
studied O
a O
thiamine-dependent O
enzyme O
, O
transketolase O
, O
from O
fibroblasts O
of O
a O
diabetic B-NEG
patient O
who O
developed O
wernicke's B-NEG
encephalopathy I-NEG
when O
treated O
with O
tolazamide O
, O
in O
order O
to O
delineate O
if O
this O
patient O
also O
had O
transketolase O
abnormality O
[high O
km O
for O
thiamine O
pyrophosphate O
(tpp)] O
, O
as O
previously O
reported O
in O
postalcoholic O
wernicke-korsakoff B-NEG
syndrome I-NEG
. O

in O
addition O
to O
this O
patient O
, O
we O
also O
studied O
this O
enzyme O
from O
three O
diabetic B-NEG
kindreds O
without O
any O
history O
of O
wernicke's B-NEG
encephalopathy I-NEG
and O
from O
four O
normal O
controls O
. O

we O
found O
that O
the O
above-mentioned O
patient O
and O
one O
of O
the O
diabetic B-NEG
kindreds O
with O
no O
history O
of O
wernicke's B-NEG
encephalopathy I-NEG
had O
abnormal O
transketolase O
as O
determined O
by O
its O
km O
for O
tpp O
. O

these O
data O
suggest O
a O
similarity O
between O
postalcoholic O
wernicke-korsakoff B-NEG
syndrome I-NEG
and O
the O
patient O
with O
tolazamide-induced O
wernicke's B-NEG
encephalopathy I-NEG
from O
the O
standpoint O
of O
transketolase O
abnormality O
. O

-DOCSTART- O

mechanisms O
of O
myocardial B-NEG
ischemia I-NEG
induced O
by O
epinephrine O
: O
comparison O
with O
exercise-induced O
ischemia B-NEG
. O

the O
role O
of O
epinephrine O
in O
eliciting O
myocardial B-NEG
ischemia I-NEG
was O
examined O
in O
patients O
with O
coronary B-NEG
artery I-NEG
disease I-NEG
. O

objective O
signs O
of O
ischemia B-NEG
and O
factors O
increasing O
myocardial O
oxygen O
consumption O
were O
compared O
during O
epinephrine O
infusion O
and O
supine O
bicycle O
exercise O
. O

both O
epinephrine O
and O
exercise O
produced O
myocardial B-NEG
ischemia I-NEG
as O
evidenced O
by O
st O
segment O
depression B-NEG
and O
angina B-NEG
. O

however O
, O
the O
mechanisms O
of O
myocardial B-NEG
ischemia I-NEG
induced O
by O
epinephrine O
were O
significantly O
different O
from O
those O
of O
exercise O
. O

exercise-induced O
myocardial B-NEG
ischemia I-NEG
was O
marked O
predominantly O
by O
increased O
heart O
rate O
and O
rate-pressure O
product O
with O
a O
minor O
contribution O
of O
end-diastolic O
volume O
, O
while O
epinephrine-induced O
ischemia B-NEG
was O
characterized O
by O
a O
marked O
increase O
in O
contractility O
and O
a O
less O
pronounced O
increase O
in O
heart O
rate O
and O
rate-pressure O
product O
. O

these O
findings O
indicate O
that O
ischemia B-NEG
produced O
by O
epinephrine O
, O
as O
may O
occur O
during O
states O
of O
emotional O
distress O
, O
has O
a O
mechanism O
distinct O
from O
that O
due O
to O
physical O
exertion O
. O

-DOCSTART- O

transient O
contralateral B-NEG
rotation I-NEG
following O
unilateral O
substantia B-NEG
nigra I-NEG
lesion I-NEG
reflects O
susceptibility O
of O
the O
nigrostriatal O
system O
to O
exhaustion O
by O
amphetamine O
. O

following O
unilateral O
6-ohda O
induced O
sn B-NEG
lesion I-NEG
, O
a O
transient O
period O
of O
contralateral B-NEG
rotation I-NEG
has O
been O
reported O
to O
precede O
the O
predominant O
ipsilateral B-NEG
circling I-NEG
. O

in O
order O
to O
clarify O
the O
nature O
of O
this O
initial O
contralateral B-NEG
rotation I-NEG
we O
examined O
the O
effect O
of O
the O
duration O
of O
recovery O
period O
after O
the O
lesion O
, O
on O
amphetamine-induced O
rotational B-NEG
behavior I-NEG
. O

three O
days O
post O
lesion O
, O
most O
rats O
circled O
predominantly O
contralaterally O
to O
the O
lesion O
. O

such O
contralateral B-NEG
rotation I-NEG
may O
result O
from O
either O
degeneration-induced O
breakdown O
of O
the O
da O
pool O
, O
or O
lesion-induced O
increase O
of O
da O
turnover O
in O
the O
spared O
neurons O
. O

a O
substantial O
degree O
of O
contralateral O
preference O
was O
still O
evident O
when O
amphetamine O
was O
administered O
for O
the O
first O
time O
24 O
days O
after O
lesioning O
, O
indicating O
involvement O
of O
spared O
cells O
in O
the O
contralateral B-NEG
rotation I-NEG
. O

however O
, O
regardless O
of O
the O
duration O
of O
recovery O
( O
and O
irrespective O
of O
either O
lesion O
volume O
, O
amphetamine O
dose O
, O
or O
post-lesion O
motor O
exercise) O
, O
amphetamine-induced O
rotation B-NEG
tended O
to O
become O
gradually O
more O
ipsilateral O
as O
the O
observation O
session O
progressed O
, O
and O
all O
rats O
circled O
ipsilaterally O
to O
the O
lesion O
in O
response O
to O
further O
amphetamine O
injections O
. O

these O
findings O
suggest O
that O
amphetamine O
has O
an O
irreversible O
effect O
on O
the O
post-lesion O
da O
pool O
contributing O
to O
contralateral B-NEG
rotation I-NEG
. O

-DOCSTART- O

thyroid O
function O
and O
urine-concentrating O
ability O
during O
lithium O
treatment O
. O

it O
has O
been O
suggested O
that O
adenylate O
cyclase O
inhibition O
may O
be O
important O
in O
the O
development O
of O
both O
nephrogenic B-NEG
diabetes I-NEG
insipidus I-NEG
and O
hypothyroidism B-NEG
during O
lithium O
treatment O
. O

we O
measured O
serum O
thyroxine O
and O
urine-concentrating O
ability O
( O
umax O
) O
in O
response O
to O
desmopressin O
( O
ddavp O
) O
in O
85 O
patients O
receiving O
lithium O
. O
hypothyroidism B-NEG
developed O
in O
eight O
patients O
while O
they O
were O
taking O
lithium O
. O

impaired O
umax O
was O
found O
in O
both O
euthyroid O
and O
hypothyroid B-NEG
patients O
while O
some O
hypothyroid B-NEG
patients O
concentrated O
their O
urine O
well O
. O

it O
is O
concluded O
that O
the O
dominant O
mechanisms O
by O
which O
lithium O
exerts O
these O
two O
effects O
are O
different O
. O

-DOCSTART- O

sensitivity O
of O
erythroid O
progenitor O
colonies O
to O
erythropoietin O
in O
azidothymidine O
treated O
immunodeficient B-NEG
mice O
. O

the O
anaemia B-NEG
induced O
by O
3'-azido-3'dideoxythymidine O
( O
azt O
) O
is O
poorly O
understood O
. O

we O
have O
used O
a O
murine O
model O
of O
aids B-NEG
, O
infection B-NEG
of O
female O
c57bl/6 O
mice O
with O
lp-bm5 O
murine O
leukaemia B-NEG
( O
mulv O
) O
virus O
, O
to O
determine O
if O
azt-induced O
anaemia B-NEG
is O
due O
, O
in O
part O
, O
to O
decreased O
responsiveness O
of O
erythropoietic O
precursors O
( O
bfu-e O
) O
to O
erythropoietin O
(epo) O
. O

mice O
in O
the O
early O
stage O
of O
lp-bm5 O
mulv O
disease O
were O
given O
azt O
in O
their O
drinking O
water O
at O
1.0 O
and O
2.5 O
mg/ml O
. O

azt O
produced O
anaemia B-NEG
in O
both O
groups O
, O
in O
a O
dose-dependent O
fashion O
. O

despite O
the O
anaemia B-NEG
, O
the O
number O
of O
splenic O
and O
bone O
marrow O
bfu-e O
in O
azt O
treated O
mice O
increased O
up O
to O
five-fold O
over O
levels O
observed O
in O
infected O
untreated O
animals O
after O
15 O
d O
of O
treatment O
. O

colony O
formation O
by O
splenic O
and O
bone O
marrow O
bfue O
was O
stimulated O
at O
lower O
concentrations O
of O
epo O
in O
mice O
receiving O
azt O
for O
15 O
d O
than O
for O
infected O
, O
untreated O
mice O
. O

by O
day O
30 O
, O
sensitivity O
of O
both O
splenic O
and O
bone O
marrow O
bfu-e O
of O
treated O
animals O
returned O
to O
that O
observed O
from O
cells O
of O
infected O
untreated O
animals O
. O

the O
mean O
plasma O
levels O
of O
epo O
observed O
in O
azt O
treated O
mice O
were O
appropriate O
for O
the O
degree O
of O
anaemia B-NEG
observed O
when O
compared O
with O
phenylhydrazine O
( O
phz O
) O
treated O
mice O
. O

the O
numbers O
of O
bfu-e O
and O
the O
percentage O
of O
bone O
marrow O
erythroblasts O
observed O
were O
comparable O
in O
azt O
and O
phz O
treated O
mice O
with O
similar O
degrees O
of O
anaemia B-NEG
. O

however O
, O
reticulocytosis B-NEG
was O
inappropriate O
for O
the O
degree O
of O
anaemia B-NEG
observed O
in O
azt O
treated O
infected O
mice O
. O

azt-induced O
peripheral O
anaemia B-NEG
in O
the O
face O
of O
increased O
numbers O
of O
bfu-e O
and O
increased O
levels O
of O
plasma O
epo O
suggest O
a O
lesion O
in O
terminal O
differentiation O
. O

-DOCSTART- O

detection O
of O
abnormal O
cardiac O
adrenergic O
neuron O
activity O
in O
adriamycin-induced O
cardiomyopathy B-NEG
with O
iodine-125-metaiodobenzylguanidine O
. O

radiolabeled O
metaiodobenzylguanidine O
(mibg) O
, O
an O
analog O
of O
norepinephrine O
(ne) O
, O
serves O
as O
an O
index O
of O
adrenergic O
neuron O
integrity O
and O
function O
. O

using O
a O
rat O
model O
of O
adriamycin-induced O
cardiomyopathy B-NEG
, O
we O
tested O
the O
hypothesis O
that O
abnormal O
cardiac O
adrenergic O
neuron O
activity O
may O
appear O
and O
be O
exacerbated O
dose-dependently O
in O
adriamycin O
cardiomyopathy B-NEG
. O

the O
degree O
of O
vacuolar B-NEG
degeneration I-NEG
of I-NEG
myocardial I-NEG
cells I-NEG
was O
analyzed O
in O
relation O
to O
the O
duration O
of O
adriamycin O
treatment O
(2 O
mg/kg O
, O
once O
a O
week) O
. O

there O
were O
no O
abnormalities O
or O
only O
isolated O
degeneration O
in O
the O
1- O
or O
2-wk O
treatment O
groups O
, O
isolated O
or O
scattered O
degeneration O
in O
half O
of O
the O
3-wk O
group O
, O
frequent O
scattered O
degeneration O
in O
the O
4-wk O
group O
, O
scattered O
or O
focal O
degeneration O
in O
the O
5-wk O
group O
, O
and O
extensive O
degeneration O
in O
the O
8-wk O
group O
. O

myocardial O
accumulation O
of O
[125i]mibg O
4 O
hr O
after O
intravenous O
injection O
did O
not O
differ O
between O
the O
controls O
and O
the O
groups O
treated O
3 O
wk O
or O
less O
. O

however O
, O
the O
4-wk O
group O
had O
a O
slightly O
lower O
accumulation O
in O
the O
right O
ventricular O
wall O
( O
82% O
of O
the O
control O
) O
and O
significantly O
lower O
accumulation O
in O
the O
left O
ventricular O
wall O
( O
about O
66% O
of O
the O
control O
: O
p O
less O
than O
0.05) O
. O

in O
the O
5-wk O
group O
, O
mibg O
accumulation O
in O
the O
right O
and O
left O
ventricular O
wall O
was O
35% O
and O
27% O
of O
that O
in O
controls O
, O
respectively O
(p O
less O
than O
0.001) O
. O

in O
the O
8-wk O
group O
, O
mibg O
accumulation O
in O
the O
right O
and O
left O
ventricular O
wall O
was O
18% O
and O
14% O
of O
that O
in O
controls O
, O
respectively O
(p O
less O
than O
0.001) O
. O

thus O
, O
mibg O
accumulation O
in O
the O
myocardium O
decreased O
in O
an O
adriamycin O
dose-dependent O
manner O
. O

the O
appearance O
of O
impaired O
cardiac O
adrenergic O
neuron O
activity O
in O
the O
presence O
of O
slight O
myocardial B-NEG
impairment I-NEG
( O
scattered O
or O
focal O
vacuolar B-NEG
degeneration I-NEG
) O
indicates O
that O
mibg O
scintigraphy O
may O
be O
a O
useful O
method O
for O
detection O
of O
adriamycin-induced O
cardiomyopathy B-NEG
. O

-DOCSTART- O

amnestic B-NEG
syndrome I-NEG
associated O
with O
propranolol O
toxicity B-NEG
: O
a O
case O
report O
. O

an O
elderly O
woman O
developed O
an O
alzheimer B-NEG
-like O
subacute O
dementia B-NEG
as O
a O
result O
of O
propranolol O
toxicity B-NEG
. O

analysis O
of O
the O
manifestations O
showed O
that O
severe O
impairment O
of O
memory O
accounted O
for O
virtually O
all O
of O
the O
abnormalities O
. O

there O
is O
evidence O
that O
cerebral O
reactions O
to O
drug O
toxicity B-NEG
can O
exhibit O
patterns O
that O
suggest O
highly O
selective O
involvement O
of O
functional O
subdivisions O
of O
the O
brain O
. O

-DOCSTART- O

biphasic O
response O
of O
the O
sa O
node O
of O
the O
dog O
heart O
in O
vivo O
to O
selective O
administration O
of O
ketamine O
. O

effect O
of O
ketamine O
on O
the O
sa O
node O
of O
the O
dog O
heart O
was O
studied O
in O
vivo O
using O
a O
selective O
perfusion O
technique O
of O
the O
sa O
node O
artery O
. O

injections O
of O
ketamine O
in O
doses O
from O
100 O
microgram O
to O
3 O
mg O
into O
the O
artery O
produced O
a O
depression B-NEG
of O
the O
sa O
nodal O
activity O
by O
a O
direct O
action O
. O

this O
depression B-NEG
was O
followed O
by O
the O
sudden O
appearance O
of O
a O
stimulatory O
phase O
. O

bilateral O
vagotomy O
and O
sympathectomy O
or O
prior O
administration O
of O
a O
ganglion O
blocker O
failed O
to O
inhibit O
the O
occurrence O
of O
the O
ketamine-induced O
tachycardia B-NEG
, O
while O
it O
was O
completely O
abolished O
in O
the O
reserpinized O
dogs O
or O
by O
a O
prior O
injection O
of O
a O
beta-blocking O
agent O
into O
the O
sa O
node O
artery O
. O

this O
may O
indicate O
that O
an O
activation O
of O
the O
peripheral O
adrenergic O
mechanism O
plays O
an O
important O
role O
in O
the O
induction O
of O
the O
excitatory O
effect O
of O
ketamine O
injected O
in O
the O
sa O
node O
artery O
. O

-DOCSTART- O

the O
use O
of O
serum O
cholinesterase O
in O
succinylcholine O
apnoea B-NEG
. O

fifteen O
patients O
demonstrating O
unexpected O
prolonged O
apnoea B-NEG
lasting O
several O
hours O
after O
succinylcholine O
have O
been O
treated O
by O
a O
new O
preparation O
of O
human O
serum O
cholinesterase O
. O

adequate O
spontaneous O
respiration O
was O
re-established O
in O
an O
average O
period O
of O
ten O
minutes O
after O
the O
injection O
. O

in O
12 O
patients O
biochemical O
genetic O
examinations O
confirmed O
the O
presence O
of O
an O
atypical O
serum O
cholinesterase O
. O

in O
three O
patients O
none O
of O
the O
usual O
variants O
were O
found O
. O

it O
is O
therefore O
supposed O
that O
other O
unknown O
variants O
of O
serum O
cholinesterase O
exist O
which O
cannot O
hydrolyze O
succinylcholine O
. O

the O
use O
of O
serum O
cholinesterase O
in O
succinylcholine O
apnoea B-NEG
provided O
considerable O
relief O
to O
both O
patient O
and O
anaesthetist O
. O

-DOCSTART- O

orthostatic B-NEG
hypotension I-NEG
occurs O
following O
alpha O
2-adrenoceptor O
blockade O
in O
chronic O
prazosin-pretreated O
conscious O
spontaneously O
hypertensive B-NEG
rats O
. O

1. O

studies O
were O
performed O
to O
evaluate O
whether O
chronic O
prazosin O
treatment O
alters O
the O
alpha O
2-adrenoceptor O
function O
for O
orthostatic O
control O
of O
arterial O
blood O
pressure O
in O
conscious O
spontaneously O
hypertensive B-NEG
rats O
(shr) O
. O

2. O

conscious O
shr O
( O
male O
300-350 O
g) O
were O
subjected O
to O
90 O
degrees O
head-up O
tilts O
for O
60 O
s O
following O
acute O
administration O
of O
prazosin O
( O
0.1 O
mg O
kg-1 O
i.p. O
) O
or O
rauwolscine O
(3 O
mg O
kg-1 O
i.v.) O
. O
orthostatic B-NEG
hypotension I-NEG
was O
determined O
by O
the O
average O
decrease O
( O
% O
) O
in O
mean O
arterial O
pressure O
( O
map O
femoral O
) O
over O
the O
60-s O
tilt O
period O
. O

the O
basal O
map O
of O
conscious O
shr O
was O
reduced O
to O
a O
similar O
extent O
by O
prazosin O
( O
-23%(-)-26% O
map O
) O
and O
rauwolscine O
( O
-16%(-)-33% O
map) O
. O

however O
, O
the O
head-up O
tilt O
induced O
orthostatic B-NEG
hypotension I-NEG
in O
the O
shr O
treated O
with O
prazosin O
( O
-16% O
map O
, O
n O
= O
6) O
, O
but O
not O
in O
the O
shr O
treated O
with O
rauwolscine O
( O
less O
than O
+2% O
map O
, O
n O
= O
6) O
. O

3. O

conscious O
shr O
were O
treated O
for O
4 O
days O
with O
prazosin O
at O
2 O
mg O
kg-1 O
day-1 O
i.p O
. O
for O
chronic O
alpha O
1-adrenoceptor O
blockade O
. O

map O
in O
conscious O
shr O
after O
chronic O
prazosin O
treatment O
was O
14% O
lower O
than O
in O
the O
untreated O
shr O
(n O
= O
8) O
. O

head-up O
tilts O
in O
these O
rats O
did O
not O
produce O
orthostatic B-NEG
hypotension I-NEG
when O
performed O
either O
prior O
to O
or O
after O
acute O
dosing O
of O
prazosin O
( O
0.1 O
mg O
kg-1 O
i.p.) O
. O

conversely O
, O
administration O
of O
rauwolscine O
(3 O
mg O
kg-1 O
i.v. O
) O
in O
chronic O
prazosin O
treated O
shr O
decreased O
the O
basal O
map O
by O
12-31% O
(n O
= O
4) O
, O
and O
subsequent O
tilts O
induced O
further O
drops O
of O
map O
by O
19-23% O
in O
these O
rats O
. O

4. O

the O
pressor O
responses O
and O
bradycardia B-NEG
to O
the O
alpha O
1-agonist O
cirazoline O
( O
0.6 O
and O
2 O
micrograms O
kg-1 O
i.v.) O
, O
the O
alpha O
2-agonist O
abbott-53693 O
(1 O
and O
3 O
micrograms O
kg-1 O
i.v.) O
, O
and O
noradrenaline O
( O
0.1 O
and O
1.0 O
micrograms O
kg-1 O
i.v. O
) O
were O
determined O
in O
conscious O
shr O
with O
and O
without O
chronic O
prazosin O
pretreatment O
. O

both O
the O
pressor O
and O
bradycardia B-NEG
effects O
of O
cirazoline O
were O
abolished O
in O
chronic O
prazosin O
treated O
shr O
(n O
= O
4) O
as O
compared O
to O
the O
untreated O
shr O
(n O
= O
4) O
. O

on O
the O
other O
hand O
, O
the O
pressor O
effects O
of O
abbott-53693 O
were O
similar O
in O
both O
groups O
of O
shr O
, O
but O
the O
accompanying O
bradycardia B-NEG
was O
greater O
in O
shr O
with O
chronic O
prazosin O
treatment O
than O
without O
such O
treatment O
. O

furthermore O
, O
the O
bradycardia B-NEG
that O
accompanied O
the O
noradrenaline-induced O
pressor O
effect O
in O
shr O
was O
similar O
with O
and O
without O
chronic O
prazosin O
treatment O
despite O
a O
47-71% O
reduction O
of O
the O
pressor O
effect O
in O
chronic O
alpha O
1-receptor O
blocked O
shr.(abstract O
truncated O
at O
400 O
words O
) O

-DOCSTART- O

coexistence O
of O
cerebral B-NEG
venous I-NEG
sinus I-NEG
and I-NEG
internal I-NEG
carotid I-NEG
artery I-NEG
thrombosis I-NEG
associated O
with O
exogenous O
sex O
hormones O
. O

a O
case O
report O
. O

a O
forty-six O
year-old O
premenopausal O
woman O
developed O
headache B-NEG
, O
nausea B-NEG
and O
vomiting B-NEG
, O
left O
hemiparesis B-NEG
and O
seizure B-NEG
two O
days O
after O
parenteral O
use O
of O
progesterone O
and O
estradiol O
. O
diabetes B-NEG
mellitus I-NEG
( O
dm B-NEG
) O
was O
found O
during O
admission O
. O

computed O
tomography O
showed O
a O
hemorrhagic B-NEG
infarct I-NEG
in O
the O
right O
frontal O
lobe O
and O
increased O
density O
in O
the O
superior O
sagittal O
sinus O
(sss) O
. O

left O
carotid O
angiography O
found O
occlusion B-NEG
of I-NEG
the I-NEG
left I-NEG
internal I-NEG
carotid I-NEG
artery I-NEG
(ica) O
. O

right O
carotid O
angiograms O
failed O
to O
show O
the O
sss O
and O
inferior O
sagittal O
sinus O
, O
suggestive O
of O
venous B-NEG
sinus I-NEG
thrombosis I-NEG
. O

coexistence O
of O
the O
cerebral B-NEG
artery I-NEG
and I-NEG
the I-NEG
venous I-NEG
sinus I-NEG
occlusion I-NEG
has O
been O
described O
infrequently O
. O

in O
this O
case O
, O
the O
authors O
postulate O
that O
the O
use O
of O
estradiol O
and O
progesterone O
and O
the O
underlying O
dm B-NEG
increased O
vascular O
thrombogenicity O
, O
which O
provided O
a O
common O
denominator O
for O
thrombosis B-NEG
of I-NEG
both I-NEG
the I-NEG
ica I-NEG
and I-NEG
the I-NEG
venous I-NEG
sinus I-NEG
. O

-DOCSTART- O

chloroquine O
related O
complete O
heart B-NEG
block I-NEG
with O
blindness B-NEG
: O
case O
report O
. O

a O
27-year O
old O
african O
woman O
with O
history O
of O
regular O
chloroquine O
ingestion O
presented O
with O
progressive O
deterioration B-NEG
of I-NEG
vision I-NEG
, O
easy O
fatiguability B-NEG
, O
dyspnoea B-NEG
, O
dizziness B-NEG
progressing O
to O
syncopal B-NEG
attacks I-NEG
. O

ophthalmological O
assessment O
revealed O
features O
of O
chloroquine O
retinopathy B-NEG
, O
cardiac O
assessment O
revealed O
features O
of O
heart B-NEG
failure I-NEG
and O
a O
complete O
heart B-NEG
block I-NEG
with O
right B-NEG
bundle I-NEG
branch I-NEG
block I-NEG
pattern O
. O

the O
heart B-NEG
block I-NEG
was O
treated O
by O
pacemaker O
insertion O
and O
the O
heart B-NEG
failure I-NEG
resolved O
spontaneously O
following O
chloroquine O
discontinuation O
. O

she O
however O
remains O
blind B-NEG
. O

-DOCSTART- O

systemic O
toxicity B-NEG
and O
resuscitation O
in O
bupivacaine- O
, O
levobupivacaine- O
, O
or O
ropivacaine-infused O
rats O
. O

we O
compared O
the O
systemic O
toxicity B-NEG
of O
bupivacaine O
, O
levobupivacaine O
, O
and O
ropivacaine O
in O
anesthetized O
rats O
. O

we O
also O
compared O
the O
ability O
to O
resuscitate O
rats O
after O
lethal O
doses O
of O
these O
local O
anesthetics O
. O

bupivacaine O
, O
levobupivacaine O
, O
or O
ropivacaine O
was O
infused O
at O
a O
rate O
of O
2 O
mg O
. O

kg(-1) O
. O

min(-1 O
) O
while O
electrocardiogram O
, O
electroencephalogram O
, O
and O
arterial O
pressure O
were O
continuously O
monitored O
. O

when O
asystole B-NEG
was O
recorded O
, O
drug O
infusion O
was O
stopped O
and O
a O
resuscitation O
sequence O
was O
begun O
. O

epinephrine O
0.01 O
mg/kg O
was O
administered O
at O
1-min O
intervals O
while O
external O
cardiac O
compressions O
were O
applied O
. O

resuscitation O
was O
considered O
successful O
when O
a O
systolic O
arterial O
pressure O
> O
or O
=100 O
mm O
hg O
was O
achieved O
within O
5 O
min O
. O

the O
cumulative O
doses O
of O
levobupivacaine O
and O
ropivacaine O
that O
produced O
seizures B-NEG
were O
similar O
and O
were O
larger O
than O
those O
of O
bupivacaine O
. O

the O
cumulative O
doses O
of O
levobupivacaine O
that O
produced O
dysrhythmias B-NEG
and O
asystole B-NEG
were O
smaller O
than O
the O
corresponding O
doses O
of O
ropivacaine O
, O
but O
they O
were O
larger O
than O
those O
of O
bupivacaine O
. O

the O
number O
of O
successful O
resuscitations O
did O
not O
differ O
among O
groups O
. O

however O
, O
a O
smaller O
dose O
of O
epinephrine O
was O
required O
in O
the O
ropivacaine O
group O
than O
in O
the O
other O
groups O
. O

we O
conclude O
that O
the O
systemic O
toxicity B-NEG
of O
levobupivacaine O
is O
intermediate O
between O
that O
of O
ropivacaine O
and O
bupivacaine O
when O
administered O
at O
the O
same O
rate O
and O
that O
ropivacaine-induced O
cardiac B-NEG
arrest I-NEG
appears O
to O
be O
more O
susceptible O
to O
treatment O
than O
that O
induced O
by O
bupivacaine O
or O
levobupivacaine O
. O

-DOCSTART- O

22-oxacalcitriol O
suppresses O
secondary B-NEG
hyperparathyroidism I-NEG
without O
inducing O
low B-NEG
bone I-NEG
turnover I-NEG
in O
dogs O
with O
renal B-NEG
failure I-NEG
. O

background O
: O
calcitriol O
therapy O
suppresses O
serum O
levels O
of O
parathyroid O
hormone O
( O
pth O
) O
in O
patients O
with O
renal B-NEG
failure I-NEG
but O
has O
several O
drawbacks O
, O
including O
hypercalcemia B-NEG
and/or O
marked O
suppression B-NEG
of I-NEG
bone I-NEG
turnover I-NEG
, O
which O
may O
lead O
to O
adynamic B-NEG
bone I-NEG
disease I-NEG
. O

a O
new O
vitamin O
d O
analogue O
, O
22-oxacalcitriol O
(oct) O
, O
has O
been O
shown O
to O
have O
promising O
characteristics O
. O

this O
study O
was O
undertaken O
to O
determine O
the O
effects O
of O
oct O
on O
serum O
pth O
levels O
and O
bone O
turnover O
in O
states O
of O
normal O
or O
impaired B-NEG
renal I-NEG
function I-NEG
. O

methods O
: O
sixty O
dogs O
were O
either O
nephrectomized O
(nx O
, O
n O
= O
38 O
) O
or O
sham-operated O
(sham O
, O
n O
= O
22) O
. O

the O
animals O
received O
supplemental O
phosphate O
to O
enhance O
pth O
secretion O
. O

fourteen O
weeks O
after O
the O
start O
of O
phosphate O
supplementation O
, O
half O
of O
the O
nx O
and O
sham O
dogs O
received O
doses O
of O
oct O
( O
three O
times O
per O
week) O
; O
the O
other O
half O
were O
given O
vehicle O
for O
60 O
weeks O
. O

thereafter O
, O
the O
treatment O
modalities O
for O
a O
subset O
of O
animals O
were O
crossed O
over O
for O
an O
additional O
eight O
months O
. O

biochemical O
and O
hormonal O
indices O
of O
calcium O
and O
bone O
metabolism O
were O
measured O
throughout O
the O
study O
, O
and O
bone O
biopsies O
were O
done O
at O
baseline O
, O
60 O
weeks O
after O
oct O
or O
vehicle O
treatment O
, O
and O
at O
the O
end O
of O
the O
crossover O
period O
. O

results O
: O
in O
nx O
dogs O
, O
oct O
significantly O
decreased O
serum O
pth O
levels O
soon O
after O
the O
induction O
of O
renal B-NEG
insufficiency I-NEG
. O

in O
long-standing O
secondary B-NEG
hyperparathyroidism I-NEG
, O
oct O
( O
0.03 O
microg/kg O
) O
stabilized O
serum O
pth O
levels O
during O
the O
first O
months O
. O

serum O
pth O
levels O
rose O
thereafter O
, O
but O
the O
rise O
was O
less O
pronounced O
compared O
with O
baseline O
than O
the O
rise O
seen O
in O
nx O
control O
. O

these O
effects O
were O
accompanied O
by O
episodes O
of O
hypercalcemia B-NEG
and O
hyperphosphatemia B-NEG
. O

in O
animals O
with O
normal O
renal O
function O
, O
oct O
induced O
a O
transient O
decrease O
in O
serum O
pth O
levels O
at O
a O
dose O
of O
0.1 O
microg/kg O
, O
which O
was O
not O
sustained O
with O
lowering O
of O
the O
doses O
. O

in O
nx O
dogs O
, O
oct O
reversed O
abnormal O
bone O
formation O
, O
such O
as O
woven B-NEG
osteoid I-NEG
and O
fibrosis B-NEG
, O
but O
did O
not O
significantly O
alter O
the O
level O
of O
bone O
turnover O
. O

in O
addition O
, O
oct O
improved O
mineralization O
lag O
time O
, O
( O
that O
is O
, O
the O
rate O
at O
which O
osteoid O
mineralizes O
) O
in O
both O
nx O
and O
sham O
dogs O
. O

conclusions O
: O
these O
results O
indicate O
that O
even O
though O
oct O
does O
not O
completely O
prevent O
the O
occurrence O
of O
hypercalcemia B-NEG
in O
experimental O
dogs O
with O
renal B-NEG
insufficiency I-NEG
, O
it O
may O
be O
of O
use O
in O
the O
management O
of O
secondary B-NEG
hyperparathyroidism I-NEG
because O
it O
does O
not O
induce O
low B-NEG
bone I-NEG
turnover I-NEG
and O
, O
therefore O
, O
does O
not O
increase O
the O
risk O
of O
adynamic B-NEG
bone I-NEG
disease I-NEG
. O

-DOCSTART- O

chemotherapy O
of O
advanced O
inoperable O
non-small B-NEG
cell I-NEG
lung I-NEG
cancer I-NEG
with O
paclitaxel O
: O
a O
phase O
ii O
trial O
. O

paclitaxel O
(taxol O
; O
bristol-myers O
squibb O
company O
, O
princeton O
, O
nj O
) O
has O
demonstrated O
significant O
antineoplastic O
activity O
against O
different O
tumor B-NEG
types O
, O
notably O
ovarian B-NEG
and I-NEG
breast I-NEG
carcinoma I-NEG
. O

two O
phase O
ii O
trials O
of O
24-hour O
paclitaxel O
infusions O
in O
chemotherapy-naive O
patients O
with O
stage O
iiib O
or O
iv O
non-small B-NEG
cell I-NEG
lung I-NEG
cancer I-NEG
( O
nsclc B-NEG
) O
reported O
response O
rates O
of O
21% O
and O
24% O
. O
leukopenia B-NEG
was O
dose O
limiting O
: O
as O
many O
as O
62.5% O
of O
patients O
experienced O
grade O
4 O
leukopenia B-NEG
. O

we O
investigated O
the O
efficacy O
and O
toxicity B-NEG
of O
a O
3-hour O
paclitaxel O
infusion O
in O
a O
phase O
ii O
trial O
in O
patients O
with O
inoperable O
stage O
iiib O
or O
iv O
nsclc B-NEG
. O

the O
58 O
patients O
treated O
( O
41 O
men O
and O
17 O
women O
) O
had O
a O
median O
age O
of O
59 O
years O
( O
age O
range O
, O
25 O
to O
75 O
) O
and O
a O
performance O
status O
of O
0 O
through O
2. O

most O
patients O
( O
72.4% O
) O
had O
stage O
iv O
nsclc B-NEG
. O

paclitaxel O
225 O
mg/m2 O
was O
infused O
over O
3 O
hours O
every O
3 O
weeks O
with O
standard O
prophylactic O
premedication O
. O

of O
50 O
patients O
evaluable O
for O
response O
, O
12 O
( O
24% O
) O
had O
partial O
remission O
, O
26 O
( O
52% O
) O
had O
no O
change O
, O
and O
12 O
had O
disease O
progression O
(24%) O
. O

hematologic O
toxicities B-NEG
were O
mild O
: O
only O
one O
patient O
( O
2% O
) O
developed O
grade O
3 O
or O
4 O
neutropenia B-NEG
, O
while O
29% O
had O
grade O
1 O
or O
2. O

grade O
1 O
or O
2 O
polyneuropathy B-NEG
affected O
56% O
of O
patients O
while O
only O
one O
( O
2% O
) O
experienced O
severe O
polyneuropathy B-NEG
. O

similarly O
, O
grade O
1 O
or O
2 O
myalgia B-NEG
/ O
arthralgia B-NEG
was O
observed O
in O
63.2% O
of O
patients O
, O
but O
only O
14.3% O
experienced O
grade O
3 O
or O
4. O
nausea B-NEG
and O
vomiting B-NEG
were O
infrequent O
, O
with O
14% O
of O
patients O
experiencing O
grade O
1 O
or O
2 O
and O
only O
2% O
experiencing O
grade O
3 O
or O
4. O

paclitaxel O
is O
thus O
an O
active O
single O
agent O
in O
this O
patient O
population O
, O
with O
a O
3-hour O
infusion O
proving O
comparably O
effective O
to O
a O
24-hour O
infusion O
and O
superior O
in O
terms O
of O
the O
incidence O
of O
hematologic O
and O
nonhematologic O
toxicity B-NEG
. O

further O
phase O
ii O
studies O
with O
paclitaxel O
combined O
with O
other O
drugs O
active O
against O
nsclc B-NEG
are O
indicated O
, O
and O
phase O
iii O
studies O
comparing O
paclitaxel O
with O
standard O
chemotherapy O
remain O
to O
be O
completed O
. O

-DOCSTART- O

cerebral B-NEG
hemorrhage I-NEG
associated O
with O
phenylpropanolamine O
in O
combination O
with O
caffeine O
. O

phenylpropanolamine O
( O
ppa O
) O
is O
a O
drug O
that O
has O
been O
associated O
with O
serious O
side O
effects O
including O
stroke B-NEG
. O

it O
is O
often O
combined O
with O
caffeine O
in O
diet O
preparations O
and O
look-alike O
pills O
. O

in O
order O
to O
determine O
if O
ppa/caffeine O
can O
lead O
to O
stroke B-NEG
in O
normotensive O
and/or O
hypertensive B-NEG
rats O
, O
we O
administered O
the O
combination O
in O
six O
times O
the O
allowed O
human O
dose O
calculated O
on O
a O
per O
weight O
basis O
for O
the O
rats O
two O
times O
per O
day O
for O
five O
days O
. O
subarachnoid B-NEG
and I-NEG
cerebral I-NEG
hemorrhage I-NEG
was O
noted O
in O
18% O
of O
the O
hypertensive B-NEG
rats O
. O

a O
single O
ppa/caffeine O
administration O
( O
same O
dose O
) O
lead O
to O
acute O
hypertension B-NEG
in O
both O
the O
normotensive O
and O
hypertensive B-NEG
animals O
. O

these O
results O
suggest O
that O
ppa/caffeine O
can O
lead O
to O
cerebral B-NEG
hemorrhage I-NEG
in O
previously O
hypertensive B-NEG
animals O
when O
administered O
in O
greater O
than O
the O
allowed O
dosage O
. O

an O
acute O
elevation O
in O
blood O
pressure O
may O
be O
a O
contributing O
factor O
. O

-DOCSTART- O

long-term O
efficacy O
and O
toxicity B-NEG
of O
high-dose O
amiodarone O
therapy O
for O
ventricular B-NEG
tachycardia I-NEG
or O
ventricular B-NEG
fibrillation I-NEG
. O

amiodarone O
was O
administered O
to O
154 O
patients O
who O
had O
sustained O
, O
symptomatic O
ventricular B-NEG
tachycardia I-NEG
( O
vt B-NEG
) O
(n O
= O
118 O
) O
or O
a O
cardiac B-NEG
arrest I-NEG
(n O
= O
36 O
) O
and O
who O
were O
refractory O
to O
conventional O
antiarrhythmic O
drugs O
. O

the O
loading O
dose O
was O
800 O
mg/day O
for O
6 O
weeks O
and O
the O
maintenance O
dose O
was O
600 O
mg/day O
. O

sixty-nine O
percent O
of O
patients O
continued O
treatment O
with O
amiodarone O
and O
had O
no O
recurrence O
of O
symptomatic O
vt B-NEG
or O
ventricular B-NEG
fibrillation I-NEG
( O
vf B-NEG
) O
over O
a O
follow-up O
of O
6 O
to O
52 O
months O
( O
mean O
+/- O
standard O
deviation O
14.2 O
+/- O
8.2) O
. O

six O
percent O
of O
the O
patients O
had O
a O
nonfatal O
recurrence O
of O
vt B-NEG
and O
were O
successfully O
managed O
by O
continuing O
amiodarone O
at O
a O
higher O
dose O
or O
by O
the O
addition O
of O
a O
conventional O
antiarrhythmic O
drug O
. O

one O
or O
more O
adverse O
drug O
reactions O
occurred O
in O
51% O
of O
patients O
. O

adverse O
effects O
forced O
a O
reduction O
in O
the O
dose O
of O
amiodarone O
in O
41% O
and O
discontinuation O
of O
amiodarone O
in O
10% O
of O
patients O
. O

the O
most O
common O
symptomatic O
adverse O
reactions O
were O
tremor B-NEG
or O
ataxia B-NEG
(35%) O
, O
nausea B-NEG
and O
anorexia B-NEG
(8%) O
, O
visual B-NEG
halos I-NEG
or I-NEG
blurring I-NEG
(6%) O
, O
thyroid B-NEG
function I-NEG
abnormalities I-NEG
( O
6% O
) O
and O
pulmonary B-NEG
interstitial I-NEG
infiltrates I-NEG
(5%) O
. O

although O
large-dose O
amiodarone O
is O
highly O
effective O
in O
the O
long-term O
treatment O
of O
vt B-NEG
or O
vf B-NEG
refractory O
to O
conventional O
antiarrhythmic O
drugs O
, O
it O
causes O
significant O
toxicity B-NEG
in O
approximately O
50% O
of O
patients O
. O

however O
, O
when O
the O
dose O
is O
adjusted O
based O
on O
clinical O
response O
or O
the O
development O
of O
adverse O
effects O
, O
75% O
of O
patients O
with O
vt B-NEG
or O
vf B-NEG
can O
be O
successfully O
managed O
with O
amiodarone O
. O

-DOCSTART- O

effect O
of O
calcium O
chloride O
and O
4-aminopyridine O
therapy O
on O
desipramine O
toxicity B-NEG
in O
rats O
. O

background O
: O
hypotension B-NEG
is O
a O
major O
contributor O
to O
mortality O
in O
tricyclic O
antidepressant O
overdose B-NEG
. O

recent O
data O
suggest O
that O
tricyclic O
antidepressants O
inhibit O
calcium O
influx O
in O
some O
tissues O
. O

this O
study O
addressed O
the O
potential O
role O
of O
calcium O
channel O
blockade O
in O
tricyclic O
antidepressant-induced O
hypotension B-NEG
. O

methods O
: O
two O
interventions O
were O
studied O
that O
have O
been O
shown O
previously O
to O
improve O
blood O
pressure O
with O
calcium O
channel O
blocker O
overdose B-NEG
. O

cacl2 O
and O
4-aminopyridine O
. O

anesthetized O
rats O
received O
the O
tricyclic O
antidepressant O
desipramine O
ip O
to O
produce O
hypotension B-NEG
, O
qrs O
prolongation O
, O
and O
bradycardia B-NEG
. O

fifteen O
min O
later O
, O
animals O
received O
cacl2 O
, O
nahco3 O
, O
or O
saline O
. O

in O
a O
second O
experiment O
, O
rats O
received O
tricyclic O
antidepressant O
desipramine O
ip O
followed O
in O
15 O
min O
by O
4-aminopyridine O
or O
saline O
. O

results O
: O
nahco3 O
briefly O
(5 O
min O
) O
reversed O
hypotension B-NEG
and O
qrs O
prolongation O
. O

cacl2 O
and O
4-aminopyridine O
failed O
to O
improve O
blood O
pressure O
. O

the O
incidence O
of O
ventricular B-NEG
arrhythmias I-NEG
(p O
= O
0.004 O
) O
and O
seizures B-NEG
(p O
= O
0.03 O
) O
in O
the O
cacl2 O
group O
was O
higher O
than O
the O
other O
groups O
. O

conclusion O
: O
the O
administration O
of O
cacl2 O
or O
4-aminopyridine O
did O
not O
reverse O
tricyclic O
antidepressant-induced O
hypotension B-NEG
in O
rats O
. O

cacl2 O
therapy O
may O
possibly O
worsen O
both O
cardiovascular B-NEG
and I-NEG
central I-NEG
nervous I-NEG
system I-NEG
toxicity I-NEG
. O

these O
findings O
do O
not O
support O
a O
role O
for O
calcium O
channel O
inhibition O
in O
the O
pathogenesis O
of O
tricyclic O
antidepressant-induced O
hypotension B-NEG
. O

-DOCSTART- O

phase O
i O
trial O
of O
13-cis-retinoic O
acid O
in O
children O
with O
neuroblastoma B-NEG
following O
bone O
marrow O
transplantation O
. O

purpose O
: O
treatment O
of O
neuroblastoma B-NEG
cell O
lines O
with O
13-cis-retinoic O
acid O
( O
cis-ra O
) O
can O
cause O
sustained O
inhibition O
of O
proliferation O
. O

since O
cis-ra O
has O
demonstrated O
clinical O
responses O
in O
neuroblastoma B-NEG
patients O
, O
it O
may O
be O
effective O
in O
preventing O
relapse O
after O
cytotoxic O
therapy O
. O

this O
phase O
i O
trial O
was O
designed O
to O
determine O
the O
maximal-tolerated O
dosage O
(mtd) O
, O
toxicities B-NEG
, O
and O
pharmacokinetics O
of O
cis-ra O
administered O
on O
an O
intermittent O
schedule O
in O
children O
with O
neuroblastoma B-NEG
following O
bone O
marrow O
transplantation O
(bmt) O
. O

patients O
and O
methods O
: O
fifty-one O
assessable O
patients O
, O
2 O
to O
12 O
years O
of O
age O
, O
were O
treated O
with O
oral O
cis-ra O
administered O
in O
two O
equally O
divided O
doses O
daily O
for O
2 O
weeks O
, O
followed O
by O
a O
2-week O
rest O
period O
, O
for O
up O
to O
12 O
courses O
. O

the O
dose O
was O
escalated O
from O
100 O
to O
200 O
mg/m2/d O
until O
dose-limiting O
toxicity B-NEG
( O
dlt O
) O
was O
observed O
. O

a O
single O
intrapatient O
dose O
escalation O
was O
permitted O
. O

results O
: O
the O
mtd O
of O
cis-ra O
was O
160 O
mg/m2/d O
. O

dose-limiting O
toxicities B-NEG
in O
six O
of O
nine O
patients O
at O
200 O
mg/m2/d O
included O
hypercalcemia B-NEG
(n O
= O
3) O
, O
rash B-NEG
(n O
= O
2) O
, O
and O
anemia B-NEG
/ O
thrombocytopenia B-NEG
/ O
emesis B-NEG
/ O
rash B-NEG
(n O
= O
1) O
. O

all O
toxicities B-NEG
resolved O
after O
cis-ra O
was O
discontinued O
. O

three O
complete O
responses O
were O
observed O
in O
marrow O
metastases B-NEG
. O

serum O
levels O
of O
7.4 O
+/- O
3.0 O
mumol/l O
( O
peak O
) O
and O
4.0 O
+/- O
2.8 O
mumol/l O
( O
trough O
) O
at O
the O
mtd O
were O
maintained O
during O
14 O
days O
of O
therapy O
. O

the O
dlt O
correlated O
with O
serum O
levels O
> O
or O
= O
10 O
mumol/l O
. O

conclusion O
: O
the O
mtd O
of O
cis-ra O
given O
on O
this O
intermittent O
schedule O
was O
160 O
mg/m2/d O
. O

serum O
levels O
known O
to O
be O
effective O
against O
neuroblastoma B-NEG
in O
vitro O
were O
achieved O
at O
this O
dose O
. O

the O
dlt O
included O
hypercalcemia B-NEG
, O
and O
may O
be O
predicted O
by O
serum O
cis-ra O
levels O
. O

monitoring O
of O
serum O
calcium O
and O
cis-ra O
levels O
is O
indicated O
in O
future O
trials O
. O

-DOCSTART- O

effect O
of O
calcium O
chloride O
on O
gross O
behavioural O
changes O
produced O
by O
carbachol O
and O
eserine O
in O
cats O
. O

the O
effect O
of O
calcium O
chloride O
injected O
into O
the O
cerebral O
ventricles O
of O
group-housed O
unanaesthetized O
cats O
upon O
vocalization O
(rage O
, O
hissing O
and O
snarling) O
, O
fighting O
( O
attack O
with O
paws O
and O
claws O
, O
defense O
with O
paws O
and O
claws O
and O
biting) O
, O
mydriasis B-NEG
, O
tremor B-NEG
and O
clonic-tonic B-NEG
convulsions I-NEG
produced O
by O
carbachol O
and O
eserine O
injected O
similarly O
was O
investigated O
. O

calcium O
chloride O
depressed O
or O
almost O
completely O
abolished O
the O
vocalization O
and O
fighting O
due O
to O
carbachol O
and O
eserine O
. O

on O
the O
other O
hand O
, O
mydriasis B-NEG
, O
tremor B-NEG
and O
clonic-tonic B-NEG
convulsions I-NEG
evoked O
by O
carbachol O
and O
eserine O
were O
not O
significantly O
changed O
by O
calcium O
chloride O
. O

it O
is O
apparent O
that O
calcium O
chloride O
can O
dissociate O
vocalization O
and O
fighting O
from O
autonomic O
and O
motor O
phenomena O
such O
as O
mydriasis B-NEG
, O
tremor B-NEG
and O
clonic-tonic B-NEG
convulsions I-NEG
caused O
by O
carbachol O
and O
eserine O
. O

calcium O
chloride O
inhibited O
the O
vocalization O
and O
fighting O
produced O
by O
carbachol O
and O
eserine O
most O
probably O
by O
a O
nonspecific O
stabilizing O
action O
on O
central O
muscarinic O
cholinoceptive O
sites O
. O

these O
results O
further O
support O
the O
view O
that O
calcium O
ions O
in O
excess O
have O
an O
atropine-like O
action O
also O
in O
the O
central O
nervous O
system O
. O

-DOCSTART- O

multiple O
side O
effects O
of O
penicillamine O
therapy O
in O
one O
patient O
with O
rheumatoid B-NEG
arthritis I-NEG
. O
skin B-NEG
rashes I-NEG
, O
proteinuria B-NEG
, O
systemic B-NEG
lupus I-NEG
erythematosus I-NEG
, O
polymyositis B-NEG
and O
myasthenia B-NEG
gravis I-NEG
have O
all O
been O
recorded O
as O
complications O
of O
penicillamine O
therapy O
in O
patients O
with O
rheumatoid B-NEG
arthritis I-NEG
. O

a O
patient O
who O
had O
developed O
all O
5 O
is O
now O
described O
. O

the O
skin B-NEG
lesion I-NEG
resembled O
elastosis B-NEG
perforans I-NEG
serpiginosa I-NEG
, O
which O
has O
been O
reported O
as O
a O
rare O
side O
effect O
in O
patients O
with O
wilson's B-NEG
disease I-NEG
but O
not O
in O
patients O
with O
rheumatoid B-NEG
arthritis I-NEG
treated O
with O
penicillamine O
. O

-DOCSTART- O

electrocardiographic O
changes O
and O
cardiac B-NEG
arrhythmias I-NEG
in O
patients O
receiving O
psychotropic O
drugs O
. O

eight O
patients O
had O
cardiac O
manifestations O
that O
were O
life-threatening O
in O
five O
while O
taking O
psychotropic O
drugs O
, O
either O
phenothiazines O
or O
tricyclic O
antidepressants O
. O

although O
most O
patients O
were O
receiving O
several O
drugs O
, O
mellaril O
( O
thioridazine O
) O
appeared O
to O
be O
responsible O
for O
five O
cases O
of O
ventricular B-NEG
tachycardia I-NEG
, O
one O
of O
which O
was O
fatal O
in O
a O
35 O
year O
old O
woman O
. O
supraventricular B-NEG
tachycardia I-NEG
developed O
in O
one O
patient O
receiving O
thorazine O
(chlorpromazine) O
. O

aventyl O
( O
nortriptyline O
) O
and O
elavil O
( O
amitriptyline O
) O
each O
produced O
left B-NEG
bundle I-NEG
branch I-NEG
block I-NEG
in O
a O
73 O
year O
old O
woman O
. O

electrocardiographic O
t O
and O
u O
wave O
abnormalities O
were O
present O
in O
most O
patients O
. O

the O
ventricular B-NEG
arrhythmias I-NEG
responded O
to O
intravenous O
administration O
of O
lidocaine O
and O
to O
direct O
current O
electric O
shock O
; O
ventricular O
pacing O
was O
required O
in O
some O
instances O
and O
intravenous O
administration O
of O
propranolol O
combined O
with O
ventricular O
pacing O
in O
one O
. O

the O
tachyarrhythmias B-NEG
generally O
subsided O
within O
48 O
hours O
after O
administration O
of O
the O
drugs O
was O
stopped O
. O

five O
of O
the O
eight O
patients O
were O
50 O
years O
of O
age O
or O
younger O
; O
only O
one O
clearly O
had O
antecedent O
heart B-NEG
disease I-NEG
. O

major O
cardiac B-NEG
arrhythmias I-NEG
are O
a O
potential O
hazard O
in O
patients O
without O
heart B-NEG
disease I-NEG
who O
are O
receiving O
customary O
therapeutic O
doses O
of O
psychotropic O
drugs O
. O

a O
prospective O
clinical O
trial O
is O
suggested O
to O
quantify O
the O
risk O
of O
cardiac B-NEG
complications I-NEG
to O
patients O
receiving O
phenothiazines O
or O
tricyclic O
antidepressant O
drugs O
. O

-DOCSTART- O

serotonergic O
drugs O
, O
benzodiazepines O
and O
baclofen O
block O
muscimol-induced O
myoclonic B-NEG
jerks I-NEG
in O
a O
strain O
of O
mice O
. O

in O
male O
swiss O
mice O
, O
muscimol O
produced O
myoclonic B-NEG
jerks I-NEG
. O

a O
3 O
mg/kg O
( O
i.p. O
) O
dose O
induced O
this O
response O
in O
all O
of O
the O
mice O
tested O
and O
the O
peak O
response O
of O
73 O
jerks O
per O
min O
was O
observed O
between O
27 O
and O
45 O
min O
. O

increasing O
the O
brain O
serotonin O
levels O
by O
the O
administration O
of O
5-hydroxytryptophan O
( O
80-160 O
mg/kg O
) O
in O
combination O
with O
a O
peripheral O
decarboxylase O
inhibitor O
resulted O
in O
an O
inhibition O
of O
the O
muscimol O
effect O
. O

however O
, O
in O
a O
similar O
experiment O
l-dopa O
( O
80-160 O
mg/kg O
) O
was O
without O
effect O
. O

in O
doses O
of O
3-10 O
mg/kg O
, O
the O
serotonin O
receptor O
agonist O
mk-212 O
caused O
a O
dose-dependent O
blockade O
of O
the O
response O
of O
muscimol O
. O

of O
the O
benzodiazepines O
, O
clonazepam O
( O
0.1-0.3 O
mg/kg O
) O
was O
found O
to O
be O
several O
fold O
more O
potent O
than O
diazepam O
( O
0.3-3 O
mg/kg O
) O
in O
blocking O
the O
myoclonic B-NEG
jerks I-NEG
. O

while O
( O
-)-baclofen O
( O
1-3 O
mg/kg O
) O
proved O
to O
be O
an O
effective O
antagonist O
of O
muscimol O
, O
its O
( O
+)-isomer O
( O
5-20 O
mg/kg O
) O
lacked O
this O
property O
. O

considering O
the O
fact O
that O
5-htp O
and O
the O
benzodiazepines O
have O
been O
found O
to O
be O
beneficial O
in O
the O
management O
of O
clinical O
myoclonus B-NEG
, O
the O
muscimol-induced O
myoclonus B-NEG
seems O
to O
be O
a O
satisfactory O
animal O
model O
that O
may O
prove O
useful O
for O
the O
development O
of O
new O
drug O
treatments O
for O
this O
condition O
. O

our O
present O
study O
indicated O
the O
possible O
value O
of O
mk-212 O
and O
( O
-)-baclofen O
in O
the O
management O
of O
clinical O
myoclonus B-NEG
. O

-DOCSTART- O

hyperglycemic B-NEG
acidotic I-NEG
coma I-NEG
and O
death O
in O
kearns-sayre B-NEG
syndrome I-NEG
. O

this O
paper O
presents O
the O
clinical O
and O
metabolic O
findings O
in O
two O
young O
boys O
with O
long-standing O
kearns-sayre B-NEG
syndrome I-NEG
. O

following O
short O
exposure O
to O
oral O
prednisone O
, O
both O
boys O
developed O
lethargy B-NEG
, O
increasing O
somnolence B-NEG
, O
polydipsia B-NEG
, O
polyphagia B-NEG
, O
and O
polyuria B-NEG
. O

both O
presented O
in O
the O
emergency O
room O
with O
profound O
coma B-NEG
, O
hypotension B-NEG
, O
severe O
hyperglycemia B-NEG
, O
and O
acidosis B-NEG
. O

nonketotic O
lactic B-NEG
acidosis I-NEG
was O
present O
in O
one O
and O
ketosis B-NEG
without O
a O
known O
serum O
lactate O
level O
was O
present O
in O
the O
other O
. O
respiratory B-NEG
failure I-NEG
rapidly O
ensued O
and O
both O
patients O
expired O
in O
spite O
of O
efforts O
at O
resuscitation O
. O

we O
believe O
these O
two O
cases O
represent O
a O
newly O
described O
and O
catastrophic O
metabolic-endocrine B-NEG
failure I-NEG
in O
the O
kearns-sayre B-NEG
syndrome I-NEG
. O

-DOCSTART- O

effects O
of O
active O
constituents O
of O
crocus O
sativus O
l. O
, O
crocin O
on O
streptozocin-induced O
model O
of O
sporadic O
alzheimer's B-NEG
disease I-NEG
in O
male O
rats O
. O

background O
: O
the O
involvement O
of O
water-soluble O
carotenoids O
, O
crocins O
, O
as O
the O
main O
and O
active O
components O
of O
crocus O
sativus O
l. O
extract O
in O
learning O
and O
memory O
processes O
has O
been O
proposed O
. O

in O
the O
present O
study O
, O
the O
effect O
of O
crocins O
on O
sporadic O
alzheimer's B-NEG
disease I-NEG
induced O
by O
intracerebroventricular O
( O
icv O
) O
streptozocin O
( O
stz O
) O
in O
male O
rats O
was O
investigated O
. O

methods O
: O
male O
adult O
wistar O
rats O
(n O
= O
90 O
and O
260-290 O
g) O
were O
divided O
into O
1, O
control O
; O
2 O
and O
3, O
crocins O
( O
15 O
and O
30 O
mg/kg) O
; O
4, O
stz O
; O
5 O
and O
6, O
stz O
+ O
crocins O
( O
15 O
and O
30 O
mg/kg O
) O
groups O
. O

in O
alzheimer's B-NEG
disease I-NEG
groups O
, O
rats O
were O
injected O
with O
stz-icv O
bilaterally O
(3 O
mg/kg O
) O
in O
first O
day O
and O
3 O
days O
later O
, O
a O
similar O
stz-icv O
application O
was O
repeated O
. O

in O
stz O
+ O
crocin O
animal O
groups O
, O
crocin O
was O
applied O
in O
doses O
of O
15 O
and O
30 O
mg/kg O
, O
i.p. O
, O
one O
day O
pre-surgery O
and O
continued O
for O
three O
weeks O
. O

prescription O
of O
crocin O
in O
each O
dose O
was O
repeated O
once O
for O
two O
days O
. O

however O
, O
the O
learning O
and O
memory O
performance O
was O
assessed O
using O
passive O
avoidance O
paradigm O
, O
and O
for O
spatial O
cognition O
evaluation O
, O
y-maze O
task O
was O
used O
. O

results O
: O
it O
was O
found O
out O
that O
crocin O
( O
30 O
mg/kg)-treated O
stz-injected O
rats O
show O
higher O
correct O
choices O
and O
lower O
errors O
in O
y-maze O
than O
vehicle-treated O
stz-injected O
rats O
. O

in O
addition O
, O
crocin O
in O
the O
mentioned O
dose O
could O
significantly O
attenuated O
learning B-NEG
and I-NEG
memory I-NEG
impairment I-NEG
in O
treated O
stz-injected O
group O
in O
passive O
avoidance O
test O
. O

conclusion O
: O
therefore O
, O
these O
results O
demonstrate O
the O
effectiveness O
of O
crocin O
( O
30 O
mg/kg O
) O
in O
antagonizing O
the O
cognitive B-NEG
deficits I-NEG
caused O
by O
stz-icv O
in O
rats O
and O
its O
potential O
in O
the O
treatment O
of O
neurodegenerative B-NEG
diseases I-NEG
such O
as O
alzheimer's B-NEG
disease I-NEG
. O

-DOCSTART- O

rosaceiform O
dermatitis B-NEG
associated O
with O
topical O
tacrolimus O
treatment O
. O

we O
describe O
herein O
3 O
patients O
who O
developed O
rosacea B-NEG
-like O
dermatitis B-NEG
eruptions B-NEG
while O
using O
0.03% O
or O
0.1% O
tacrolimus O
ointment O
for O
facial B-NEG
dermatitis I-NEG
. O

skin O
biopsy O
specimens O
showed O
telangiectasia B-NEG
and O
noncaseating O
epithelioid O
granulomatous O
tissue O
formation O
in O
the O
papillary O
to O
mid O
dermis O
. O

continuous O
topical O
use O
of O
immunomodulators O
such O
as O
tacrolimus O
or O
pimecrolimus O
should O
be O
regarded O
as O
a O
potential O
cause O
of O
rosaceiform O
dermatitis B-NEG
, O
although O
many O
cases O
have O
not O
been O
reported O
. O

-DOCSTART- O

a O
novel O
animal O
model O
to O
evaluate O
the O
ability O
of O
a O
drug O
delivery O
system O
to O
promote O
the O
passage O
through O
the O
bbb O
. O

the O
purpose O
of O
this O
investigation O
was O
to O
explore O
the O
potentiality O
of O
a O
novel O
animal O
model O
to O
be O
used O
for O
the O
in O
vivo O
evaluation O
of O
the O
ability O
of O
a O
drug O
delivery O
system O
to O
promote O
the O
passage O
through O
the O
blood-brain O
barrier O
( O
bbb O
) O
and/or O
to O
improve O
the O
brain O
localization O
of O
a O
bioactive O
compound O
. O

a O
tween O
80-coated O
poly-l-lactid O
acid O
nanoparticles O
was O
used O
as O
a O
model O
of O
colloidal O
drug O
delivery O
system O
, O
able O
to O
trespass O
the O
bbb O
. O

tacrine O
, O
administered O
in O
licl O
pre-treated O
rats O
, O
induces O
electrocorticographic O
seizures B-NEG
and O
delayed O
hippocampal B-NEG
damage I-NEG
. O

the O
toxic O
effects O
of O
tacrine-loaded O
poly-l-lactid O
acid O
nanoparticles O
(5mg/kg) O
, O
a O
saline O
solution O
of O
tacrine O
( O
5mg/kg O
) O
and O
an O
empty O
colloidal O
nanoparticle O
suspension O
were O
compared O
following O
i.p O
. O
administration O
in O
licl-pre-treated O
wistar O
rats O
. O

all O
the O
animals O
treated O
with O
tacrine-loaded O
nanoparticles O
showed O
an O
earlier O
outcome O
of O
cns O
adverse O
symptoms O
, O
i.e O
. O
epileptic B-NEG
onset O
, O
with O
respect O
to O
those O
animals O
treated O
with O
the O
free O
compound O
( O
10 O
min O
vs O
. O
22 O
min O
respectively) O
. O

in O
addition O
, O
tacrine-loaded O
nanoparticles O
administration O
induced O
damage B-NEG
of I-NEG
neuronal I-NEG
cells I-NEG
in O
ca1 O
field O
of O
the O
hippocampus O
in O
all O
treated O
animals O
, O
while O
the O
saline O
solution O
of O
tacrine O
only O
in O
60% O
of O
animals O
. O

empty O
nanoparticles O
provided O
similar O
results O
to O
control O
( O
saline-treated O
) O
group O
of O
animals O
. O

in O
conclusion O
, O
the O
evaluation O
of O
time-to-onset O
of O
symptoms O
and O
the O
severity O
of O
neurodegenerative O
processes O
induced O
by O
the O
tacrine-lithium O
model O
of O
epilepsy B-NEG
in O
the O
rat O
, O
could O
be O
used O
to O
evaluate O
preliminarily O
the O
capability O
of O
a O
drug O
delivery O
system O
to O
trespass O
( O
or O
not O
) O
the O
bbb O
in O
vivo O
. O

-DOCSTART- O

the O
antiarrhythmic O
effect O
and O
possible O
ionic O
mechanisms O
of O
pilocarpine O
on O
animal O
models O
. O

this O
study O
was O
designed O
to O
evaluate O
the O
effects O
of O
pilocarpine O
and O
explore O
the O
underlying O
ionic O
mechanism O
, O
using O
both O
aconitine-induced O
rat O
and O
ouabain-induced O
guinea O
pig O
arrhythmia B-NEG
models O
. O

confocal O
microscopy O
was O
used O
to O
measure O
intracellular O
free-calcium O
concentrations O
( O
[ca(2+)](i) O
) O
in O
isolated O
myocytes O
. O

the O
current O
data O
showed O
that O
pilocarpine O
significantly O
delayed O
onset O
of O
arrhythmias B-NEG
, O
decreased O
the O
time O
course O
of O
ventricular B-NEG
tachycardia I-NEG
and I-NEG
fibrillation I-NEG
, O
reduced O
arrhythmia B-NEG
score O
, O
and O
increased O
the O
survival O
time O
of O
arrhythmic B-NEG
rats O
and O
guinea O
pigs O
. O

[ca(2+)](i O
) O
overload O
induced O
by O
aconitine O
or O
ouabain O
was O
reduced O
in O
isolated O
myocytes O
pretreated O
with O
pilocarpine O
. O

moreover O
, O
m(3)-muscarinic O
acetylcholine O
receptor O
( O
machr O
) O
antagonist O
4-damp O
( O
4-diphenylacetoxy-n-methylpiperidine-methiodide O
) O
partially O
abolished O
the O
beneficial O
effects O
of O
pilocarpine O
. O

these O
data O
suggest O
that O
pilocarpine O
produced O
antiarrhythmic O
actions O
on O
arrhythmic B-NEG
rat O
and O
guinea O
pig O
models O
induced O
by O
aconitine O
or O
ouabain O
via O
stimulating O
the O
cardiac O
m(3)-machr O
. O

the O
mechanism O
may O
be O
related O
to O
the O
improvement O
of O
ca(2+ O
) O
handling O
. O

-DOCSTART- O

disulfiram-induced O
transient O
optic B-NEG
and I-NEG
peripheral I-NEG
neuropathy I-NEG
: O
a O
case O
report O
. O

aim O
: O
to O
report O
a O
case O
of O
optic B-NEG
and I-NEG
peripheral I-NEG
neuropathy I-NEG
after O
chronic O
use O
of O
disulfiram O
for O
alcohol B-NEG
dependence I-NEG
management O
. O

materials O
and O
methods O
: O
a O
case O
report O
. O

results O
: O
a O
57-year-old O
male O
presented O
with O
gradual O
loss B-NEG
of I-NEG
vision I-NEG
in O
both O
eyes O
with O
intermittent O
headaches B-NEG
for O
2 O
months O
. O

he O
also O
complained O
of O
paraesthesia B-NEG
with O
numbness B-NEG
in O
both O
feet O
. O

his O
vision O
was O
6/15 O
and O
2/60 O
in O
the O
right O
and O
left O
eyes O
, O
respectively O
. O

fundoscopy O
revealed O
bilaterally O
swollen O
optic O
nerve O
heads O
. O

visual O
field O
testing O
confirmed O
bilateral O
central-caecal O
scotomata B-NEG
. O

he O
had O
been O
taking O
disulfiram O
for O
alcohol B-NEG
dependence I-NEG
for O
the O
preceding O
3 O
years O
. O

disulfiram O
discontinuation O
lead O
to O
an O
immediate O
symptomatic O
improvement O
. O

conclusion O
: O
physicians O
initiating O
long-term O
disulfiram O
therapy O
should O
be O
aware O
of O
these O
adverse O
effects O
. O

they O
should O
recommend O
annual O
ophthalmic O
reviews O
with O
visual O
field O
testing O
. O

patients O
should O
be O
reassured O
with O
respect O
to O
the O
reversibility O
of O
these O
adverse O
effects O
. O

-DOCSTART- O

sustained O
clinical O
improvement O
of O
a O
patient O
with O
decompensated O
hepatitis B-NEG
b I-NEG
virus-related O
cirrhosis B-NEG
after O
treatment O
with O
lamivudine O
monotherapy O
. O
hepatitis B-NEG
b I-NEG
virus I-NEG
( O
hbv I-NEG
) O
infection I-NEG
, O
which O
causes O
liver B-NEG
cirrhosis I-NEG
and O
hepatocellular B-NEG
carcinoma I-NEG
, O
remains O
a O
major O
health O
problem O
in O
asian O
countries O
. O

recent O
development O
of O
vaccine O
for O
prevention O
is O
reported O
to O
be O
successful O
in O
reducing O
the O
size O
of O
chronically O
infected O
carriers O
, O
although O
the O
standard O
medical O
therapies O
have O
not O
been O
established O
up O
to O
now O
. O

in O
this O
report O
, O
we O
encountered O
a O
patient O
with O
decompensated O
hbv-related O
cirrhosis B-NEG
who O
exhibited O
the O
dramatic O
improvements O
after O
antiviral O
therapy O
. O

the O
patient O
was O
a O
50-year-old O
woman O
. O

previous O
conventional O
medical O
treatments O
were O
not O
effective O
for O
this O
patient O
, O
thus O
this O
patient O
had O
been O
referred O
to O
our O
hospital O
. O

however O
, O
the O
administration O
of O
lamivudine O
, O
a O
reverse O
transcriptase O
inhibitor O
, O
for O
23 O
months O
dramatically O
improved O
her O
liver O
severity O
. O

during O
this O
period O
, O
no O
drug O
resistant O
mutant O
hbv O
emerged O
, O
and O
the O
serum O
hbv-dna O
level O
was O
continuously O
suppressed O
. O

these O
virological O
responses O
were O
also O
maintained O
even O
after O
the O
antiviral O
therapy O
was O
discontinued O
. O

moreover O
, O
both O
hepatitis O
b O
surface O
antigen O
and O
e O
antigen O
were O
observed O
to O
have O
disappeared O
in O
this O
patient O
. O

the O
administration O
of O
lamivudine O
to O
patients O
with O
hbv-related O
cirrhosis B-NEG
, O
like O
our O
present O
case O
, O
should O
be O
considered O
as O
an O
initial O
medical O
therapeutic O
option O
, O
especially O
in O
countries O
where O
liver O
transplantation O
is O
not O
reliably O
available O
. O

-DOCSTART- O

dual O
effects O
of O
melatonin O
on O
barbiturate-induced O
narcosis B-NEG
in O
rats O
. O

melatonin O
affects O
the O
circadian O
sleep/wake O
cycle O
, O
but O
it O
is O
not O
clear O
whether O
it O
may O
influence O
drug-induced O
narcosis B-NEG
. O

sodium O
thiopenthal O
was O
administered O
intraperitoneally O
into O
male O
rats O
pre-treated O
with O
melatonin O
(0.05 O
, O
0.5 O
, O
5 O
and O
50 O
mg/kg) O
. O

melatonin O
pre-treatment O
affected O
in O
a O
dual O
manner O
barbiturate O
narcosis B-NEG
, O
however O
, O
no O
dose-effect O
correlation O
was O
found O
. O

in O
particular O
, O
low O
doses O
reduced O
the O
latency O
to O
and O
prolonged O
the O
duration O
of O
barbiturate O
narcosis B-NEG
. O

in O
contrast O
, O
the O
highest O
dose O
of O
melatonin O
( O
50 O
mg/kg O
) O
caused O
a O
paradoxical O
increase O
in O
the O
latency O
and O
produced O
a O
sustained O
reduction O
of O
the O
duration O
of O
narcosis B-NEG
, O
and O
a O
reduction O
in O
mortality O
rate O
. O

melatonin O
0.5 O
and O
5 O
mg/kg O
influenced O
the O
duration O
but O
not O
the O
latency O
of O
ketamine- O
or O
diazepam-induced O
narcosis B-NEG
. O

thus O
, O
the O
dual O
action O
of O
melatonin O
on O
pharmacological O
narcosis B-NEG
seems O
to O
be O
specific O
for O
the O
barbiturate O
mechanism O
of O
action O
. O

-DOCSTART- O

effects O
of O
nik-247 O
on O
cholinesterase O
and O
scopolamine-induced O
amnesia B-NEG
. O

the O
effects O
of O
nik-247 O
on O
cholinesterase O
, O
scopolamine-induced O
amnesia B-NEG
and O
spontaneous O
movement O
were O
examined O
and O
compared O
with O
those O
of O
the O
well-known O
cholinesterase O
inhibitors O
tacrine O
and O
e-2020 O
. O

nik-247 O
, O
tacrine O
and O
e-2020 O
all O
strongly O
inhibited O
acetylcholinesterase O
( O
ache O
) O
in O
human O
red O
blood O
cells O
( O
ic50s O
= O
1.0 O
x O
10(-6) O
, O
2.9 O
x O
10(-7 O
) O
and O
3.7 O
x O
10(-8 O
) O
m, O
respectively) O
. O

in O
addition O
, O
nik-247 O
and O
tacrine O
, O
but O
not O
e-2020 O
, O
strongly O
inhibited O
butyrylcholinestrase O
( O
buche O
) O
in O
human O
serum O
. O

all O
three O
drugs O
produced O
mixed O
inhibition O
of O
ache O
activity O
. O

moreover O
, O
the O
inhibitory O
effect O
of O
nik-247 O
on O
ache O
was O
reversible O
. O

all O
compounds O
at O
0.1-1 O
mg/kg O
p.o O
. O
significantly O
improved O
the O
amnesia B-NEG
induced O
by O
scopolamine O
( O
0.5 O
mg/kg O
s.c. O
) O
in O
rats O
performing O
a O
passive O
avoidance O
task O
. O

the O
three O
compounds O
at O
1 O
and O
3 O
mg/kg O
p.o O
. O
did O
not O
significantly O
decrease O
spontaneous O
movement O
by O
rats O
. O

these O
findings O
suggest O
that O
nik-247 O
at O
a O
low O
dose O
( O
0.1-1 O
mg/kg O
p.o. O
) O
improves O
scopolamine-induced O
amnesia B-NEG
but O
does O
not O
affect O
spontaneous O
movement O
. O

the O
findings O
suggest O
that O
nik-247 O
may O
be O
a O
useful O
drug O
for O
the O
treatment O
of O
alzheimer's B-NEG
disease I-NEG
. O

-DOCSTART- O

nightmares O
and O
hallucinations B-NEG
after O
long-term O
intake O
of O
tramadol O
combined O
with O
antidepressants O
. O

tramadol O
is O
a O
weak O
opioid O
with O
effects O
on O
adrenergic O
and O
serotonergic O
neurotransmission O
that O
is O
used O
to O
treat O
cancer B-NEG
pain B-NEG
and O
chronic O
non O
malignant O
pain B-NEG
. O

this O
drug O
was O
initiated O
in O
association O
with O
paroxetine O
and O
dosulepine O
hydrochloride O
in O
a O
tetraparetic B-NEG
patient O
with O
chronic B-NEG
pain I-NEG
. O

fifty-six O
days O
after O
initiation O
of O
the O
treatment O
the O
patient O
presented O
hallucinations B-NEG
that O
only O
stopped O
after O
the O
withdrawal O
of O
psycho-active O
drugs O
and O
tramadol O
. O

the O
case O
report O
questions O
the O
long O
term O
use O
of O
pain B-NEG
killers O
combined O
with O
psycho-active O
drugs O
in O
chronic O
non O
malignant O
pain B-NEG
, O
especially O
if O
pain B-NEG
is O
under O
control O
. O

-DOCSTART- O

apparent O
cure O
of O
rheumatoid B-NEG
arthritis I-NEG
by O
bone O
marrow O
transplantation O
. O

we O
describe O
the O
induction O
of O
sustained O
remissions O
and O
possible O
cure O
of O
severe O
erosive O
rheumatoid B-NEG
arthritis I-NEG
( O
ra B-NEG
) O
by O
bone O
marrow O
transplantation O
( O
bmt O
) O
in O
2 O
patients O
. O

bmt O
was O
used O
to O
treat O
severe O
aplastic B-NEG
anemia I-NEG
which O
was O
caused O
by O
gold O
in O
one O
case O
and O
d-penicillamine O
in O
the O
other O
. O

in O
the O
8 O
and O
6 O
years O
since O
the O
transplants O
( O
representing O
8 O
and O
4 O
years O
since O
cessation O
of O
all O
immunosuppressive O
therapy O
, O
respectively) O
, O
the O
ra B-NEG
in O
each O
case O
has O
been O
completely O
quiescent O
. O

although O
short O
term O
remission O
of O
severe O
ra B-NEG
following O
bmt O
has O
been O
reported O
, O
these O
are O
the O
first O
cases O
for O
which O
prolonged O
followup O
has O
been O
available O
. O

this O
experience O
raises O
the O
question O
of O
the O
role O
of O
bmt O
itself O
as O
a O
therapeutic O
option O
for O
patients O
with O
uncontrolled O
destructive O
synovitis B-NEG
. O

-DOCSTART- O

urinary O
enzymes O
and O
protein O
patterns O
as O
indicators O
of O
injury B-NEG
to I-NEG
different I-NEG
regions I-NEG
of I-NEG
the I-NEG
kidney I-NEG
. O
acute B-NEG
experimental I-NEG
models I-NEG
of I-NEG
renal I-NEG
damage I-NEG
to O
the O
proximal O
tubular O
, O
glomerular O
, O
and O
papillary O
regions O
of O
the O
rat O
were O
produced O
by O
administration O
of O
hexachloro-1:3-butadiene O
(hcbd) O
, O
puromycin O
aminonucleoside O
(pan) O
, O
and O
2-bromoethylamine O
(bea) O
, O
respectively O
. O

several O
routine O
indicators O
of O
nephrotoxicity B-NEG
, O
the O
enzymes O
alkaline O
phosphatase O
and O
n-acetyl-beta-glucosaminidase O
, O
and O
the O
molecular O
weight O
of O
protein B-NEG
excretion I-NEG
were O
determined O
on O
urine O
samples O
. O

tubular O
damage O
produced O
by O
hcbd O
or O
bea O
was O
discriminated O
both O
quantitatively O
and O
qualitatively O
from O
glomerular B-NEG
damage I-NEG
produced O
by O
pan O
. O

the O
latter O
was O
characterized O
by O
a O
pronounced O
increase O
in O
protein B-NEG
excretion I-NEG
, O
especially O
proteins O
with O
molecular O
weight O
greater O
than O
40,000 O
da O
. O

in O
contrast O
, O
protein B-NEG
excretion I-NEG
in O
tubular O
damage O
was O
raised O
only O
slightly O
and O
characterized O
by O
excretion B-NEG
of I-NEG
proteins I-NEG
of O
a O
wide O
range O
of O
molecular O
weights O
. O

proximal O
tubular O
damage O
caused O
by O
hcbd O
and O
papillary O
damage O
caused O
by O
bea O
were O
distinguished O
both O
by O
conventional O
urinalysis O
( O
volume O
and O
specific O
gravity O
) O
and O
by O
measurement O
of O
the O
two O
urinary O
enzymes O
. O

alkaline O
phosphatase O
and O
glucose O
were O
markedly O
and O
transiently O
elevated O
in O
proximal O
tubular O
damage O
and O
n-acetyl-beta-glucosaminidase O
showed O
a O
sustained O
elevation O
in O
papillary O
damage O
. O

it O
is O
concluded O
that O
both O
selective O
urinary O
enzymes O
and O
the O
molecular O
weight O
pattern O
of O
urinary O
proteins O
can O
be O
used O
to O
provide O
diagnostic O
information O
about O
the O
possible O
site O
of O
renal B-NEG
damage I-NEG
. O

-DOCSTART- O

neuromuscular B-NEG
blockade I-NEG
with O
magnesium O
sulfate O
and O
nifedipine O
. O

a O
patient O
who O
received O
tocolysis O
with O
nifedipine O
developed O
neuromuscular B-NEG
blockade I-NEG
after O
500 O
mg O
of O
magnesium O
sulfate O
was O
administered O
. O

this O
reaction O
demonstrates O
that O
nifedipine O
can O
seriously O
potentiate O
the O
toxicity B-NEG
of O
magnesium O
. O

caution O
should O
be O
exercised O
when O
these O
two O
tocolytics O
are O
combined O
. O

-DOCSTART- O

ifosfamide O
continuous O
infusion O
without O
mesna O
. O

a O
phase O
i O
trial O
of O
a O
14-day O
cycle O
. O

twenty O
patients O
received O
27 O
courses O
of O
ifosfamide O
administered O
as O
a O
24-hour O
continuous O
infusion O
for O
14 O
days O
without O
mesna O
. O

the O
goal O
of O
the O
study O
was O
to O
deliver O
a O
dose O
rate O
and O
total O
cumulative O
dose O
of O
ifosfamide O
that O
would O
be O
comparable O
to O
standard O
bolus O
or O
short-term O
infusions O
administered O
with O
mesna O
. O

dose O
escalations O
proceeded O
from O
200 O
to O
300 O
, O
400 O
, O
450 O
, O
500 O
, O
and O
550 O
mg/m2/d O
. O

four O
patients O
developed O
transient O
microscopic O
hematuria B-NEG
at O
400 O
, O
450 O
, O
and O
500 O
mg/m2/d O
. O

there O
were O
no O
instances O
of O
macroscopic O
hematuria B-NEG
. O

at O
550 O
mg/m2/d O
, O
three O
patients O
experienced O
nonurologic O
toxicity B-NEG
; O
confusion B-NEG
(1) O
, O
nausea B-NEG
(1) O
, O
and O
grade O
2 O
leukopenia B-NEG
(1) O
. O

the O
recommended O
dose O
of O
500 O
mg/m2/d O
delivers O
a O
total O
dose O
of O
7 O
g/m2 O
per O
cycle O
, O
which O
is O
comparable O
to O
that O
delivered O
in O
clinical O
practice O
for O
bolus O
or O
short-term O
infusion O
. O

because O
few O
patients O
received O
multiple O
courses O
over O
time O
, O
the O
cumulative O
effects O
are O
indeterminate O
in O
the O
present O
trial O
. O

the O
frequency O
and O
predictability O
of O
hematuria B-NEG
are O
not O
precise O
, O
and O
at O
least O
daily O
monitoring O
by O
urine O
hematest O
is O
essential O
, O
adding O
mesna O
to O
the O
infusate O
in O
patients O
with O
persistent O
hematuria B-NEG
. O

the O
protracted O
infusion O
schedule O
for O
ifosfamide O
permits O
convenient O
outpatient O
administration O
without O
mesna O
and O
reduces O
the O
drug O
cost O
of O
clinical O
usage O
of O
this O
agent O
by O
up O
to O
890 O
per O
cycle O
. O

clinical O
activity O
was O
demonstrated O
in O
a O
single O
patient O
, O
but O
a O
comparative O
trial O
of O
standard O
bolus O
schedules O
with O
the O
protracted O
infusion O
schedule O
will O
be O
necessary O
to O
determine O
if O
the O
clinical O
effectiveness O
of O
the O
drug O
is O
maintained O
. O

-DOCSTART- O

myocardial B-NEG
infarction I-NEG
in O
pregnancy O
associated O
with O
clomiphene O
citrate O
for O
ovulation O
induction O
: O
a O
case O
report O
. O

background O
: O
clomiphene O
citrate O
( O
cc O
) O
is O
commonly O
prescribed O
for O
ovulation O
induction O
. O

it O
is O
considered O
safe O
, O
with O
minimal O
side O
effects O
. O
thromboembolism B-NEG
is O
a O
rare O
but O
life-threatening O
complication O
that O
has O
been O
reported O
after O
ovulation O
induction O
with O
cc O
. O

spontaneous O
coronary B-NEG
thrombosis I-NEG
or O
thromboembolism B-NEG
with O
subsequent O
clot O
lysis O
has O
been O
suggested O
as O
one O
of O
the O
most O
common O
causes O
of O
myocardial B-NEG
infarction I-NEG
( O
mi B-NEG
) O
during O
pregnancy O
, O
with O
a O
subsequently O
normal O
coronary O
angiogram O
. O

case O
: O
a O
33-year-old O
woman O
with O
a O
5-week O
gestation O
had O
recently O
received O
cc O
for O
ovulation O
induction O
and O
presented O
with O
chest B-NEG
pain I-NEG
. O

an O
electrocardiogram O
showed O
a O
lateral O
and O
anterior O
wall O
myocardial B-NEG
infarction I-NEG
. O

cardiac O
enzymes O
showed O
a O
peak O
rise O
in O
troponin O
i O
to O
9.10 O
ng/ml O
. O

an O
initial O
exercise O
stress O
test O
was O
normal O
. O

at O
the O
time O
of O
admission O
, O
the O
patient O
was O
at O
high O
risk O
of O
radiation B-NEG
injury I-NEG
to O
the O
fetus O
, O
so O
a O
coronary O
angiogram O
was O
postponed O
until O
the O
second O
trimester O
. O

it O
showed O
normal O
coronary O
vessels O
. O

conclusion O
: O
this O
appears O
to O
be O
the O
first O
reported O
case O
documenting O
a O
possible O
association O
between O
cc O
and O
myocardial B-NEG
infarction I-NEG
. O
thrombosis B-NEG
might O
be O
a O
rare O
but O
hazardous O
complication O
of O
cc O
. O

given O
this O
life-threatening O
complication O
, O
appropriate O
prophylactic O
measures O
should O
be O
used O
in O
high-risk O
woman O
undergoing O
ovarian O
stimulation O
. O

-DOCSTART- O

hepatonecrosis B-NEG
and O
cholangitis B-NEG
related O
to O
long-term O
phenobarbital O
therapy O
: O
an O
autopsy O
report O
of O
two O
patients O
. O

phenobarbital O
( O
pb O
) O
has O
a O
reputation O
for O
safety O
, O
and O
it O
is O
commonly O
believed O
that O
pb-related O
increases O
in O
serum O
aminotransferase O
levels O
do O
not O
indicate O
or O
predict O
the O
development O
of O
significant O
chronic O
liver B-NEG
disease I-NEG
. O

here O
we O
report O
of O
two O
adult O
patients O
with O
a O
long O
history O
of O
epilepsy B-NEG
treated O
with O
pb O
who O
died O
suddenly O
: O
one O
as O
consequence O
of O
cardiac B-NEG
arrest I-NEG
, O
the O
other O
of O
acute O
bronchopneumonia B-NEG
. O

at O
autopsy O
, O
analysis O
of O
liver O
parenchyma O
revealed O
rich O
portal O
inflammatory O
infiltrate O
, O
which O
consisted O
of O
mixed O
eosinophil O
and O
monocyte O
cells O
, O
associated O
with O
several O
foci O
of O
necrosis B-NEG
surrounded O
by O
a O
hard O
ring O
of O
non-specific O
granulomatous O
tissue O
. O

inflammatory O
reactions O
of O
internal O
and O
external O
hepatic O
biliary O
ducts O
were O
also O
seen O
. O

our O
findings O
illustrate O
that O
pb O
may O
be O
associated O
with O
chronic O
liver B-NEG
damage I-NEG
, O
which O
may O
lead O
to O
more O
serious O
and O
deleterious O
consequences O
. O

for O
this O
reason O
, O
each O
clinician O
should O
recognize O
this O
entity O
in O
the O
differential O
diagnosis O
of O
pb-related O
asymptomatic O
chronic B-NEG
hepatic I-NEG
enzyme I-NEG
dysfunction I-NEG
. O

-DOCSTART- O

ethambutol-associated O
optic B-NEG
neuropathy I-NEG
. O

introduction O
: O
ethambutol O
is O
used O
in O
the O
treatment O
of O
tuberculosis B-NEG
, O
which O
is O
still O
prevalent O
in O
southeast O
asia O
, O
and O
can O
be O
associated O
with O
permanent O
visual B-NEG
loss I-NEG
. O

we O
report O
3 O
cases O
which O
presented O
with O
bitemporal B-NEG
hemianopia I-NEG
. O

clinical O
picture O
: O
three O
patients O
with O
ethambutol-associated O
toxic O
optic B-NEG
neuropathy I-NEG
are O
described O
. O

all O
3 O
patients O
had O
loss B-NEG
of I-NEG
central I-NEG
visual I-NEG
acuity I-NEG
, O
colour I-NEG
vision I-NEG
( O
ishihara I-NEG
) O
and I-NEG
visual I-NEG
field I-NEG
. O

the O
visual B-NEG
field I-NEG
loss I-NEG
had O
a O
bitemporal O
flavour O
, O
suggesting O
involvement O
of O
the O
optic O
chiasm O
. O

treatment O
: O
despite O
stopping O
ethambutol O
on O
diagnosis O
, O
visual O
function O
continued O
to O
deteriorate O
for O
a O
few O
months O
. O

subsequent O
improvement O
was O
mild O
in O
2 O
cases O
. O

in O
the O
third O
case O
, O
visual O
acuity O
and O
colour O
vision O
normalised O
but O
the O
optic O
discs O
were O
pale O
. O

outcome O
: O
all O
3 O
patients O
had O
some O
permanent O
loss B-NEG
of I-NEG
visual I-NEG
function I-NEG
. O

conclusions O
: O
ethambutol O
usage O
is O
associated O
with O
permanent O
visual B-NEG
loss I-NEG
and O
should O
be O
avoided O
if O
possible O
or O
used O
with O
caution O
and O
proper O
ophthalmological O
follow-up O
. O

the O
author O
postulates O
that O
in O
cases O
of O
ethambutol O
associated O
chiasmopathy O
, O
ethambutol O
may O
initially O
affect O
the O
optic O
nerves O
and O
subsequently O
progress O
to O
involve O
the O
optic O
chiasm O
. O

-DOCSTART- O

tolerability O
of O
nimesulide O
and O
paracetamol O
in O
patients O
with O
nsaid-induced O
urticaria B-NEG
/ O
angioedema B-NEG
. O

previous O
studies O
evaluated O
the O
tolerance O
of O
nimesulide O
and O
paracetamol O
in O
subjects O
with O
cutaneous O
, O
respiratory O
and O
anaphylactoid O
reactions O
induced O
by O
nonsteroidal O
anti-inflammatory O
drugs O
(nsaids) O
. O

in O
this O
study O
we O
investigated O
tolerability O
and O
reliability O
of O
nimesulide O
and O
paracetamol O
in O
a O
very O
large O
number O
of O
patients O
with O
an O
exclusive O
well-documented O
history O
of O
nsaid-induced O
urticaria B-NEG
/ O
angioedema B-NEG
. O

furthermore O
, O
we O
evaluated O
whether O
some O
factors O
have O
the O
potential O
to O
increase O
the O
risk O
of O
reaction O
to O
paracetamol O
and O
nimesulide O
. O

a O
single-placebo-controlled O
oral O
challenge O
procedure O
with O
nimesulide O
or O
paracetamol O
was O
applied O
to O
829 O
patients O
with O
a O
history O
of O
nsaid-induced O
urticaria B-NEG
/ O
angioedema B-NEG
. O

a O
total O
of O
75/829 O
( O
9.4% O
) O
patients O
experienced O
reactions O
to O
nimesulide O
or O
paracetamol O
. O

of O
the O
715 O
patients O
tested O
with O
nimesulide O
62 O
( O
8.6% O
) O
showed O
a O
positive O
test O
, O
while O
of O
114 O
subjects O
submitted O
to O
the O
challenge O
with O
paracetamol O
, O
13 O
( O
9.6% O
) O
did O
not O
tolerate O
this O
drug O
. O

furthermore O
, O
18.28% O
of O
patients O
with O
a O
history O
of O
chronic O
urticaria B-NEG
and O
11.8% O
of O
subjects O
with O
an O
history O
of O
nsaid-induced O
urticaria B-NEG
/ O
angioedema B-NEG
or O
angioedema B-NEG
alone O
( O
with O
or O
without O
chronic O
urticaria B-NEG
) O
resulted O
to O
be O
intolerant O
to O
alternative O
drugs O
. O

taken O
together O
, O
our O
results O
confirm O
the O
good O
tolerability O
of O
nimesulide O
and O
paracetamol O
in O
patients O
who O
experienced O
urticaria B-NEG
/ O
angioedema B-NEG
caused O
by O
nsaids O
. O

however O
, O
the O
risk O
of O
reaction O
to O
these O
alternative O
study O
drugs O
is O
statistically O
increased O
by O
a O
history O
of O
chronic O
urticaria B-NEG
and O
, O
above O
all O
, O
by O
a O
history O
of O
nsaid-induced O
angioedema B-NEG
. O

-DOCSTART- O

effects O
of O
verapamil O
on O
atrial B-NEG
fibrillation I-NEG
and O
its O
electrophysiological O
determinants O
in O
dogs O
. O

background O
: O
atrial B-NEG
tachycardia I-NEG
-induced O
remodeling O
promotes O
the O
occurrence O
and O
maintenance O
of O
atrial B-NEG
fibrillation I-NEG
( O
af B-NEG
) O
and O
decreases O
l-type O
ca(2+ O
) O
current O
. O

there O
is O
also O
a O
clinical O
suggestion O
that O
acute O
l-type O
ca(2 O
) O
channel O
blockade O
can O
promote O
af B-NEG
, O
consistent O
with O
an O
af B-NEG
promoting O
effect O
of O
ca(2+ O
) O
channel O
inhibition O
. O

methods O
: O
to O
evaluate O
the O
potential O
mechanisms O
of O
af B-NEG
promotion O
by O
ca(2+ O
) O
channel O
blockers O
, O
we O
administered O
verapamil O
to O
morphine-chloralose O
anesthetized O
dogs O
. O

diltiazem O
was O
used O
as O
a O
comparison O
drug O
and O
autonomic O
blockade O
with O
atropine O
and O
nadolol O
was O
applied O
in O
some O
experiments O
. O

epicardial O
mapping O
with O
240 O
epicardial O
electrodes O
was O
used O
to O
evaluate O
activation O
during O
af B-NEG
. O

results O
: O
verapamil O
caused O
af B-NEG
promotion O
in O
six O
dogs O
, O
increasing O
mean O
duration O
of O
af B-NEG
induced O
by O
burst O
pacing O
, O
from O
8+/-4 O
s O
( O
mean+/-s.e. O
) O
to O
95+/-39 O
s O
( O
p<0.01 O
vs O
. O
control O
) O
at O
a O
loading O
dose O
of O
0.1 O
mg/kg O
and O
228+/-101 O
s O
( O
p<0.0005 O
vs O
. O
control O
) O
at O
a O
dose O
of O
0.2 O
mg/kg O
. O

underlying O
electrophysiological O
mechanisms O
were O
studied O
in O
detail O
in O
five O
additional O
dogs O
under O
control O
conditions O
and O
in O
the O
presence O
of O
the O
higher O
dose O
of O
verapamil O
. O

in O
these O
experiments O
, O
verapamil O
shortened O
mean O
effective O
refractory O
period O
( O
erp O
) O
from O
122+/-5 O
to O
114+/-4 O
ms O
( O
p<0.02 O
) O
at O
a O
cycle O
length O
of O
300 O
ms O
, O
decreased O
erp O
heterogeneity O
( O
from O
15+/-1 O
to O
10+/-1% O
, O
p<0.05) O
, O
heterogeneously O
accelerated O
atrial O
conduction O
and O
decreased O
the O
cycle O
length O
of O
af B-NEG
( O
94+/-4 O
to O
84+/-3 O
ms O
, O
p<0.005) O
. O

diltiazem O
did O
not O
affect O
erp O
, O
af B-NEG
cycle O
length O
or O
af B-NEG
duration O
, O
but O
produced O
conduction O
acceleration O
similar O
to O
that O
caused O
by O
verapamil O
(n=5) O
. O

in O
the O
presence O
of O
autonomic O
blockade O
, O
verapamil O
failed O
to O
promote O
af B-NEG
and O
increased O
, O
rather O
than O
decreasing O
, O
refractoriness O
. O

neither O
verapamil O
nor O
diltiazem O
affected O
atrial O
conduction O
in O
the O
presence O
of O
autonomic O
blockade O
. O

epicardial O
mapping O
suggested O
that O
verapamil O
promoted O
af B-NEG
by O
increasing O
the O
number O
of O
simultaneous O
wavefronts O
reflected O
by O
separate O
zones O
of O
reactivation O
in O
each O
cycle O
. O

conclusions O
: O
verapamil O
promotes O
af B-NEG
in O
normal O
dogs O
by O
promoting O
multiple O
circuit O
reentry O
, O
an O
effect O
dependent O
on O
intact O
autonomic O
tone O
and O
not O
shared O
by O
diltiazem O
. O

-DOCSTART- O

hypotension B-NEG
, O
bradycardia B-NEG
, O
and O
asystole B-NEG
after O
high-dose O
intravenous O
methylprednisolone O
in O
a O
monitored O
patient O
. O

we O
report O
a O
case O
of O
hypotension B-NEG
, O
bradycardia B-NEG
, O
and O
asystole B-NEG
after O
intravenous O
administration O
of O
high-dose O
methylprednisolone O
in O
a O
73-year-old O
patient O
who O
underwent O
electrocardiographic O
( O
ecg O
) O
monitoring O
throughout O
the O
episode O
. O

there O
was O
a O
history O
of O
ischemic B-NEG
cardiac B-NEG
disease I-NEG
9 O
years O
earlier O
. O

the O
patient O
was O
admitted O
with O
a O
pulmonary-renal B-NEG
syndrome I-NEG
with O
hemoptysis B-NEG
, O
rapidly O
progressive O
renal B-NEG
failure I-NEG
, O
and O
hypoxemia B-NEG
that O
required O
mechanical O
ventilation O
in O
the O
intensive O
care O
unit O
. O

after O
receiving O
advanced O
cardiopulmonary O
resuscitation O
, O
the O
patient O
recovered O
cardiac O
rhythm O
. O

the O
ecg O
showed O
a O
junctional O
rhythm O
without O
ventricular B-NEG
arrhythmia I-NEG
. O

this O
study O
reviews O
the O
current O
proposed O
mechanisms O
of O
sudden B-NEG
death I-NEG
after O
a O
high O
dose O
of O
intravenous O
methylprednisolone O
(ivmp) O
. O

these O
mechanisms O
are O
not O
well O
understood O
because O
, O
in O
most O
cases O
, O
the O
patients O
were O
not O
monitored O
at O
the O
moment O
of O
the O
event O
. O

rapid O
infusion O
and O
underlying O
cardiac B-NEG
disease I-NEG
were O
important O
risk O
factors O
in O
the O
case O
reported O
here O
, O
and O
the O
authors O
discount O
ventricular B-NEG
arrhythmia I-NEG
as O
the O
main O
mechanism O
. O

-DOCSTART- O

lifetime O
treatment O
of O
mice O
with O
azidothymidine O
( O
azt O
) O
produces O
myelodysplasia B-NEG
. O

azt O
has O
induced O
a O
macrocytic B-NEG
anemia I-NEG
in O
aids B-NEG
patients O
on O
long O
term O
azt O
therapy O
. O

it O
is O
generally O
assumed O
that O
dna O
elongation O
is O
stopped O
by O
the O
insertion O
of O
azt O
into O
the O
chain O
in O
place O
of O
thymidine O
thus O
preventing O
the O
phosphate O
hydroxyl O
linkages O
and O
therefore O
suppresses O
hemopoietic O
progenitor O
cell O
proliferation O
in O
an O
early O
stage O
of O
differentiation O
. O

cba/ca O
male O
mice O
started O
on O
azt O
0.75 O
mg/ml O
h2o O
at O
84 O
days O
of O
age O
and O
kept O
on O
it O
for O
687 O
days O
when O
dosage O
reduced O
to O
0.5 O
mg/ml O
h2o O
for O
a O
group O
, O
another O
group O
removed O
from O
azt O
to O
see O
recovery O
, O
and O
third O
group O
remained O
on O
0.75 O
mg O
. O

at O
687 O
days O
mice O
that O
had O
been O
on O
0.75 O
mg O
had O
average O
platelet O
counts O
of O
2.5 O
x O
10(6) O
. O

histological O
examination O
on O
9 O
of O
10 O
mice O
with O
such O
thrombocytopenia B-NEG
showed O
changes O
compatible O
with O
myelodysplastic B-NEG
syndrome I-NEG
( O
mds B-NEG
). O

a O
variety O
of O
histological O
patterns O
was O
observed O
. O

there O
were O
two O
cases O
of O
hypocellular O
myelodysplasia B-NEG
, O
two O
cases O
of O
hypersegmented O
myelodysplastic B-NEG
granulocytosis O
, O
two O
cases O
of O
hypercellular O
marrow O
with O
abnormal O
megakaryocytes O
with O
bizarre O
nuclei O
, O
one O
case O
of O
megakaryocytic O
myelosis O
associated O
with O
a O
hyperplastic B-NEG
marrow I-NEG
, O
dysmyelopoiesis B-NEG
and O
a O
hypocellular B-NEG
marrow I-NEG
and O
two O
cases O
of O
myelodysplasia B-NEG
with O
dyserythropoiesis B-NEG
, O
hemosiderosis B-NEG
and O
a O
hypocellular B-NEG
marrow I-NEG
. O

above O
mentioned O
azt O
incorporation O
may O
have O
induced O
an O
ineffective O
hemopoiesis O
in O
the O
primitive O
hemopoietic O
progenitor O
cells O
, O
which O
is O
known O
to O
be O
seen O
commonly O
in O
the O
myelodysplastic B-NEG
syndrome I-NEG
. O

-DOCSTART- O

influence O
of O
diet O
free O
of O
nad-precursors O
on O
acetaminophen O
hepatotoxicity B-NEG
in O
mice O
. O

recently O
, O
we O
demonstrated O
the O
hepatoprotective O
effects O
of O
nicotinic O
acid O
amide O
, O
a O
selective O
inhibitor O
of O
poly(adp-ribose O
) O
polymerase O
(parp O
; O
ec O
2.4.2.30 O
) O
on O
mice O
suffering O
from O
acetaminophen O
( O
aap)- O
hepatitis B-NEG
, O
suggesting O
that O
the O
aap-induced O
liver B-NEG
injury I-NEG
involves O
a O
step O
which O
depends O
on O
adenoribosylation O
. O

the O
present O
study O
investigates O
the O
effects O
of O
a O
diet O
free O
of O
precursors O
of O
nad O
, O
the O
substrate O
on O
which O
parp O
acts O
, O
in O
female O
nmri O
mice O
with O
aap O
hepatitis B-NEG
and O
evaluates O
the O
influence O
of O
simultaneous O
ethanol O
consumption O
in O
these O
animals O
. O
liver B-NEG
injuries I-NEG
were O
quantified O
as O
serum O
activities O
of O
glutamate-oxaloacetate O
transaminase O
( O
got O
) O
and O
glutamate-pyruvate O
transaminase O
(gpt) O
. O

while O
aap O
caused O
a O
117-fold O
elevation O
of O
serum O
transaminase O
activities O
in O
mice O
kept O
on O
a O
standard O
laboratory O
diet O
, O
which O
was O
significantly O
exacerbated O
by O
ethanol O
and O
inhibited O
by O
nicotinic O
acid O
amide O
(naa) O
, O
adverse O
effects O
were O
noted O
in O
animals O
fed O
a O
diet O
free O
of O
precursors O
of O
nad O
. O

in O
these O
animals O
, O
only O
minor O
increases O
of O
serum O
transaminase O
activities O
were O
measured O
in O
the O
presence O
of O
aap O
, O
and O
unlike O
the O
exacerbation O
caused O
by O
ethanol O
in O
mice O
on O
a O
standard O
diet O
, O
the O
liver B-NEG
damage I-NEG
was O
inhibited O
by O
50% O
by O
ethanol O
. O

a O
further O
64% O
reduction O
of O
hepatitis B-NEG
was O
observed O
, O
when O
naa O
was O
given O
to O
ethanol/aap-mice O
. O

our O
results O
provide O
evidence O
that O
the O
aap-induced O
hepatitis B-NEG
and O
its O
exacerbation O
by O
ethanol O
can O
either O
be O
reduced O
by O
end-product O
inhibition O
of O
parp O
by O
naa O
or O
by O
dietary O
depletion O
of O
the O
enzyme's O
substrate O
nad O
. O

we O
see O
the O
main O
application O
of O
naa O
as O
for O
the O
combinational O
use O
in O
pharmaceutical O
preparations O
of O
acetaminophen O
in O
order O
to O
avoid O
hepatic B-NEG
damage I-NEG
in O
patients O
treated O
with O
this O
widely O
used O
analgesic O
. O

-DOCSTART- O

antiarrhythmic O
plasma O
concentrations O
of O
cibenzoline O
on O
canine O
ventricular B-NEG
arrhythmias I-NEG
. O

using O
two-stage O
coronary O
ligation- O
, O
digitalis- O
, O
and O
adrenaline-induced O
canine O
ventricular B-NEG
arrhythmias I-NEG
, O
antiarrhythmic O
effects O
of O
cibenzoline O
were O
examined O
and O
the O
minimum O
effective O
plasma O
concentration O
for O
each O
arrhythmia B-NEG
model O
was O
determined O
. O

cibenzoline O
suppressed O
all O
the O
arrhythmias B-NEG
, O
and O
the O
minimum O
effective O
plasma O
concentrations O
for O
arrhythmias B-NEG
induced O
by O
24-h O
coronary O
ligation O
, O
48-h O
coronary O
ligation O
, O
digitalis O
, O
and O
adrenaline O
were O
1.9 O
+/- O
0.9 O
( O
by O
8 O
mg/kg O
i.v.) O
, O
1.6 O
+/- O
0.5 O
( O
by O
8 O
mg/kg O
i.v.) O
, O
0.6 O
+/- O
0.2 O
( O
by O
2 O
mg/kg O
i.v.) O
, O
and O
3.5 O
+/- O
1.3 O
( O
by O
5 O
mg/kg O
i.v. O
) O
micrograms/ml O
, O
respectively O
( O
mean O
+/- O
sdm O
, O
n O
= O
6-7) O
. O

the O
concentration O
for O
adrenaline-induced O
arrhythmia B-NEG
was O
significantly O
higher O
than O
those O
for O
the O
other O
types O
of O
arrhythmias B-NEG
. O

this O
pharmacological O
profile O
is O
similar O
to O
those O
of O
mexiletine O
and O
tocainide O
, O
and O
all O
three O
drugs O
have O
central O
nervous O
system O
( O
cns O
) O
stimulant O
action O
. O

because O
cibenzoline O
had O
only O
weak O
hypotensive B-NEG
and O
sinus O
node O
depressive B-NEG
effects O
and O
was O
found O
to O
be O
orally O
active O
when O
given O
to O
coronary O
ligation O
arrhythmia B-NEG
dogs O
, O
its O
clinical O
usefulness O
is O
expected O
. O

-DOCSTART- O

immunopathology O
of O
penicillamine-induced O
glomerular B-NEG
disease I-NEG
. O

four O
patients O
with O
rheumatoid B-NEG
arthritis I-NEG
developed O
heavy O
proteinuria B-NEG
after O
five O
to O
12 O
months O
of O
treatment O
with O
d-penicillamine O
. O

light O
microscopy O
of O
renal O
biopsy O
samples O
showed O
minimal O
glomerular O
capillary O
wall O
thickening O
and O
mesangial O
matrix O
increase O
, O
or O
no O
departure O
from O
normal O
. O

electron O
microscopy O
, O
however O
, O
revealed O
subepithelial O
electron-dense O
deposits O
, O
fusion O
of O
epithelial O
cell O
foot O
processes O
, O
and O
evidence O
of O
mesangial O
cell O
hyperactivity O
. O

immunofluorescence O
microscopy O
demonstrated O
granular O
capillary O
wall O
deposits O
of O
igg O
and O
c3 O
. O

the O
findings O
were O
similar O
to O
those O
in O
early O
membranous B-NEG
glomerulonephritis I-NEG
, O
differences O
being O
observed O
however O
in O
the O
results O
of O
staining O
for O
the O
early-acting O
complement O
components O
c1q O
and O
c4 O
. O

it O
is O
tentatively O
concluded O
that O
complement O
was O
activated O
by O
the O
classical O
pathway O
. O

-DOCSTART- O

ventricular B-NEG
fibrillation I-NEG
from O
diatrizoate O
with O
and O
without O
chelating O
agents O
. O

the O
toxicity B-NEG
of O
renografin O
76% O
was O
compared O
with O
that O
of O
hypaque O
76% O
by O
selective O
injection O
of O
each O
into O
the O
right O
coronary O
artery O
of O
dogs O
. O

renografin O
contains O
the O
chelating O
agents O
sodium O
citrate O
and O
disodium O
edetate O
, O
while O
hypaque O
contains O
calcium O
disodium O
edetate O
and O
no O
sodium O
citrate O
. O
ventricular B-NEG
fibrillation I-NEG
occurred O
significantly O
more O
often O
with O
renografin O
, O
suggesting O
that O
chelating O
agents O
contribute O
to O
toxicity B-NEG
in O
coronary O
angiography O
. O

-DOCSTART- O

rapid O
reversal O
of O
anticoagulation O
reduces O
hemorrhage B-NEG
volume O
in O
a O
mouse O
model O
of O
warfarin-associated O
intracerebral B-NEG
hemorrhage I-NEG
. O

warfarin-associated O
intracerebral B-NEG
hemorrhage I-NEG
( O
w- O
ich B-NEG
) O
is O
a O
severe O
type O
of O
stroke B-NEG
. O

there O
is O
no O
consensus O
on O
the O
optimal O
treatment O
for O
w- O
ich B-NEG
. O

using O
a O
mouse O
model O
, O
we O
tested O
whether O
the O
rapid O
reversal O
of O
anticoagulation O
using O
human O
prothrombin O
complex O
concentrate O
( O
pcc O
) O
can O
reduce O
hemorrhagic O
blood O
volume O
. O

male O
cd-1 O
mice O
were O
treated O
with O
warfarin O
(2 O
mg/kg O
over O
24 O
h) O
, O
resulting O
in O
a O
mean O
( O
+/-s.d. O
) O
international O
normalized O
ratio O
of O
3.5+/-0.9 O
. O

first O
, O
we O
showed O
that O
an O
intravenous O
administration O
of O
human O
pcc O
rapidly O
reversed O
anticoagulation O
in O
mice O
. O

second O
, O
a O
stereotactic O
injection O
of O
collagenase O
was O
administered O
to O
induce O
hemorrhage B-NEG
in O
the O
right O
striatum O
. O

forty-five O
minutes O
later O
, O
the O
animals O
were O
randomly O
treated O
with O
pcc O
( O
100 O
u/kg O
) O
or O
saline O
i.v O
. O

( O
n=12 O
per O
group) O
. O

twenty-four O
hours O
after O
hemorrhage B-NEG
induction O
, O
hemorrhagic O
blood O
volume O
was O
quantified O
using O
a O
photometric O
hemoglobin O
assay O
. O

the O
mean O
hemorrhagic O
blood O
volume O
was O
reduced O
in O
pcc-treated O
animals O
( O
6.5+/-3.1 O
microl O
) O
compared O
with O
saline O
controls O
( O
15.3+/-11.2 O
microl O
, O
p=0.015) O
. O

in O
the O
saline O
group O
, O
45% O
of O
the O
mice O
developed O
large O
hematomas B-NEG
(i.e. O
, O
>15 O
microl) O
. O

in O
contrast O
, O
such O
extensive O
lesions O
were O
never O
found O
in O
the O
pcc O
group O
. O

we O
provide O
experimental O
data O
suggesting O
pcc O
to O
be O
an O
effective O
acute O
treatment O
for O
w- O
ich B-NEG
in O
terms O
of O
reducing O
hemorrhagic O
blood O
volume O
. O

future O
studies O
are O
needed O
to O
assess O
the O
therapeutic O
potential O
emerging O
from O
our O
finding O
for O
human O
w- O
ich B-NEG
. O

-DOCSTART- O

impact O
of O
alcohol O
exposure O
after O
pregnancy O
recognition O
on O
ultrasonographic O
fetal O
growth O
measures O
. O

background O
: O
more O
than O
3 O
decades O
after O
jones O
and O
smith O
( O
1973 O
) O
reported O
on O
the O
devastation O
caused O
by O
alcohol O
exposure O
on O
fetal O
development O
, O
the O
rates O
of O
heavy O
drinking O
during O
pregnancy O
remain O
relatively O
unchanged O
. O

early O
identification O
of O
fetal O
alcohol O
exposure O
and O
maternal O
abstinence O
led O
to O
better O
infant O
outcomes O
. O

this O
study O
examined O
the O
utility O
of O
biometry O
for O
detecting O
alcohol-related O
fetal O
growth B-NEG
impairment I-NEG
. O

methods O
: O
we O
obtained O
fetal O
ultrasound O
measures O
from O
routine O
ultrasound O
examinations O
for O
167 O
pregnant O
hazardous O
drinkers O
who O
were O
enrolled O
in O
a O
brief O
alcohol O
intervention O
study O
. O

the O
fetal O
measures O
for O
women O
who O
quit O
after O
learning O
of O
their O
pregnancies O
were O
compared O
with O
measures O
for O
women O
who O
continued O
some O
drinking O
throughout O
the O
course O
of O
their O
pregnancies O
. O

because O
intensity O
of O
alcohol O
consumption O
is O
associated O
with O
poorer O
fetal O
outcomes O
, O
separate O
analyses O
were O
conducted O
for O
the O
heavy O
( O
average O
of O
>or=5 O
drinks O
per O
drinking O
day O
) O
alcohol O
consumers O
. O

fetal O
measures O
from O
the O
heavy-exposed O
fetuses O
were O
also O
compared O
with O
measures O
from O
a O
nondrinking O
group O
that O
was O
representative O
of O
normal O
, O
uncomplicated O
pregnancies O
from O
our O
clinics O
. O

analyses O
of O
covariance O
were O
used O
to O
determine O
whether O
there O
were O
differences O
between O
groups O
after O
controlling O
for O
influences O
of O
gestational O
age O
and O
drug B-NEG
abuse I-NEG
. O

results O
: O
nearly O
half O
of O
the O
pregnant O
drinkers O
abstained O
after O
learning O
of O
their O
pregnancies O
. O

when O
women O
reportedly O
quit O
drinking O
early O
in O
their O
pregnancies O
, O
fetal O
growth O
measures O
were O
not O
significantly O
different O
from O
a O
non-alcohol-exposed O
group O
, O
regardless O
of O
prior O
drinking O
patterns O
. O

any O
alcohol O
consumption O
postpregnancy O
recognition O
among O
the O
heavy O
drinkers O
resulted O
in O
reduced B-NEG
cerebellar I-NEG
growth I-NEG
as O
well O
as O
decreased B-NEG
cranial I-NEG
to I-NEG
body I-NEG
growth I-NEG
in O
comparison O
with O
women O
who O
either O
quit O
drinking O
or O
who O
were O
nondrinkers O
. O

amphetamine O
abuse O
was O
predictive O
of O
larger O
cranial O
to O
body O
growth O
ratios O
. O

conclusions O
: O
alterations O
in O
fetal O
biometric O
measurements O
were O
observed O
among O
the O
heavy O
drinkers O
only O
when O
they O
continued O
drinking O
after O
becoming O
aware O
of O
their O
pregnancies O
. O

although O
the O
reliance O
on O
self-reported O
drinking O
is O
a O
limitation O
in O
this O
study O
, O
these O
findings O
support O
the O
benefits O
of O
early O
abstinence O
and O
the O
potential O
for O
ultrasound O
examinations O
in O
the O
detection O
of O
fetal O
alcohol O
effects O
. O

-DOCSTART- O

urinary O
symptoms O
and O
quality O
of O
life O
changes O
in O
thai O
women O
with O
overactive B-NEG
bladder I-NEG
after O
tolterodine O
treatment O
. O

objectives O
: O
to O
study O
the O
urinary O
symptoms O
and O
quality O
of O
life O
changes O
in O
thai O
women O
with O
overactive B-NEG
bladder I-NEG
( O
oab B-NEG
) O
after O
tolterodine O
treatment O
. O

material O
and O
method O
: O
thirty O
women O
( O
aged O
30-77 O
years O
) O
diagnosed O
as O
having O
oab B-NEG
at O
the O
gynecology O
clinic O
, O
king O
chulalongkorn O
memorial O
hospital O
from O
january O
to O
april O
2004 O
were O
included O
in O
the O
present O
study O
. O

tolterodine O
2 O
mg O
, O
twice O
daily O
was O
given O
. O

after O
8 O
weeks O
treatment O
, O
changes O
in O
micturition O
diary O
variables O
and O
tolerability O
were O
determined O
. O

short O
form O
36 O
( O
sf36 O
) O
questionaires O
( O
thai O
version O
) O
were O
given O
before O
and O
after O
8 O
weeks O
of O
treatment O
. O

results O
: O
at O
8 O
weeks O
, O
all O
micturition O
per O
day O
decreased O
from O
16 O
. O

7 O
+/- O
5. O

3 O
to O
6. O

7 O
+/- O
2.4 O
times O
per O
day O
. O

the O
number O
of O
nocturia B-NEG
episodes O
decreased O
from O
5.4 O
+/- O
4.2 O
to O
1.1 O
+/- O
1.0 O
times O
per O
night O
. O

the O
most O
common O
side O
effect O
was O
dry B-NEG
month I-NEG
in O
5 O
cases O
( O
16.7% O
) O
with O
2 O
cases O
reporting O
a O
moderate O
degree O
and O
1 O
case O
with O
severe O
degree O
. O

only O
one O
case O
( O
3.3% O
) O
withdrew O
from O
the O
present O
study O
due O
to O
a O
severe O
dry B-NEG
mouth I-NEG
. O

the O
sf-36 O
scores O
changed O
significantly O
in O
the O
domains O
of O
physical O
functioning O
, O
role O
function O
emotional O
, O
social O
function O
and O
mental O
heath O
. O

conclusion O
: O
tolterodine O
was O
well O
tolerated O
and O
its O
effects O
improved O
the O
quality O
of O
life O
in O
thai O
women O
with O
oab B-NEG
. O

-DOCSTART- O

absence O
of O
acute O
cerebral O
vasoconstriction O
after O
cocaine-associated O
subarachnoid B-NEG
hemorrhage I-NEG
. O

introduction O
: O
cocaine O
use O
has O
been O
associated O
with O
neurovascular B-NEG
complications I-NEG
, O
including O
arterial O
vasoconstriction O
and O
vasculitis B-NEG
. O

however O
, O
there O
are O
few O
studies O
of O
angiographic O
effects O
of O
cocaine O
on O
human O
cerebral O
arteries O
. O

information O
on O
these O
effects O
could O
be O
obtained O
from O
angiograms O
of O
patients O
with O
cocaine-associated O
subarachnoid B-NEG
hemorrhage I-NEG
( O
sah B-NEG
) O
who O
underwent O
angiography O
shortly O
after O
cocaine O
use O
. O

methods O
: O
we O
screened O
patients O
with O
sah B-NEG
retrospectively O
and O
identified O
those O
with O
positive O
urine O
toxicology O
for O
cocaine O
or O
its O
metabolites O
. O

quantitative O
arterial O
diameter O
measurements O
from O
angiograms O
of O
these O
patients O
were O
compared O
to O
measurements O
from O
control O
patients O
with O
sah B-NEG
who O
were O
matched O
for O
factors O
known O
to O
influence O
arterial O
diameter O
. O

qualitative O
comparisons O
of O
small O
artery O
changes O
also O
were O
made O
. O

results O
: O
thirteen O
patients O
with O
positive O
cocaine O
toxicology O
were O
compared O
to O
26 O
controls O
. O

there O
were O
no O
significant O
differences O
between O
groups O
in O
the O
mean O
diameters O
of O
the O
intradural O
internal O
carotid O
, O
sphenoidal O
segment O
of O
the O
middle O
cerebral O
, O
precommunicating O
segment O
of O
the O
anterior O
cerebral O
, O
or O
basilar O
arteries O
(p O
greater O
than O
0.05 O
for O
all O
comparisons O
, O
unpaired O
t-tests) O
. O

there O
also O
were O
no O
significant O
differences O
between O
groups O
when O
expressing O
diameters O
as O
the O
sum O
of O
the O
precommunicating O
segment O
of O
the O
anterior O
cerebral O
+ O
sphenoidal O
segment O
of O
the O
middle O
cerebral O
+ O
supraclinoid O
internal O
carotid O
artery O
+ O
basilar O
artery O
divided O
by O
the O
diameter O
of O
the O
petrous O
internal O
carotid O
artery O
(p O
greater O
than O
0.05 O
, O
unpaired O
t-tests) O
. O

qualitative O
assessments O
showed O
two O
arterial O
irregularities O
in O
the O
distal O
vasculature O
in O
each O
group O
. O

conclusion O
: O
no O
quantitative O
evidence O
for O
narrowing O
of O
large O
cerebral O
arteries O
or O
qualitative O
angiographic O
evidence O
for O
distal O
narrowing O
or O
vasculitis B-NEG
could O
be O
found O
in O
patients O
who O
underwent O
angiography O
after O
aneurysmal B-NEG
sah B-NEG
associated O
with O
cocaine O
use O
. O

-DOCSTART- O

atrial B-NEG
fibrillation I-NEG
following O
chemotherapy O
for O
stage O
iiie O
diffuse O
large O
b-cell O
gastric B-NEG
lymphoma I-NEG
in O
a O
patient O
with O
myotonic B-NEG
dystrophy I-NEG
( O
steinert's B-NEG
disease I-NEG
). O

the O
authors O
describe O
the O
unusual O
association O
between O
diffuse O
b-cell O
gastric B-NEG
lymphoma I-NEG
and O
myotonic B-NEG
dystrophy I-NEG
, O
the O
most O
common O
form O
of O
adult O
muscular B-NEG
dystrophy I-NEG
, O
and O
sudden O
atrial B-NEG
fibrillation I-NEG
following O
one O
cycle O
of O
doxorubicin-based O
chemotherapy O
in O
the O
same O
patient O
. O
atrial B-NEG
fibrillation I-NEG
or O
other O
cardiac B-NEG
arrhythmias I-NEG
are O
unusual O
complications O
in O
patients O
treated O
with O
chemotherapy O
. O

the O
cardiac B-NEG
toxicity I-NEG
intrinsically O
associated O
with O
the O
aggressive O
chemotherapy O
employed O
could O
function O
as O
a O
triggering O
factor O
for O
the O
arrhythmia B-NEG
in O
the O
predisposed O
myocardium O
of O
this O
patient O
. O

-DOCSTART- O

a O
phase O
ii O
study O
of O
thalidomide O
in O
advanced O
metastatic O
renal B-NEG
cell I-NEG
carcinoma I-NEG
. O

objectives O
: O
to O
evaluate O
the O
toxicity B-NEG
and O
activity O
of O
thalidomide O
in O
patients O
with O
advanced O
metastatic O
renal B-NEG
cell I-NEG
cancer I-NEG
and O
to O
measure O
changes O
of O
one O
angiogenic O
factor O
, O
vascular O
endothelial O
growth O
factor O
(vegf)165 O
, O
with O
therapy O
. O

patients O
and O
methods O
: O
29 O
patients O
were O
enrolled O
on O
a O
study O
of O
thalidomide O
using O
an O
intra-patient O
dose O
escalation O
schedule O
. O

patients O
began O
thalidomide O
at O
400 O
mg/d O
and O
escalated O
as O
tolerated O
to O
1200 O
mg/d O
by O
day O
54 O
. O

fifty-nine O
per O
cent O
of O
patients O
had O
had O
previous O
therapy O
with O
il-2 O
and O
52% O
were O
performance O
status O
2 O
or O
3. O

systemic O
plasma O
vegf165 O
levels O
were O
measured O
by O
dual O
monoclonal O
elisa O
in O
8 O
patients O
. O

results O
: O
24 O
patients O
were O
evaluable O
for O
response O
with O
one O
partial O
response O
of O
11 O
months O
duration O
of O
a O
patient O
with O
hepatic O
and O
pulmonary O
metastases B-NEG
(4%) O
, O
one O
minor O
response O
, O
and O
2 O
patients O
stable O
for O
over O
6 O
months O
. O
somnolence B-NEG
and O
constipation B-NEG
were O
prominent O
toxicities B-NEG
and O
most O
patients O
could O
not O
tolerate O
the O
1200 O
mg/day O
dose O
level O
. O

systemic O
plasma O
vegf165 O
levels O
did O
not O
change O
with O
therapy O
. O

conclusion O
: O
these O
results O
are O
consistent O
with O
a O
low O
level O
of O
activity O
of O
thalidomide O
in O
renal B-NEG
cell I-NEG
carcinoma I-NEG
. O

administration O
of O
doses O
over O
800 O
mg/day O
was O
difficult O
to O
achieve O
in O
this O
patient O
population O
, O
however O
lower O
doses O
were O
practical O
. O

the O
dose-response O
relationship O
, O
if O
any O
, O
of O
thalidomide O
for O
renal B-NEG
cell I-NEG
carcinoma I-NEG
is O
unclear O
. O

-DOCSTART- O

the O
striatum O
as O
a O
target O
for O
anti-rigor O
effects O
of O
an O
antagonist O
of O
mglur1 O
, O
but O
not O
an O
agonist O
of O
group O
ii O
metabotropic O
glutamate O
receptors O
. O

the O
aim O
of O
the O
present O
study O
was O
to O
find O
out O
whether O
the O
metabotropic O
receptor O
1 O
( O
mglur1 O
) O
and O
group O
ii O
mglurs O
, O
localized O
in O
the O
striatum O
, O
are O
involved O
in O
antiparkinsonian-like O
effects O
in O
rats O
. O

haloperidol O
(1 O
mg/kg O
ip O
) O
induced O
parkinsonian B-NEG
-like O
muscle B-NEG
rigidity I-NEG
, O
measured O
as O
an O
increased O
resistance O
of O
a O
rat's O
hind O
foot O
to O
passive O
flexion O
and O
extension O
at O
the O
ankle O
joint O
. O

( O
rs)-1-aminoindan-1,5-dicarboxylic O
acid O
(aida O
; O
0.5-15 O
microg/0.5 O
microl) O
, O
a O
potent O
and O
selective O
mglur1 O
antagonist O
, O
or O
( O
2r,4r)-4-aminopyrrolidine-2,4-dicarboxylate O
(2r,4r-apdc O
; O
7.5-15 O
microg/0.5 O
microl) O
, O
a O
selective O
group O
ii O
agonist O
, O
was O
injected O
bilaterally O
into O
the O
striatum O
of O
haloperidol-treated O
animals O
. O

aida O
in O
doses O
of O
7.5-15 O
microg/0.5 O
microl O
diminished O
the O
haloperidol-induced O
muscle B-NEG
rigidity I-NEG
. O

in O
contrast O
, O
2r,4r-apdc O
injections O
were O
ineffective O
. O

the O
present O
results O
may O
suggest O
that O
the O
blockade O
of O
striatal O
mglur1 O
, O
but O
not O
the O
stimulation O
of O
group O
ii O
mglurs O
, O
may O
ameliorate O
parkinsonian B-NEG
muscle B-NEG
rigidity I-NEG
. O

-DOCSTART- O

acute O
cholestatic B-NEG
hepatitis I-NEG
after O
exposure O
to O
isoflurane O
. O

objective O
: O
to O
report O
a O
case O
of O
acute O
cholestatic B-NEG
hepatitis I-NEG
following O
exposure O
to O
the O
inhalational O
anesthetic O
isoflurane O
. O

case O
summary O
: O
a O
70-year-old O
healthy O
woman O
from O
iraq O
developed O
acute O
cholestatic B-NEG
hepatitis I-NEG
3 O
weeks O
following O
repair O
of O
the O
right O
rotator O
cuff O
under O
general O
anesthesia O
. O

there O
was O
no O
evidence O
for O
viral O
, O
autoimmune O
, O
or O
metabolic O
causes O
of O
hepatitis B-NEG
. O

no O
other O
medications O
were O
involved O
except O
for O
dipyrone O
for O
analgesia B-NEG
. O

the O
alanine O
aminotransferase O
was O
elevated O
to O
a O
peak O
concentration O
of O
1533 O
u/l O
and O
the O
serum O
bilirubin O
reached O
a O
peak O
of O
17.0 O
mg/dl O
. O

there O
was O
slow O
improvement O
over O
4 O
months O
. O

accidental O
reexposure O
by O
the O
patient O
to O
dipyrone O
was O
uneventful O
. O

discussion O
: O
the O
clinical O
and O
histologic O
picture O
of O
this O
case O
resembles O
halothane B-NEG
hepatitis I-NEG
, O
which O
has O
a O
significant O
mortality O
rate O
. O

conclusions O
: O
isoflurane O
, O
a O
common O
anesthetic O
agent O
, O
can O
cause O
severe O
cholestatic B-NEG
hepatitis I-NEG
. O

-DOCSTART- O

calcitonin O
gene-related O
peptide O
levels O
during O
nitric O
oxide-induced O
headache B-NEG
in O
patients O
with O
chronic O
tension-type B-NEG
headache I-NEG
. O

it O
has O
been O
proposed O
that O
nitric O
oxide O
( O
no O
) O
induced O
headache B-NEG
in O
primary B-NEG
headaches I-NEG
may O
be O
associated O
with O
release O
of O
calcitonin O
gene-related O
peptide O
(cgrp) O
. O

in O
the O
present O
study O
we O
aimed O
to O
investigate O
plasma O
levels O
of O
cgrp O
during O
headache B-NEG
induced O
by O
the O
no O
donor O
glyceryl O
trinitrate O
( O
gtn O
) O
in O
16 O
patients O
with O
chronic O
tension-type B-NEG
headache I-NEG
and O
16 O
healthy O
controls O
. O

the O
subjects O
were O
randomly O
allocated O
to O
receive O
0.5 O
microg/kg/min O
gtn O
or O
placebo O
over O
20 O
min O
on O
two O
headache B-NEG
-free O
days O
. O

blood O
samples O
were O
collected O
at O
baseline O
, O
10 O
, O
20 O
and O
60 O
min O
after O
start O
of O
infusion O
. O

both O
patients O
and O
controls O
developed O
significantly O
stronger O
immediate O
headache B-NEG
on O
the O
gtn O
day O
than O
on O
the O
placebo O
day O
and O
the O
headache B-NEG
was O
significantly O
more O
pronounced O
in O
patients O
than O
in O
controls O
. O

there O
was O
no O
difference O
between O
the O
area O
under O
the O
cgrp O
curve O
( O
auccgrp O
) O
on O
gtn O
vs O
. O
placebo O
day O
in O
either O
patients O
( O
p=0.65 O
) O
or O
controls O
(p=0.48) O
. O

the O
auccgrp O
recorded O
on O
the O
gtn O
day O
did O
not O
differ O
between O
patients O
and O
controls O
(p=0.36) O
. O

both O
in O
patients O
and O
controls O
, O
cgrp O
levels O
changed O
significantly O
over O
time O
, O
on O
both O
the O
gtn O
and O
placebo O
days O
(p O
< O
0.05) O
. O

the O
present O
study O
indicates O
that O
no-induced O
immediate O
headache B-NEG
is O
not O
associated O
with O
release O
of O
cgrp O
. O

-DOCSTART- O

myocardial B-NEG
ischemia I-NEG
due O
to O
coronary B-NEG
artery I-NEG
spasm I-NEG
during O
dobutamine O
stress O
echocardiography O
. O

dobutamine O
stress O
echocardiography O
( O
dse O
) O
is O
a O
useful O
and O
safe O
provocation O
test O
for O
myocardial B-NEG
ischemia I-NEG
. O

until O
now O
, O
the O
test O
has O
been O
focused O
only O
on O
the O
organic O
lesion O
in O
the O
coronary O
artery O
, O
and O
positive O
dse O
has O
indicated O
the O
presence O
of O
significant O
fixed O
coronary B-NEG
artery I-NEG
stenosis I-NEG
. O

the O
aim O
of O
the O
present O
study O
is O
to O
examine O
whether O
myocardial B-NEG
ischemia I-NEG
due O
to O
coronary B-NEG
spasm I-NEG
is O
induced O
by O
dobutamine O
. O

we O
performed O
dse O
on O
51 O
patients O
with O
coronary B-NEG
spastic I-NEG
angina I-NEG
but O
without O
significant O
fixed O
coronary B-NEG
artery I-NEG
stenosis I-NEG
. O

all O
patients O
had O
anginal B-NEG
attacks O
at O
rest O
with O
st O
elevation O
on O
the O
electrocardiogram O
( O
variant B-NEG
angina I-NEG
). O

coronary O
spasm O
was O
induced O
by O
intracoronary O
injection O
of O
acetylcholine O
, O
and O
no O
fixed O
coronary B-NEG
artery I-NEG
stenosis I-NEG
was O
documented O
on O
angiograms O
in O
all O
patients O
. O

dse O
was O
performed O
with O
intravenous O
dobutamine O
infusion O
with O
an O
incremental O
doses O
of O
5, O
10 O
, O
20 O
, O
30 O
, O
and O
40 O
microg/kg/min O
every O
5 O
minutes O
. O

of O
the O
51 O
patients O
, O
7 O
patients O
showed O
asynergy O
with O
st O
elevation O
. O

all O
7 O
patients O
( O
13.7% O
) O
had O
chest B-NEG
pain I-NEG
during O
asynergy O
, O
and O
both O
chest B-NEG
pain I-NEG
and O
electrocardiographic O
changes O
were O
preceded O
by O
asynergy O
. O

these O
findings O
indicate O
that O
dobutamine O
can O
provoke O
coronary B-NEG
spasm I-NEG
in O
some O
patients O
with O
coronary B-NEG
spastic I-NEG
angina I-NEG
. O

when O
dse O
is O
performed O
to O
evaluate O
coronary B-NEG
artery I-NEG
disease I-NEG
, O
not O
only O
fixed O
coronary B-NEG
stenosis I-NEG
, O
but O
also O
coronary B-NEG
spasm I-NEG
should O
be O
considered O
as O
a O
genesis O
of O
asynergy O
. O

-DOCSTART- O

nitric O
oxide O
synthase O
expression O
in O
the O
course O
of O
lead-induced O
hypertension B-NEG
. O

we O
recently O
showed O
elevated O
reactive O
oxygen O
species O
(ros) O
, O
reduced O
urinary O
excretion O
of O
no O
metabolites O
(nox) O
, O
and O
increased O
no O
sequestration O
as O
nitrotyrosine O
in O
various O
tissues O
in O
rats O
with O
lead-induced O
hypertension B-NEG
. O

this O
study O
was O
designed O
to O
discern O
whether O
the O
reduction O
in O
urinary O
nox O
in O
lead-induced O
hypertension B-NEG
is O
, O
in O
part O
, O
due O
to O
depressed O
no O
synthase O
( O
nos O
) O
expression O
. O

male O
sprague-dawley O
rats O
were O
randomly O
assigned O
to O
a O
lead-treated O
group O
( O
given O
lead O
acetate O
, O
100 O
ppm O
, O
in O
drinking O
water O
and O
regular O
rat O
chow) O
, O
a O
group O
given O
lead O
and O
vitamin O
e-fortified O
chow O
, O
or O
a O
normal O
control O
group O
given O
either O
regular O
food O
and O
water O
or O
vitamin O
e-fortified O
food O
for O
12 O
weeks O
. O

tail O
blood O
pressure O
, O
urinary O
nox O
excretion O
, O
plasma O
malondialdehyde O
(mda) O
, O
and O
endothelial O
and O
inducible O
nos O
( O
enos O
and O
inos O
) O
isotypes O
in O
the O
aorta O
and O
kidney O
were O
measured O
. O

the O
lead-treated O
group O
exhibited O
a O
rise O
in O
blood O
pressure O
and O
plasma O
mda O
concentration O
, O
a O
fall O
in O
urinary O
nox O
excretion O
, O
and O
a O
paradoxical O
rise O
in O
vascular O
and O
renal O
tissue O
enos O
and O
inos O
expression O
. O

vitamin O
e O
supplementation O
ameliorated O
hypertension B-NEG
, O
lowered O
plasma O
mda O
concentration O
, O
and O
raised O
urinary O
nox O
excretion O
while O
significantly O
lowering O
vascular O
, O
but O
not O
renal O
, O
tissue O
enos O
and O
inos O
expression O
. O

vitamin O
e O
supplementation O
had O
no O
effect O
on O
either O
blood O
pressure O
, O
plasma O
mda O
, O
or O
nos O
expression O
in O
the O
control O
group O
. O

the O
study O
also O
revealed O
significant O
inhibition O
of O
nos O
enzymatic O
activity O
by O
lead O
in O
cell-free O
preparations O
. O

in O
conclusion O
, O
lead-induced O
hypertension B-NEG
in O
this O
model O
was O
associated O
with O
a O
compensatory O
upregulation O
of O
renal O
and O
vascular O
enos O
and O
inos O
expression O
. O

this O
is O
, O
in O
part O
, O
due O
to O
ros-mediated O
no O
inactivation O
, O
lead-associated O
inhibition O
of O
nos O
activity O
, O
and O
perhaps O
stimulatory O
actions O
of O
increased O
shear O
stress O
associated O
with O
hypertension B-NEG
. O

-DOCSTART- O

risk O
for O
valvular B-NEG
heart I-NEG
disease I-NEG
among O
users O
of O
fenfluramine O
and O
dexfenfluramine O
who O
underwent O
echocardiography O
before O
use O
of O
medication O
. O

background O
: O
because O
uncontrolled O
echocardiographic O
surveys O
suggested O
that O
up O
to O
30% O
to O
38% O
of O
users O
of O
fenfluramine O
and O
dexfenfluramine O
had O
valvular B-NEG
disease I-NEG
, O
these O
drugs O
were O
withdrawn O
from O
the O
market O
. O

objective O
: O
to O
determine O
the O
risk O
for O
new O
or O
worsening O
valvular B-NEG
abnormalities I-NEG
among O
users O
of O
fenfluramine O
or O
dexfenfluramine O
who O
underwent O
echocardiography O
before O
they O
began O
to O
take O
these O
medications O
. O

design O
: O
cohort O
study O
. O

setting O
: O
academic O
primary O
care O
practices O
. O

patients O
: O
46 O
patients O
who O
used O
fenfluramine O
or O
dexfenfluramine O
for O
14 O
days O
or O
more O
and O
had O
echocardiograms O
obtained O
before O
therapy O
. O

measurements O
: O
follow-up O
echocardiography O
. O

the O
primary O
outcome O
was O
new O
or O
worsening O
valvulopathy B-NEG
, O
defined O
as O
progression O
of O
either O
aortic B-NEG
or I-NEG
mitral I-NEG
regurgitation I-NEG
by O
at O
least O
one O
degree O
of O
severity O
and O
disease O
that O
met O
u.s O
. O

food O
and O
drug O
administration O
criteria O
( O
at O
least O
mild O
aortic B-NEG
regurgitation I-NEG
or O
moderate O
mitral B-NEG
regurgitation I-NEG
). O

results O
: O
two O
patients O
( O
4.3% O
[95% O
ci O
, O
0.6% O
to O
14.8%] O
) O
receiving O
fenfluramine-phentermine O
developed O
valvular B-NEG
heart I-NEG
disease I-NEG
. O

one O
had O
baseline O
bicuspid B-NEG
aortic I-NEG
valve I-NEG
and O
mild O
aortic B-NEG
regurgitation I-NEG
that O
progressed O
to O
moderate O
regurgitation O
. O

the O
second O
patient O
developed O
new O
moderate O
aortic B-NEG
insufficiency I-NEG
. O

conclusion O
: O
users O
of O
diet O
medications O
are O
at O
risk O
for O
valvular B-NEG
heart I-NEG
disease I-NEG
. O

however O
, O
the O
incidence O
may O
be O
lower O
than O
that O
reported O
previously O
. O

-DOCSTART- O

carboplatin O
toxic O
effects O
on O
the O
peripheral O
nervous O
system O
of O
the O
rat O
. O

background O
: O
the O
most O
striking O
of O
carboplatin's O
advantages O
( O
cbdca O
) O
over O
cisplatin O
( O
cddp O
) O
is O
its O
markedly O
reduced O
rate O
of O
neurotoxic B-NEG
effects O
. O

however O
, O
the O
use O
of O
cbdca O
higher-intensity O
schedules O
and O
the O
association O
with O
other O
neurotoxic B-NEG
drugs O
in O
polychemotherapy O
may O
cause O
some O
concern O
about O
its O
safety O
with O
respect O
to O
peripheral B-NEG
nervous I-NEG
system I-NEG
damage I-NEG
. O

materials O
and O
methods O
: O
two O
different O
schedules O
of O
cbdca O
administration O
( O
10 O
mg/kg O
and O
15 O
mg/kg O
i.p O
. O
twice O
a O
week O
for O
nine O
times O
) O
were O
evaluated O
in O
wistar O
rats O
. O
neurotoxicity B-NEG
was O
assessed O
for O
behavioral O
( O
tail-flick O
test) O
, O
neurophysiological O
( O
nerve O
conduction O
velocity O
in O
the O
tail O
nerve) O
, O
morphological O
, O
morphometrical O
and O
analytical O
effects O
. O

results O
: O
cbdca O
administration O
induced O
dose-dependent O
peripheral B-NEG
neurotoxicity I-NEG
. O
pain B-NEG
perception O
and O
nerve O
conduction O
velocity O
in O
the O
tail O
were O
significantly O
impaired O
, O
particularly O
after O
the O
high-dose O
treatment O
. O

the O
dorsal O
root O
ganglia O
sensory O
neurons O
and O
, O
to O
a O
lesser O
extent O
, O
satellite O
cells O
showed O
the O
same O
changes O
as O
those O
induced O
by O
cddp O
, O
mainly O
affecting O
the O
nucleus O
and O
nucleolus O
of O
ganglionic O
sensory O
neurons O
. O

moreover O
, O
significant O
amounts O
of O
platinum O
were O
detected O
in O
the O
dorsal O
root O
ganglia O
and O
kidney O
after O
cbdca O
treatment O
. O

conclusions O
: O
cbdca O
is O
neurotoxic B-NEG
in O
our O
model O
, O
and O
the O
type O
of O
pathological O
changes O
it O
induces O
are O
so O
closely O
similar O
to O
those O
caused O
by O
cddp O
that O
it O
is O
probable O
that O
neurotoxicity B-NEG
is O
induced O
in O
the O
two O
drugs O
by O
the O
same O
mechanism O
. O

this O
model O
can O
be O
used O
alone O
or O
in O
combination O
with O
other O
drugs O
to O
explore O
the O
effect O
of O
cbdca O
on O
the O
peripheral O
nervous O
system O
. O

-DOCSTART- O

iatrogenic O
risks O
of O
endometrial B-NEG
carcinoma I-NEG
after O
treatment O
for O
breast B-NEG
cancer I-NEG
in O
a O
large O
french O
case-control O
study O
. O

f O
d O
ration O
nationale O
des O
centres O
de O
lutte O
contre O
le O
cancer O
(fnclcc) O
. O

since O
tamoxifen O
is O
widely O
used O
in O
breast B-NEG
cancer I-NEG
treatment O
and O
has O
been O
proposed O
for O
the O
prevention O
of O
breast B-NEG
cancer I-NEG
, O
its O
endometrial O
iatrogenic O
effects O
must O
be O
carefully O
examined O
. O

we O
have O
investigated O
the O
association O
between O
endometrial B-NEG
cancer I-NEG
and O
tamoxifen O
use O
or O
other O
treatments O
in O
women O
treated O
for O
breast B-NEG
cancer I-NEG
in O
a O
case-control O
study O
. O

cases O
of O
endometrial B-NEG
cancer I-NEG
diagnosed O
after O
breast B-NEG
cancer I-NEG
(n O
= O
135 O
) O
and O
467 O
controls O
matched O
for O
age O
, O
year O
of O
diagnosis O
of O
breast B-NEG
cancer I-NEG
and O
hospital O
and O
survival O
time O
with O
an O
intact O
uterus O
were O
included O
. O

women O
who O
had O
received O
tamoxifen O
were O
significantly O
more O
likely O
to O
have O
endometrial B-NEG
cancer I-NEG
diagnosed O
than O
those O
who O
had O
not O
( O
crude O
relative O
risk O
= O
4.9 O
, O
p O
= O
0.0001) O
. O

univariate O
and O
adjusted O
analyses O
showed O
that O
the O
risk O
increased O
with O
the O
length O
of O
treatment O
(p O
= O
0.0001 O
) O
or O
the O
cumulative O
dose O
of O
tamoxifen O
received O
(p O
= O
0.0001) O
, O
irrespective O
of O
the O
daily O
dose O
. O

women O
who O
had O
undergone O
pelvic O
radiotherapy O
also O
had O
a O
higher O
risk O
( O
crude O
relative O
risk O
= O
7.8 O
, O
p O
= O
0.0001) O
. O

after O
adjusting O
for O
confounding O
factors O
, O
the O
risk O
was O
higher O
for O
tamoxifen O
users O
(p O
= O
0.0012) O
, O
treatment O
for O
more O
than O
3 O
years O
( O
all O
p O
< O
0.03 O
) O
and O
pelvic O
radiotherapy O
(p O
= O
0.012) O
. O

women O
who O
had O
endometrial B-NEG
cancer I-NEG
and O
had O
received O
tamoxifen O
had O
more O
advanced B-NEG
disease I-NEG
and O
poorer O
prognosis O
than O
those O
with O
endometrial B-NEG
cancer I-NEG
who O
had O
not O
received O
this O
treatment O
. O

our O
results O
suggest O
a O
causal O
role O
of O
tamoxifen O
in O
endometrial B-NEG
cancer I-NEG
, O
particularly O
when O
used O
as O
currently O
proposed O
for O
breast B-NEG
cancer I-NEG
prevention O
. O

pelvic O
radiotherapy O
may O
be O
an O
additional O
iatrogenic O
factor O
for O
women O
with O
breast B-NEG
cancer I-NEG
. O
endometrial B-NEG
cancers I-NEG
diagnosed O
in O
women O
treated O
with O
tamoxifen O
have O
poorer O
prognosis O
. O

women O
who O
receive O
tamoxifen O
for O
breast B-NEG
cancer I-NEG
should O
be O
offered O
gynaecological O
surveillance O
during O
and O
after O
treatment O
. O

a O
long-term O
evaluation O
of O
the O
risk-benefit O
ratio O
of O
tamoxifen O
as O
a O
preventive O
treatment O
for O
breast B-NEG
cancer I-NEG
is O
clearly O
warranted O
. O

-DOCSTART- O

granulosa B-NEG
cell I-NEG
tumor I-NEG
of I-NEG
the I-NEG
ovary I-NEG
associated O
with O
antecedent O
tamoxifen O
use O
. O

background O
: O
increased O
attention O
has O
been O
focused O
recently O
on O
the O
estrogenic O
effects O
of O
tamoxifen O
. O

review O
of O
the O
literature O
reveals O
an O
association O
between O
tamoxifen O
use O
and O
gynecologic O
tumors B-NEG
. O

case O
: O
a O
52-year-old O
postmenopausal O
woman O
was O
treated O
with O
tamoxifen O
for O
stage O
ii O
estrogen O
receptor-positive O
breast B-NEG
carcinoma I-NEG
. O

her O
aspartate O
transaminase O
and O
alanine O
transaminase O
levels O
increase O
markedly O
after O
6 O
months O
of O
tamoxifen O
use O
. O

after O
an O
additional O
17 O
months O
of O
elevated O
serum O
transaminases O
, O
the O
patient O
was O
found O
to O
have O
a O
stage O
ic O
granulosa B-NEG
cell I-NEG
tumor I-NEG
of I-NEG
the I-NEG
ovary I-NEG
. O

conclusion O
: O
patients O
with O
tamoxifen-induced O
liver B-NEG
dysfunction I-NEG
may O
be O
at O
increased O
risk O
for O
granulosa B-NEG
cell I-NEG
tumors I-NEG
because O
of O
alterations O
in O
tamoxifen O
metabolism O
. O

-DOCSTART- O

a O
murine O
model O
of O
adenomyosis B-NEG
: O
the O
effects O
of O
hyperprolactinemia B-NEG
induced O
by O
fluoxetine O
hydrochloride O
, O
a O
selective O
serotonin O
reuptake O
inhibitor O
, O
on O
adenomyosis B-NEG
induction O
in O
wistar O
albino O
rats O
. O

objective O
: O
the O
aim O
of O
this O
study O
was O
to O
investigate O
whether O
fluoxetine O
given O
to O
castrated O
and O
noncastrated O
rats O
caused O
hyperprolactinemia B-NEG
and O
its O
effects O
with O
respect O
to O
adenomyosis B-NEG
. O

design O
: O
fluoxetine O
, O
a O
serotonin O
reuptake O
inhibitor O
, O
was O
given O
to O
wistar O
albino O
rats O
for O
98 O
days O
to O
produce O
hyperprolactinemia B-NEG
. O

the O
drug O
was O
given O
to O
two O
groups O
consisting O
of O
castrated O
and O
noncastrated O
rats O
and O
compared O
to O
two O
groups O
of O
castrated O
and O
noncastrated O
controls O
. O

prolactin O
levels O
were O
measured O
and O
the O
uteri O
of O
the O
rats O
were O
removed O
for O
histopathological O
analysis O
at O
the O
end O
of O
98 O
days O
. O

setting O
: O
marmara O
university O
school O
of O
medicine O
, O
department O
of O
histology O
and O
embryology O
, O
zeynep O
kamil O
women O
and O
children's O
hospital O
. O

main O
outcome O
measures O
: O
serum O
prolactin O
levels O
, O
uterine O
histopathology O
. O

results O
: O
the O
prolactin O
levels O
of O
castrated O
and O
noncastrated O
groups O
treated O
with O
fluoxetine O
were O
statistically O
significantly O
higher O
when O
compared O
to O
their O
respective O
control O
groups O
. O

histological O
studies O
revealed O
11 O
cases O
of O
adenomyosis B-NEG
, O
all O
within O
the O
noncastrated O
group O
receiving O
fluoxetine O
. O

conclusion O
: O
it O
was O
suggested O
that O
high O
serum O
prolactin O
levels O
cause O
degeneration O
of O
myometrial O
cells O
in O
the O
presence O
of O
ovarian O
steroids O
that O
results O
in O
a O
myometrial O
invasion O
by O
endometrial O
stroma O
. O

this O
invasion O
eventually O
progresses O
to O
adenomyosis B-NEG
. O

-DOCSTART- O

effects O
of O
deliberate O
hypotension B-NEG
induced O
by O
labetalol O
with O
isoflurane O
on O
neuropsychological O
function O
. O

the O
effect O
of O
deliberate O
hypotension B-NEG
on O
brain O
function O
measured O
by O
neuropsychological O
tests O
was O
studied O
in O
41 O
adult O
patients O
. O

twenty-four O
patients O
were O
anaesthetized O
for O
middle-ear O
surgery O
with O
deliberate O
hypotension B-NEG
induced O
by O
labetalol O
with O
isoflurane O
( O
hypotensive B-NEG
group) O
. O

seventeen O
patients O
without O
hypotension B-NEG
served O
as O
a O
control O
group O
. O

the O
mean O
arterial O
pressure O
was O
77 O
+/- O
2 O
mmhg O
( O
10.3 O
+/- O
0.3 O
kpa O
) O
before O
hypotension B-NEG
and O
50 O
+/- O
0 O
mmhg O
( O
6.7 O
+/- O
0.0 O
kpa O
) O
during O
hypotension B-NEG
in O
the O
hypotensive B-NEG
group O
, O
and O
86 O
+/- O
2 O
mmhg O
( O
11.5 O
+/- O
0.3 O
kpa O
) O
during O
anaesthesia O
in O
the O
control O
group O
. O

the O
following O
psychological O
tests O
were O
performed O
: O
four O
subtests O
of O
the O
wechsler O
adult O
intelligence O
scale O
(similarities O
, O
digit O
span O
, O
vocabulary O
and O
digit O
symbol) O
, O
trail-making O
tests O
a O
and O
b, O
zung O
tests O
( O
self-rating O
anxiety B-NEG
scale O
and O
self-rating O
depression B-NEG
scale O
) O
and O
two-part O
memory O
test O
battery O
with O
immediate O
and O
delayed O
recall O
. O

the O
tests O
were O
performed O
preoperatively O
and O
2 O
days O
postoperatively O
. O

there O
were O
no O
statistically O
significant O
differences O
between O
the O
groups O
in O
any O
of O
the O
tests O
in O
the O
changes O
from O
preoperative O
value O
to O
postoperative O
value O
. O

the O
results O
indicate O
that O
hypotension B-NEG
induced O
by O
labetalol O
with O
isoflurane O
has O
no O
significant O
harmful O
effects O
on O
mental O
functions O
compared O
to O
normotensive O
anaesthesia O
. O

-DOCSTART- O

auditory O
disturbance O
associated O
with O
interscalene O
brachial O
plexus O
block O
. O

we O
performed O
an O
audiometric O
study O
in O
20 O
patients O
who O
underwent O
surgery O
of O
the O
shoulder O
region O
under O
an O
interscalene O
brachial O
plexus O
block O
(ibpb) O
. O

bupivacaine O
0.75% O
with O
adrenaline O
was O
given O
followed O
by O
a O
24-hr O
continuous O
infusion O
of O
0.25% O
bupivacaine O
. O

three O
audiometric O
threshold O
measurements O
( O
0.25-18 O
khz O
) O
were O
made O
: O
the O
first O
before O
ibpb O
, O
the O
second O
2-6 O
h O
after O
surgery O
and O
the O
third O
on O
the O
first O
day O
after O
operation O
. O

in O
four O
patients O
hearing B-NEG
impairment I-NEG
on O
the O
side O
of O
the O
block O
was O
demonstrated O
after O
operation O
, O
in O
three O
measurements O
on O
the O
day O
of O
surgery O
and O
in O
one O
on O
the O
following O
day O
. O

the O
frequencies O
at O
which O
the O
impairment O
occurred O
varied O
between O
patients O
; O
in O
one O
only O
low O
frequencies O
( O
0.25-0.5 O
khz O
) O
were O
involved O
. O

the O
maximum O
change O
in O
threshold O
was O
35 O
db O
at O
6 O
khz O
measured O
at O
the O
end O
of O
the O
continuous O
infusion O
of O
bupivacaine O
. O

this O
patient O
had O
hearing O
threshold O
changes O
( O
15-20 O
db O
) O
at O
6-10 O
khz O
on O
the O
opposite O
side O
also O
. O

ibpb O
may O
cause O
transient O
auditory B-NEG
dysfunction I-NEG
in O
the O
ipsilateral O
ear O
, O
possibly O
via O
an O
effect O
on O
sympathetic O
innervation O
. O

-DOCSTART- O

midazolam O
compared O
with O
thiopentone O
as O
an O
induction O
agent O
. O

in O
patients O
premedicated O
with O
scopolamine O
+ O
morphine O
( O
+5 O
mg O
nitrazepam O
the O
evening O
before O
surgery) O
, O
the O
sleep-inducing O
effect O
of O
midazolam O
0.15 O
mg/kg O
i.v O
. O
was O
clearly O
slower O
in O
onset O
than O
that O
of O
thiopentone O
4.67 O
mg/kg O
i.v O
. O

somewhat O
fewer O
cardiovascular O
and O
local O
sequelae O
were O
found O
in O
the O
midazolam O
group O
, O
but O
, O
although O
apnoea B-NEG
occurred O
less O
often O
in O
the O
midazolam O
group O
it O
lasted O
longer O
. O

on O
the O
whole O
, O
the O
differences O
between O
midazolam O
and O
thiopentone O
had O
no O
apparent O
clinical O
consequences O
. O

midazolam O
is O
a O
new O
alternative O
agent O
for O
induction O
in O
combination O
anaesthesia O
. O

-DOCSTART- O

cardiotoxic B-NEG
and O
possible O
leukemogenic O
effects O
of O
adriamycin O
in O
nonhuman O
primates O
. O

10 O
monkeys O
( O
macaques O
) O
received O
adriamycin O
by O
monthly O
intravenous O
injections O
at O
12 O
mg/m2 O
(1 O
mg/kg) O
. O

8 O
of O
the O
10 O
monkeys O
developed O
congestive B-NEG
heart I-NEG
failure I-NEG
at O
an O
average O
cumulative O
adriamycin O
dose O
( O
310 O
mg/m2 O
) O
well O
below O
that O
considered O
the O
safe O
upper O
limit O
( O
550 O
mg/m2 O
) O
in O
man O
. O

histologically O
, O
the O
myocardial B-NEG
lesions I-NEG
resembled O
those O
found O
in O
human O
anthracycline-induced O
cardiomyopathy B-NEG
. O

1 O
of O
the O
10 O
monkeys O
developed O
acute B-NEG
myeloblastic I-NEG
leukemia I-NEG
after O
receiving O
324 O
mg/m2 O
of O
adriamycin O
; O
the O
10th O
monkey O
is O
alive O
and O
well O
26 O
months O
after O
the O
last O
dose O
of O
drug O
. O

our O
results O
suggest O
that O
adriamycin O
is O
a O
more O
potent O
cardiotoxin O
in O
monkeys O
than O
in O
man O
, O
and O
that O
leukemia B-NEG
may O
be O
a O
consequence O
of O
prolonged O
treatment O
with O
this O
drug O
. O

-DOCSTART- O

doxorubicin O
cardiomyopathy B-NEG
in O
children O
with O
left-sided O
wilms B-NEG
tumor I-NEG
. O

two O
children O
with O
wilms B-NEG
tumor I-NEG
of O
the O
left O
kidney O
experienced O
severe O
anthracycline O
cardiomyopathy B-NEG
after O
irradiation O
to O
the O
tumor B-NEG
bed O
and O
conventional O
dosage O
of O
doxorubicin O
. O

the O
cardiomyopathy B-NEG
is O
attributed O
1) O
to O
the O
fact O
that O
radiation O
fields O
for O
left O
wilms B-NEG
tumor I-NEG
include O
the O
lower O
portion O
of O
the O
heart O
and O
2) O
to O
the O
interaction O
of O
doxorubicin O
and O
irradiation O
on O
cardiac O
muscle O
. O

it O
is O
recommended O
that O
doxorubicin O
dosage O
be O
sharply O
restricted O
in O
children O
with O
wilms B-NEG
tumor I-NEG
of O
the O
left O
kidney O
who O
receive O
postoperative O
irradiation O
. O

-DOCSTART- O

promotional O
effects O
of O
testosterone O
and O
dietary O
fat O
on O
prostate O
carcinogenesis B-NEG
in O
genetically O
susceptible O
rats O
. O

germfree O
( O
gf O
) O
lobund O
strain O
wistar O
( O
lw O
) O
rats O
, O
fed O
vegetable O
diet O
l-485 O
, O
have O
developed O
prostate B-NEG
adenocarcinomas I-NEG
spontaneously O
( O
10% O
incidence O
) O
at O
average O
age O
34 O
months O
. O

conventional O
lw O
rats O
, O
implanted O
with O
testosterone O
at O
age O
4 O
months O
, O
developed O
a O
higher O
incidence O
of O
prostate B-NEG
cancer I-NEG
after O
an O
average O
interval O
of O
14 O
months O
: O
24% O
had O
developed O
gross O
tumors B-NEG
, O
and O
40% O
when O
it O
included O
microscopic O
tumors B-NEG
. O

preliminary O
results O
indicate O
that O
testosterone-treated O
lw O
rats O
that O
were O
fed O
the O
same O
diet O
, O
which O
was O
supplemented O
with O
corn O
oil O
up O
to O
20% O
fat O
, O
developed O
prostate B-NEG
cancer I-NEG
after O
intervals O
of O
6-12 O
months O
. O

aged O
gf O
sprague-dawley O
( O
sd O
) O
rats O
have O
not O
developed O
prostate B-NEG
cancer I-NEG
spontaneously O
. O

conventional O
sd O
rats O
fed O
diet O
l-485 O
and O
treated O
with O
testosterone O
developed O
only O
prostatitis B-NEG
. O

experimental O
designs O
should O
consider O
genetic O
susceptibility O
as O
a O
basic O
prerequisite O
for O
studies O
on O
experimental O
prostate B-NEG
cancer I-NEG
. O

-DOCSTART- O

mitomycin O
c O
associated O
hemolytic B-NEG
uremic I-NEG
syndrome I-NEG
. O

mitomycin O
c O
associated O
hemolytic B-NEG
uremic I-NEG
syndrome I-NEG
( O
hus B-NEG
) O
is O
a O
potentially O
fatal O
but O
uncommon O
condition O
that O
is O
not O
yet O
widely O
recognised O
. O

it O
consists O
of O
microangiopathic O
hemolytic B-NEG
anemia I-NEG
, O
thrombocytopenia B-NEG
and O
progressive O
renal B-NEG
failure I-NEG
associated O
with O
mitomycin O
c O
treatment O
and O
affects O
about O
10% O
of O
patients O
treated O
with O
this O
agent O
. O

the O
renal B-NEG
failure I-NEG
usually O
develops O
about O
8-10 O
mth O
after O
start O
of O
mitomycin O
c O
treatment O
and O
the O
mortality O
is O
approximately O
60% O
from O
renal B-NEG
failure I-NEG
or O
pulmonary B-NEG
edema I-NEG
. O
renal B-NEG
lesions I-NEG
are O
similar O
to O
those O
seen O
in O
idiopathic O
hus B-NEG
and O
include O
arteriolar O
fibrin O
thrombi B-NEG
, O
expanded O
subendothelial O
zones O
in O
glomerular O
capillary O
walls O
, O
ischemic B-NEG
wrinkling O
of O
glomerular O
basement O
membranes O
and O
mesangiolysis O
. O

the O
mechanism O
of O
action O
is O
postulated O
as O
mitomycin O
c-induced O
endothelial O
cell O
damage O
. O

we O
describe O
the O
clinical O
course O
and O
pathological O
findings O
in O
a O
65 O
yr-old O
man O
with O
gastric B-NEG
adenocarcinoma I-NEG
who O
developed O
renal B-NEG
failure I-NEG
and O
thrombocytopenia B-NEG
while O
on O
treatment O
with O
mitomycin O
c O
and O
died O
in O
pulmonary B-NEG
edema I-NEG
. O

-DOCSTART- O

continuous O
ambulatory O
ecg O
monitoring O
during O
fluorouracil O
therapy O
: O
a O
prospective O
study O
. O

although O
there O
have O
been O
anecdotal O
reports O
of O
cardiac B-NEG
toxicity I-NEG
associated O
with O
fluorouracil O
( O
5-fu O
) O
therapy O
, O
this O
phenomenon O
has O
not O
been O
studied O
in O
a O
systematic O
fashion O
. O

we O
prospectively O
performed O
continuous O
ambulatory O
ecg O
monitoring O
on O
25 O
patients O
undergoing O
5-fu O
infusion O
for O
treatment O
of O
solid O
tumors B-NEG
in O
order O
to O
assess O
the O
incidence O
of O
ischemic B-NEG
st O
changes O
. O

patients O
were O
monitored O
for O
23 O
+/- O
4 O
hours O
before O
5-fu O
infusion O
, O
and O
98 O
+/- O
9 O
hours O
during O
5-fu O
infusion O
. O
anginal B-NEG
episodes O
were O
rare O
: O
only O
one O
patient O
had O
angina B-NEG
( O
during O
5-fu O
infusion) O
. O

however O
, O
asymptomatic O
st O
changes O
( O
greater O
than O
or O
equal O
to O
1 O
mm O
st O
deviation O
) O
were O
common O
: O
six O
of O
25 O
patients O
( O
24% O
) O
had O
st O
changes O
before O
5-fu O
infusion O
v O
17 O
( O
68% O
) O
during O
5-fu O
infusion O
(p O
less O
than O
.002) O
. O

the O
incidence O
of O
ischemic B-NEG
episodes O
per O
patient O
per O
hour O
was O
0.05 O
+/- O
0.02 O
prior O
to O
5-fu O
infusion O
v O
0.13 O
+/- O
0.03 O
during O
5-fu O
infusion O
(p O
less O
than O
.001) O
; O
the O
duration O
of O
ecg O
changes O
was O
0.6 O
+/- O
0.3 O
minutes O
per O
patient O
per O
hour O
before O
5-fu O
v O
1.9 O
+/- O
0.5 O
minutes O
per O
patient O
per O
hour O
during O
5-fu O
(p O
less O
than O
.01) O
. O

ecg O
changes O
were O
more O
common O
among O
patients O
with O
known O
coronary B-NEG
artery I-NEG
disease I-NEG
. O

there O
were O
two O
cases O
of O
sudden B-NEG
death I-NEG
, O
both O
of O
which O
occurred O
at O
the O
end O
of O
the O
chemotherapy O
course O
. O

we O
conclude O
that O
5-fu O
infusion O
is O
associated O
with O
a O
significant O
increase O
in O
silent O
st O
segment O
deviation O
suggestive O
of O
ischemia B-NEG
, O
particularly O
among O
patients O
with O
coronary B-NEG
artery I-NEG
disease I-NEG
. O

the O
mechanism O
and O
clinical O
significance O
of O
these O
ecg O
changes O
remain O
to O
be O
determined O
. O

-DOCSTART- O

lethal O
anuria B-NEG
complicating O
high O
dose O
ifosfamide O
chemotherapy O
in O
a O
breast B-NEG
cancer I-NEG
patient O
with O
an O
impaired B-NEG
renal I-NEG
function I-NEG
. O

a O
sixty-year-old O
woman O
with O
advanced O
breast B-NEG
cancer I-NEG
, O
previously O
treated O
with O
cisplatin O
, O
developed O
an O
irreversible O
lethal O
renal B-NEG
failure I-NEG
with O
anuria B-NEG
, O
the O
day O
after O
5 O
g/m2 O
bolus O
ifosfamide O
. O
postrenal B-NEG
failure I-NEG
was O
excluded O
by O
echography O
. O

a O
prerenal O
component O
could O
have O
contributed O
to O
renal B-NEG
failure I-NEG
because O
of O
a O
transient O
hypotension B-NEG
, O
due O
to O
an O
increasing O
ascitis O
, O
occurring O
just O
before O
anuria B-NEG
. O

however O
, O
correction O
of O
the O
hemodynamic O
parameters O
did O
not O
improve O
renal O
function O
. O

ifosfamide O
is O
a O
known O
nephrotoxic B-NEG
drug O
with O
demonstrated O
tubulopathies B-NEG
. O

we O
strongly O
suspect O
that O
this O
lethal O
anuria B-NEG
was O
mainly O
due O
to O
ifosfamide O
, O
occurring O
in O
a O
patient O
having O
received O
previous O
cisplatin O
chemotherapy O
and O
with O
poor O
kidney O
perfusion O
due O
to O
transient O
hypotension B-NEG
. O

we O
recommend O
careful O
use O
of O
ifosfamide O
in O
patients O
pretreated O
with O
nephrotoxic B-NEG
chemotherapy O
and O
inadequate O
renal O
perfusion O
. O

-DOCSTART- O

central O
vein B-NEG
thrombosis I-NEG
and O
topical O
dipivalyl O
epinephrine O
. O

a O
report O
is O
given O
on O
an O
83-year-old O
female O
who O
acquired O
central O
vein B-NEG
thrombosis I-NEG
in O
her O
seeing O
eye O
one O
day O
after O
having O
started O
topical O
medication O
with O
dipivalyl O
epinephrine O
for O
advanced O
glaucoma B-NEG
discovered O
in O
the O
other O
eye O
. O

from O
present O
knowledge O
about O
the O
effects O
of O
adrenergic O
eye O
drops O
on O
ocular O
blood O
circulation O
, O
it O
is O
difficult O
to O
suggest O
an O
association O
between O
the O
two O
events O
, O
which O
may O
be O
coincidental O
only O
. O

-DOCSTART- O

amelioration O
of O
bendrofluazide-induced O
hypokalemia B-NEG
by O
timolol O
. O

the O
beta O
adrenergic O
blocking O
drug O
, O
timolol O
, O
tended O
to O
correct O
the O
hypokalemia B-NEG
of O
short-term O
bendrofluazide O
treatment O
in O
6 O
healthy O
male O
subjects O
and O
although O
the O
effect O
was O
small O
it O
was O
significant O
. O

timolol O
also O
reduced O
the O
rise O
in O
plasma O
aldosterone O
and O
urine O
potassium O
excretion O
following O
bendrofluazide O
and O
increased O
the O
urine O
sodium/potassium O
ratio O
. O

there O
was O
no O
evidence O
of O
a O
shift O
of O
potassium O
from O
the O
intracellular O
to O
the O
extracellular O
space O
. O

-DOCSTART- O

a O
cross-sectional O
evaluation O
of O
the O
effect O
of O
risperidone O
and O
selective O
serotonin O
reuptake O
inhibitors O
on O
bone O
mineral O
density O
in O
boys O
. O

objective O
: O
the O
aim O
of O
the O
present O
study O
was O
to O
investigate O
the O
effect O
of O
risperidone-induced O
hyperprolactinemia B-NEG
on O
trabecular O
bone O
mineral O
density O
( O
bmd O
) O
in O
children O
and O
adolescents O
. O

method O
: O
medically O
healthy O
7- O
to O
17-year-old O
males O
chronically O
treated O
, O
in O
a O
naturalistic O
setting O
, O
with O
risperidone O
were O
recruited O
for O
this O
cross-sectional O
study O
through O
child O
psychiatry O
outpatient O
clinics O
between O
november O
2005 O
and O
june O
2007 O
. O

anthropometric O
measurements O
and O
laboratory O
testing O
were O
conducted O
. O

the O
clinical O
diagnoses O
were O
based O
on O
chart O
review O
, O
and O
developmental O
and O
treatment O
history O
was O
obtained O
from O
the O
medical O
record O
. O

volumetric O
bmd O
of O
the O
ultradistal O
radius O
was O
measured O
using O
peripheral O
quantitative O
computed O
tomography O
, O
and O
areal O
bmd O
of O
the O
lumbar O
spine O
was O
estimated O
using O
dual-energy O
x-ray O
absorptiometry O
. O

results O
: O
hyperprolactinemia B-NEG
was O
present O
in O
49% O
of O
83 O
boys O
(n O
= O
41 O
) O
treated O
with O
risperidone O
for O
a O
mean O
of O
2.9 O
years O
. O

serum O
testosterone O
concentration O
increased O
with O
pubertal O
status O
but O
was O
not O
affected O
by O
hyperprolactinemia B-NEG
. O

as O
expected O
, O
bone O
mineral O
content O
and O
bmd O
increased O
with O
sexual O
maturity O
. O

after O
adjusting O
for O
the O
stage O
of O
sexual O
development O
and O
height O
and O
bmi O
z O
scores O
, O
serum O
prolactin O
was O
negatively O
associated O
with O
trabecular O
volumetric O
bmd O
at O
the O
ultradistal O
radius O
(p O
< O
.03) O
. O

controlling O
for O
relevant O
covariates O
, O
we O
also O
found O
treatment O
with O
selective O
serotonin O
reuptake O
inhibitors O
( O
ssris O
) O
to O
be O
associated O
with O
lower O
trabecular O
bmd O
at O
the O
radius O
(p O
= O
.03 O
) O
and O
bmd O
z O
score O
at O
the O
lumbar O
spine O
(p O
< O
.05) O
. O

these O
findings O
became O
more O
marked O
when O
the O
analysis O
was O
restricted O
to O
non-hispanic O
white O
patients O
. O

of O
13 O
documented O
fractures B-NEG
, O
3 O
occurred O
after O
risperidone O
and O
ssris O
were O
started O
, O
and O
none O
occurred O
in O
patients O
with O
hyperprolactinemia B-NEG
. O

conclusions O
: O
this O
is O
the O
first O
study O
to O
link O
risperidone-induced O
hyperprolactinemia B-NEG
and O
ssri O
treatment O
to O
lower O
bmd O
in O
children O
and O
adolescents O
. O

future O
research O
should O
evaluate O
the O
longitudinal O
course O
of O
this O
adverse O
event O
to O
determine O
its O
temporal O
stability O
and O
whether O
a O
higher O
fracture O
rate O
ensues O
. O

-DOCSTART- O

seizures B-NEG
associated O
with O
levofloxacin O
: O
case O
presentation O
and O
literature O
review O
. O

purpose O
: O
we O
present O
a O
case O
of O
a O
patient O
who O
developed O
seizures B-NEG
shortly O
after O
initiating O
treatment O
with O
levofloxacin O
and O
to O
discuss O
the O
potential O
drug-drug O
interactions O
related O
to O
the O
inhibition O
of O
cytochrome O
p450 O
( O
cyp O
) O
1a2 O
in O
this O
case O
, O
as O
well O
as O
in O
other O
cases O
, O
of O
levofloxacin-induced O
seizures B-NEG
. O

methods O
: O
several O
biomedical O
databases O
were O
searched O
including O
medline O
, O
cochrane O
and O
ovid O
. O

the O
main O
search O
terms O
utilized O
were O
case O
report O
and O
levofloxacin O
. O

the O
search O
was O
limited O
to O
studies O
published O
in O
english O
. O

results O
: O
six O
cases O
of O
levofloxacin-induced O
seizures B-NEG
have O
been O
reported O
in O
the O
literature O
. O

drug-drug O
interactions O
related O
to O
the O
inhibition O
of O
cyp1a2 O
by O
levofloxacin O
are O
likely O
involved O
in O
the O
clinical O
outcome O
of O
these O
cases O
. O

conclusions O
: O
clinicians O
are O
exhorted O
to O
pay O
close O
attention O
when O
initiating O
levofloxacin O
therapy O
in O
patients O
taking O
medications O
with O
epileptogenic O
properties O
that O
are O
cyp1a2 O
substrates O
. O

-DOCSTART- O

mice O
lacking O
mpges-1 O
are O
resistant O
to O
lithium-induced O
polyuria B-NEG
. O

cyclooxygenase-2 O
activity O
is O
required O
for O
the O
development O
of O
lithium-induced O
polyuria B-NEG
. O

however O
, O
the O
involvement O
of O
a O
specific O
, O
terminal O
prostaglandin O
( O
pg O
) O
isomerase O
has O
not O
been O
evaluated O
. O

the O
present O
study O
was O
undertaken O
to O
assess O
lithium-induced O
polyuria B-NEG
in O
mice O
deficient O
in O
microsomal O
prostaglandin O
e O
synthase-1 O
(mpges-1) O
. O

a O
2-wk O
administration O
of O
licl O
(4 O
mmol.kg(-1).day(-1 O
) O
ip O
) O
in O
mpges-1 O
+/+ O
mice O
led O
to O
a O
marked O
polyuria B-NEG
with O
hyposmotic O
urine O
. O

this O
was O
associated O
with O
elevated O
renal O
mpges-1 O
protein O
expression O
and O
increased O
urine O
pge(2 O
) O
excretion O
. O

in O
contrast O
, O
mpges-1 O
-/- O
mice O
were O
largely O
resistant O
to O
lithium-induced O
polyuria B-NEG
and O
a O
urine O
concentrating O
defect O
, O
accompanied O
by O
nearly O
complete O
blockade O
of O
high O
urine O
pge(2 O
) O
and O
camp O
output O
. O

immunoblotting O
, O
immunohistochemistry O
, O
and O
quantitative O
( O
q O
) O
rt-pcr O
consistently O
detected O
a O
significant O
decrease O
in O
aquaporin-2 O
( O
aqp2 O
) O
protein O
expression O
in O
both O
the O
renal O
cortex O
and O
medulla O
of O
lithium-treated O
+/+ O
mice O
. O

this O
decrease O
was O
significantly O
attenuated O
in O
the O
-/- O
mice O
. O

qrt-pcr O
detected O
similar O
patterns O
of O
changes O
in O
aqp2 O
mrna O
in O
the O
medulla O
but O
not O
in O
the O
cortex O
. O

similarly O
, O
the O
total O
protein O
abundance O
of O
the O
na-k-2cl O
cotransporter O
( O
nkcc2 O
) O
in O
the O
medulla O
but O
not O
in O
the O
cortex O
of O
the O
+/+ O
mice O
was O
significantly O
reduced O
by O
lithium O
treatment O
. O

in O
contrast O
, O
the O
dowregulation O
of O
renal O
medullary O
nkcc2 O
expression O
was O
significantly O
attenuated O
in O
the O
-/- O
mice O
. O

we O
conclude O
that O
mpges-1-derived O
pge(2 O
) O
mediates O
lithium-induced O
polyuria B-NEG
likely O
via O
inhibition O
of O
aqp2 O
and O
nkcc2 O
expression O
. O

-DOCSTART- O

identification O
of O
a O
simple O
and O
sensitive O
microplate O
method O
for O
the O
detection O
of O
oversulfated O
chondroitin O
sulfate O
in O
heparin O
products O
. O

heparin O
is O
a O
commonly O
implemented O
anticoagulant O
used O
to O
treat O
critically O
ill O
patients O
. O

recently O
, O
a O
number O
of O
commercial O
lots O
of O
heparin O
products O
were O
found O
to O
be O
contaminated O
with O
an O
oversulfated O
chondroitin O
sulfate O
( O
oscs O
) O
derivative O
that O
could O
elicit O
a O
hypotensive B-NEG
response O
in O
pigs O
following O
a O
single O
high-dose O
infusion O
. O

using O
both O
contaminated O
heparin O
products O
and O
the O
synthetically O
produced O
derivative O
, O
we O
showed O
that O
the O
oscs O
produces O
dose-dependent O
hypotension B-NEG
in O
pigs O
. O

the O
no O
observed O
effect O
level O
( O
noel O
) O
for O
this O
contaminant O
appears O
to O
be O
approximately O
1mg/kg O
, O
corresponding O
to O
a O
contamination O
level O
of O
approximately O
3% O
. O

we O
also O
demonstrated O
that O
oscs O
can O
be O
identified O
in O
heparin O
products O
using O
a O
simple O
, O
inexpensive O
, O
commercially O
available O
heparin O
enzyme O
immunoassay O
( O
eia O
) O
kit O
that O
has O
a O
limit O
of O
detection O
of O
approximately O
0.1% O
, O
well O
below O
the O
noel O
. O

this O
kit O
may O
provide O
a O
useful O
method O
to O
test O
heparin O
products O
for O
contamination O
with O
oversulfated O
gag O
derivatives O
. O

-DOCSTART- O

doxorubicin O
cardiomyopathy B-NEG
-induced O
inflammation B-NEG
and O
apoptosis O
are O
attenuated O
by O
gene O
deletion O
of O
the O
kinin O
b1 O
receptor O
. O

clinical O
use O
of O
the O
anthracycline O
doxorubicin O
( O
dox O
) O
is O
limited O
by O
its O
cardiotoxic B-NEG
effects O
, O
which O
are O
attributed O
to O
the O
induction O
of O
apoptosis O
. O

to O
elucidate O
the O
possible O
role O
of O
the O
kinin O
b1 O
receptor O
( O
b1r O
) O
during O
the O
development O
of O
dox O
cardiomyopathy B-NEG
, O
we O
studied O
b1r O
knockout O
mice O
( O
b1r(-/-) O
) O
by O
investigating O
cardiac O
inflammation B-NEG
and O
apoptosis O
after O
induction O
of O
dox-induced O
cardiomyopathy B-NEG
. O

dox O
control O
mice O
showed O
cardiac B-NEG
dysfunction I-NEG
measured O
by O
pressure-volume O
loops O
in O
vivo O
. O

this O
was O
associated O
with O
a O
reduced O
activation O
state O
of O
akt O
, O
as O
well O
as O
an O
increased O
bax/bcl2 O
ratio O
in O
western O
blots O
, O
indicating O
cardiac B-NEG
apoptosis I-NEG
. O

furthermore O
, O
mrna O
levels O
of O
the O
proinflammatory O
cytokine O
interleukin O
6 O
were O
increased O
in O
the O
cardiac O
tissue O
. O

in O
dox O
b1r(-/- O
) O
mice O
, O
cardiac B-NEG
dysfunction I-NEG
was O
improved O
compared O
to O
dox O
control O
mice O
, O
which O
was O
associated O
with O
normalization O
of O
the O
bax/bcl-2 O
ratio O
and O
interleukin O
6, O
as O
well O
as O
akt O
activation O
state O
. O

these O
findings O
suggest O
that O
b1r O
is O
detrimental O
in O
dox O
cardiomyopathy B-NEG
in O
that O
it O
mediates O
the O
inflammatory O
response O
and O
apoptosis O
. O

these O
insights O
might O
have O
useful O
implications O
for O
future O
studies O
utilizing O
b1r O
antagonists O
for O
treatment O
of O
human O
dox O
cardiomyopathy B-NEG
. O

-DOCSTART- O

hepatotoxicity B-NEG
associated O
with O
sulfasalazine O
in O
inflammatory O
arthritis B-NEG
: O
a O
case O
series O
from O
a O
local O
surveillance O
of O
serious O
adverse O
events O
. O

background O
: O
spontaneous O
reporting O
systems O
for O
adverse O
drug O
reactions O
( O
adrs O
) O
are O
handicapped O
by O
under-reporting O
and O
limited O
detail O
on O
individual O
cases O
. O

we O
report O
an O
investigation O
from O
a O
local O
surveillance O
for O
serious O
adverse O
drug O
reactions O
associated O
with O
disease O
modifying O
anti-rheumatic O
drugs O
that O
was O
triggered O
by O
the O
occurrence O
of O
liver B-NEG
failure I-NEG
in O
two O
of O
our O
patients O
. O

methods O
: O
serious O
adr O
reports O
have O
been O
solicited O
from O
local O
clinicians O
by O
regular O
postcards O
over O
the O
past O
seven O
years O
. O

patients' O
, O
who O
had O
hepatotoxicity B-NEG
on O
sulfasalazine O
and O
met O
a O
definition O
of O
a O
serious O
adr O
, O
were O
identified O
. O

two O
clinicians O
reviewed O
structured O
case O
reports O
and O
assessed O
causality O
by O
consensus O
and O
by O
using O
a O
causality O
assessment O
instrument O
. O

the O
likely O
frequency O
of O
hepatotoxicity B-NEG
with O
sulfasalazine O
was O
estimated O
by O
making O
a O
series O
of O
conservative O
assumptions O
. O

results O
: O
ten O
cases O
were O
identified O
: O
eight O
occurred O
during O
surveillance O
. O

eight O
patients O
were O
hospitalised O
, O
two O
in O
hepatic B-NEG
failure I-NEG
- O
one O
died O
after O
a O
liver O
transplant O
. O

all O
but O
one O
event O
occurred O
within O
6 O
weeks O
of O
treatment O
. O

seven O
patients O
had O
a O
skin B-NEG
rash I-NEG
, O
three O
eosinophilia B-NEG
and O
one O
interstitial B-NEG
nephritis I-NEG
. O

five O
patients O
were O
of O
black O
british O
of O
african O
or O
caribbean O
descent O
. O

liver O
enzymes O
showed O
a O
hepatocellular O
pattern O
in O
four O
cases O
and O
a O
mixed O
pattern O
in O
six O
. O

drug-related O
hepatotoxicity B-NEG
was O
judged O
probable O
or O
highly O
probable O
in O
8 O
patients O
. O

the O
likely O
frequency O
of O
serious O
hepatotoxicity B-NEG
with O
sulfasalazine O
was O
estimated O
at O
0.4% O
of O
treated O
patients O
. O

conclusion O
: O
serious O
hepatotoxicity B-NEG
associated O
with O
sulfasalazine O
appears O
to O
be O
under-appreciated O
and O
intensive O
monitoring O
and O
vigilance O
in O
the O
first O
6 O
weeks O
of O
treatment O
is O
especially O
important O
. O

-DOCSTART- O

an O
evaluation O
of O
amikacin O
nephrotoxicity B-NEG
in O
the O
hematology/oncology O
population O
. O

amikacin O
is O
an O
aminoglycoside O
commonly O
used O
to O
provide O
empirical O
double O
gram-negative O
treatment O
for O
febrile B-NEG
neutropenia I-NEG
and O
other O
suspected O
infections B-NEG
. O

strategies O
of O
extended-interval O
and O
conventional O
dosing O
have O
been O
utilized O
extensively O
in O
the O
general O
medical O
population O
; O
however O
, O
data O
are O
lacking O
to O
support O
a O
dosing O
strategy O
in O
the O
hematology/oncology O
population O
. O

to O
evaluate O
amikacin-associated O
nephrotoxicity B-NEG
in O
an O
adult O
hematology/oncology O
population O
, O
a O
prospective O
, O
randomized O
, O
open-label O
trial O
was O
conducted O
at O
a O
university-affiliated O
medical O
center O
. O

forty O
patients O
with O
a O
diagnosis O
consistent O
with O
a O
hematologic/oncologic B-NEG
disorder I-NEG
that O
required O
treatment O
with O
an O
aminoglycoside O
were O
randomized O
to O
either O
conventional O
or O
extended-interval O
amikacin O
. O

the O
occurrence O
of O
nephrotoxicity B-NEG
by O
means O
of O
an O
increase O
in O
serum O
creatinine O
and O
evaluation O
of O
efficacy O
via O
amikacin O
serum O
concentrations O
with O
respective O
pathogens O
were O
assessed O
. O

the O
occurrence O
of O
nephrotoxicity B-NEG
was O
similar O
between O
the O
conventional O
and O
extended-interval O
groups O
, O
at O
10% O
and O
5% O
, O
respectively O
(p O
= O
1.00) O
. O

six O
patients O
in O
the O
conventional O
group O
had O
a O
positive O
culture O
, O
compared O
with O
none O
in O
the O
extended-interval O
group O
(p O
= O
0.002) O
. O

the O
occurrence O
of O
nephrotoxicity B-NEG
was O
similar O
between O
the O
two O
dosing O
regimens O
, O
but O
the O
distribution O
of O
risk O
factors O
was O
variable O
between O
the O
two O
groups O
. O

efficacy O
could O
not O
be O
assessed O
. O

-DOCSTART- O

memory O
function O
and O
serotonin O
transporter O
promoter O
gene O
polymorphism O
in O
ecstasy O
( O
mdma O
) O
users O
. O

although O
3,4-methylenedioxymethamphetamine O
( O
mdma O
or O
ecstasy O
) O
has O
been O
shown O
to O
damage O
brain O
serotonin O
( O
5-ht O
) O
neurons O
in O
animals O
and O
possibly O
humans O
, O
little O
is O
known O
about O
the O
long-term O
consequences O
of O
mdma-induced O
5-ht O
neurotoxic B-NEG
lesions I-NEG
on O
functions O
in O
which O
5-ht O
is O
involved O
, O
such O
as O
cognitive O
function O
. O

because O
5-ht O
transporters O
play O
a O
key O
element O
in O
the O
regulation O
of O
synaptic O
5-ht O
transmission O
it O
may O
be O
important O
to O
control O
for O
the O
potential O
covariance O
effect O
of O
a O
polymorphism O
in O
the O
5-ht O
transporter O
promoter O
gene O
region O
( O
5-httlpr O
) O
when O
studying O
the O
effects O
of O
mdma O
as O
well O
as O
cognitive O
functioning O
. O

the O
aim O
of O
the O
study O
was O
to O
investigate O
the O
effects O
of O
moderate O
and O
heavy O
mdma O
use O
on O
cognitive O
function O
, O
as O
well O
as O
the O
effects O
of O
long-term O
abstention O
from O
mdma O
, O
in O
subjects O
genotyped O
for O
5-httlpr O
. O

a O
second O
aim O
of O
the O
study O
was O
to O
determine O
whether O
these O
effects O
differ O
for O
females O
and O
males O
. O

fifteen O
moderate O
mdma O
users O
( O
<55 O
lifetime O
tablets) O
, O
22 O
heavy O
mdma+ O
users O
( O
>55 O
lifetime O
tablets) O
, O
16 O
ex-mdma+ O
users O
( O
last O
tablet O
> O
1 O
year O
ago O
) O
and O
13 O
controls O
were O
compared O
on O
a O
battery O
of O
neuropsychological O
tests O
. O

dna O
from O
peripheral O
nuclear O
blood O
cells O
was O
genotyped O
for O
5-httlpr O
using O
standard O
polymerase O
chain O
reaction O
methods.a O
significant O
group O
effect O
was O
observed O
only O
on O
memory O
function O
tasks O
(p O
= O
0.04 O
) O
but O
not O
on O
reaction O
times O
(p O
= O
0.61 O
) O
or O
attention/executive O
functioning O
(p O
= O
0.59) O
. O

heavy O
and O
ex-mdma+ O
users O
performed O
significantly O
poorer O
on O
memory O
tasks O
than O
controls O
. O

in O
contrast O
, O
no O
evidence O
of O
memory B-NEG
impairment I-NEG
was O
observed O
in O
moderate O
mdma O
users O
. O

no O
significant O
effect O
of O
5-httlpr O
or O
gender O
was O
observed O
. O

while O
the O
use O
of O
mdma O
in O
quantities O
that O
may O
be O
considered O
moderate O
is O
not O
associated O
with O
impaired B-NEG
memory I-NEG
functioning I-NEG
, O
heavy O
use O
of O
mdma O
use O
may O
lead O
to O
long O
lasting O
memory B-NEG
impairments I-NEG
. O

no O
effect O
of O
5-httlpr O
or O
gender O
on O
memory O
function O
or O
mdma O
use O
was O
observed O
. O

-DOCSTART- O

aging O
process O
of O
epithelial O
cells O
of O
the O
rat O
prostate O
lateral O
lobe O
in O
experimental O
hyperprolactinemia B-NEG
induced O
by O
haloperidol O
. O

the O
aim O
of O
the O
study O
was O
to O
examine O
the O
influence O
of O
hyperprolactinemia B-NEG
, O
induced O
by O
haloperidol O
( O
hal O
) O
on O
age O
related O
morphology O
and O
function O
changes O
of O
epithelial O
cells O
in O
rat O
prostate O
lateral O
lobe O
. O

the O
study O
was O
performed O
on O
sexually O
mature O
male O
rats O
. O

serum O
concentrations O
of O
prolactin O
( O
prl O
) O
and O
testosterone O
( O
t O
) O
were O
measured O
. O

tissue O
sections O
were O
evaluated O
with O
light O
and O
electron O
microscopy O
. O

immunohistochemical O
reactions O
for O
anti-proliferating O
cell O
nuclear O
antigen O
( O
pcna O
) O
were O
performed O
. O

in O
rats O
of O
the O
experimental O
group O
, O
the O
mean O
concentration O
of O
: O
prl O
was O
more O
than O
twice O
higher O
, O
whereas O
t O
concentration O
was O
almost O
twice O
lower O
than O
that O
in O
the O
control O
group O
. O

light O
microscopy O
visualized O
the O
following O
: O
hypertrophy B-NEG
and O
epithelium O
hyperplasia B-NEG
of O
the O
glandular O
ducts O
, O
associated O
with O
increased O
pcna O
expression O
. O

electron O
microscopy O
revealed O
changes O
in O
columnar O
epithelial O
cells O
, O
concerning O
organelles O
, O
engaged O
in O
protein O
synthesis O
and O
secretion O
. O

-DOCSTART- O

does O
supplemental O
vitamin O
c O
increase O
cardiovascular B-NEG
disease I-NEG
risk O
in O
women O
with O
diabetes B-NEG
? O

background O
: O
vitamin O
c O
acts O
as O
a O
potent O
antioxidant O
; O
however O
, O
it O
can O
also O
be O
a O
prooxidant O
and O
glycate O
protein O
under O
certain O
circumstances O
in O
vitro O
. O

these O
observations O
led O
us O
to O
hypothesize O
that O
a O
high O
intake O
of O
vitamin O
c O
in O
diabetic B-NEG
persons O
might O
promote O
atherosclerosis B-NEG
. O

objective O
: O
the O
objective O
was O
to O
examine O
the O
relation O
between O
vitamin O
c O
intake O
and O
mortality O
from O
cardiovascular B-NEG
disease I-NEG
. O

design O
: O
we O
studied O
the O
relation O
between O
vitamin O
c O
intake O
and O
mortality O
from O
total O
cardiovascular B-NEG
disease I-NEG
(n O
= O
281) O
, O
coronary B-NEG
artery I-NEG
disease I-NEG
(n O
= O
175) O
, O
and O
stroke B-NEG
(n O
= O
57 O
) O
in O
1923 O
postmenopausal O
women O
who O
reported O
being O
diabetic B-NEG
at O
baseline O
. O

diet O
was O
assessed O
with O
a O
food-frequency O
questionnaire O
at O
baseline O
, O
and O
subjects O
initially O
free O
of O
coronary B-NEG
artery I-NEG
disease I-NEG
were O
prospectively O
followed O
for O
15 O
y. O

results O
: O
after O
adjustment O
for O
cardiovascular B-NEG
disease I-NEG
risk O
factors O
, O
type O
of O
diabetes B-NEG
medication O
used O
, O
duration O
of O
diabetes B-NEG
, O
and O
intakes O
of O
folate O
, O
vitamin O
e, O
and O
beta-carotene O
, O
the O
adjusted O
relative O
risks O
of O
total O
cardiovascular B-NEG
disease I-NEG
mortality O
were O
1.0 O
, O
0.97 O
, O
1.11 O
, O
1.47 O
, O
and O
1.84 O
(p O
for O
trend O
< O
0.01 O
) O
across O
quintiles O
of O
total O
vitamin O
c O
intake O
from O
food O
and O
supplements O
. O

adjusted O
relative O
risks O
of O
coronary B-NEG
artery I-NEG
disease I-NEG
were O
1.0 O
, O
0.81 O
, O
0.99 O
, O
1.26 O
, O
and O
1.91 O
(p O
for O
trend O
= O
0.01 O
) O
and O
of O
stroke B-NEG
were O
1.0 O
, O
0.52 O
, O
1.23 O
, O
2.22 O
, O
and O
2.57 O
(p O
for O
trend O
< O
0.01) O
. O

when O
dietary O
and O
supplemental O
vitamin O
c O
were O
analyzed O
separately O
, O
only O
supplemental O
vitamin O
c O
showed O
a O
positive O
association O
with O
mortality O
endpoints O
. O

vitamin O
c O
intake O
was O
unrelated O
to O
mortality O
from O
cardiovascular B-NEG
disease I-NEG
in O
the O
nondiabetic O
subjects O
at O
baseline O
. O

conclusion O
: O
a O
high O
vitamin O
c O
intake O
from O
supplements O
is O
associated O
with O
an O
increased O
risk O
of O
cardiovascular B-NEG
disease I-NEG
mortality O
in O
postmenopausal O
women O
with O
diabetes B-NEG
. O

-DOCSTART- O

absolute O
and O
attributable O
risk O
of O
venous B-NEG
thromboembolism I-NEG
in O
women O
on O
combined O
cyproterone O
acetate O
and O
ethinylestradiol O
. O

objective O
: O
to O
achieve O
absolute O
risk O
estimates O
of O
venous B-NEG
thromboembolism I-NEG
( O
vte B-NEG
) O
among O
women O
on O
cyproterone O
acetate O
plus O
ethinylestradiol O
(cpa/ee) O
, O
and O
among O
women O
on O
combined O
oral O
contraceptives O
(cocs) O
. O

methods O
: O
from O
the O
danish O
national O
register O
of O
patients O
(nrp) O
, O
1996 O
to O
1998 O
, O
the O
records O
of O
1.1 O
million O
danish O
women O
, O
ages O
15 O
to O
44 O
years O
, O
were O
searched O
for O
evidence O
of O
vte B-NEG
. O

coc O
use O
was O
ascertained O
through O
mailed O
questionnaires O
. O

sales O
statistics O
of O
cocs O
and O
cpa/ee O
were O
provided O
through O
danish O
drug O
statistics O
. O

results O
: O
during O
the O
time O
frame O
of O
the O
study O
, O
330 O
women O
were O
found O
to O
have O
had O
vte B-NEG
while O
on O
cocs O
. O

of O
these O
women O
, O
67 O
were O
on O
levonorgestrel-containing O
cocs O
. O

eleven O
were O
on O
cpa/ee O
. O

the O
corresponding O
absolute O
risk O
of O
vte B-NEG
was O
3.4 O
(range O
, O
3.1-3.8 O
) O
per O
10 O
000 O
women O
years O
among O
the O
women O
on O
cocs O
, O
4.2 O
(range O
, O
3.2-5.2 O
) O
per O
10 O
000 O
women O
years O
among O
women O
on O
levonorgestrel-containing O
cocs O
, O
and O
3.1 O
(range O
, O
1.3-4.9 O
) O
per O
10 O
000 O
women O
years O
among O
the O
women O
on O
cpa/ee O
. O

conclusion O
: O
our O
results O
suggest O
the O
absolute O
risk O
of O
vte B-NEG
among O
danish O
women O
on O
cocs O
is O
similar O
to O
that O
among O
women O
taking O
cpa/ee O
. O

-DOCSTART- O

effect O
of O
lindane O
on O
hepatic O
and O
brain O
cytochrome O
p450s O
and O
influence O
of O
p450 O
modulation O
in O
lindane O
induced O
neurotoxicity B-NEG
. O

oral O
administration O
of O
lindane O
(2.5 O
, O
5, O
10 O
and O
15 O
mg/kg O
, O
body O
weight O
) O
for O
5 O
days O
was O
found O
to O
produce O
a O
dose-dependent O
increase O
in O
the O
activity O
of O
p450 O
dependent O
7-ethoxyresorufin-o-deethylase O
(erod) O
, O
7-pentoxyresorufin-o-dealkylase O
( O
prod O
) O
and O
n-nitrosodimethylamine O
demethylase O
( O
ndma-d O
) O
in O
rat O
brain O
and O
liver O
. O

a O
significant O
increase O
in O
the O
hepatic O
and O
brain O
p450 O
monooxygenases O
was O
also O
observed O
when O
the O
duration O
of O
exposure O
of O
low O
dose O
( O
2.5 O
mg/kg O
) O
of O
lindane O
was O
increased O
from O
5 O
days O
to O
15 O
or O
21 O
days O
. O

as O
observed O
with O
different O
doses O
, O
the O
magnitude O
of O
induction O
in O
the O
activity O
of O
p450 O
monooxygenases O
was O
several O
fold O
higher O
in O
liver O
microsomes O
when O
compared O
with O
the O
brain O
. O

western O
blotting O
studies O
have O
indicated O
that O
the O
increase O
in O
the O
p450 O
enzymes O
could O
be O
due O
to O
the O
increase O
in O
the O
expression O
of O
p450 O
1a1/1a2 O
, O
2b1/2b2 O
and O
2e1 O
isoenzymes O
. O

in O
vitro O
studies O
using O
organic O
inhibitors O
specific O
for O
individual O
p450 O
isoenzymes O
and O
antibody O
inhibition O
experiments O
have O
further O
demonstrated O
that O
the O
increase O
in O
the O
activity O
of O
prod O
, O
erod O
and O
ndma-d O
are O
due O
to O
the O
increase O
in O
the O
levels O
of O
p450 O
2b1/2b2 O
, O
1a1/1a2 O
and O
2e1 O
isoenzymes O
, O
respectively O
. O

induction O
studies O
have O
further O
shown O
that O
while O
pretreatment O
of O
3-methylcholanthrene O
(mc) O
, O
an O
inducer O
of O
p4501a1/1a2 O
, O
did O
not O
produce O
any O
significant O
effect O
in O
the O
incidence O
of O
lindane O
induced O
convulsions B-NEG
, O
pretreatment O
with O
phenobarbital O
(pb) O
, O
an O
inducer O
of O
p450 O
2b1/2b2 O
or O
ethanol O
, O
an O
inducer O
of O
p450 O
2e1 O
catalysed O
reactions O
, O
significantly O
increased O
the O
incidence O
of O
lindane O
induced O
convulsions B-NEG
. O

similarly O
, O
when O
the O
p450-mediated O
metabolism O
of O
lindane O
was O
blocked O
by O
cobalt O
chloride O
incidence O
of O
convulsions B-NEG
was O
increased O
in O
animals O
treated O
with O
lindane O
indicating O
that O
lindane O
per O
se O
or O
its O
metabolites O
formed O
by O
pb O
or O
ethanol O
inducible O
p450 O
isoenzymes O
are O
involved O
in O
its O
neurobehavioral O
toxicity B-NEG
. O

-DOCSTART- O

seizure B-NEG
associated O
with O
sleep B-NEG
deprivation I-NEG
and O
sustained-release O
bupropion O
. O

this O
case O
report O
describes O
a O
generalized O
seizure B-NEG
associated O
with O
sustained-release O
bupropion O
use O
and O
sleep B-NEG
deprivation I-NEG
. O

the O
subject O
, O
a O
31-year-old O
female O
smoker O
, O
was O
participating O
in O
a O
clinical O
trial O
evaluating O
an O
investigational O
medication O
for O
smoking O
cessation O
that O
used O
sustained-release O
bupropion O
as O
an O
active O
control O
. O

after O
5 O
weeks O
of O
bupropion O
use O
, O
the O
subject O
experienced O
a O
generalized O
tonic O
clonic O
seizure B-NEG
after O
staying O
up O
nearly O
all O
night O
packing O
and O
moving O
to O
a O
new O
residence O
. O

the O
patient O
had O
no O
other O
risk O
factors O
for O
seizures B-NEG
. O

we O
suggest O
that O
sleep B-NEG
deprivation I-NEG
may O
add O
to O
the O
risk O
of O
bupropion-associated O
seizures B-NEG
. O

-DOCSTART- O

nephrotoxic B-NEG
effects O
in O
high-risk O
patients O
undergoing O
angiography O
. O

background O
: O
the O
use O
of O
iodinated O
contrast O
medium O
can O
result O
in O
nephropathy B-NEG
. O

whether O
iso-osmolar O
contrast O
medium O
is O
less O
nephrotoxic B-NEG
than O
low-osmolar O
contrast O
medium O
in O
high-risk O
patients O
is O
uncertain O
. O

methods O
: O
we O
conducted O
a O
randomized O
, O
double-blind O
, O
prospective O
, O
multicenter O
study O
comparing O
the O
nephrotoxic B-NEG
effects O
of O
an O
iso-osmolar O
, O
dimeric O
, O
nonionic O
contrast O
medium O
, O
iodixanol O
, O
with O
those O
of O
a O
low-osmolar O
, O
nonionic O
, O
monomeric O
contrast O
medium O
, O
iohexol O
. O

the O
study O
involved O
129 O
patients O
with O
diabetes B-NEG
with O
serum O
creatinine O
concentrations O
of O
1.5 O
to O
3.5 O
mg O
per O
deciliter O
who O
underwent O
coronary O
or O
aortofemoral O
angiography O
. O

the O
primary O
end O
point O
was O
the O
peak O
increase O
from O
base O
line O
in O
the O
creatinine O
concentration O
during O
the O
three O
days O
after O
angiography O
. O

other O
end O
points O
were O
an O
increase O
in O
the O
creatinine O
concentration O
of O
0.5 O
mg O
per O
deciliter O
or O
more O
, O
an O
increase O
of O
1.0 O
mg O
per O
deciliter O
or O
more O
, O
and O
a O
change O
in O
the O
creatinine O
concentration O
from O
day O
0 O
to O
day O
7. O

results O
: O
the O
creatinine O
concentration O
increased O
significantly O
less O
in O
patients O
who O
received O
iodixanol O
. O

from O
day O
0 O
to O
day O
3, O
the O
mean O
peak O
increase O
in O
creatinine O
was O
0.13 O
mg O
per O
deciliter O
in O
the O
iodixanol O
group O
and O
0.55 O
mg O
per O
deciliter O
in O
the O
iohexol O
group O
(p=0.001 O
; O
the O
increase O
with O
iodixanol O
minus O
the O
increase O
with O
iohexol O
, O
-0.42 O
mg O
per O
deciliter O
[95 O
percent O
confidence O
interval O
, O
-0.73 O
to O
-0.22]) O
. O

two O
of O
the O
64 O
patients O
in O
the O
iodixanol O
group O
(3 O
percent O
) O
had O
an O
increase O
in O
the O
creatinine O
concentration O
of O
0.5 O
mg O
per O
deciliter O
or O
more O
, O
as O
compared O
with O
17 O
of O
the O
65 O
patients O
in O
the O
iohexol O
group O
( O
26 O
percent O
) O
(p=0.002 O
; O
odds O
ratio O
for O
such O
an O
increase O
in O
the O
iodixanol O
group O
, O
0.09 O
[95 O
percent O
confidence O
interval O
, O
0.02 O
to O
0.41]) O
. O

no O
patient O
receiving O
iodixanol O
had O
an O
increase O
of O
1.0 O
mg O
per O
deciliter O
or O
more O
, O
but O
10 O
patients O
in O
the O
iohexol O
group O
( O
15 O
percent O
) O
did O
. O

the O
mean O
change O
in O
the O
creatinine O
concentration O
from O
day O
0 O
to O
day O
7 O
was O
0.07 O
mg O
per O
deciliter O
in O
the O
iodixanol O
group O
and O
0.24 O
mg O
per O
deciliter O
in O
the O
iohexol O
group O
(p=0.003 O
; O
value O
in O
the O
iodixanol O
group O
minus O
the O
value O
in O
the O
iohexol O
group O
, O
-0.17 O
mg O
per O
deciliter O
[95 O
percent O
confidence O
interval O
, O
-0.34 O
to O
-0.07]) O
. O

conclusions O
: O
nephropathy B-NEG
induced O
by O
contrast O
medium O
may O
be O
less O
likely O
to O
develop O
in O
high-risk O
patients O
when O
iodixanol O
is O
used O
rather O
than O
a O
low-osmolar O
, O
nonionic O
contrast O
medium O
. O

-DOCSTART- O

experimental O
cranial O
pain B-NEG
elicited O
by O
capsaicin O
: O
a O
pet O
study O
. O

using O
a O
positron O
emission O
tomography O
( O
pet O
) O
study O
it O
was O
shown O
recently O
that O
in O
migraine B-NEG
without O
aura O
certain O
areas O
in O
the O
brain O
stem O
were O
activated O
during O
the O
headache B-NEG
state O
, O
but O
not O
in O
the O
headache B-NEG
free O
interval O
. O

it O
was O
suggested O
that O
this O
brain O
stem O
activation O
is O
inherent O
to O
the O
migraine B-NEG
attack O
itself O
and O
represents O
the O
so O
called O
' O
migraine B-NEG
generator' O
. O

to O
test O
this O
hypothesis O
we O
performed O
an O
experimental O
pain B-NEG
study O
in O
seven O
healthy O
volunteers O
, O
using O
the O
same O
positioning O
in O
the O
pet O
scanner O
as O
in O
the O
migraine B-NEG
patients O
. O

a O
small O
amount O
of O
capsaicin O
was O
administered O
subcutaneously O
in O
the O
right O
forehead O
to O
evoke O
a O
burning O
painful B-NEG
sensation O
in O
the O
first O
division O
of O
the O
trigeminal O
nerve O
. O

increases O
of O
regional O
cerebral O
blood O
flow O
( O
rcbf O
) O
were O
found O
bilaterally O
in O
the O
insula O
, O
in O
the O
anterior O
cingulate O
cortex O
, O
the O
cavernous O
sinus O
and O
the O
cerebellum O
. O

using O
the O
same O
stereotactic O
space O
limits O
as O
in O
the O
above O
mentioned O
migraine B-NEG
study O
no O
brain O
stem O
activation O
was O
found O
in O
the O
acute O
pain B-NEG
state O
compared O
to O
the O
pain B-NEG
free O
state O
. O

the O
increase O
of O
activation O
in O
the O
region O
of O
the O
cavernous O
sinus O
however O
, O
suggests O
that O
this O
structure O
is O
more O
likely O
to O
be O
involved O
in O
trigeminal O
transmitted O
pain B-NEG
as O
such O
, O
rather O
than O
in O
a O
specific O
type O
of O
headache B-NEG
as O
was O
suggested O
for O
cluster B-NEG
headache I-NEG
. O

-DOCSTART- O

neuroleptic B-NEG
malignant I-NEG
syndrome I-NEG
with O
risperidone O
. O
neuroleptic B-NEG
malignant I-NEG
syndrome I-NEG
is O
thought O
to O
be O
a O
result O
of O
dopamine O
d2 O
receptor O
blockade O
in O
the O
striatum O
of O
the O
basal O
ganglia O
. O

risperidone O
, O
a O
benzisoxazole O
derivative O
antipsychotic O
, O
has O
high O
serotonin O
5-ht2 O
receptor O
blockade O
and O
dose-related O
d2 O
receptor O
blockade O
. O

the O
high O
ratio O
is O
believed O
to O
impart O
the O
low O
frequency O
of O
extrapyramidal B-NEG
symptoms I-NEG
with O
risperidone O
at O
low O
dosages O
. O

with O
this O
low O
frequency O
of O
extrapyramidal B-NEG
symptoms I-NEG
, O
it O
was O
thought O
the O
frequency O
of O
neuroleptic B-NEG
malignant I-NEG
syndrome I-NEG
might O
also O
be O
lowered O
. O

a O
73-year-old O
woman O
developed O
neuroleptic B-NEG
malignant I-NEG
syndrome I-NEG
after O
monotherapy O
with O
risperidone O
. O

the O
syndrome O
reversed O
after O
discontinuing O
risperidone O
and O
starting O
treatment O
with O
dantrolene O
and O
bromocriptine O
. O

it O
appears O
that O
the O
protection O
from O
extrapyramidal O
side O
effects O
observed O
with O
risperidone O
does O
not O
ensure O
protection O
from O
neuroleptic B-NEG
malignant I-NEG
syndrome I-NEG
. O

-DOCSTART- O

hepatic O
and O
extrahepatic O
angiotensinogen O
gene O
expression O
in O
rats O
with O
acute O
nephrotic B-NEG
syndrome I-NEG
. O

plasma O
concentration O
and O
urine O
excretion O
of O
the O
renin-angiotensin O
system O
proteins O
are O
altered O
in O
rats O
with O
nephrotic B-NEG
syndrome I-NEG
( O
ns B-NEG
). O

in O
this O
work O
the O
messenger O
ribonucleic O
acid O
( O
mrna O
) O
levels O
of O
angiotensinogen O
( O
ao O
) O
were O
analyzed O
with O
the O
slot-blot O
hybridization O
technique O
in O
liver O
and O
other O
extrahepatic O
tissues O
: O
kidney O
, O
heart O
, O
brain O
, O
and O
adrenal O
gland O
from O
control O
, O
nephrotic B-NEG
, O
and O
pair-fed O
( O
pf O
) O
rats O
. O
ns B-NEG
was O
induced O
by O
a O
single O
injection O
of O
puromycin O
amino-nucleoside O
(pan) O
. O

although O
a O
great O
urinary O
excretion O
and O
half-normal O
plasma O
levels O
of O
ao O
were O
observed O
on O
day O
6 O
after O
pan O
injection O
, O
when O
ns B-NEG
was O
clearly O
established O
, O
hepatic O
ao O
mrna O
levels O
did O
not O
change O
. O

furthermore O
, O
the O
ao O
mrna O
levels O
did O
not O
change O
in O
any O
of O
the O
extrahepatic O
tissues O
studied O
on O
day O
6, O
nor O
did O
its O
hepatic O
levels O
at O
days O
1, O
3, O
5, O
or O
7 O
after O
pan O
injection O
. O

these O
data O
suggest O
that O
the O
hepatic O
and O
extrahepatic O
ao O
mrna O
levels O
are O
unaltered O
during O
the O
development O
of O
the O
acute O
ns B-NEG
induced O
by O
pan O
. O

-DOCSTART- O

cyclophosphamide O
associated O
bladder B-NEG
cancer I-NEG
--a O
highly O
aggressive O
disease O
: O
analysis O
of O
12 O
cases O
. O

purpose O
: O
we O
gained O
knowledge O
of O
the O
etiology O
, O
treatment O
and O
prevention O
of O
cyclophosphamide O
associated O
urothelial B-NEG
cancer I-NEG
. O

materials O
and O
methods O
: O
the O
medical O
records O
of O
6 O
men O
and O
6 O
women O
( O
mean O
age O
55 O
years O
) O
with O
cyclophosphamide O
associated O
bladder B-NEG
cancer I-NEG
were O
reviewed O
. O

results O
: O
all O
tumors B-NEG
were O
grade O
3 O
or O
4 O
transitional O
cell O
carcinoma B-NEG
. O

of O
the O
5 O
patients O
initially O
treated O
with O
endoscopic O
resection O
alone O
only O
1 O
is O
alive O
without O
disease O
. O

of O
the O
6 O
patients O
who O
underwent O
early O
cystectomy O
4 O
were O
alive O
at O
24 O
to O
111 O
months O
. O

the O
remaining O
patient O
with O
extensive O
cancer B-NEG
underwent O
partial O
cystectomy O
for O
palliation O
and O
died O
3 O
months O
later O
. O

conclusions O
: O
cyclophosphamide O
associated O
bladder B-NEG
tumor I-NEG
is O
an O
aggressive O
disease O
. O

however O
, O
long-term O
survival O
is O
possible O
when O
radical O
cystectomy O
is O
performed O
for O
bladder B-NEG
tumors I-NEG
with O
any O
sign O
of O
invasion O
and O
for O
recurrent O
high O
grade O
disease O
, O
even O
when O
noninvasive O
. O

-DOCSTART- O

leg B-NEG
and I-NEG
back I-NEG
pain I-NEG
after O
spinal O
anaesthesia O
involving O
hyperbaric O
5% O
lignocaine O
. O

fifty-four O
patients O
, O
aged O
27-90 O
years O
, O
who O
were O
given O
lignocaine O
5% O
in O
6.8% O
glucose O
solution O
for O
spinal O
anaesthesia O
were O
studied O
. O

thirteen O
of O
these O
patients O
experienced O
pain B-NEG
in I-NEG
the I-NEG
legs I-NEG
and/or I-NEG
back I-NEG
after O
recovery O
from O
anaesthesia O
. O

the O
patients O
affected O
were O
younger O
(p O
< O
0.05 O
) O
and O
the O
site O
of O
the O
dural O
puncture O
was O
higher O
(p O
< O
0.01 O
) O
than O
those O
individuals O
without O
pain B-NEG
. O

five O
of O
the O
13 O
patients O
( O
38% O
) O
with O
pain B-NEG
and O
seven O
of O
the O
41 O
patients O
( O
17% O
) O
without O
pain B-NEG
admitted O
to O
a O
high O
alcohol O
intake O
, O
which O
might O
be O
a O
contributing O
factor O
. O
leg B-NEG
and/or I-NEG
back I-NEG
pain I-NEG
is O
associated O
with O
the O
intrathecal O
use O
of O
hyperbaric O
5% O
lignocaine O
. O

-DOCSTART- O

acute O
blood O
pressure O
elevations O
with O
caffeine O
in O
men O
with O
borderline O
systemic O
hypertension B-NEG
. O

whether O
the O
vasoconstrictive O
actions O
of O
caffeine O
are O
enhanced O
in O
hypertensive B-NEG
persons O
has O
not O
been O
demonstrated O
. O

thus O
, O
caffeine O
( O
3.3 O
mg/kg O
) O
versus O
placebo O
was O
tested O
in O
48 O
healthy O
men O
( O
aged O
20 O
to O
35 O
years O
) O
selected O
after O
screening O
on O
2 O
separate O
occasions O
. O

borderline O
hypertensive B-NEG
men O
(n O
= O
24 O
) O
were O
selected O
with O
screening O
systolic O
blood O
pressure O
( O
bp O
) O
of O
140 O
to O
160 O
mm O
hg O
and/or O
diastolic O
bp O
90 O
to O
99 O
mm O
hg O
. O

low-risk O
controls O
(n O
= O
24 O
) O
reported O
no O
parental O
history O
of O
hypertension B-NEG
and O
had O
screening O
bp O
< O
130/85 O
mm O
hg O
. O

participants O
were O
then O
tested O
on O
2 O
occasions O
after O
12-hour O
abstinence O
from O
caffeine O
in O
each O
of O
2 O
protocols O
; O
this O
required O
a O
total O
of O
4 O
laboratory O
visits O
. O

caffeine-induced O
changes O
in O
diastolic O
bp O
were O
2 O
to O
3 O
times O
larger O
in O
borderline O
subjects O
than O
in O
controls O
( O
+8.4 O
vs O
+3.8 O
mm O
hg O
, O
p O
< O
0.0001) O
, O
and O
were O
attributable O
to O
larger O
changes O
in O
impedance-derived O
measures O
of O
systemic O
vascular O
resistance O
( O
+135 O
vs O
+45 O
dynes.s.cm-5 O
, O
p O
< O
0.004) O
. O

these O
findings O
were O
consistent O
and O
reached O
significance O
in O
both O
protocols O
. O

the O
percentage O
of O
borderline O
subjects O
in O
whom O
diastolic O
bp O
changes O
exceeded O
the O
median O
control O
response O
was O
96% O
. O

consequently O
, O
whereas O
all O
participants O
exhibited O
normotensive O
levels O
during O
the O
resting O
predrug O
baseline O
, O
33% O
of O
borderline O
subjects O
achieved O
hypertensive B-NEG
bp O
levels O
after O
caffeine O
ingestion O
. O

thus O
, O
in O
borderline O
hypertensive B-NEG
men O
, O
exaggerated O
responses O
to O
caffeine O
were O
: O
selective O
for O
diastolic O
bp O
, O
consistent O
with O
greater O
vasoconstriction O
, O
replicated O
in O
2 O
protocols O
, O
and O
representative O
of O
nearly O
all O
borderline O
hypertensives B-NEG
. O

we O
suspect O
that O
the O
potential O
for O
caffeine O
to O
stabilize O
high O
resistance O
states O
in O
susceptible O
persons O
suggests O
that O
its O
use O
may O
facilitate O
their O
disease O
progression O
, O
as O
well O
as O
hinder O
accurate O
diagnosis O
and O
treatment O
. O

-DOCSTART- O

hallucinations B-NEG
and O
ifosfamide-induced O
neurotoxicity B-NEG
. O

background O
: O
hallucinations B-NEG
as O
a O
symptom O
of O
central O
neurotoxicity B-NEG
are O
a O
known O
but O
poorly O
described O
side O
effect O
of O
ifosfamide O
. O

most O
cases O
of O
ifosfamide-induced O
hallucinations B-NEG
have O
been O
reported O
with O
other O
mental O
status O
changes O
. O

methods O
: O
the O
authors O
interviewed O
six O
persons O
with O
ifosfamide-induced O
hallucinations B-NEG
in O
the O
presence O
of O
a O
clear O
sensorium O
. O

all O
patients O
were O
receiving O
high-dose O
ifosfamide O
as O
part O
of O
their O
bone O
marrow O
transplant O
procedure O
. O

results O
: O
hallucinations B-NEG
occurred O
only O
when O
the O
patient's O
eyes O
were O
closed O
and O
, O
in O
all O
but O
one O
case O
, O
were O
reported O
as O
disturbing O
or O
frightening O
. O

underreporting O
of O
these O
hallucinations B-NEG
by O
patients O
is O
likely O
. O

conclusions O
: O
hallucinations B-NEG
may O
be O
the O
sole O
or O
first O
manifestation O
of O
neurotoxicity B-NEG
. O

the O
incidence O
may O
be O
dose O
and O
infusion-time O
related O
. O

the O
clinician O
should O
be O
alerted O
for O
possible O
ifosfamide-induced O
hallucinations B-NEG
, O
which O
may O
occur O
without O
other O
signs O
of O
neurotoxicity B-NEG
. O

eyes-closed O
hallucinatory B-NEG
experiences O
appear O
to O
be O
an O
unusual O
feature O
of O
this O
presentation O
. O

patients O
anxious O
about O
this O
experience O
respond O
well O
to O
support O
and O
education O
about O
this O
occurrence O
. O

optimal O
pharmacologic O
management O
of O
disturbed O
patients O
is O
unclear O
. O

if O
agitation B-NEG
becomes O
marked O
, O
high-potency O
neuroleptics O
(i.e. O
, O
haloperidol O
) O
may O
be O
effective O
. O

-DOCSTART- O

chlorpropamide-induced O
optic B-NEG
neuropathy I-NEG
. O

a O
65-year-old O
woman O
with O
adult-onset B-NEG
diabetes I-NEG
treated O
with O
chlorpropamide O
( O
diabenese O
) O
had O
a O
toxic B-NEG
optic I-NEG
neuropathy I-NEG
that O
resolved O
with O
discontinuation O
of O
chlorpropamide O
therapy O
. O
visual B-NEG
loss I-NEG
occurs O
in O
diabetics B-NEG
for O
a O
variety O
of O
reasons O
, O
and O
accurate O
diagnosis O
is O
necessary O
to O
institute O
appropriate O
therapy O
. O

the O
possibility O
of O
a O
drug-induced O
optic B-NEG
neuropathy I-NEG
should O
be O
considered O
in O
the O
differential O
diagnosis O
of O
visual B-NEG
loss I-NEG
in O
diabetics B-NEG
. O

-DOCSTART- O

levodopa-induced O
dyskinesia B-NEG
and O
thalamotomy O
. O

levodopa-induced O
dyskinesia B-NEG
of O
the O
limbs O
in O
thirteen O
cases O
of O
parkinsonism B-NEG
, O
which O
was O
choreic O
, O
ballistic O
or O
dystonic B-NEG
in O
type O
, O
was O
alleviated O
almost O
completely O
by O
stereotaxic O
surgery O
using O
a O
microelectrode O
technique O
for O
the O
ventralis O
oralis O
anterior O
and O
posterior O
nuclei O
of O
the O
thalamus O
, O
but O
much O
less O
by O
the O
ventralis O
intermedius O
nucleus O
. O

control O
of O
levodopa-induced O
dyskinesias B-NEG
by O
thalamic B-NEG
lesions I-NEG
in O
the O
course O
of O
routine O
treatment O
of O
parkinsonism B-NEG
is O
discussed O
. O

-DOCSTART- O

factors O
associated O
with O
nephrotoxicity B-NEG
and O
clinical O
outcome O
in O
patients O
receiving O
amikacin O
. O

data O
from O
60 O
patients O
treated O
with O
amikacin O
were O
analyzed O
for O
factors O
associated O
with O
nephrotoxicity B-NEG
. O

in O
42 O
of O
these O
patients O
, O
data O
were O
examined O
for O
factors O
associated O
with O
clinical O
outcome O
. O

variables O
evaluated O
included O
patient O
weight O
, O
age O
, O
sex O
, O
serum O
creatinine O
level O
, O
creatinine O
clearance O
, O
duration O
of O
therapy O
, O
total O
dose O
, O
mean O
daily O
dose O
, O
organism O
minimum O
inhibitory O
concentration O
(mic) O
, O
mean O
peak O
levels O
, O
mean O
trough O
levels O
, O
mean O
area O
under O
the O
serum O
concentration-time O
curve O
(auc) O
, O
total O
auc O
, O
mean O
auc O
greater O
than O
mic O
, O
total O
auc O
greater O
than O
mic O
, O
mean O
schumacher's O
intensity O
factor O
(if) O
, O
total O
if O
, O
in O
( O
mean O
maximum O
concentration O
[cmax]/mic) O
. O

model-dependent O
pharmacokinetic O
parameters O
were O
calculated O
by O
computer O
based O
on O
a O
one-compartment O
model O
. O

when O
the O
parameters O
were O
examined O
individually O
, O
duration O
of O
therapy O
and O
total O
auc O
correlated O
significantly O
(p O
less O
than O
.05 O
) O
with O
nephrotoxicity B-NEG
. O

in O
contrast O
, O
a O
stepwise O
discriminant O
function O
analysis O
identified O
only O
duration O
of O
therapy O
(p O
less O
than O
.001 O
) O
as O
an O
important O
factor O
. O

based O
on O
this O
model O
and O
on O
bayes' O
theorem O
, O
the O
predictive O
accuracy O
of O
identifying O
nephrotoxic B-NEG
patients O
increased O
from O
0.17 O
to O
0.39 O
. O

when O
examined O
individually O
, O
mean O
if O
, O
mic O
, O
total O
dose O
, O
mean O
daily O
dose O
, O
and O
ln O
( O
mean O
cmax/mic O
) O
correlated O
significantly O
(p O
less O
than O
.05 O
) O
with O
cure O
. O

in O
contrast O
, O
a O
simultaneous O
multivariable O
analysis O
identified O
if O
, O
mic O
, O
and O
total O
dose O
according O
to O
one O
model O
and O
ln O
( O
mean O
cmax/mic O
) O
according O
to O
a O
second O
statistical O
model O
of O
parameters O
selected O
to O
have O
the O
greatest O
prospective O
value O
. O

based O
on O
bayes' O
theorem O
and O
the O
first O
model O
, O
the O
predictive O
accuracy O
of O
identifying O
patients O
not O
cured O
increased O
from O
0.19 O
to O
0.83 O
. O

for O
the O
second O
model O
, O
the O
predictive O
accuracy O
increased O
from O
0.19 O
to O
0.50.(abstract O
truncated O
at O
250 O
words O
) O

-DOCSTART- O

cardiac O
transplantation O
: O
improved O
quality O
of O
survival O
with O
a O
modified O
immunosuppressive O
protocol O
. O

the O
effects O
on O
renal O
function O
on O
two O
different O
immunosuppressive O
protocols O
were O
evaluated O
retrospectively O
in O
two O
subsequent O
groups O
of O
heart O
transplant O
recipients O
. O

in O
group O
i, O
cyclosporine O
was O
given O
before O
the O
procedure O
at O
a O
loading O
dose O
of O
17.5 O
mg/kg O
and O
then O
continued O
after O
the O
procedure O
to O
keep O
a O
whole O
blood O
level O
about O
1000 O
ng/ml O
. O

in O
group O
ii O
, O
cyclosporine O
was O
started O
only O
after O
the O
procedure O
at O
a O
lower O
dosage O
and O
was O
complemented O
by O
azathioprine O
, O
which O
was O
used O
for O
the O
first O
postoperative O
week O
. O

group O
ii O
showed O
a O
better O
perioperative O
renal O
function O
as O
determined O
by O
serum O
blood O
urea O
nitrogen O
and O
serum O
creatinine O
levels O
. O

group O
ii O
also O
showed O
a O
significant O
decrease O
of O
chronic O
nephrotoxicity B-NEG
secondary O
to O
long-term O
therapy O
with O
cyclosporine O
. O

despite O
this O
improvement O
in O
late O
renal O
function O
, O
group O
ii O
still O
shows O
a O
slow O
rise O
in O
serum O
creatinine O
. O

we O
think O
that O
even O
these O
lower O
dosages O
of O
cyclosporine O
can O
cause O
chronic O
nephrotoxicity B-NEG
and O
that O
further O
modification O
of O
the O
immunosuppressive O
regimen O
is O
required O
to O
completely O
abolish O
this O
toxic O
side O
effect O
. O

-DOCSTART- O

reversible O
cholestasis B-NEG
with O
bile B-NEG
duct I-NEG
injury I-NEG
following O
azathioprine O
therapy O
. O

a O
case O
report O
. O

a O
67-year-old O
patient O
, O
with O
primary O
polymyositis B-NEG
and O
without O
previous O
evidence O
of O
liver B-NEG
disease I-NEG
, O
developed O
clinical O
and O
biochemical O
features O
of O
severe O
cholestasis B-NEG
3 O
months O
after O
initiation O
of O
azathioprine O
therapy O
. O

liver O
biopsy O
showed O
cholestasis B-NEG
with O
both O
cytological O
and O
architectural O
alterations O
of O
interlobular O
bile O
ducts O
. O

azathioprine O
withdrawal O
resulted O
after O
7 O
weeks O
in O
the O
resolution O
of O
clinical O
and O
biochemical O
abnormalities O
. O

it O
is O
believed O
that O
this O
is O
the O
first O
reported O
case O
of O
reversible O
azathioprine-induced O
cholestasis B-NEG
associated O
with O
histological O
evidence O
of O
bile B-NEG
duct I-NEG
injury I-NEG
. O

-DOCSTART- O

renal O
function O
and O
hemodynamics O
during O
prolonged O
isoflurane-induced O
hypotension B-NEG
in O
humans O
. O

the O
effect O
of O
isoflurane-induced O
hypotension B-NEG
on O
glomerular O
function O
and O
renal O
blood O
flow O
was O
investigated O
in O
20 O
human O
subjects O
. O

glomerular O
filtration O
rate O
( O
gfr O
) O
and O
effective O
renal O
plasma O
flow O
( O
erpf O
) O
were O
measured O
by O
inulin O
and O
para-aminohippurate O
( O
pah O
) O
clearance O
, O
respectively O
. O

anesthesia O
was O
maintained O
with O
fentanyl O
, O
nitrous O
oxide O
, O
oxygen O
, O
and O
isoflurane O
. O
hypotension B-NEG
was O
induced O
for O
236.9 O
+/- O
15.1 O
min O
by O
increasing O
the O
isoflurane O
inspired O
concentration O
to O
maintain O
a O
mean O
arterial O
pressure O
of O
59.8 O
+/- O
0.4 O
mmhg O
. O

gfr O
and O
erpf O
decreased O
with O
the O
induction O
of O
anesthesia O
but O
not O
significantly O
more O
during O
hypotension B-NEG
. O

postoperatively O
, O
erpf O
returned O
to O
preoperative O
values O
, O
whereas O
gfr O
was O
higher O
than O
preoperative O
values O
. O

renal O
vascular O
resistance O
increased O
during O
anesthesia O
but O
decreased O
when O
hypotension B-NEG
was O
induced O
, O
allowing O
the O
maintenance O
of O
renal O
blood O
flow O
. O

we O
conclude O
that O
renal O
compensatory O
mechanisms O
are O
preserved O
during O
isoflurane-induced O
hypotension B-NEG
and O
that O
renal O
function O
and O
hemodynamics O
quickly O
return O
to O
normal O
when O
normotension O
is O
resumed O
. O

-DOCSTART- O

debrisoquine O
phenotype O
and O
the O
pharmacokinetics O
and O
beta-2 O
receptor O
pharmacodynamics O
of O
metoprolol O
and O
its O
enantiomers O
. O

the O
metabolism O
of O
the O
cardioselective O
beta-blocker O
metoprolol O
is O
under O
genetic O
control O
of O
the O
debrisoquine/sparteine O
type O
. O

the O
two O
metabolic O
phenotypes O
, O
extensive O
( O
em O
) O
and O
poor O
metabolizers O
(pm) O
, O
show O
different O
stereoselective O
metabolism O
, O
resulting O
in O
apparently O
higher O
beta-1 O
adrenoceptor O
antagonistic O
potency O
of O
racemic O
metoprolol O
in O
ems O
. O

we O
investigated O
if O
the O
latter O
also O
applies O
to O
the O
beta-2 O
adrenoceptor O
antagonism O
by O
metoprolol O
. O

the O
drug O
effect O
studied O
was O
the O
antagonism O
by O
metoprolol O
of O
terbutaline-induced O
hypokalemia B-NEG
. O

by O
using O
pharmacokinetic O
pharmacodynamic O
modeling O
the O
pharmacodynamics O
of O
racemic O
metoprolol O
and O
the O
active O
s-isomer O
, O
were O
quantitated O
in O
ems O
and O
pms O
in O
terms O
of O
ic50 O
values O
, O
representing O
metoprolol O
plasma O
concentrations O
resulting O
in O
half-maximum O
receptor O
occupancy O
. O

six O
ems O
received O
0.5 O
mg O
of O
terbutaline O
s.c O
. O
on O
two O
different O
occasions O
: O
1) O
1 O
hr O
after O
administration O
of O
a O
placebo O
and O
2) O
1 O
hr O
after O
150 O
mg O
of O
metoprolol O
p.o O
. O

five O
pms O
were O
studied O
according O
to O
the O
same O
protocol O
, O
except O
for O
a O
higher O
terbutaline O
dose O
( O
0.75 O
mg O
) O
on O
day O
2. O

blood O
samples O
for O
the O
analysis O
of O
plasma O
potassium O
, O
terbutaline O
, O
metoprolol O
(racemic O
, O
r- O
and O
s-isomer) O
, O
and O
alpha-hydroxymetoprolol O
concentrations O
were O
taken O
at O
regular O
time O
intervals O
, O
during O
8 O
hr O
after O
metoprolol O
. O

in O
pms O
, O
metoprolol O
increased O
the O
terbutaline O
area O
under O
the O
plasma O
concentration O
vs O
. O
time O
curve O
(+67%) O
. O

higher O
metoprolol/alpha-hydroxymetoprolol O
ratios O
in O
pms O
were O
predictive O
for O
higher O
r-/s-isomer O
ratios O
of O
unchanged O
drug O
. O

there O
was O
a O
difference O
in O
metoprolol O
potency O
with O
higher O
racemic O
metoprolol O
ic50 O
values O
in O
pms O
( O
72 O
+/- O
7 O
ng.ml-1 O
) O
than O
ems O
( O
42 O
+/- O
8 O
ng.ml-1 O
, O
p O
less O
than O
.001).(abstract O
truncated O
at O
250 O
words O
) O

-DOCSTART- O

cefotetan-induced O
immune O
hemolytic B-NEG
anemia I-NEG
. O

immune O
hemolytic B-NEG
anemia I-NEG
due O
to O
a O
drug-adsorption O
mechanism O
has O
been O
described O
primarily O
in O
patients O
receiving O
penicillins O
and O
first-generation O
cephalosporins O
. O

we O
describe O
a O
patient O
who O
developed O
anemia B-NEG
while O
receiving O
intravenous O
cefotetan O
. O

cefotetan-dependent O
antibodies O
were O
detected O
in O
the O
patient's O
serum O
and O
in O
an O
eluate O
prepared O
from O
his O
red O
blood O
cells O
. O

the O
eluate O
also O
reacted O
weakly O
with O
red O
blood O
cells O
in O
the O
absence O
of O
cefotetan O
, O
suggesting O
the O
concomitant O
formation O
of O
warm-reactive O
autoantibodies O
. O

these O
observations O
, O
in O
conjunction O
with O
clinical O
and O
laboratory O
evidence O
of O
extravascular O
hemolysis B-NEG
, O
are O
consistent O
with O
drug-induced O
hemolytic B-NEG
anemia I-NEG
, O
possibly O
involving O
both O
drug-adsorption O
and O
autoantibody O
formation O
mechanisms O
. O

this O
case O
emphasizes O
the O
need O
for O
increased O
awareness O
of O
hemolytic O
reactions O
to O
all O
cephalosporins O
. O

-DOCSTART- O

acute B-NEG
renal I-NEG
failure I-NEG
subsequent O
to O
the O
administration O
of O
rifampicin O
. O

a O
follow-up O
study O
of O
cases O
reported O
earlier O
. O

a O
clinical O
presentation O
is O
made O
of O
a O
2-3 O
year O
follow-up O
of O
six O
cases O
of O
acute B-NEG
renal I-NEG
failure I-NEG
that O
have O
been O
reported O
earlier O
. O

the O
patients O
had O
developed O
transient O
renal B-NEG
failure I-NEG
after O
the O
intermittent O
administration O
of O
rifampicin O
. O

the O
stage O
of O
olig- O
anuria B-NEG
lasted O
for O
1-3 O
weeks O
, O
and O
five O
of O
the O
patients O
were O
treated O
by O
hemodialysis O
. O

two O
of O
the O
patients O
died O
due O
to O
unrelated O
causes O
during O
the O
follow-up O
period O
. O

the O
four O
patients O
re-examined O
were O
clinically O
cured O
. O

pathologic O
findings O
by O
light O
microscopy O
and O
immunofluorescence O
at O
biopsy O
were O
scarce O
. O

nothing O
abnormal O
was O
seen O
by O
electron O
microscopy O
in O
two O
of O
the O
cases O
studied O
. O

renal O
function O
was O
normal O
. O

in O
three O
cases O
the O
excretion O
at O
131i-hippuran O
renography O
was O
slightly O
slowed O
. O

although O
in O
the O
acute O
stage O
the O
renal B-NEG
lesions I-NEG
histologically O
appeared O
toxic O
, O
evidence O
suggestive O
of O
an O
immunological O
mechanism O
cannot O
be O
excluded O
. O

-DOCSTART- O

type B-NEG
b I-NEG
hepatitis I-NEG
after O
needle-stick O
exposure O
: O
prevention O
with O
hepatitis B-NEG
b I-NEG
immune O
globulin O
. O

final O
report O
of O
the O
veterans O
administration O
cooperative O
study O
. O
hepatitis B-NEG
b I-NEG
immune O
globulin O
( O
hbig O
) O
and O
immune O
serum O
globulin O
( O
isg O
) O
were O
examined O
in O
a O
randomized O
, O
double-blind O
trial O
to O
assess O
their O
relative O
efficacies O
in O
preventing O
type B-NEG
b I-NEG
hepatitis I-NEG
after O
needle-stick O
exposure O
to O
hepatitis O
b O
surface O
antigen O
( O
hbsag)-positive O
donors O
. O

clinical O
hepatitis B-NEG
developed O
in O
1.4% O
of O
hbig O
and O
in O
5.9% O
of O
isg O
recipients O
(p O
= O
0.016) O
, O
and O
seroconversion O
( O
anti-hbs O
) O
occurred O
in O
5.6% O
and O
20.7% O
of O
them O
respectively O
(p O
less O
than O
0.001) O
. O

mild O
and O
transient O
side-effects O
were O
noted O
in O
3.0% O
of O
isg O
and O
in O
3.2% O
of O
hbig O
recipients O
. O

available O
donor O
sera O
were O
examined O
for O
dna O
polymerase O
( O
dnap O
) O
and O
e O
antigen O
and O
antibody O
(hbeag O
; O
anti-hbe) O
. O

both O
dnap O
and O
hbeag O
showed O
a O
highly O
statistically O
significant O
correlation O
with O
the O
infectivity O
of O
hbsag-positive O
donors O
. O
hepatitis B-NEG
b I-NEG
immune O
globulin O
remained O
significantly O
superior O
to O
isg O
in O
preventing O
type B-NEG
b I-NEG
hepatitis I-NEG
even O
when O
the O
analysis O
was O
confined O
to O
these O
two O
high-risk O
subgroups O
. O

the O
efficacy O
of O
isg O
in O
preventing O
type B-NEG
b I-NEG
hepatitis I-NEG
cannot O
be O
ascertained O
because O
a O
true O
placebo O
group O
was O
not O
included O
. O

-DOCSTART- O

serotonin B-NEG
syndrome I-NEG
from O
venlafaxine-tranylcypromine O
interaction O
. O

excessive O
stimulation O
of O
serotonin O
5ht1a O
receptors O
causes O
a O
syndrome O
of O
serotonin O
excess O
that O
consists O
of O
shivering O
, O
muscle B-NEG
rigidity I-NEG
, O
salivation B-NEG
, O
confusion B-NEG
, O
agitation B-NEG
and O
hyperthermia B-NEG
. O

the O
most O
common O
cause O
of O
this O
syndrome O
is O
an O
interaction O
between O
a O
monoamine O
oxidase O
inhibitor O
( O
maoi O
) O
and O
a O
specific O
serotonin O
reuptake O
inhibitor O
. O

venlafaxine O
is O
a O
new O
antidepressant O
agent O
that O
inhibits O
the O
reuptake O
of O
serotonin O
and O
norepinephrine O
. O

we O
report O
a O
venlafaxine-maoi O
interaction O
that O
resulted O
in O
the O
serotonin B-NEG
syndrome I-NEG
in O
a O
23-y-old O
male O
who O
was O
taking O
tranylcypromine O
for O
depression B-NEG
. O

he O
had O
been O
well O
until O
the O
morning O
of O
presentation O
when O
he O
took O
1/2 O
tab O
of O
venlafaxine O
. O

within O
2 O
h O
he O
became O
confused O
with O
jerking O
movements O
of O
his O
extremities O
, O
tremors B-NEG
and O
rigidity B-NEG
. O

he O
was O
brought O
directly O
to O
a O
hospital O
where O
he O
was O
found O
to O
be O
agitated O
and O
confused O
with O
shivering O
, O
myoclonic B-NEG
jerks I-NEG
, O
rigidity B-NEG
, O
salivation B-NEG
and O
diaphoresis O
. O

his O
pupils O
were O
7 O
mm O
and O
sluggishly O
reactive O
to O
light O
. O

vital O
signs O
were O
: O
blood O
pressure O
120/67 O
mm O
hg O
, O
heart O
rate O
127/min O
, O
respiratory O
rate O
28/min O
, O
and O
temperature O
97 O
f. O

after O
180 O
mg O
of O
diazepam O
i.v O
. O
he O
remained O
tremulous O
with O
muscle B-NEG
rigidity I-NEG
and O
clenched O
jaws O
. O

he O
was O
intubated O
for O
airway O
protection O
and O
because O
of O
hypoventilation B-NEG
, O
and O
was O
paralyzed B-NEG
to O
control O
muscle B-NEG
rigidity I-NEG
. O

his O
subsequent O
course O
was O
remarkable O
for O
non-immune O
thrombocytopenia B-NEG
which O
resolved O
. O

the O
patient's O
maximal O
temperature O
was O
101.2 O
f O
and O
his O
cpk O
remained O
< O
500 O
units/l O
with O
no O
other O
evidence O
of O
rhabdomyolysis B-NEG
. O

his O
mental O
status O
normalized O
and O
he O
was O
transferred O
to O
a O
psychiatry O
ward O
. O

this O
patient O
survived O
without O
sequelae O
due O
to O
the O
aggressive O
sedation O
and O
neuromuscular O
paralysis B-NEG
. O

-DOCSTART- O

effect O
of O
nondopaminergic O
drugs O
on O
l-dopa-induced O
dyskinesias B-NEG
in O
mptp-treated O
monkeys O
. O

a O
group O
of O
four O
monkeys O
was O
rendered O
parkinsonian B-NEG
with O
the O
toxin O
mptp O
. O

they O
were O
then O
treated O
chronically O
with O
l-dopa/benserazide O
50/12.5 O
mg/kg O
given O
orally O
daily O
for O
2 O
months O
. O

this O
dose O
produced O
a O
striking O
antiparkinsonian O
effect O
, O
but O
all O
animals O
manifested O
dyskinesia B-NEG
. O

a O
series O
of O
agents O
acting O
primarily O
on O
neurotransmitters O
other O
than O
dopamine O
were O
then O
tested O
in O
combination O
with O
l-dopa O
to O
see O
if O
the O
dyskinetic B-NEG
movements O
would O
be O
modified O
. O

several O
drugs O
, O
including O
clonidine O
, O
physostigmine O
, O
methysergide O
, O
5-mdot O
, O
propranolol O
, O
and O
mk-801 O
, O
markedly O
reduced O
the O
dyskinetic B-NEG
movements O
but O
at O
the O
cost O
of O
a O
return O
of O
parkinsonian B-NEG
symptomatology O
. O

however O
, O
yohimbine O
and O
meperidine O
reduced O
predominantly O
the O
dyskinetic B-NEG
movements O
. O

baclofen O
was O
also O
useful O
in O
one O
monkey O
against O
a O
more O
dystonic B-NEG
form O
of O
dyskinesia B-NEG
. O

atropine O
converted O
the O
dystonic B-NEG
movements O
into O
chorea B-NEG
. O

-DOCSTART- O

ccnu O
( O
lomustine O
) O
toxicity B-NEG
in O
dogs O
: O
a O
retrospective O
study O
(2002-07) O
. O

objective O
: O
to O
describe O
the O
incidence O
of O
haematological B-NEG
, O
renal I-NEG
, O
hepatic I-NEG
and I-NEG
gastrointestinal I-NEG
toxicities I-NEG
in O
tumour-bearing O
dogs O
receiving O
1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea O
(ccnu) O
. O

design O
: O
the O
medical O
records O
of O
206 O
dogs O
that O
were O
treated O
with O
ccnu O
at O
the O
melbourne O
veterinary O
specialist O
centre O
between O
february O
2002 O
and O
december O
2007 O
were O
retrospectively O
evaluated O
. O

results O
: O
of O
the O
206 O
dogs O
treated O
with O
ccnu O
, O
185 O
met O
the O
inclusion O
criteria O
for O
at O
least O
one O
class O
of O
toxicity B-NEG
. O

ccnu O
was O
used O
most O
commonly O
in O
the O
treatment O
of O
lymphoma B-NEG
, O
mast B-NEG
cell I-NEG
tumour I-NEG
, O
brain B-NEG
tumour I-NEG
, O
histiocytic B-NEG
tumours I-NEG
and O
epitheliotropic B-NEG
lymphoma I-NEG
. O

throughout O
treatment O
, O
56.9% O
of O
dogs O
experienced O
neutropenia B-NEG
, O
34.2% O
experienced O
anaemia B-NEG
and O
14.2% O
experienced O
thrombocytopenia B-NEG
. O
gastrointestinal B-NEG
toxicosis I-NEG
was O
detected O
in O
37.8% O
of O
dogs O
, O
the O
most O
common O
sign O
of O
which O
was O
vomiting B-NEG
(24.3%) O
. O

potential O
renal O
toxicity B-NEG
and O
elevated O
alanine O
transaminase O
( O
alt O
) O
concentration O
were O
reported O
in O
12.2% O
and O
48.8% O
of O
dogs O
, O
respectively O
. O

the O
incidence O
of O
hepatic B-NEG
failure I-NEG
was O
1.2% O
. O

conclusions O
: O
ccnu-associated O
toxicity B-NEG
in O
dogs O
is O
common O
, O
but O
is O
usually O
not O
life O
threatening O
. O

-DOCSTART- O

neuroactive O
steroids O
protect O
against O
pilocarpine- O
and O
kainic O
acid-induced O
limbic O
seizures B-NEG
and O
status B-NEG
epilepticus I-NEG
in O
mice O
. O

several O
structurally O
related O
metabolites O
of O
progesterone O
(3 O
alpha-hydroxy O
pregnane-20-ones O
) O
and O
deoxycorticosterone O
(3 O
alpha-hydroxy O
pregnane-21-diol-20-ones O
) O
and O
their O
3 O
beta-epimers O
were O
evaluated O
for O
protective O
activity O
against O
pilocarpine- O
, O
kainic O
acid- O
and O
n-methyl-d-aspartate O
( O
nmda)-induced O
seizures B-NEG
in O
mice O
. O

steroids O
with O
the O
3-hydroxy O
group O
in O
the O
alpha-position O
and O
5-h O
in O
the O
alpha- O
or O
beta-configurations O
were O
highly O
effective O
in O
protecting O
against O
pilocarpine O
( O
416 O
mg/kg O
, O
s.c.)-induced O
limbic O
motor O
seizures B-NEG
and O
status B-NEG
epilepticus I-NEG
( O
ed50 O
values O
, O
7.0-18.7 O
mg/kg O
, O
i.p.) O
. O

the O
corresponding O
epimers O
with O
the O
3-hydroxy O
group O
in O
the O
beta-position O
were O
also O
effective O
but O
less O
potent O
( O
ed50 O
values O
, O
33.8-63.5 O
, O
i.p.) O
. O

although O
the O
neuroactive O
steroids O
were O
considerably O
less O
potent O
than O
the O
benzodiazepine O
clonazepam O
in O
protecting O
against O
pilocarpine O
seizures B-NEG
, O
steroids O
with O
the O
5 O
alpha,3 O
alpha-configuration O
had O
comparable O
or O
higher O
protective O
index O
values O
( O
td50 O
for O
motor O
impairment O
divided O
by O
ed50 O
for O
seizure B-NEG
protection O
) O
than O
clonazepam O
, O
indicating O
that O
some O
neuroactive O
steroids O
may O
have O
lower O
relative O
toxicity B-NEG
. O

steroids O
with O
the O
5 O
alpha,3 O
alpha- O
or O
5 O
beta,3 O
alpha-configurations O
also O
produced O
a O
dose-dependent O
delay O
in O
the O
onset O
of O
limbic O
seizures B-NEG
induced O
by O
kainic O
acid O
( O
32 O
mg/kg O
, O
s.c.) O
, O
but O
did O
not O
completely O
protect O
against O
the O
seizures B-NEG
. O

however O
, O
when O
a O
second O
dose O
of O
the O
steroid O
was O
administered O
1 O
hr O
after O
the O
first O
dose O
, O
complete O
protection O
from O
the O
kainic O
acid-induced O
limbic O
seizures B-NEG
and O
status B-NEG
epilepticus I-NEG
was O
obtained O
. O

the O
steroids O
also O
caused O
a O
dose-dependent O
delay O
in O
nmda O
( O
257 O
mg/kg O
, O
s.c.)-induced O
lethality O
, O
but O
did O
not O
completely O
protect O
against O
nmda O
seizures B-NEG
or O
lethality O
. O

we O
conclude O
that O
neuroactive O
steroids O
are O
highly O
effective O
in O
protecting O
against O
pilocarpine- O
and O
kainic O
acid-induced O
seizures B-NEG
and O
status B-NEG
epilepticus I-NEG
in O
mice O
, O
and O
may O
be O
of O
utility O
in O
the O
treatment O
of O
some O
forms O
of O
status B-NEG
epilepticus I-NEG
in O
humans O
. O

-DOCSTART- O

the O
safety O
and O
efficacy O
of O
combination O
n-butyl-deoxynojirimycin O
( O
sc-48334 O
) O
and O
zidovudine O
in O
patients O
with O
hiv-1 B-NEG
infection I-NEG
and O
200-500 O
cd4 O
cells/mm3 O
. O

we O
conducted O
a O
double-blind O
, O
randomized O
phase O
ii O
study O
to O
evaluate O
the O
safety O
and O
activity O
of O
combination O
therapy O
with O
n-butyl-deoxynojirimycin O
( O
sc-48334 O
) O
( O
an O
alpha-glucosidase O
i O
inhibitor O
) O
and O
zidovudine O
versus O
zidovudine O
alone O
. O

patients O
with O
200 O
to O
500 O
cd4 O
cells/mm3 O
who O
tolerated O
< O
or O
= O
12 O
weeks O
of O
prior O
zidovudine O
therapy O
received O
sc-48334 O
( O
1000 O
mg O
every O
8 O
h) O
and O
zidovudine O
( O
100 O
mg O
every O
8 O
h) O
or O
zidovudine O
and O
placebo O
. O

sixty O
patients O
received O
combination O
therapy O
and O
58 O
, O
zidovudine O
and O
placebo O
. O

twenty-three O
patients O
( O
38% O
) O
and O
15 O
(26%) O
, O
in O
the O
combination O
and O
zidovudine O
groups O
, O
respectively O
, O
discontinued O
therapy O
(p O
= O
0.15) O
. O

the O
mean O
sc-48334 O
steady-state O
trough O
level O
( O
4.04 O
+/- O
0.99 O
micrograms/ml O
) O
was O
below O
the O
in O
vitro O
inhibitory O
concentration O
for O
human O
immunodeficiency B-NEG
virus O
(hiv) O
. O

the O
mean O
increase O
in O
cd4 O
cells O
at O
week O
4 O
was O
73.8 O
cells/mm3 O
and O
52.4 O
cells/mm3 O
for O
the O
combination O
and O
zidovudine O
groups O
, O
respectively O
(p O
> O
0.36) O
. O

for O
patients O
with O
prior O
zidovudine O
therapy O
, O
the O
mean O
change O
in O
cd4 O
cells O
in O
the O
combination O
and O
zidovudine O
groups O
was O
63.7 O
cells/mm3 O
and O
4.9 O
cells/mm3 O
at O
week O
8 O
and O
6.8 O
cells/mm3 O
and O
-45.1 O
cells/mm3 O
at O
week O
16 O
, O
respectively O
. O

the O
number O
of O
patients O
with O
suppression O
of O
hiv O
p24 O
antigenemia O
in O
the O
combination O
and O
zidovudine O
groups O
was O
six O
( O
40% O
) O
and O
two O
( O
11% O
) O
at O
week O
4 O
(p O
= O
0.10 O
) O
and O
five O
( O
45% O
) O
and O
two O
( O
14% O
) O
at O
week O
24 O
(p O
= O
0.08) O
, O
respectively O
. O
diarrhea B-NEG
, O
flatulence B-NEG
, O
abdominal B-NEG
pain I-NEG
, O
and O
weight B-NEG
loss I-NEG
were O
common O
for O
combination O
recipients.(abstract O
truncated O
at O
250 O
words O
) O

-DOCSTART- O

recent O
preclinical O
and O
clinical O
studies O
with O
the O
thymidylate O
synthase O
inhibitor O
n10-propargyl-5,8-dideazafolic O
acid O
( O
cb O
3717) O
. O

cb O
3717 O
, O
n10-propargyl-5,8-dideazafolic O
acid O
, O
is O
a O
tight-binding O
inhibitor O
of O
thymidylate O
synthase O
( O
ts O
) O
whose O
cytotoxicity B-NEG
is O
mediated O
solely O
through O
the O
inhibition O
of O
this O
enzyme O
. O

recent O
preclinical O
studies O
have O
focused O
on O
the O
intracellular O
formation O
of O
cb O
3717 O
polyglutamates O
. O

following O
a O
12-hour O
exposure O
of O
l1210 O
cells O
to O
50 O
microm O
[3h]cb O
3717 O
, O
30% O
of O
the O
extractable O
radioactivity O
could O
be O
accounted O
for O
as O
cb O
3717 O
tetra- O
and O
pentaglutamate O
, O
as O
determined O
by O
high-pressure O
liquid O
chromatography O
( O
hplc O
) O
analyses O
. O

as O
inhibitors O
of O
isolated O
l1210 O
ts O
, O
cb O
3717 O
di- O
, O
tri- O
, O
tetra- O
and O
pentaglutamate O
are O
26- O
, O
87- O
, O
119- O
and O
114-fold O
more O
potent O
than O
cb O
3717 O
, O
respectively O
, O
and O
their O
formation O
may O
, O
therefore O
, O
be O
an O
important O
determinant O
of O
cb O
3717 O
cytotoxicity B-NEG
. O

in O
early O
clinical O
studies O
with O
cb O
3717 O
, O
activity O
has O
been O
seen O
in O
breast B-NEG
cancer I-NEG
, O
ovarian B-NEG
cancer I-NEG
, O
hepatoma B-NEG
, O
and O
mesothelioma B-NEG
. O
toxicities B-NEG
included O
hepatotoxicity B-NEG
, O
malaise B-NEG
, O
and O
dose-limiting O
nephrotoxicity B-NEG
. O

this O
latter O
effect O
is O
thought O
to O
be O
due O
to O
drug O
precipitation O
within O
the O
renal O
tubule O
as O
a O
result O
of O
the O
poor O
solubility O
of O
cb O
3717 O
under O
acidic O
conditions O
. O

in O
an O
attempt O
to O
overcome O
this O
problem O
, O
a O
clinical O
trial O
of O
cb O
3717 O
administered O
with O
alkaline O
diuresis O
is O
under O
way O
. O

preliminary O
results O
at O
400 O
and O
500 O
mg/m2 O
suggest O
that O
a O
reduction O
in O
nephrotoxicity B-NEG
may O
have O
been O
achieved O
with O
only O
1 O
instance O
of O
renal B-NEG
toxicity I-NEG
in O
10 O
patients O
. O
hepatotoxicity B-NEG
and O
malaise B-NEG
are O
again O
the O
most O
frequent O
side O
effects O
. O

evidence O
of O
antitumor O
activity O
has O
been O
seen O
in O
3 O
patients O
. O

pharmacokinetic O
investigations O
have O
shown O
that O
alkaline O
diuresis O
does O
not O
alter O
cb O
3717 O
plasma O
levels O
or O
urinary O
excretion O
and O
that O
satisfactory O
urinary O
alkalinization O
can O
be O
readily O
achieved O
. O

-DOCSTART- O

ethopropazine O
and O
benztropine O
in O
neuroleptic-induced O
parkinsonism B-NEG
. O

in O
a O
12-week O
controlled O
study O
ethopropazine O
was O
compared O
to O
benztropine O
in O
the O
treatment O
of O
parkinsonism B-NEG
induced O
by O
fluphenazine O
enanthate O
in O
60 O
schizophrenic B-NEG
outpatients O
. O

ethopropazine O
and O
benztropine O
were O
found O
to O
be O
equally O
effective O
in O
controlling O
parkinsonian B-NEG
symptoms I-NEG
and O
were O
as O
efficacious O
as O
procyclidine O
, O
their O
previous O
antiparkinsonian O
drug O
. O

however O
, O
benztropine O
treated O
patients O
had O
a O
significant O
increase O
in O
tardive B-NEG
dyskinesia I-NEG
compared O
to O
their O
condition O
during O
procyclindine O
treatment O
, O
and O
significantly O
more O
anxiety B-NEG
and O
depression B-NEG
than O
ethopropazine O
treated O
patients O
. O

this O
suggests O
that O
benztropine O
is O
not O
the O
anticholinergic O
drug O
of O
choice O
in O
the O
treatment O
of O
neuroleptic-induced O
parkinsonian B-NEG
symptoms I-NEG
, O
because O
of O
its O
more O
toxic O
central O
and O
peripheral O
atropinic O
effect O
. O

-DOCSTART- O

effect O
of O
alpha-tocopherol O
and O
deferoxamine O
on O
methamphetamine-induced O
neurotoxicity B-NEG
. O

methamphetamine O
( O
ma)-induced O
dopaminergic O
neurotoxicity B-NEG
is O
believed O
to O
be O
associated O
with O
the O
increased O
formation O
of O
free O
radicals O
. O

this O
study O
examined O
the O
effect O
of O
alpha-tocopherol O
(alpha-tc) O
, O
a O
scavenger O
of O
reactive O
oxygen O
species O
, O
and O
deferoxamine O
(dfo) O
, O
an O
iron O
chelator O
, O
on O
the O
ma-induced O
neurotoxicity B-NEG
. O

male O
rats O
were O
treated O
with O
ma O
( O
10 O
mg/kg O
, O
every O
2 O
h O
for O
four O
injections) O
. O

the O
rat O
received O
either O
alpha-tc O
( O
20 O
mg/kg O
) O
intraperitoneally O
for O
3 O
days O
and O
30 O
min O
prior O
to O
ma O
administration O
or O
dfo O
( O
50 O
mg/kg O
) O
subcutaneously O
30 O
min O
before O
ma O
administration O
. O

the O
concentrations O
of O
dopamine O
(da) O
, O
serotonin O
and O
their O
metabolites O
decreased O
significantly O
after O
ma O
administration O
, O
which O
was O
inhibited O
by O
the O
alpha-tc O
and O
dfo O
pretreatment O
. O

alpha-tc O
and O
dfo O
attenuated O
the O
ma-induced O
hyperthermia B-NEG
as O
well O
as O
the O
alterations O
in O
the O
locomotor O
activity O
. O

the O
level O
of O
lipid O
peroxidation O
was O
higher O
and O
the O
reduced O
glutathione O
concentration O
was O
lower O
in O
the O
ma-treated O
rats O
. O

these O
changes O
were O
significantly O
attenuated O
by O
alpha-tc O
and O
dfo O
. O

this O
suggests O
that O
alpha-tc O
and O
dfo O
ameliorate O
the O
ma-induced O
neuronal B-NEG
damage I-NEG
by O
decreasing O
the O
level O
of O
oxidative O
stress O
. O

-DOCSTART- O

use O
of O
dexamethasone O
with O
mesna O
for O
the O
prevention O
of O
ifosfamide-induced O
hemorrhagic B-NEG
cystitis I-NEG
. O

aim O
: O
hemorrhagic B-NEG
cystitis I-NEG
( O
hc B-NEG
) O
is O
a O
limiting O
side-effect O
of O
chemotherapy O
with O
ifosfamide O
(ifs) O
. O

in O
the O
study O
presented O
here O
, O
we O
investigated O
the O
use O
of O
dexamethasone O
in O
combination O
with O
mesna O
for O
the O
prevention O
of O
ifs-induced O
hc B-NEG
. O

methods O
: O
male O
wistar O
rats O
( O
150-200 O
g; O
6 O
rats O
per O
group O
) O
were O
treated O
with O
saline O
or O
mesna O
5 O
min O
( O
i.p. O
) O
before O
and O
2 O
and O
6 O
h O
after O
( O
v.o. O
) O
administration O
of O
ifs O
. O

one O
, O
two O
or O
three O
doses O
of O
mesna O
were O
replaced O
with O
dexamethasone O
alone O
or O
with O
dexamethasone O
plus O
mesna O
. O
cystitis B-NEG
was O
evaluated O
24 O
h O
after O
its O
induction O
by O
the O
changes O
in O
bladder O
wet O
weight O
and O
by O
macroscopic O
and O
microscopic O
analysis O
. O

results O
: O
the O
replacement O
of O
the O
last O
dose O
or O
the O
last O
two O
doses O
of O
mesna O
with O
dexamethasone O
reduced O
the O
increase O
in O
bladder O
wet O
weight O
induced O
by O
ifs O
by O
84.79% O
and O
89.13% O
, O
respectively O
. O

in O
addition O
, O
it O
almost O
abolished O
the O
macroscopic O
and O
microscopic O
alterations O
induced O
by O
ifs O
. O

moreover O
, O
the O
addition O
of O
dexamethasone O
to O
the O
last O
two O
doses O
of O
mesna O
was O
more O
efficient O
than O
three O
doses O
of O
mesna O
alone O
when O
evaluated O
microscopically O
. O

conclusion O
: O
dexamethasone O
in O
combination O
with O
mesna O
was O
efficient O
in O
blocking O
ifs-induced O
hc B-NEG
. O

however O
, O
the O
replacement O
of O
last O
two O
doses O
of O
mesna O
with O
saline O
or O
all O
of O
the O
mesna O
doses O
with O
dexamethasone O
did O
not O
prevent O
hc B-NEG
. O

-DOCSTART- O

behavioral O
effects O
of O
mk-801 O
on O
reserpine-treated O
mice O
. O

the O
effects O
of O
dizocilpine O
(mk-801) O
, O
a O
noncompetitive O
n-methyl-d-aspartate O
( O
nmda O
) O
receptor O
antagonist O
, O
were O
studied O
on O
dopamine-related O
behaviors O
induced O
by O
reserpine O
treatments O
. O

this O
study O
focuses O
on O
behavioral O
syndromes O
that O
may O
used O
as O
models O
for O
parkinson's B-NEG
disease I-NEG
, O
or O
tardive B-NEG
dyskinesia I-NEG
, O
and O
its O
response O
after O
glutamatergic O
blockage O
. O

reserpine O
(1 O
mg/kg) O
, O
administered O
once O
every O
other O
day O
for O
4 O
days O
, O
produced O
increases O
in O
orofacial B-NEG
dyskinesia I-NEG
, O
tongue O
protrusion O
and O
vacuous O
chewing O
in O
mice O
, O
which O
are O
signs O
indicative O
of O
tardive B-NEG
dyskinesia I-NEG
. O

reserpine O
also O
produced O
tremor B-NEG
and O
catalepsy B-NEG
, O
which O
are O
signs O
suggestive O
of O
parkinson's B-NEG
disease I-NEG
. O

mk-801 O
( O
0.1 O
mg/kg) O
, O
administered O
30 O
min O
before O
the O
observation O
test O
, O
prevented O
the O
vacuous O
chewing O
movements O
, O
tongue O
protrusions O
and O
catalepsy B-NEG
induced O
by O
reserpine O
. O

however O
, O
mk-801 O
injection O
produced O
a O
significant O
increase O
of O
tremor B-NEG
in O
reserpine-treated O
mice O
. O

reserpine O
(1 O
mg/kg) O
, O
administered O
90 O
min O
before O
the O
test O
and O
followed O
by O
apomophine O
injection O
( O
0.1 O
mg/kg O
) O
5 O
min O
before O
the O
test O
, O
did O
not O
produce O
oral B-NEG
dyskinesia I-NEG
in O
mice O
. O

on O
the O
other O
hand O
, O
reserpine O
induced O
increases O
in O
tremor B-NEG
and O
catalepsy B-NEG
compared O
to O
control O
mice O
. O

mk-801 O
( O
0.1 O
mg/kg O
) O
administration O
attenuated O
the O
catalepsy B-NEG
and O
tremor B-NEG
induced O
by O
reserpine O
. O

pretreatment O
with O
reserpine O
(1 O
mg/kg O
) O
24 O
h O
before O
the O
observation O
test O
produced O
increases O
in O
vacuous O
chewing O
movements O
and O
tongue O
protrusion O
, O
as O
well O
as O
increases O
in O
tremor B-NEG
and O
catalepsy B-NEG
, O
whereas O
mk-801 O
( O
0.1 O
mg/kg O
) O
injection O
90 O
min O
before O
the O
test O
reversed O
the O
effects O
of O
reserpine O
. O

these O
results O
show O
that O
reserpine O
produces O
different O
and O
abnormal B-NEG
movements I-NEG
, O
which O
are O
related O
to O
dose O
and O
schedule O
employed O
and O
can O
be O
considered O
as O
parkinsonian B-NEG
-like O
and O
tardive B-NEG
dsykinesia I-NEG
signs O
. O

the O
glutamatergic O
blockage O
produced O
by O
nmda O
can O
restore O
these O
signs O
, O
such O
as O
vacuous O
chewing O
movements O
, O
tongue O
protrusions O
, O
catalepsy B-NEG
and O
tremor B-NEG
according O
to O
the O
employed O
model O
. O

-DOCSTART- O

effect O
of O
glyceryl O
trinitrate O
on O
the O
sphincter B-NEG
of I-NEG
oddi I-NEG
spasm I-NEG
evoked O
by O
prostigmine-morphine O
administration O
. O

objective O
: O
in O
this O
study O
the O
effect O
of O
glyceryl O
trinitrate O
on O
the O
prostigmine-morphine-induced O
sphincter B-NEG
of I-NEG
oddi I-NEG
spasm I-NEG
was O
evaluated O
in O
nine O
female O
patients O
with O
sphincter B-NEG
of I-NEG
oddi I-NEG
dyskinesia I-NEG
. O

method O
: O
sphincter B-NEG
of I-NEG
oddi I-NEG
spasm I-NEG
was O
induced O
by O
prostigmine-morphine O
administration O
( O
0.5 O
mg O
prostigmine O
intramuscularly O
and O
10 O
mg O
morphine O
subcutaneously O
) O
and O
visualized O
by O
quantitative O
hepatobiliary O
scintigraphy O
. O

the O
entire O
procedure O
was O
repeated O
during O
glyceryl O
trinitrate O
infusion O
( O
nitrolingual O
1 O
microg/kg/min O
for O
120 O
min) O
. O

results O
: O
prostigmine-morphine O
provocation O
caused O
significant O
increases O
in O
the O
time O
to O
peak O
activity O
( O
tmax O
) O
over O
the O
hepatic O
hilum O
(hh O
: O
34.33 O
+/- O
5.05 O
vs O
. O
22.77 O
+/- O
3.26 O
) O
and O
the O
common O
bile O
duct O
(cbd O
: O
60.44 O
+/- O
5.99 O
vs O
. O
40.0 O
+/- O
2.88 O
) O
and O
in O
the O
half-time O
of O
excretion O
( O
t1/2 O
) O
over O
the O
liver O
parenchyma O
(lp O
: O
120.04 O
+/- O
16.01 O
vs O
. O
27.37 O
+/- O
2.19) O
, O
hh O
( O
117.61 O
+/- O
14.71 O
vs O
. O
31.85 O
+/- O
3.99 O
) O
and O
cbd O
( O
158.11 O
+/- O
9.18 O
vs O
. O
40.1 O
+/- O
6.24) O
, O
indicating O
a O
complete O
spasm B-NEG
at O
the O
level O
of O
the O
sphincter O
of O
oddi O
. O

glyceryl O
trinitrate O
infusion O
completely O
normalized O
the O
prostigmine-morphine-induced O
alterations O
in O
these O
quantitative O
parameters O
( O
tmax O
over O
the O
lp O
: O
11.33 O
+/- O
1.13 O
; O
over O
the O
hh O
: O
18.88 O
+/- O
1.48 O
; O
and O
over O
the O
cbd O
: O
36.22 O
+/- O
1.92 O
; O
and O
t1/2 O
over O
the O
lp O
: O
28.21 O
+/- O
1.83 O
; O
over O
the O
hh O
: O
33.42 O
+/- O
3.10 O
; O
and O
over O
the O
cbd O
: O
41.66 O
+/- O
6.33) O
, O
suggesting O
an O
effective O
sphincter-relaxing O
effect O
of O
glyceryl O
trinitrate O
. O

conclusion O
: O
these O
results O
provide O
the O
first O
evidence O
of O
the O
effectiveness O
of O
glyceryl O
trinitrate O
on O
the O
morphine-induced O
sphincter B-NEG
of I-NEG
oddi I-NEG
spasm I-NEG
in O
humans O
. O

since O
glyceryl O
trinitrate O
is O
able O
to O
overcome O
even O
the O
drastic O
effect O
of O
morphine O
, O
it O
might O
be O
of O
relevance O
in O
the O
treatment O
of O
sphincter B-NEG
of I-NEG
oddi I-NEG
dyskinesia I-NEG
. O

-DOCSTART- O

effects O
of O
acute O
steroid O
administration O
on O
ventilatory O
and O
peripheral O
muscles O
in O
rats O
. O

occasional O
case O
reports O
have O
shown O
that O
acute O
myopathy B-NEG
may O
occur O
in O
patients O
treated O
with O
massive O
doses O
of O
corticosteroids O
. O

the O
mechanism O
of O
this O
myopathy B-NEG
is O
poorly O
understood O
. O

therefore O
, O
60 O
male O
rats O
were O
randomly O
assigned O
to O
receive O
daily O
injection O
of O
saline O
(c) O
, O
methylprednisolone O
(m) O
, O
or O
triamcinolone O
( O
t O
) O
80 O
mg/kg/d O
for O
5 O
d. O

nutritional O
intake O
, O
measured O
daily O
in O
15 O
animals O
, O
showed O
a O
significant O
reduction B-NEG
of I-NEG
food I-NEG
intake I-NEG
in O
the O
steroid-treated O
groups O
( O
-50 O
and O
-79% O
in O
m O
and O
t, O
respectively) O
. O

this O
was O
associated O
with O
a O
similar O
loss B-NEG
in I-NEG
body I-NEG
weight I-NEG
. O

in O
the O
45 O
remaining O
animals O
, O
diaphragm O
contractility O
and O
histopathologic O
features O
of O
several O
muscles O
were O
studied O
. O

weights O
of O
respiratory O
and O
peripheral O
muscles O
were O
similarly O
decreased O
after O
steroid O
treatment O
. O

maximal O
twitches O
of O
the O
diaphragm O
were O
lower O
in O
the O
c O
group O
( O
653 O
+/- O
174 O
g/cm(2) O
) O
than O
in O
the O
m O
group O
( O
837 O
+/- O
171 O
g/cm(2) O
; O
p O
< O
0.05 O
) O
and O
the O
t O
group O
( O
765 O
+/- O
145 O
g/cm(2) O
, O
ns) O
. O

half-relaxation O
time O
was O
prolonged O
in O
both O
steroid O
groups O
, O
and O
time O
to O
peak O
tension O
was O
longer O
with O
m, O
whereas O
tetanic B-NEG
tensions O
were O
similar O
. O

steroid O
treatment O
also O
induced O
a O
leftward O
shift O
of O
the O
force-frequency O
curve O
at O
25 O
and O
50 O
hz O
when O
compared O
with O
saline O
treatment O
(p O
< O
0.05) O
. O

atpase O
staining O
of O
the O
diaphragm O
, O
scalenus O
medius O
, O
and O
gastrocnemius O
showed O
type O
iib O
fiber O
atrophy B-NEG
in O
the O
steroid O
groups O
and O
also O
diaphragmatic O
type O
iia O
atrophy B-NEG
with O
t, O
whereas O
histologic O
examinations O
revealed O
a O
normal O
muscular O
pattern O
with O
absence O
of O
necrosis B-NEG
. O

finally O
, O
a O
pair-fed O
( O
pf O
) O
study O
, O
performed O
in O
18 O
rats O
(c O
, O
t, O
and O
pf) O
, O
showed O
that O
muscle B-NEG
atrophy I-NEG
was O
considerably O
less O
pronounced O
in O
pf O
animals O
than O
in O
t-treated O
animals O
. O

we O
conclude O
that O
( O
1 O
) O
short-term O
treatment O
with O
massive O
doses O
of O
steroids O
induced O
severe O
respiratory O
and O
limb O
muscle O
wasting O
; O
( O
2 O
) O
both O
types O
of O
steroids O
induced O
predominantly O
type O
iib O
atrophy B-NEG
, O
resulting O
in O
the O
expected O
alterations O
in O
diaphragm O
contractile O
properties O
; O
( O
3 O
) O
neither O
steroid O
caused O
muscle O
necrosis B-NEG
; O
( O
4 O
) O
type O
iib O
atrophy B-NEG
was O
not O
caused O
by O
acute O
nutritional O
deprivation O
alone O
. O

-DOCSTART- O

refractory O
cardiogenic B-NEG
shock I-NEG
and O
complete O
heart B-NEG
block I-NEG
after O
verapamil O
sr O
and O
metoprolol O
treatment O
. O

a O
case O
report O
. O

a O
seventy-eight-year-old O
woman O
presented O
with O
complete O
heart B-NEG
block I-NEG
and O
refractory O
hypotension B-NEG
two O
days O
after O
a O
therapeutic O
dose O
of O
sustained-release O
verapamil O
with O
concomitant O
use O
of O
metoprolol O
. O

the O
patient O
continued O
to O
remain O
hypotensive B-NEG
with O
complete O
heart B-NEG
block I-NEG
, O
even O
with O
multiple O
uses O
of O
intravenous O
atropine O
as O
well O
as O
high O
doses O
of O
pressor O
agents O
such O
as O
dopamine O
and O
dobutamine O
. O

however O
, O
shortly O
after O
the O
use O
of O
intravenous O
calcium O
chloride O
, O
the O
refractory O
hypotension B-NEG
and O
complete O
heart B-NEG
block I-NEG
resolved O
. O

-DOCSTART- O

a O
phase O
i O
clinical O
study O
of O
the O
antipurine O
antifolate O
lometrexol O
( O
ddathf O
) O
given O
with O
oral O
folic O
acid O
. O

lometrexol O
is O
an O
antifolate O
which O
inhibits O
glycinamide O
ribonucleotide O
formyltransferase O
(garft) O
, O
an O
enzyme O
essential O
for O
de O
novo O
purine O
synthesis O
. O

extensive O
experimental O
and O
limited O
clinical O
data O
have O
shown O
that O
lometrexol O
has O
activity O
against O
tumours B-NEG
which O
are O
refractory O
to O
other O
drugs O
, O
notably O
methotrexate O
. O

however O
, O
the O
initial O
clinical O
development O
of O
lometrexol O
was O
curtailed O
because O
of O
severe O
and O
cumulative O
antiproliferative O
toxicities B-NEG
. O

preclinical O
murine O
studies O
demonstrated O
that O
the O
toxicity B-NEG
of O
lometrexol O
can O
be O
prevented O
by O
low O
dose O
folic O
acid O
administration O
, O
i.e O
. O
for O
7 O
days O
prior O
to O
and O
7 O
days O
following O
a O
single O
bolus O
dose O
. O

this O
observation O
prompted O
a O
phase O
i O
clinical O
study O
of O
lometrexol O
given O
with O
folic O
acid O
supplementation O
which O
has O
confirmed O
that O
the O
toxicity B-NEG
of O
lometrexol O
can O
be O
markedly O
reduced O
by O
folic O
acid O
supplementation O
. O
thrombocytopenia B-NEG
and O
mucositis B-NEG
were O
the O
major O
toxicities B-NEG
. O

there O
was O
no O
clear O
relationship O
between O
clinical O
toxicity B-NEG
and O
the O
extent O
of O
plasma O
folate O
elevation O
. O

associated O
studies O
demonstrated O
that O
lometrexol O
plasma O
pharmacokinetics O
were O
not O
altered O
by O
folic O
acid O
administration O
indicating O
that O
supplementation O
is O
unlikely O
to O
reduce O
toxicity B-NEG
by O
enhancing O
lometrexol O
plasma O
clearance O
. O

the O
work O
described O
in O
this O
report O
has O
identified O
for O
the O
first O
time O
a O
clinically O
acceptable O
schedule O
for O
the O
administration O
of O
a O
garft O
inhibitor O
. O

this O
information O
will O
facilitate O
the O
future O
evaluation O
of O
this O
class O
of O
compounds O
in O
cancer B-NEG
therapy O
. O

-DOCSTART- O

involvement O
of O
the O
mu-opiate O
receptor O
in O
peripheral O
analgesia B-NEG
. O

the O
intradermal O
injection O
of O
mu O
(morphine O
, O
tyr-d-ala-gly-nme-phe-gly-ol O
and O
morphiceptin) O
, O
kappa O
( O
trans-3,4-dichloro-n-methyl-n[2-(1-pyrrolidinyl O
) O
cyclohexyl]benzeneactemide O
) O
and O
delta O
( O
[d-pen2.5]-enkephalin O
and O
[d-ser2]-[leu]enkephalin-thr O
) O
selective O
opioid-agonists O
, O
by O
themselves O
, O
did O
not O
significantly O
affect O
the O
mechanical O
nociceptive O
threshold O
in O
the O
hindpaw O
of O
the O
rat O
. O

intradermal O
injection O
of O
mu O
, O
but O
not O
delta O
or O
kappa O
opioid-agonists O
, O
however O
, O
produced O
dose-dependent O
inhibition O
of O
prostaglandin O
e2-induced O
hyperalgesia B-NEG
. O

the O
analgesic O
effect O
of O
the O
mu-agonist O
morphine O
was O
dose-dependently O
antagonized O
by O
naloxone O
and O
prevented O
by O
co-injection O
of O
pertussis O
toxin O
. O

morphine O
did O
not O
, O
however O
, O
alter O
the O
hyperalgesia B-NEG
induced O
by O
8-bromo O
cyclic O
adenosine O
monophosphate O
. O

we O
conclude O
that O
the O
analgesic O
action O
of O
opioids O
on O
the O
peripheral O
terminals O
of O
primary O
afferents O
is O
via O
a O
binding O
site O
with O
characteristics O
of O
the O
mu-opioid O
receptor O
and O
that O
this O
action O
is O
mediated O
by O
inhibition O
of O
the O
cyclic O
adenosine O
monophosphate O
second O
messenger O
system O
. O

-DOCSTART- O

adequate O
timing O
of O
ribavirin O
reduction O
in O
patients O
with O
hemolysis B-NEG
during O
combination O
therapy O
of O
interferon O
and O
ribavirin O
for O
chronic B-NEG
hepatitis I-NEG
c I-NEG
. O

background O
: O
hemolytic B-NEG
anemia I-NEG
is O
one O
of O
the O
major O
adverse O
events O
of O
the O
combination O
therapy O
of O
interferon O
and O
ribavirin O
. O

because O
of O
ribavirin-related O
hemolytic B-NEG
anemia I-NEG
, O
dose O
reduction O
is O
a O
common O
event O
in O
this O
therapy O
. O

in O
this O
clinical O
retrospective O
cohort O
study O
we O
have O
examined O
the O
suitable O
timing O
of O
ribavirin O
reduction O
in O
patients O
with O
hemolysis B-NEG
during O
combination O
therapy O
. O

methods O
: O
thirty-seven O
of O
160 O
patients O
who O
had O
hcv-genotype O
1b O
, O
had O
high O
virus O
load O
, O
and O
received O
24-week O
combination O
therapy O
developed O
anemia B-NEG
with O
hemoglobin O
level O
<10 O
g/dl O
or O
anemia B-NEG
-related O
signs O
during O
therapy O
. O

after O
that O
, O
these O
37 O
patients O
were O
reduced O
one O
tablet O
of O
ribavirin O
( O
200 O
mg O
) O
per O
day O
. O

after O
reduction O
of O
ribavirin O
, O
27 O
of O
37 O
patients O
could O
continue O
combination O
therapy O
for O
a O
total O
of O
24 O
weeks O
( O
group O
a) O
. O

however O
, O
10 O
of O
37 O
patients O
with O
reduction O
of O
ribavirin O
could O
not O
continue O
combination O
therapy O
because O
their O
<8.5 O
g/dl O
hemoglobin O
values O
decreased O
to O
or O
anemia B-NEG
-related O
severe O
side O
effects O
occurred O
( O
group O
b) O
. O

we O
assessed O
the O
final O
efficacy O
and O
safety O
after O
reduction O
of O
ribavirin O
in O
groups O
a O
and O
b. O

results O
: O
a O
sustained O
virological O
response O
( O
svr O
) O
was O
29.6% O
( O
8/27 O
) O
in O
group O
a O
and O
10% O
( O
1/10 O
) O
in O
group O
b, O
respectively O
. O

a O
34.4% O
( O
12/27 O
) O
of O
svr O
+ O
biological O
response O
in O
group O
a O
was O
higher O
than O
10% O
( O
1/10 O
) O
in O
group O
b O
( O
p O
= O
0.051) O
, O
with O
slight O
significance O
. O

with O
respect O
to O
hemoglobin O
level O
at O
the O
time O
of O
ribavirin O
reduction O
, O
a O
rate O
of O
continuation O
of O
therapy O
in O
patients O
with O
> O
or O
=10 O
g/dl O
hemoglobin O
was O
higher O
than O
that O
in O
patients O
with O
<10 O
g/dl O
( O
p O
= O
0.036) O
. O

conclusions O
: O
reduction O
of O
ribavirin O
at O
hemoglobin O
level O
> O
or O
=10 O
g/dl O
is O
suitable O
in O
terms O
of O
efficacy O
and O
side O
effects O
. O

-DOCSTART- O

increased O
expression O
and O
apical O
targeting O
of O
renal O
enac O
subunits O
in O
puromycin O
aminonucleoside-induced O
nephrotic B-NEG
syndrome I-NEG
in O
rats O
. O
nephrotic B-NEG
syndrome I-NEG
is O
often O
accompanied O
by O
sodium O
retention O
and O
generalized O
edema B-NEG
. O

however O
, O
the O
molecular O
basis O
for O
the O
decreased O
renal O
sodium O
excretion O
remains O
undefined O
. O

we O
hypothesized O
that O
epithelial O
na O
channel O
( O
enac O
) O
subunit O
dysregulation O
may O
be O
responsible O
for O
the O
increased O
sodium O
retention O
. O

an O
experimental O
group O
of O
rats O
was O
treated O
with O
puromycin O
aminonucleoside O
(pan O
; O
180 O
mg/kg O
iv) O
, O
whereas O
the O
control O
group O
received O
only O
vehicle O
. O

after O
7 O
days O
, O
pan O
treatment O
induced O
significant O
proteinuria B-NEG
, O
hypoalbuminemia B-NEG
, O
decreased O
urinary O
sodium O
excretion O
, O
and O
extensive O
ascites B-NEG
. O

the O
protein O
abundance O
of O
alpha-enac O
and O
beta-enac O
was O
increased O
in O
the O
inner O
stripe O
of O
the O
outer O
medulla O
( O
isom O
) O
and O
in O
the O
inner O
medulla O
( O
im O
) O
but O
was O
not O
altered O
in O
the O
cortex O
. O

gamma-enac O
abundance O
was O
increased O
in O
the O
cortex O
, O
isom O
, O
and O
im O
. O

immunoperoxidase O
brightfield- O
and O
laser-scanning O
confocal O
fluorescence O
microscopy O
demonstrated O
increased O
targeting O
of O
alpha-enac O
, O
beta-enac O
, O
and O
gamma-enac O
subunits O
to O
the O
apical O
plasma O
membrane O
in O
the O
distal O
convoluted O
tubule O
(dct2) O
, O
connecting O
tubule O
, O
and O
cortical O
and O
medullary O
collecting O
duct O
segments O
. O

immunoelectron O
microscopy O
further O
revealed O
an O
increased O
labeling O
of O
alpha-enac O
in O
the O
apical O
plasma O
membrane O
of O
cortical O
collecting O
duct O
principal O
cells O
of O
pan-treated O
rats O
, O
indicating O
enhanced O
apical O
targeting O
of O
alpha-enac O
subunits O
. O

in O
contrast O
, O
the O
protein O
abundances O
of O
na(+)/h(+ O
) O
exchanger O
type O
3 O
(nhe3) O
, O
na(+)-k(+)-2cl(- O
) O
cotransporter O
(bsc-1) O
, O
and O
thiazide-sensitive O
na(+)-cl(- O
) O
cotransporter O
( O
tsc O
) O
were O
decreased O
. O

moreover O
, O
the O
abundance O
of O
the O
alpha(1)-subunit O
of O
the O
na-k-atpase O
was O
decreased O
in O
the O
cortex O
and O
isom O
, O
but O
it O
remained O
unchanged O
in O
the O
im O
. O

in O
conclusion O
, O
the O
increased O
or O
sustained O
expression O
of O
enac O
subunits O
combined O
with O
increased O
apical O
targeting O
in O
the O
dct2 O
, O
connecting O
tubule O
, O
and O
collecting O
duct O
are O
likely O
to O
play O
a O
role O
in O
the O
sodium O
retention O
associated O
with O
pan-induced O
nephrotic B-NEG
syndrome I-NEG
. O

the O
decreased O
abundance O
of O
nhe3 O
, O
bsc-1 O
, O
tsc O
, O
and O
na-k-atpase O
may O
play O
a O
compensatory O
role O
to O
promote O
sodium O
excretion O
. O

-DOCSTART- O

does O
hormone O
therapy O
for O
the O
treatment O
of O
breast B-NEG
cancer I-NEG
have O
a O
detrimental B-NEG
effect I-NEG
on I-NEG
memory I-NEG
and I-NEG
cognition I-NEG
? O

a O
pilot O
study O
. O

this O
pilot O
study O
examines O
whether O
hormone O
therapy O
for O
breast B-NEG
cancer I-NEG
affects O
cognition O
. O

patients O
participating O
in O
a O
randomised O
trial O
of O
anastrozole O
, O
tamoxifen O
alone O
or O
combined O
( O
atac O
) O
( O
n=94 O
) O
and O
a O
group O
of O
women O
without O
breast B-NEG
cancer I-NEG
( O
n=35 O
) O
completed O
a O
battery O
of O
neuropsychological O
measures O
. O

compared O
with O
the O
control O
group O
, O
the O
patients O
were O
impaired O
on O
a O
processing O
speed O
task O
( O
p=0.032 O
) O
and O
on O
a O
measure O
of O
immediate O
verbal O
memory O
( O
p=0.026 O
) O
after O
controlling O
for O
the O
use O
of O
hormone O
replacement O
therapy O
in O
both O
groups O
. O

patient O
group O
performance O
was O
not O
significantly O
related O
to O
length O
of O
treatment O
or O
measures O
of O
psychological O
morbidity O
. O

the O
results O
showed O
specific O
impairments O
in O
processing O
speed O
and O
verbal O
memory O
in O
women O
receiving O
hormonal O
therapy O
for O
the O
treatment O
of O
breast B-NEG
cancer I-NEG
. O

verbal O
memory O
may O
be O
especially O
sensitive O
to O
changes O
in O
oestrogen O
levels O
, O
a O
finding O
commonly O
reported O
in O
studies O
of O
hormone O
replacement O
therapy O
in O
healthy O
women O
. O

in O
view O
of O
the O
increased O
use O
of O
hormone O
therapies O
in O
an O
adjuvant O
and O
preventative O
setting O
their O
impact O
on O
cognitive O
functioning O
should O
be O
investigated O
more O
thoroughly O
. O

-DOCSTART- O

association O
of O
nitric O
oxide O
production O
and O
apoptosis O
in O
a O
model O
of O
experimental O
nephropathy B-NEG
. O

background O
: O
in O
recent O
studies O
increased O
amounts O
of O
nitric O
oxide O
( O
no O
) O
and O
apoptosis O
have O
been O
implicated O
in O
various O
pathological O
conditions O
in O
the O
kidney O
. O

we O
have O
studied O
the O
role O
of O
no O
and O
its O
association O
with O
apoptosis O
in O
an O
experimental O
model O
of O
nephrotic B-NEG
syndrome I-NEG
induced O
by O
a O
single O
injection O
of O
adriamycin O
(adr) O
. O

methods O
: O
the O
alteration O
in O
the O
no O
pathway O
was O
assessed O
by O
measuring O
nitrite O
levels O
in O
serum/urine O
and O
by O
evaluating O
the O
changes O
in O
vascular O
reactivity O
of O
the O
isolated O
perfused O
rat O
kidney O
( O
iprk O
) O
system O
. O

rats O
were O
stratified O
into O
control O
groups O
and O
adr-induced O
nephropathy B-NEG
groups O
. O

these O
two O
groups O
were O
then O
divided O
into O
: O
group O
1, O
animals O
receiving O
saline O
; O
and O
group O
2, O
animals O
receiving O
aminoguanidine O
( O
ag O
) O
which O
is O
a O
specific O
inhibitor O
of O
inducible-no O
synthase O
. O

on O
day O
21 O
, O
rats O
were O
sacrificed O
after O
obtaining O
material O
for O
biochemical O
analysis O
. O

results O
: O
histopathological O
examination O
of O
the O
kidneys O
of O
rats O
treated O
with O
adr O
revealed O
focal O
areas O
of O
mesangial B-NEG
proliferation I-NEG
and O
mild O
tubulointerstitial B-NEG
inflammation I-NEG
. O

they O
also O
had O
significantly O
higher O
levels O
of O
proteinuria B-NEG
compared O
with O
control O
and O
treatment O
groups O
(p O
< O
0.05) O
. O

urine O
nitrite O
levels O
were O
significantly O
increased O
in O
the O
adr- O
nephropathy B-NEG
group O
(p O
< O
0.05) O
. O

in O
the O
iprk O
phenylephrine O
and O
acetylcholine O
related O
responses O
were O
significantly O
impaired O
in O
the O
adr- O
nephropathy B-NEG
group O
. O

apoptosis O
was O
not O
detected O
in O
controls O
. O

however O
, O
in O
the O
adr- O
nephropathy B-NEG
group O
, O
numerous O
apoptotic O
cells O
were O
identified O
in O
the O
tubulointerstitial O
areas O
. O

double O
staining O
revealed O
numerous O
interstitial O
apoptotic O
cells O
to O
stain O
for O
ed1 O
, O
a O
marker O
for O
monocytes/macrophages O
. O

treatment O
with O
ag O
prevented O
the O
impairment O
of O
renal O
vascular O
bed O
responses O
and O
reduced O
both O
urine O
nitrite O
levels O
and O
apoptosis O
to O
control O
levels O
. O

conclusion O
: O
we O
suggest O
that O
interactions O
between O
no O
and O
apoptosis O
are O
important O
in O
the O
pathogenesis O
of O
the O
adr-induced O
nephrosis B-NEG
. O

-DOCSTART- O

the O
attenuating O
effect O
of O
carteolol O
hydrochloride O
, O
a O
beta-adrenoceptor O
antagonist O
, O
on O
neuroleptic-induced O
catalepsy B-NEG
in O
rats O
. O

it O
is O
known O
that O
beta-adrenoceptor O
antagonists O
are O
effective O
in O
the O
treatment O
of O
akathisia B-NEG
, O
one O
of O
the O
extrapyramidal O
side O
effects O
that O
occur O
during O
neuroleptic O
treatment O
. O

neuroleptic-induced O
catalepsy B-NEG
, O
a O
model O
of O
neuroleptic-induced O
extrapyramidal O
side O
effects O
, O
was O
considered O
suitable O
as O
a O
model O
for O
predicting O
neuroleptic-induced O
akathisia B-NEG
in O
humans O
, O
although O
neuroleptic-induced O
catalepsy B-NEG
was O
not O
considered O
a O
specific O
test O
for O
neuroleptic-induced O
akathisia B-NEG
. O

therefore O
, O
the O
effects O
of O
carteolol O
, O
a O
beta-adrenoceptor O
antagonist O
, O
on O
haloperidol-induced O
catalepsy B-NEG
in O
rats O
were O
behaviorally O
studied O
and O
compared O
with O
those O
of O
propranolol O
and O
biperiden O
, O
a O
muscarinic O
receptor O
antagonist O
. O

carteolol O
, O
as O
well O
as O
propranolol O
and O
biperiden O
, O
inhibited O
the O
haloperidol-induced O
catalepsy B-NEG
. O

the O
inhibitory O
effect O
of O
carteolol O
was O
almost O
comparable O
to O
that O
of O
propranolol O
, O
but O
was O
weaker O
than O
that O
of O
biperiden O
. O

carteolol O
did O
not O
evoke O
postsynaptic O
dopamine O
receptor-stimulating O
behavioral O
signs O
such O
as O
stereotypy O
and O
hyperlocomotion B-NEG
in O
rats O
. O

carteolol O
did O
not O
antagonize O
the O
inhibitory O
effects O
of O
haloperidol O
on O
apomorphine-induced O
stereotypy O
and O
locomotor O
activity O
in O
rats O
. O

in O
addition O
, O
carteolol O
did O
not O
evoke O
5-ht1a O
receptor-stimulating O
behavioral O
signs O
such O
as O
flat O
body O
posture O
and O
forepaw O
treading O
and O
did O
not O
inhibit O
5-hydroxytryptophan-induced O
head O
twitch O
in O
rats O
. O

finally O
, O
carteolol O
did O
not O
inhibit O
physostigmine-induced O
lethality O
in O
rats O
. O

these O
results O
strongly O
suggest O
that O
carteolol O
improves O
haloperidol-induced O
catalepsy B-NEG
via O
its O
beta-adrenoceptor O
antagonistic O
activity O
and O
is O
expected O
to O
be O
effective O
in O
the O
treatment O
of O
akathisia B-NEG
without O
attenuating O
neuroleptic-induced O
antipsychotic O
effects O
due O
to O
its O
postsynaptic O
dopamine O
receptor O
antagonistic O
activity O
. O

-DOCSTART- O

penicillamine-induced O
rapidly O
progressive O
glomerulonephritis B-NEG
in O
a O
patient O
with O
rheumatoid B-NEG
arthritis I-NEG
. O

a O
67-year-old O
woman O
with O
rheumatoid B-NEG
arthritis I-NEG
presented O
rapidly O
progressive O
glomerulonephritis B-NEG
( O
rpgn B-NEG
) O
after O
5 O
months O
of O
d-penicillamine O
( O
250 O
mg/day O
) O
treatment O
. O

light O
microscopy O
study O
showed O
severe O
glomerulonephritis B-NEG
with O
crescent O
formation O
in O
60% O
of O
the O
glomeruli O
and O
infiltration O
of O
inflammatory O
cells O
in O
the O
wall O
of O
an O
arteriole O
. O

immunofluorescence O
revealed O
scanty O
granular O
igg O
, O
iga O
and O
c3 O
deposits O
along O
the O
capillary O
walls O
and O
mesangium O
. O

the O
patient O
was O
treated O
with O
steroid O
pulse O
, O
plasmapheresis O
, O
cyclophosphamide O
and O
antiplatelet O
agents O
. O

a O
complete O
recovery O
of O
renal O
function O
was O
achieved O
in O
a O
few O
weeks O
. O

this O
new O
case O
of O
rpgn B-NEG
in O
the O
course O
of O
d-penicillamine O
treatment O
emphasizes O
the O
need O
for O
frequent O
monitoring O
of O
renal O
function O
and O
evaluation O
of O
urinary O
sediment O
and O
proteinuria B-NEG
in O
these O
patients O
. O

the O
prompt O
discontinuation O
of O
d-penicillamine O
and O
vigorous O
treatment O
measures O
could O
allow O
for O
a O
good O
prognosis O
as O
in O
this O
case O
. O

-DOCSTART- O

nature O
, O
time O
course O
and O
dose O
dependence O
of O
zidovudine-related O
side O
effects O
: O
results O
from O
the O
multicenter O
canadian O
azidothymidine O
trial O
. O

to O
characterize O
the O
nature O
, O
time O
course O
and O
dose O
dependency O
of O
zidovudine-related O
side O
effects O
, O
we O
undertook O
a O
multicenter O
, O
prospective O
, O
dose-range O
finding O
study O
. O

our O
study O
group O
consisted O
of O
74 O
hiv-positive O
homosexual O
men O
belonging O
to O
groups O
ii O
b, O
iii O
and O
iv O
c2 O
from O
the O
centers O
for O
disease O
control O
( O
cdc O
) O
classification O
of O
hiv B-NEG
disease I-NEG
. O

following O
a O
3-week O
observation O
period O
, O
volunteers O
were O
treated O
with O
zidovudine O
600 O
mg/day O
for O
18 O
weeks O
, O
900 O
mg/day O
for O
9 O
weeks O
and O
1200 O
mg/day O
for O
9 O
weeks O
, O
followed O
by O
a O
washout O
period O
of O
6 O
weeks O
after O
which O
they O
were O
re-started O
on O
1200 O
mg/day O
or O
the O
highest O
tolerated O
dose O
at O
8-hourly O
intervals O
. O

subjects O
were O
randomly O
assigned O
to O
4-hourly O
or O
8-hourly O
regimens O
within O
cdc O
groups O
while O
taking O
600 O
and O
1200 O
mg/day O
. O

clinical O
and O
laboratory O
evaluations O
were O
performed O
at O
3-week O
intervals O
. O

symptomatic O
adverse O
effects O
were O
present O
in O
96% O
of O
subjects O
, O
most O
commonly O
nausea B-NEG
(64%) O
, O
fatigue B-NEG
( O
55% O
) O
and O
headache B-NEG
(49%) O
. O

these O
were O
generally O
self-limited O
, O
reappearing O
briefly O
at O
each O
dose O
increment O
. O

a O
decrease O
in O
hemoglobin O
occurred O
shortly O
after O
initiation O
of O
therapy O
. O

this O
was O
not O
dose O
dependent O
and O
reversed O
rapidly O
upon O
discontinuation O
of O
treatment O
. O

a O
red O
blood O
cell O
count O
decrease O
, O
a O
mean O
cell O
volume O
increase O
and O
a O
granulocyte O
count O
decrease O
developed O
early O
in O
a O
dose-independent O
fashion O
, O
reverting O
at O
least O
partially O
during O
the O
washout O
phase O
. O

the O
decrease O
in O
reticulocyte O
count O
was O
dose O
related O
between O
600 O
and O
900 O
mg/day O
with O
no O
further O
change O
when O
the O
dose O
was O
escalated O
to O
1200 O
mg/day O
. O

bone O
marrow O
changes O
occurred O
rapidly O
as O
demonstrated O
by O
megaloblastosis B-NEG
in O
95% O
of O
65 O
specimens O
at O
week O
18.(abstract O
truncated O
at O
250 O
words O
) O

-DOCSTART- O

bilateral B-NEG
optic I-NEG
neuropathy I-NEG
due O
to O
combined O
ethambutol O
and O
isoniazid O
treatment O
. O

the O
case O
of O
a O
40-year-old O
patient O
who O
underwent O
an O
unsuccessful O
cadaver O
kidney O
transplantation O
and O
was O
treated O
with O
ethambutol O
and O
isoniazid O
is O
reported O
. O

a O
bilateral B-NEG
retrobulbar I-NEG
neuropathy I-NEG
with O
an O
unusual O
central O
bitemporal O
hemianopic O
scotoma B-NEG
was O
found O
. O

ethambutol O
was O
stopped O
and O
only O
small O
improvement O
of O
the O
visual O
acuity O
followed O
. O

isoniazid O
was O
discontinued O
later O
, O
followed O
by O
a O
dramatic O
improvement O
in O
the O
visual O
acuity O
. O

the O
hazards O
of O
optic O
nerve O
toxicity B-NEG
due O
to O
ethambutol O
are O
known O
. O

we O
emphasize O
the O
potential O
danger O
in O
the O
use O
of O
ethambutol O
and O
isoniazid O
. O

-DOCSTART- O

progestational O
agents O
and O
blood B-NEG
coagulation I-NEG
. O

vii O
. O
thromboembolic B-NEG
and O
other O
complications O
of O
oral O
contraceptive O
therapy O
in O
relationship O
to O
pretreatment O
levels O
of O
blood B-NEG
coagulation I-NEG
factors O
: O
summary O
report O
of O
a O
ten-year O
study O
. O

during O
a O
ten-year O
period O
, O
348 O
women O
were O
studied O
for O
a O
total O
of O
5,877 O
patient O
months O
in O
four O
separate O
studies O
relating O
oral O
contraceptives O
to O
changes O
in O
hematologic O
parameters O
. O

significant O
increases O
in O
certain O
factors O
of O
the O
blood B-NEG
coagulation I-NEG
and O
fibrinolysin O
systems O
( O
factors O
i,ii,vii,viii,ix O
, O
and O
x O
and O
plasminogen O
) O
were O
observed O
in O
the O
treated O
groups O
. O

severe O
complications O
developed O
in O
four O
patients O
. O

all O
four O
had O
an O
abnormal O
blood B-NEG
coagulation I-NEG
profile O
, O
suggesting O
hypercoagulability B-NEG
before O
initiation O
of O
therapy O
. O

some O
of O
these O
findings O
represented O
the O
most O
extreme O
abnormalities O
seen O
in O
the O
entire O
group O
of O
patients O
; O
some O
increased O
further O
during O
therapy O
. O

one O
of O
these O
patients O
developed O
a O
myocardial B-NEG
infarction I-NEG
before O
receiving O
any O
medication O
, O
shortly O
after O
the O
base-line O
values O
were O
obtained O
. O

one O
patient O
developed O
retinopathy B-NEG
19 O
months O
after O
she O
began O
therapy O
, O
and O
another O
developed O
thrombophlebitis B-NEG
after O
27 O
months O
of O
therapy O
. O

the O
fourth O
patient O
developed O
thrombophlebitis B-NEG
14 O
days O
after O
initiation O
of O
contraceptive O
therapy O
. O

all O
four O
patients O
were O
of O
the O
a O
or O
ab O
blood O
group O
. O

previous O
studies O
suggested O
the O
possiblility O
of O
increased O
propensity O
for O
thromboembolic B-NEG
episodes I-NEG
in O
patients O
possessing O
the O
a O
antigen O
. O

it O
appears O
from O
these O
data O
that O
hematologic O
work-ups O
may O
be O
useful O
in O
women O
who O
are O
about O
to O
start O
long-term O
oral O
contraceptive O
therapy O
. O

-DOCSTART- O

cardiac B-NEG
arrest I-NEG
in O
a O
child O
with O
cerebral B-NEG
palsy I-NEG
undergoing O
sevoflurane O
induction O
of O
anesthesia O
after O
preoperative O
clonidine O
. O

clonidine O
is O
a O
frequently O
administered O
alpha2-adrenergic O
agonist O
which O
can O
decrease O
heart O
rate O
and O
blood O
pressure O
. O

we O
present O
a O
case O
of O
a O
5-year-old O
child O
with O
cerebral B-NEG
palsy I-NEG
and O
seizure B-NEG
disorder I-NEG
, O
receiving O
clonidine O
for O
restlessness B-NEG
, O
who O
presented O
for O
placement O
of O
a O
baclofen O
pump O
. O

without O
the O
knowledge O
of O
the O
medical O
personnel O
, O
the O
patient's O
mother O
administered O
three O
doses O
of O
clonidine O
during O
the O
evening O
before O
and O
morning O
of O
surgery O
to O
reduce O
anxiety B-NEG
. O

during O
induction O
of O
anesthesia O
, O
the O
patient O
developed O
bradycardia B-NEG
and O
hypotension B-NEG
requiring O
cardiac O
resuscitation O
. O

there O
are O
no O
previous O
reports O
of O
clonidine-associated O
cardiac B-NEG
arrest I-NEG
in O
a O
child O
undergoing O
induction O
of O
anesthesia O
. O

-DOCSTART- O

effects O
of O
umb24 O
and O
( O
+/-)-sm O
21 O
, O
putative O
sigma2-preferring O
antagonists O
, O
on O
behavioral O
toxic O
and O
stimulant O
effects O
of O
cocaine O
in O
mice O
. O

earlier O
studies O
have O
demonstrated O
that O
antagonism O
of O
sigma1 O
receptors O
attenuates O
the O
convulsive B-NEG
, O
lethal O
, O
locomotor O
stimulatory O
and O
rewarding O
actions O
of O
cocaine O
in O
mice O
. O

in O
contrast O
, O
the O
contribution O
of O
sigma2 O
receptors O
is O
unclear O
because O
experimental O
tools O
to O
selectively O
target O
this O
subtype O
are O
unavailable O
. O

to O
begin O
addressing O
this O
need O
, O
we O
characterized O
umb24 O
( O
1-(2-phenethyl)-4-(2-pyridyl)-piperazine O
) O
and O
( O
+/-)-sm O
21 O
( O
3alpha-tropanyl-2-(4-chorophenoxy)butyrate O
) O
in O
receptor O
binding O
and O
behavioral O
studies O
. O

receptor O
binding O
studies O
confirmed O
that O
umb24 O
and O
( O
+/-)-sm O
21 O
display O
preferential O
affinity O
for O
sigma2 O
over O
sigma1 O
receptors O
. O

in O
behavioral O
studies O
, O
pretreatment O
of O
swiss O
webster O
mice O
with O
umb24 O
or O
( O
+/-)-sm O
21 O
significantly O
attenuated O
cocaine-induced O
convulsions B-NEG
and O
locomotor O
activity O
, O
but O
not O
lethality O
. O

when O
administered O
alone O
, O
( O
+/-)-sm O
21 O
produced O
no O
significant O
effects O
compared O
to O
control O
injections O
of O
saline O
, O
but O
umb24 O
had O
locomotor O
depressant O
actions O
. O

together O
, O
the O
data O
suggest O
that O
sigma2 O
receptor O
antagonists O
have O
the O
potential O
to O
attenuate O
some O
of O
the O
behavioral O
effects O
of O
cocaine O
, O
and O
further O
development O
of O
more O
selective O
, O
high O
affinity O
ligands O
are O
warranted O
. O

-DOCSTART- O

methimazole-induced O
cholestatic B-NEG
jaundice I-NEG
. O

methimazole O
is O
a O
widely O
used O
and O
generally O
well-tolerated O
antithyroid O
agent O
. O

a O
43-year-old O
woman O
had O
severe O
jaundice B-NEG
and O
itching B-NEG
1 O
month O
after O
receiving O
methimazole O
( O
10 O
mg O
tid O
) O
and O
propranolol O
( O
20 O
mg O
tid O
) O
for O
treatment O
of O
hyperthyroidism B-NEG
. O

the O
patient O
continued O
treatment O
for O
another O
4 O
days O
after O
the O
appearance O
of O
jaundice B-NEG
until O
she O
finished O
both O
medications O
. O

when O
seen O
at O
the O
emergency O
department O
2 O
weeks O
later O
, O
she O
still O
had O
severe O
icterus B-NEG
, O
pruritus B-NEG
, O
and O
hyperbilirubinemia B-NEG
, O
formed O
mainly O
of O
the O
conjugated O
fraction O
. O

methimazole-induced O
cholestasis B-NEG
was O
diagnosed O
, O
and O
propranolol O
therapy O
was O
resumed O
. O

over O
the O
following O
9 O
days O
, O
the O
symptoms O
improved O
and O
plasma O
bilirubin O
levels O
were O
normal O
after O
12 O
weeks O
without O
methimazole O
. O

in O
rare O
cases O
within O
the O
first O
few O
weeks O
of O
therapy O
, O
this O
drug O
can O
cause O
severe O
and O
reversible O
cholestatic B-NEG
jaundice I-NEG
. O

physicians O
and O
patients O
should O
be O
aware O
of O
this O
adverse O
effect O
so O
that O
, O
upon O
occurrence O
, O
they O
can O
discontinue O
methimazole O
therapy O
and O
avoid O
unnecessary O
invasive O
procedures O
. O

-DOCSTART- O

ciprofloxacin-induced O
acute O
interstitial B-NEG
nephritis I-NEG
and O
autoimmune B-NEG
hemolytic I-NEG
anemia I-NEG
. O

ciprofloxacin O
has O
been O
associated O
with O
several O
side O
effects O
including O
interstitial B-NEG
nephritis I-NEG
and O
hemolytic B-NEG
anemia I-NEG
. O

the O
combination O
of O
both O
side O
effects O
is O
extremely O
rare O
. O

in O
this O
report O
, O
we O
describe O
a O
case O
of O
ciprofloxacin-induced O
interstitial B-NEG
nephritis I-NEG
and O
autoimmune B-NEG
hemolytic I-NEG
anemia I-NEG
. O
hemolytic B-NEG
anemia I-NEG
improved O
after O
stopping O
the O
drug O
and O
initiation O
of O
steroid O
therapy O
. O

unfortunately O
, O
acute O
interstitial B-NEG
nephritis I-NEG
was O
irreversible O
and O
the O
patient O
developed O
end-stage B-NEG
renal I-NEG
disease I-NEG
. O

-DOCSTART- O

contribution O
of O
sodium O
valproate O
to O
the O
syndrome B-NEG
of I-NEG
inappropriate I-NEG
secretion I-NEG
of I-NEG
antidiuretic I-NEG
hormone I-NEG
. O

we O
report O
the O
case O
of O
a O
62-year-old O
man O
who O
was O
administered O
sodium O
valproate O
( O
vpa O
) O
and O
who O
subsequently O
developed O
the O
syndrome B-NEG
of I-NEG
inappropriate I-NEG
secretion I-NEG
of I-NEG
antidiuretic I-NEG
hormone I-NEG
( O
siadh B-NEG
). O

he O
had O
been O
taking O
vpa O
for O
treatment O
of O
idiopathic O
generalized O
tonic-clonic B-NEG
convulsions I-NEG
since O
he O
was O
56 O
years O
old O
. O

after O
substituting O
vpa O
with O
zonisamide O
, O
the O
serum O
sodium O
level O
returned O
to O
normal O
. O

we O
consider O
this O
episode O
of O
siadh B-NEG
to O
be O
the O
result O
of O
a O
combination O
of O
factors O
including O
a O
weakness B-NEG
of I-NEG
the I-NEG
central I-NEG
nervous I-NEG
system I-NEG
and O
the O
long-term O
administration O
of O
vpa O
. O

-DOCSTART- O

vasopressin O
in O
the O
treatment O
of O
milrinone-induced O
hypotension B-NEG
in O
severe O
heart B-NEG
failure I-NEG
. O

the O
use O
of O
phosphodiesterase O
inhibitors O
such O
as O
milrinone O
in O
the O
treatment O
of O
severe O
heart B-NEG
failure I-NEG
is O
frequently O
restricted O
because O
they O
cause O
vasodilation O
and O
hypotension B-NEG
. O

in O
patients O
with O
decompensated O
heart B-NEG
failure I-NEG
with O
hypotension B-NEG
after O
treatment O
with O
milrinone O
, O
low O
doses O
of O
vasopressin O
restored O
blood O
pressure O
without O
inhibiting O
the O
inotropic O
effect O
of O
milrinone O
. O

-DOCSTART- O

halogenated O
anesthetics O
form O
liver O
adducts O
and O
antigens O
that O
cross-react O
with O
halothane-induced O
antibodies O
. O

two O
halogenated O
anesthetics O
, O
enflurane O
and O
isoflurane O
, O
have O
been O
associated O
with O
an O
allergic-type O
hepatic B-NEG
injury I-NEG
both O
alone O
and O
following O
previous O
exposure O
to O
halothane O
. O

halothane O
hepatitis B-NEG
appears O
to O
involve O
an O
aberrant O
immune O
response O
. O

an O
antibody O
response O
to O
a O
protein-bound O
biotransformation O
product O
( O
trifluoroacetyl O
adduct O
) O
has O
been O
detected O
on O
halothane O
hepatitis B-NEG
patients O
. O

this O
study O
was O
performed O
to O
determine O
cross-reactivity O
between O
enflurane O
and O
isoflurane O
with O
the O
hypersensitivity B-NEG
induced O
by O
halothane O
. O

the O
subcellular O
and O
lobular O
production O
of O
hepatic O
neoantigens O
recognized O
by O
halothane-induced O
antibodies O
following O
enflurane O
and O
isoflurane O
, O
and O
the O
biochemical O
nature O
of O
these O
neoantigens O
was O
investigated O
in O
two O
animal O
models O
. O

enflurane O
administration O
resulted O
in O
neoantigens O
detected O
in O
both O
the O
microsomal O
and O
cytosolic O
fraction O
of O
liver O
homogenates O
and O
in O
the O
centrilobular O
region O
of O
the O
liver O
. O

in O
the O
same O
liver O
, O
biochemical O
analysis O
detected O
fluorinated O
liver O
adducts O
that O
were O
up O
to O
20-fold O
greater O
in O
guinea O
pigs O
than O
in O
rats O
. O

this O
supports O
and O
extends O
previous O
evidence O
for O
a O
mechanism O
by O
which O
enflurane O
and/or O
isoflurane O
could O
produce O
a O
hypersensitivity B-NEG
condition O
similar O
to O
that O
of O
halothane O
hepatitis B-NEG
either O
alone O
or O
subsequent O
to O
halothane O
administration O
. O

the O
guinea O
pig O
would O
appear O
to O
be O
a O
useful O
model O
for O
further O
investigations O
of O
the O
immunological O
response O
to O
these O
antigens O
. O

-DOCSTART- O

induction O
by O
paracetamol O
of O
bladder B-NEG
and I-NEG
liver I-NEG
tumours I-NEG
in O
the O
rat O
. O

effects O
on O
hepatocyte O
fine O
structure O
. O

groups O
of O
male O
and O
female O
inbred O
leeds O
strain O
rats O
were O
fed O
diets O
containing O
either O
0.5% O
or O
1.0% O
paracetamol O
by O
weight O
for O
up O
to O
18 O
months O
. O

at O
the O
1.0% O
dosage O
level O
, O
20% O
of O
rats O
of O
both O
sexes O
developed O
neoplastic O
nodules O
of O
the O
liver O
, O
a O
statistically O
significant O
incidence O
. O

these O
rats O
also O
showed O
gross O
enlargement O
of O
their O
livers O
and O
an O
increase O
in O
foci O
of O
cellular O
alteration O
, O
the O
latter O
also O
being O
observed O
in O
the O
low O
dosage O
male O
rats O
. O
papillomas B-NEG
of O
the O
transitional O
epithelium O
of O
the O
bladder O
developed O
in O
all O
paracetamol-treated O
groups O
, O
and O
three O
rats O
bore O
bladder B-NEG
carcinomas I-NEG
. O

however O
, O
significant O
yields O
of O
bladder B-NEG
tumours I-NEG
were O
only O
obtained O
from O
low O
dosage O
females O
and O
high O
dosage O
males O
. O

additionally O
, O
20 O
to O
25% O
of O
paracetamol-treated O
rats O
developed O
hyperplasia B-NEG
of O
the O
bladder O
epithelium O
, O
which O
was O
not O
coincident O
with O
the O
presence O
of O
bladder B-NEG
calculi I-NEG
. O

a O
low O
yield O
of O
tumours B-NEG
at O
various O
other O
sites O
also O
arose O
following O
paracetamol O
feeding O
. O

an O
electron O
microscope O
study O
of O
the O
livers O
of O
paracetamol-treated O
rats O
revealed O
ultrastructural O
changes O
in O
the O
hepatocytes O
that O
resemble O
those O
that O
result O
from O
exposure O
to O
a O
variety O
of O
known O
hepatocarcinogens B-NEG
. O

-DOCSTART- O

rat O
extraocular O
muscle O
regeneration O
. O

repair O
of O
local O
anesthetic-induced O
damage O
. O

local O
anesthetics O
that O
are O
commonly O
used O
in O
ophthalmic O
surgery O
( O
0.75% O
bupivacaine O
hydrochloride O
, O
2.0% O
mepivacaine O
hydrochloride O
, O
and O
2.0% O
lidocaine O
hydrochloride O
plus O
1:100,000 O
epinephrine O
) O
were O
injected O
into O
the O
retrobulbar O
area O
of O
rat O
eyes O
. O

controls O
were O
injected O
with O
physiological O
saline O
. O

all O
three O
anesthetics O
produced O
massive O
degeneration O
of O
the O
extraocular O
muscles O
. O
muscle B-NEG
degeneration I-NEG
is O
followed O
by O
regeneration O
of O
the O
damaged O
muscle O
fibers O
. O

in O
addition O
to O
muscle B-NEG
damage I-NEG
, O
severe O
damage O
was O
also O
seen O
in O
harderian O
glands O
, O
especially O
after O
exposure O
to O
mepivacaine O
and O
lidocaine O
plus O
epinephrine O
. O

with O
these O
findings O
in O
rats O
, O
it O
is O
hypothesized O
that O
the O
temporary O
diplopia B-NEG
sometimes O
seen O
in O
patients O
after O
ophthalmic O
surgery O
might O
be O
due O
to O
anesthetic-induced O
damage O
to O
the O
extraocular O
muscles O
. O

-DOCSTART- O

reversal O
of O
neuroleptic-induced O
catalepsy B-NEG
by O
novel O
aryl-piperazine O
anxiolytic O
drugs O
. O

the O
novel O
anxiolytic O
drug O
, O
buspirone O
, O
reverses O
catalepsy B-NEG
induced O
by O
haloperidol O
. O

a O
series O
of O
aryl-piperazine O
analogues O
of O
buspirone O
and O
other O
5-hydroxytryptaminergic O
agonists O
were O
tested O
for O
their O
ability O
to O
reverse O
haloperidol O
induced O
catalepsy B-NEG
. O

those O
drugs O
with O
strong O
affinity O
for O
5-hydroxytryptamine1a O
receptors O
were O
able O
to O
reverse O
catalepsy B-NEG
. O

drugs O
with O
affinity O
for O
other O
5-ht O
receptors O
or O
weak O
affinity O
were O
ineffective O
. O

however O
, O
inhibition O
of O
postsynaptic O
5-ht O
receptors O
neither O
inhibited O
nor O
potentiated O
reversal O
of O
catalepsy B-NEG
and O
leaves O
open O
the O
question O
as O
to O
the O
site O
or O
mechanism O
for O
this O
effect O
. O

-DOCSTART- O

diazepam O
facilitates O
reflex O
bradycardia B-NEG
in O
conscious O
rats O
. O

the O
effects O
of O
diazepam O
on O
cardiovascular O
function O
were O
assessed O
in O
conscious O
rats O
. O

intravenous O
administration O
of O
diazepam O
( O
1-30 O
mg O
kg-1 O
) O
produced O
a O
dose-dependent O
decrease O
in O
both O
the O
mean O
arterial O
pressure O
and O
the O
heart O
rate O
. O

also O
, O
reflex O
bradycardia B-NEG
was O
produced O
in O
rats O
by O
intravenous O
infusion O
of O
adrenaline O
( O
1.25-2.5 O
micrograms O
kg-1) O
. O

intravenous O
pretreatment O
of O
the O
rats O
with O
diazepam O
, O
although O
causing O
no O
change O
in O
the O
adrenaline-induced O
pressor O
effect O
, O
did O
enhance O
the O
adrenaline-induced O
reflex O
bradycardia B-NEG
. O

however O
, O
the O
diazepam O
enhancement O
of O
adrenaline-induced O
reflex O
bradycardia B-NEG
was O
antagonized O
by O
pretreatment O
of O
rats O
with O
an O
intravenous O
dose O
of O
picrotoxin O
( O
an O
agent O
blocks O
chloride O
channels O
by O
binding O
to O
sites O
associated O
with O
the O
benzodiazepine-gaba-chloride O
channel O
macromolecular O
complex) O
. O

the O
data O
indicate O
that O
diazepam O
acts O
through O
the O
benzodiazepine-gaba-chloride O
channel O
macromolecular O
complex O
within O
the O
central O
nervous O
system O
to O
facilitate O
reflex O
bradycardia B-NEG
mediated O
through O
baroreceptor O
reflexes O
in O
response O
to O
an O
acute O
increase O
in O
arterial O
pressure O
. O

-DOCSTART- O

chronic O
carbamazepine O
inhibits O
the O
development O
of O
local O
anesthetic O
seizures B-NEG
kindled O
by O
cocaine O
and O
lidocaine O
. O

the O
effects O
of O
carbamazepine O
( O
cbz O
) O
treatment O
on O
local O
anesthetic-kindled O
seizures B-NEG
and O
lethality O
were O
evaluated O
in O
different O
stages O
of O
the O
kindling O
process O
and O
under O
different O
methods O
of O
cbz O
administration O
. O

chronic O
oral O
cbz O
inhibited O
the O
development O
of O
both O
lidocaine- O
and O
cocaine-induced O
seizures B-NEG
, O
but O
had O
little O
effect O
on O
the O
fully O
developed O
local O
anesthetic O
seizures B-NEG
. O

chronic O
cbz O
also O
decreased O
the O
incidence O
of O
seizure B-NEG
-related O
mortality O
in O
the O
cocaine-injected O
rats O
. O

acute O
cbz O
over O
a O
range O
of O
doses O
( O
15-50 O
mg/kg O
) O
had O
no O
effect O
on O
completed O
lidocaine-kindled O
or O
acute O
cocaine-induced O
seizures B-NEG
. O

repeated O
i.p O
. O
injection O
of O
cbz O
( O
15 O
mg/kg O
) O
also O
was O
without O
effect O
on O
the O
development O
of O
lidocaine- O
or O
cocaine-kindled O
seizures B-NEG
. O

the O
differential O
effects O
of O
cbz O
depending O
upon O
stage O
of O
seizure B-NEG
development O
suggest O
that O
distinct O
mechanisms O
underlie O
the O
development O
versus O
maintenance O
of O
local O
anesthetic-kindled O
seizures B-NEG
. O

the O
effectiveness O
of O
chronic O
but O
not O
repeated O
, O
intermittent O
injections O
of O
cbz O
suggests O
that O
different O
biochemical O
consequences O
result O
from O
the O
different O
treatment O
regimens O
. O

the O
possible O
utility O
of O
chronic O
cbz O
in O
preventing O
the O
development O
of O
toxic O
side O
effects O
in O
human O
cocaine O
users O
is O
suggested O
by O
these O
data O
, O
but O
remains O
to O
be O
directly O
evaluated O
. O

-DOCSTART- O

d-penicillamine O
in O
the O
treatment O
of O
localized B-NEG
scleroderma I-NEG
. O
localized B-NEG
scleroderma I-NEG
has O
no O
recognized O
internal O
organ O
involvement O
but O
may O
be O
disfiguring O
and O
disabling O
when O
the O
cutaneous O
lesions O
are O
extensive O
or O
affect O
children O
. O

there O
is O
no O
accepted O
or O
proven O
treatment O
for O
localized B-NEG
scleroderma I-NEG
. O

case O
reports O
of O
11 O
patients O
with O
severe O
, O
extensive O
localized B-NEG
scleroderma I-NEG
who O
were O
treated O
with O
d-penicillamine O
are O
summarized O
in O
this O
article O
. O

this O
drug O
was O
judged O
to O
have O
a O
favorable O
effect O
on O
the O
disease O
course O
in O
7 O
( O
64% O
) O
of O
11 O
patients O
. O

improvement O
began O
within O
3 O
to O
6 O
months O
and O
consisted O
of O
cessation O
of O
active O
cutaneous O
lesions O
in O
all O
7 O
patients O
, O
skin O
softening O
in O
5, O
and O
more O
normal O
growth O
of O
the O
affected O
limb O
in O
2 O
of O
3 O
children O
. O

joint O
stiffness O
and O
contractures B-NEG
also O
improved O
. O

the O
dose O
of O
d-penicillamine O
associated O
with O
a O
favorable O
response O
was O
as O
low O
as O
2 O
to O
5 O
mg/kg O
per O
day O
given O
over O
a O
period O
ranging O
from O
15 O
to O
53 O
months O
. O

d-penicillamine O
caused O
nephrotic B-NEG
syndrome I-NEG
in O
1 O
patient O
and O
milder O
reversible O
proteinuria B-NEG
in O
3 O
other O
patients O
; O
none O
developed O
renal B-NEG
insufficiency I-NEG
. O

these O
data O
suggest O
that O
d-penicillamine O
may O
be O
effective O
in O
severe O
cases O
of O
localized B-NEG
scleroderma I-NEG
. O

-DOCSTART- O

preservation O
of O
renal O
blood O
flow O
during O
hypotension B-NEG
induced O
with O
fenoldopam O
in O
dogs O
. O

the O
introduction O
of O
drugs O
that O
could O
induce O
hypotension B-NEG
with O
different O
pharmacological O
actions O
would O
be O
advantageous O
because O
side O
effects O
unique O
to O
a O
specific O
drug O
could O
be O
minimized O
by O
selecting O
appropriate O
therapy O
. O

specific O
dopamine-1 O
, O
( O
da1 O
) O
and O
dopamine-2 O
( O
da2 O
) O
receptor O
agonists O
are O
now O
under O
clinical O
investigation O
. O

fenoldopam O
mesylate O
is O
a O
specific O
da1 O
receptor O
agonist O
that O
lowers O
blood O
pressure O
by O
vasodilatation O
. O

the O
hypothesis O
that O
fenoldopam O
could O
be O
used O
to O
induce O
hypotension B-NEG
and O
preserve O
blood O
flow O
to O
the O
kidney O
was O
tested O
. O

systemic O
aortic O
blood O
pressure O
and O
renal O
blood O
flow O
were O
measured O
continuously O
with O
a O
carotid O
arterial O
catheter O
and O
an O
electromagnetic O
flow O
probe O
respectively O
, O
in O
order O
to O
compare O
the O
cardiovascular O
and O
renal O
vascular O
effects O
of O
fenoldopam O
and O
sodium O
nitroprusside O
in O
ten O
dogs O
under O
halothane O
general O
anaesthesia O
. O

mean O
arterial O
pressure O
was O
decreased O
30 O
+/- O
8 O
per O
cent O
from O
control O
with O
infusion O
of O
fenoldopam O
( O
3.4 O
+/- O
2.0 O
micrograms.kg-1.min-1 O
) O
and O
34 O
+/- O
4 O
per O
cent O
with O
infusion O
of O
sodium O
nitroprusside O
( O
5.9 O
micrograms.kg-1.min-1 O
) O
(ns) O
. O

renal O
blood O
flow O
( O
rbf O
) O
increased O
during O
fenoldopam-induced O
hypotension B-NEG
11 O
+/- O
7 O
per O
cent O
and O
decreased O
21 O
+/- O
8 O
per O
cent O
during O
sodium O
nitroprusside-induced O
hypotension B-NEG
(p O
less O
than O
0.01) O
. O

sodium O
nitroprusside O
is O
a O
non-selective O
arteriolar O
and O
venous O
vasodilator O
that O
can O
produce O
redistribution O
of O
blood O
flow O
away O
from O
the O
kidney O
during O
induced O
hypotension B-NEG
. O

fenoldopam O
is O
a O
selective O
dopamine-1 O
( O
da1 O
) O
receptor O
agonist O
that O
causes O
vasodilatation O
to O
the O
kidney O
and O
other O
organs O
with O
da1 O
receptors O
and O
preserves O
blood O
flow O
to O
the O
kidney O
during O
induced O
hypotension B-NEG
. O

-DOCSTART- O

antiarrhythmic O
effects O
of O
optical O
isomers O
of O
cibenzoline O
on O
canine O
ventricular B-NEG
arrhythmias I-NEG
. O

antiarrhythmic O
effects O
of O
( O
+)-cibenzoline O
and O
( O
-)-cibenzoline O
were O
examined O
using O
two O
canine O
ventricular B-NEG
arrhythmia I-NEG
models O
. O

digitalis O
arrhythmia B-NEG
, O
which O
is O
suppressed O
by O
na O
channel O
blockers O
, O
was O
induced O
by O
intermittent O
intravenous O
( O
i.v. O
) O
injection O
of O
ouabain O
in O
pentobarbital-anesthetized O
dogs O
. O
adrenaline B-NEG
arrhythmia I-NEG
, O
which O
is O
suppressed O
by O
ca O
channel O
blockers O
, O
was O
induced O
by O
adrenaline O
infusion O
in O
halothane-anesthetized O
dogs O
. O

ten O
and O
5 O
mg/kg O
i.v O
. O
( O
+)-cibenzoline O
suppressed O
digitalis- O
and O
adrenaline-induced O
arrhythmias B-NEG
, O
respectively O
. O

the O
minimum O
effective O
plasma O
concentrations O
of O
( O
+)-cibenzoline O
for O
digitalis- O
and O
adrenaline-induced O
arrhythmias B-NEG
were O
1.4 O
+/- O
0.4 O
and O
2.0 O
+/- O
0.6 O
micrograms/ml O
, O
respectively O
( O
mean O
+/- O
sd O
, O
n O
= O
6) O
. O

a O
lower O
dose O
of O
1 O
mg/kg O
i.v O
. O
of O
( O
-)-cibenzoline O
suppressed O
the O
digitalis-induced O
arrhythmia B-NEG
, O
whereas O
5 O
mg/kg O
i.v O
. O
was O
needed O
to O
suppress O
adrenaline-induced O
arrhythmias B-NEG
. O

the O
minimum O
effective O
plasma O
concentrations O
of O
( O
-)-cibenzoline O
for O
digitalis- O
and O
adrenaline-induced O
arrhythmia B-NEG
were O
0.06 O
+/- O
0.04 O
and O
0.7 O
+/- O
0.1 O
micrograms/ml O
, O
respectively O
( O
mean O
+/- O
sd O
, O
n O
= O
6) O
. O

the O
stronger O
antiarrhythmic O
effect O
of O
( O
-)-cibenzoline O
indicates O
that O
( O
-)-isomer O
may O
have O
an O
effect O
nearly O
5-20 O
times O
stronger O
in O
suppressing O
na O
channels O
, O
but O
effects O
of O
both O
drugs O
on O
ca O
channels O
may O
be O
almost O
equipotent O
. O

-DOCSTART- O

effect O
of O
hibiscus O
rosa O
sinensis O
on O
reserpine-induced O
neurobehavioral O
and O
biochemical O
alterations O
in O
rats O
. O

effect O
of O
methanolic O
extract O
of O
hibiscus O
rosa O
sinensis O
( O
100-300 O
mg/kg O
) O
was O
studied O
on O
reserpine-induced O
orofacial O
dyskinesia B-NEG
and O
neurochemical O
alterations O
. O

the O
rats O
were O
treated O
with O
intraperitoneal O
reserpine O
(1 O
mg/kg O
, O
ip O
) O
for O
3 O
days O
every O
other O
day O
. O

on O
day O
5, O
vacuous O
chewing O
movements O
and O
tongue O
protrusions O
were O
counted O
for O
5 O
min O
. O

reserpine O
treated O
rats O
significantly O
developed O
vacuous O
chewing O
movements O
and O
tongue O
protrusions O
however O
, O
coadministration O
of O
hibiscus O
rosa O
sinensis O
roots O
extract O
(100 O
, O
200 O
and O
300 O
mg/kg O
, O
per O
orally O
) O
attenuated O
the O
effects O
. O

biochemical O
analysis O
of O
brain O
revealed O
that O
the O
reserpine O
treatment O
significantly O
increased O
lipid O
peroxidation O
and O
decreased O
levels O
of O
superoxide O
dismutase O
(sod) O
, O
catalase O
( O
cat O
) O
and O
glutathione O
reductase O
(gsh) O
, O
an O
index O
of O
oxidative O
stress O
process O
. O

coadministration O
of O
extract O
significantly O
reduced O
the O
lipid O
peroxidation O
and O
reversed O
the O
decrease O
in O
brain O
sod O
, O
cat O
and O
gsh O
levels O
. O

the O
results O
of O
the O
present O
study O
suggested O
that O
hibiscus O
rosa O
sinensis O
had O
a O
protective O
role O
against O
reserpine-induced O
orofacial O
dyskinesia B-NEG
and O
oxidative O
stress O
. O

-DOCSTART- O

comparison O
of O
aqueous O
and O
gellan O
ophthalmic O
timolol O
with O
placebo O
on O
the O
24-hour O
heart O
rate O
response O
in O
patients O
on O
treatment O
for O
glaucoma B-NEG
. O

purpose O
: O
topical O
beta-blocker O
treatment O
is O
routine O
therapy O
in O
the O
management O
of O
patients O
with O
glaucoma B-NEG
. O

therapy O
results O
in O
systemic O
absorption O
, O
however O
, O
the O
degree O
of O
reduction O
of O
resting O
and O
peak O
heart O
rate O
has O
not O
been O
quantified O
. O

design O
: O
this O
trial O
evaluated O
the O
effect O
of O
placebo O
, O
0.5% O
aqueous O
timolol O
( O
timolol O
solution O
) O
and O
a O
0.5% O
timolol O
suspension O
that O
forms O
a O
gel O
on O
application O
to O
the O
conjunctiva O
( O
timolol O
gellan O
) O
on O
the O
24-hour O
heart O
rate O
in O
patients O
currently O
being O
treated O
for O
glaucoma B-NEG
to O
quantify O
the O
reduction O
in O
mean O
heart O
rate O
. O

methods O
: O
forty-three O
caucasian O
patients O
with O
primary O
open-angle B-NEG
glaucoma I-NEG
or O
ocular B-NEG
hypertension I-NEG
with O
a O
mean O
( O
+/-sd O
) O
age O
of O
63 O
( O
+/-8 O
) O
years O
were O
randomized O
and O
crossed O
over O
in O
a O
double-masked O
manner O
to O
14 O
days O
of O
treatment O
with O
placebo O
( O
morning O
and O
evening O
in O
both O
eyes) O
, O
timolol O
solution O
( O
morning O
and O
evening O
in O
both O
eyes) O
, O
or O
timolol O
gellan O
( O
morning O
in O
both O
eyes O
with O
placebo O
in O
the O
evening) O
. O

on O
the O
13th O
day O
of O
each O
period O
, O
heart O
rate O
was O
recorded O
continuously O
during O
a O
typical O
, O
ambulant O
24-hour O
period O
. O

results O
: O
both O
timolol O
solution O
and O
timolol O
gellan O
reduced O
the O
mean O
24-hour O
heart O
rate O
compared O
with O
placebo O
(p O
< O
or O
= O
.001) O
, O
and O
this O
reduction O
was O
most O
pronounced O
during O
the O
daytime O
( O
-7.5% O
change O
in O
mean O
heart O
rate O
, O
-5.7 O
beats/min) O
. O

timolol O
gellan O
showed O
a O
numerically O
but O
not O
significantly O
smaller O
reduction O
in O
24-hour O
heart O
rate O
, O
compared O
with O
timolol O
solution O
. O

during O
the O
night O
, O
the O
mean O
12-hour O
heart O
rate O
on O
placebo O
and O
timolol O
gellan O
were O
both O
significantly O
less O
than O
on O
timolol O
solution O
; O
the O
difference O
between O
solution O
and O
gellan O
treatments O
was O
statistically O
significant O
(p O
= O
.01) O
. O

conclusions O
: O
both O
timolol O
solution O
and O
timolol O
gellan O
decrease O
the O
mean O
24-hour O
heart O
rate O
compared O
with O
placebo O
. O

this O
response O
was O
most O
pronounced O
during O
the O
active O
daytime O
period O
. O

these O
data O
quantify O
the O
modest O
bradycardia B-NEG
associated O
with O
ophthalmic O
beta-blocker O
therapy O
in O
a O
typical O
patient O
population O
on O
therapy O
for O
glaucoma B-NEG
. O

although O
exercise O
performance O
was O
not O
assessed O
in O
this O
trial O
, O
reductions O
of O
this O
magnitude O
should O
not O
have O
substantial O
clinical O
consequences O
. O

-DOCSTART- O

5 O
flourouracil-induced O
apical B-NEG
ballooning I-NEG
syndrome I-NEG
: O
a O
case O
report O
. O

the O
apical B-NEG
ballooning I-NEG
syndrome I-NEG
( O
abs B-NEG
) O
is O
a O
recently O
described O
stress-mediated O
acute B-NEG
cardiac I-NEG
syndrome I-NEG
characterized O
by O
transient O
wall-motion O
abnormalities O
involving O
the O
apex O
and O
midventricle O
with O
hyperkinesis B-NEG
of O
the O
basal O
left O
ventricular O
( O
lv O
) O
segments O
without O
obstructive O
epicardial B-NEG
coronary I-NEG
disease I-NEG
. O
cardiotoxicity B-NEG
is O
not O
an O
uncommon O
adverse O
effect O
of O
chemotherapeutic O
agents O
. O

however O
, O
there O
are O
no O
reports O
of O
abs B-NEG
secondary O
to O
chemotherapeutic O
agents O
. O

we O
describe O
the O
case O
of O
a O
woman O
who O
developed O
the O
syndrome O
after O
chemotherapy O
for O
metastatic O
cancer B-NEG
. O

a O
79-year-old O
woman O
presented O
with O
typical O
ischemic B-NEG
chest B-NEG
pain I-NEG
, O
elevated O
cardiac O
enzymes O
with O
significant O
st-segment O
abnormalities O
on O
her O
electrocardiogram O
. O

she O
underwent O
recent O
chemotherapy O
with O
fluorouracil O
for O
metastatic O
colorectal B-NEG
cancer I-NEG
. O

echocardiography O
revealed O
a O
wall-motion O
abnormality O
involving O
the O
apical O
and O
periapical O
segments O
which O
appeared O
akinetic B-NEG
. O

coronary O
angiography O
revealed O
no O
obstructive O
coronary O
lesions O
. O

the O
patient O
was O
stabilized O
with O
medical O
therapy O
. O

four O
weeks O
later O
she O
remained O
completely O
asymptomatic O
. O

echocardiogram O
revealed O
a O
normal O
ejection O
fraction O
and O
a O
resolution O
of O
the O
apical O
akinesis B-NEG
. O

pathogenetic O
mechanisms O
of O
cardiac B-NEG
complications I-NEG
in O
cancer B-NEG
patients O
undergoing O
chemotherapy O
include O
coronary B-NEG
vasospasm I-NEG
, O
endothelial O
damage O
and O
consequent O
thrombus B-NEG
formation O
. O

in O
our O
patient O
, O
both O
supraphysiologic O
levels O
of O
plasma O
catecholamines O
and O
stress O
related O
neuropeptides O
caused O
by O
cancer B-NEG
diagnosis O
as O
well O
as O
chemotherapy O
may O
have O
contributed O
the O
development O
of O
abs B-NEG
. O

-DOCSTART- O

reduction O
of O
pain B-NEG
during O
induction O
with O
target-controlled O
propofol O
and O
remifentanil O
. O

background O
: O
pain B-NEG
on O
injection O
of O
propofol O
is O
unpleasant O
. O

we O
hypothesized O
that O
propofol O
infusion O
pain B-NEG
might O
be O
prevented O
by O
infusing O
remifentanil O
before O
starting O
the O
propofol O
infusion O
in O
a O
clinical O
setting O
where O
target-controlled O
infusions O
( O
tci O
) O
of O
both O
drugs O
were O
used O
. O

a O
prospective O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
was O
performed O
to O
determine O
the O
effect-site O
concentration O
( O
ce O
) O
of O
remifentanil O
to O
prevent O
the O
pain B-NEG
without O
producing O
complications O
. O

methods O
: O
a O
total O
of O
128 O
patients O
undergoing O
general O
surgery O
were O
randomly O
allocated O
to O
receive O
normal O
saline O
( O
control O
) O
or O
remifentanil O
to O
a O
target O
ce O
of O
2 O
ng O
ml(-1 O
) O
(r2) O
, O
4 O
ng O
ml(-1 O
) O
(r4) O
, O
or O
6 O
ng O
ml(-1 O
) O
( O
r6 O
) O
administered O
via O
tci O
. O

after O
the O
target O
ce O
was O
achieved O
, O
the O
infusion O
of O
propofol O
was O
started O
. O

remifentanil-related O
complications O
were O
assessed O
during O
the O
remifentanil O
infusion O
, O
and O
pain B-NEG
caused O
by O
propofol O
was O
evaluated O
using O
a O
four-point O
scale O
during O
the O
propofol O
infusion O
. O

results O
: O
the O
incidence O
of O
pain B-NEG
was O
significantly O
lower O
in O
groups O
r4 O
and O
r6 O
than O
in O
the O
control O
and O
r2 O
groups O
( O
12/32 O
and O
6/31 O
vs O
26/31 O
and O
25/32 O
, O
respectively O
, O
p<0.001) O
. O
pain B-NEG
was O
less O
severe O
in O
groups O
r4 O
and O
r6 O
than O
in O
the O
control O
and O
r2 O
groups O
(p<0.001) O
. O

however O
, O
both O
incidence O
and O
severity O
of O
pain B-NEG
were O
not O
different O
between O
groups O
r4 O
and O
r6 O
. O

no O
significant O
complications O
were O
observed O
during O
the O
study O
. O

conclusions O
: O
during O
induction O
of O
anaesthesia O
with O
tci O
of O
propofol O
and O
remifentanil O
, O
a O
significant O
reduction O
in O
propofol O
infusion O
pain B-NEG
was O
achieved O
without O
significant O
complications O
by O
prior O
administration O
of O
remifentanil O
at O
a O
target O
ce O
of O
4 O
ng O
ml(-1) O
. O

-DOCSTART- O

prenatal O
exposure O
to O
fluoxetine O
induces O
fetal B-NEG
pulmonary I-NEG
hypertension I-NEG
in O
the O
rat O
. O

rationale O
: O
fluoxetine O
is O
a O
selective O
serotonin O
reuptake O
inhibitor O
antidepressant O
widely O
used O
by O
pregnant O
women O
. O

epidemiological O
data O
suggest O
that O
fluoxetine O
exposure O
prenatally O
increases O
the O
prevalence O
of O
persistent O
pulmonary B-NEG
hypertension I-NEG
syndrome I-NEG
of O
the O
newborn O
. O

the O
mechanism O
responsible O
for O
this O
effect O
is O
unclear O
and O
paradoxical O
, O
considering O
the O
current O
evidence O
of O
a O
pulmonary B-NEG
hypertension I-NEG
protective O
fluoxetine O
effect O
in O
adult O
rodents O
. O

objectives O
: O
to O
evaluate O
the O
fluoxetine O
effect O
on O
fetal O
rat O
pulmonary O
vascular O
smooth O
muscle O
mechanical O
properties O
and O
cell O
proliferation O
rate O
. O

methods O
: O
pregnant O
rats O
were O
treated O
with O
fluoxetine O
( O
10 O
mg/kg O
) O
from O
day O
11 O
through O
day O
21 O
of O
gestation O
. O

measurements O
and O
main O
results O
: O
fetuses O
were O
delivered O
by O
cesarean O
section O
. O

as O
compared O
with O
controls O
, O
fluoxetine O
exposure O
resulted O
in O
fetal B-NEG
pulmonary I-NEG
hypertension I-NEG
as O
evidenced O
by O
an O
increase O
in O
the O
weight O
ratio O
of O
the O
right O
ventricle O
to O
the O
left O
ventricle O
plus O
septum O
(p O
= O
0.02 O
) O
and O
by O
an O
increase O
in O
pulmonary O
arterial O
medial O
thickness O
(p O
< O
0.01) O
. O

postnatal O
mortality O
was O
increased O
among O
experimental O
animals O
, O
and O
arterial O
oxygen O
saturation O
was O
96 O
+/- O
1% O
in O
1-day-old O
control O
animals O
and O
significantly O
lower O
(p O
< O
0.01 O
) O
in O
fluoxetine-exposed O
pups O
( O
79 O
+/- O
2%) O
. O

in O
vitro O
, O
fluoxetine O
induced O
pulmonary O
arterial O
muscle O
contraction O
in O
fetal O
, O
but O
not O
adult O
, O
animals O
(p O
< O
0.01 O
) O
and O
reduced O
serotonin-induced O
contraction O
at O
both O
ages O
(p O
< O
0.01) O
. O

after O
in O
utero O
exposure O
to O
a O
low O
fluoxetine O
concentration O
the O
pulmonary O
arterial O
smooth O
muscle O
cell O
proliferation O
rate O
was O
significantly O
increased O
in O
fetal O
, O
but O
not O
adult O
, O
cells O
(p O
< O
0.01) O
. O

conclusions O
: O
in O
contrast O
to O
the O
adult O
, O
fluoxetine O
exposure O
in O
utero O
induces O
pulmonary B-NEG
hypertension I-NEG
in O
the O
fetal O
rat O
as O
a O
result O
of O
a O
developmentally O
regulated O
increase O
in O
pulmonary O
vascular O
smooth O
muscle O
proliferation O
. O

-DOCSTART- O

syncope B-NEG
and O
qt B-NEG
prolongation I-NEG
among O
patients O
treated O
with O
methadone O
for O
heroin O
dependence O
in O
the O
city O
of O
copenhagen O
. O

background O
: O
methadone O
is O
prescribed O
to O
heroin O
addicts O
to O
decrease O
illicit O
opioid O
use O
. O

prolongation O
of O
the O
qt O
interval O
in O
the O
ecg O
of O
patients O
with O
torsade B-NEG
de I-NEG
pointes I-NEG
( O
tdp B-NEG
) O
has O
been O
reported O
in O
methadone O
users O
. O

as O
heroin O
addicts O
sometimes O
faint O
while O
using O
illicit O
drugs O
, O
doctors O
might O
attribute O
too O
many O
episodes O
of O
syncope B-NEG
to O
illicit O
drug O
use O
and O
thereby O
underestimate O
the O
incidence O
of O
tdp B-NEG
in O
this O
special O
population O
, O
and O
the O
high O
mortality O
in O
this O
population O
may O
, O
in O
part O
, O
be O
caused O
by O
the O
proarrhythmic O
effect O
of O
methadone O
. O

methods O
: O
in O
this O
cross-sectional O
study O
interview O
, O
ecgs O
and O
blood O
samples O
were O
collected O
in O
a O
population O
of O
adult O
heroin O
addicts O
treated O
with O
methadone O
or O
buprenorphine O
on O
a O
daily O
basis O
. O

of O
the O
patients O
at O
the O
drug O
addiction O
service O
in O
the O
municipal O
of O
copenhagen O
, O
450 O
( O
approximately O
52% O
) O
were O
included O
. O

the O
qt O
interval O
was O
estimated O
from O
12 O
lead O
ecgs O
. O

all O
participants O
were O
interviewed O
about O
any O
experience O
of O
syncope B-NEG
. O

the O
association O
between O
opioid O
dose O
and O
qt O
, O
and O
methadone O
dose O
and O
reporting O
of O
syncope B-NEG
was O
assessed O
using O
multivariate O
linear O
regression O
and O
logistic O
regression O
, O
respectively O
. O

results O
: O
methadone O
dose O
was O
associated O
with O
longer O
qt O
interval O
of O
0.140 O
ms/mg O
(p O
= O
0.002) O
. O

no O
association O
between O
buprenorphine O
and O
qtc O
was O
found O
. O

among O
the O
subjects O
treated O
with O
methadone O
, O
28% O
men O
and O
32% O
women O
had O
prolonged B-NEG
qtc I-NEG
interval I-NEG
. O

none O
of O
the O
subjects O
treated O
with O
buprenorphine O
had O
qtc O
interval O
>0.440 O
s((1/2)) O
. O

a O
50 O
mg O
higher O
methadone O
dose O
was O
associated O
with O
a O
1.2 O
( O
95% O
ci O
1.1 O
to O
1.4 O
) O
times O
higher O
odds O
for O
syncope B-NEG
. O

conclusions O
: O
methadone O
is O
associated O
with O
qt B-NEG
prolongation I-NEG
and O
higher O
reporting O
of O
syncope B-NEG
in O
a O
population O
of O
heroin O
addicts O
. O

-DOCSTART- O

peripheral B-NEG
neuropathy I-NEG
caused O
by O
high-dose O
cytosine O
arabinoside O
treatment O
in O
a O
patient O
with O
acute B-NEG
myeloid I-NEG
leukemia I-NEG
. O

the O
central O
nervous O
system O
toxicity B-NEG
of O
high-dose O
cytosine O
arabinoside O
is O
well O
recognized O
, O
but O
the O
toxicity B-NEG
of O
cytosine O
arabinoside O
in O
the O
peripheral O
nervous O
system O
has O
been O
infrequently O
reported O
. O

a O
49-year-old O
japanese O
man O
was O
diagnosed O
with O
acute B-NEG
myeloid I-NEG
leukemia I-NEG
. O

after O
he O
achieved O
complete O
remission O
, O
he O
received O
high-dose O
cytosine O
arabinoside O
treatment O
(2 O
g/m2 O
twice O
a O
day O
for O
5 O
days O
; O
total O
, O
20 O
g/m2 O
) O
as O
consolidation O
therapy O
. O

the O
first O
course O
of O
high-dose O
cytosine O
arabinoside O
resulted O
in O
no O
unusual O
symptoms O
, O
but O
on O
day O
21 O
of O
the O
second O
course O
of O
treatment O
, O
the O
patient O
complained O
of O
numbness B-NEG
in O
his O
right O
foot O
. O

electromyogram O
and O
nerve-conduction O
studies O
showed O
peripheral B-NEG
neuropathy I-NEG
in O
both O
peroneal O
nerves O
. O

this O
neuropathy B-NEG
was O
gradually O
resolving O
; O
however O
, O
after O
the O
patient O
received O
allogeneic O
bone O
marrow O
transplantation O
, O
the O
symptoms O
worsened O
, O
with O
the O
development O
of O
graft-versus-host B-NEG
disease I-NEG
, O
and O
the O
symptoms O
subsequently O
responded O
to O
methylprednisolone O
. O

although O
the O
mechanisms O
of O
peripheral B-NEG
neuropathy I-NEG
are O
still O
unclear O
, O
high-dose O
cytosine O
arabinoside O
is O
a O
therapy O
that O
is O
potentially O
toxic O
to O
the O
peripheral O
nervous O
system O
, O
and O
auto/alloimmunity O
may O
play O
an O
important O
role O
in O
these O
mechanisms O
. O

-DOCSTART- O

atorvastatin O
prevented O
and O
reversed O
dexamethasone-induced O
hypertension B-NEG
in O
the O
rat O
. O

to O
assess O
the O
antioxidant O
effects O
of O
atorvastatin O
( O
atorva O
) O
on O
dexamethasone O
( O
dex)-induced O
hypertension B-NEG
, O
60 O
male O
sprague-dawley O
rats O
were O
treated O
with O
atorva O
30 O
mg/kg/day O
or O
tap O
water O
for O
15 O
days O
. O

dex O
increased O
systolic O
blood O
pressure O
( O
sbp O
) O
from O
109 O
+/- O
1.8 O
to O
135 O
+/- O
0.6 O
mmhg O
and O
plasma O
superoxide O
( O
5711 O
+/- O
284.9 O
saline O
, O
7931 O
+/- O
392.8 O
u/ml O
dex O
, O
p O
< O
0.001) O
. O

in O
this O
prevention O
study O
, O
sbp O
in O
the O
atorva O
+ O
dex O
group O
was O
increased O
from O
115 O
+/- O
0.4 O
to O
124 O
+/- O
1.5 O
mmhg O
, O
but O
this O
was O
significantly O
lower O
than O
in O
the O
dex-only O
group O
( O
p' O
< O
0.05) O
. O

atorva O
reversed O
dex-induced O
hypertension B-NEG
( O
129 O
+/- O
0.6 O
mmhg O
, O
vs O
. O
135 O
+/- O
0.6 O
mmhg O
p' O
< O
0.05 O
) O
and O
decreased O
plasma O
superoxide O
( O
7931 O
+/- O
392.8 O
dex O
, O
1187 O
+/- O
441.2 O
atorva O
+ O
dex O
, O
p O
< O
0.0001) O
. O

plasma O
nitrate/nitrite O
( O
nox O
) O
was O
decreased O
in O
dex-treated O
rats O
compared O
to O
saline-treated O
rats O
( O
11.2 O
+/- O
1.08 O
microm O
, O
15.3 O
+/- O
1.17 O
microm O
, O
respectively O
, O
p O
< O
0.05) O
. O

atorva O
affected O
neither O
plasma O
nox O
nor O
thymus O
weight O
. O

thus O
, O
atorvastatin O
prevented O
and O
reversed O
dexamethasone-induced O
hypertension B-NEG
in O
the O
rat O
. O

-DOCSTART- O

two O
prodrugs O
of O
potent O
and O
selective O
glur5 O
kainate O
receptor O
antagonists O
actives O
in O
three O
animal O
models O
of O
pain B-NEG
. O

amino O
acids O
5 O
and O
7, O
two O
potent O
and O
selective O
competitive O
glur5 O
ka O
receptor O
antagonists O
, O
exhibited O
high O
glur5 O
receptor O
affinity O
over O
other O
glutamate O
receptors O
. O

their O
ester O
prodrugs O
6 O
and O
8 O
were O
orally O
active O
in O
three O
models O
of O
pain B-NEG
: O
reversal O
of O
formalin-induced O
paw O
licking O
, O
carrageenan-induced O
thermal B-NEG
hyperalgesia I-NEG
, O
and O
capsaicin-induced O
mechanical B-NEG
hyperalgesia I-NEG
. O

-DOCSTART- O

sirolimus O
and O
mycophenolate O
mofetil O
for O
calcineurin-free O
immunosuppression O
in O
renal O
transplant O
recipients O
. O

calcineurin O
inhibitors O
, O
such O
as O
cyclosporine O
and O
tacrolimus O
, O
have O
been O
available O
for O
almost O
20 O
years O
. O

although O
these O
drugs O
are O
highly O
effective O
and O
represent O
the O
mainstay O
of O
transplant O
immunosuppression O
, O
they O
are O
associated O
with O
acute O
and O
chronic O
nephrotoxicity B-NEG
. O

acute O
nephrotoxicity B-NEG
, O
which O
occurs O
in O
the O
early O
period O
after O
transplantation O
, O
leads O
to O
a O
higher O
rate O
of O
dialysis O
, O
and O
chronic O
nephrotoxicity B-NEG
may O
eventually O
result O
in O
graft O
loss O
. O

acute O
and O
chronic O
nephrotoxicity B-NEG
is O
becoming O
more O
common O
as O
the O
use O
of O
marginal O
kidneys O
for O
transplantation O
increases O
. O

two O
recently O
available O
immunosuppressive O
agents O
, O
mycophenolate O
mofetil O
and O
sirolimus O
(rapamycin) O
, O
have O
no O
nephrotoxicity B-NEG
. O

the O
use O
of O
these O
drugs O
in O
combination O
with O
other O
agents O
has O
led O
to O
the O
development O
of O
new O
paradigms O
of O
immunosuppressive O
therapy O
. O

this O
paper O
reviews O
the O
results O
of O
clinical O
trials O
that O
have O
investigated O
these O
new O
approaches O
to O
immunosuppression O
in O
renal O
transplant O
recipients O
. O

-DOCSTART- O

erythropoietin O
restores O
the O
anemia B-NEG
-induced O
reduction O
in O
cyclophosphamide O
cytotoxicity B-NEG
in O
rat O
tumors B-NEG
. O

the O
aim O
of O
this O
study O
was O
to O
examine O
the O
impact O
of O
anemia B-NEG
prevention O
by O
recombinant O
human O
erythropoietin O
( O
rhuepo O
) O
treatment O
on O
the O
cytotoxicity B-NEG
of O
cyclophosphamide O
in O
solid O
experimental O
tumors B-NEG
. O
anemia B-NEG
was O
induced O
using O
a O
single O
dose O
of O
carboplatin O
( O
50 O
mg/kg O
i.v. O
) O
resulting O
in O
a O
long-lasting O
reduction O
( O
30% O
) O
of O
the O
hemoglobin O
concentration O
. O

in O
a O
second O
group O
, O
the O
development O
of O
anemia B-NEG
was O
prevented O
by O
rhuepo O
( O
1000 O
iu/kg O
) O
administered O
s.c O
. O
three O
times/week O
starting O
7 O
days O
before O
carboplatin O
application O
. O

four O
days O
after O
carboplatin O
treatment O
, O
tumors B-NEG
( O
ds- O
sarcoma B-NEG
of O
the O
rat O
) O
were O
implanted O
s.c O
. O
onto O
the O
hind O
food O
dorsum O
. O

neither O
carboplatin O
nor O
rhuepo O
treatment O
influenced O
tumor B-NEG
growth O
rate O
per O
se O
. O

when O
tumors B-NEG
were O
treated O
with O
a O
single O
dose O
of O
cyclophosphamide O
( O
60 O
mg/kg O
i.p. O
) O
5 O
days O
after O
implantation O
, O
a O
growth O
delay O
with O
a O
subsequent O
regrowth O
of O
the O
tumors B-NEG
was O
observed O
. O

in O
the O
anemia B-NEG
group O
, O
the O
growth O
delay O
was O
significantly O
shorter O
compared O
with O
nonanemic O
controls O
( O
13.3 O
days O
versus O
8.6 O
days) O
. O

in O
the O
group O
where O
anemia B-NEG
was O
prevented O
by O
rhuepo O
treatment O
, O
growth O
delay O
was O
comparable O
with O
that O
of O
nonanemic O
controls O
( O
13.3 O
days) O
. O

these O
results O
suggest O
that O
chemotherapy-induced O
anemia B-NEG
reduces O
cytotoxicity B-NEG
of O
cyclophosphamide O
in O
tumors B-NEG
, O
whereas O
correction O
of O
anemia B-NEG
by O
rhuepo O
treatment O
( O
epoetin O
alpha O
) O
increases O
the O
sensitivity O
, O
probably O
as O
a O
result O
of O
an O
improved O
oxygen O
supply O
to O
tumor B-NEG
tissue O
. O

-DOCSTART- O

the O
role O
of O
nitrergic O
system O
in O
lidocaine-induced O
convulsion B-NEG
in O
the O
mouse O
. O

the O
effects O
of O
n-nitro-l-arginine-methyl O
ester O
( O
l-name O
) O
a O
nitric O
oxide O
( O
no O
) O
synthase O
inhibitor O
and O
l-arginine O
, O
a O
no O
precursor O
, O
were O
investigated O
on O
lidocaine-induced O
convulsions B-NEG
. O

in O
the O
first O
experiment O
, O
four O
groups O
of O
mice O
received O
physiological O
saline O
(0.9%) O
, O
l-arginine O
( O
300 O
mg/kg O
, O
i.p.) O
, O
l-name O
( O
100 O
mg/kg O
, O
i.p. O
) O
and O
diazepam O
(2 O
mg/kg) O
, O
respectively O
. O

thirty O
minutes O
after O
these O
injections O
, O
all O
mice O
received O
lidocaine O
( O
50 O
mg/kg O
, O
i.p.) O
. O

in O
the O
second O
experiment O
, O
four O
groups O
of O
mice O
received O
similar O
treatment O
in O
the O
first O
experiment O
, O
and O
30 O
min O
after O
these O
injections O
, O
all O
mice O
received O
a O
higher O
dose O
of O
lidocaine O
( O
80 O
mg/kg) O
. O

l-name O
( O
100 O
mg/kg O
, O
i.p. O
) O
and O
diazepam O
(2 O
mg/kg O
) O
significantly O
decreased O
the O
incidence O
of O
lidocaine O
( O
50 O
mg/kg)-induced O
convulsions B-NEG
. O

in O
contrast O
, O
the O
l-arginine O
treatment O
increased O
the O
incidence O
of O
lidocaine O
( O
80 O
mg/kg O
, O
i.p.)-induced O
convulsions B-NEG
significantly O
. O

these O
results O
may O
suggest O
that O
no O
is O
a O
proconvulsant O
mediator O
in O
lidocaine-induced O
convulsions B-NEG
. O

-DOCSTART- O

effect O
of O
intravenous O
metoprolol O
or O
intravenous O
metoprolol O
plus O
glucagon O
on O
dobutamine-induced O
myocardial B-NEG
ischemia I-NEG
. O

study O
objective O
: O
to O
determine O
the O
effect O
of O
metoprolol O
on O
dobutamine O
stress O
testing O
with O
technetium-99m O
sestamibi O
single-photon O
emission O
computed O
tomography O
imaging O
and O
st-segment O
monitoring O
, O
and O
to O
assess O
the O
impact O
of O
intravenous O
glucagon O
on O
metoprolol's O
effects O
. O

design O
: O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
. O

setting O
: O
community O
hospital O
. O

patients O
: O
twenty-two O
patients O
with O
known O
reversible O
perfusion O
defects O
. O

intervention O
: O
patients O
underwent O
dobutamine O
stress O
tests O
per O
standard O
protocol O
. O

before O
dobutamine O
was O
begun O
, O
no O
therapy O
was O
given O
during O
the O
first O
visit O
, O
and O
patients O
were O
randomized O
on O
subsequent O
visits O
to O
receive O
metoprolol O
or O
metoprolol O
plus O
glucagon O
1 O
mg O
. O

metoprolol O
was O
dosed O
to O
achieve O
a O
resting O
predobutamine O
heart O
rate O
below O
65 O
beats/minute O
or O
a O
total O
intravenous O
dose O
of O
20 O
mg O
. O

measurements O
and O
main O
results O
: O
metoprolol O
reduced O
maximum O
heart O
rate O
31% O
, O
summed O
stress O
scores O
29% O
, O
and O
summed O
difference O
scores O
43% O
versus O
control O
. O

metoprolol O
plus O
glucagon O
also O
reduced O
the O
maximum O
heart O
rate O
29% O
versus O
control O
. O

summed O
stress O
and O
summed O
difference O
scores O
were O
not O
significantly O
reduced O
, O
although O
they O
were O
18% O
and O
30% O
lower O
, O
respectively O
, O
than O
control O
. O

no O
significant O
differences O
were O
found O
in O
any O
parameter O
between O
metoprolol O
and O
metoprolol-glucagon O
. O

conclusion O
: O
during O
dobutamine O
stress O
testing O
, O
metoprolol O
attenuates O
or O
eliminates O
evidence O
of O
myocardial B-NEG
ischemia I-NEG
. O

glucagon O
1 O
mg O
, O
although O
somewhat O
effective O
, O
does O
not O
correct O
this O
effect O
to O
the O
extent O
that O
it O
can O
be O
administered O
clinically O
. O

-DOCSTART- O

prednisolone-induced O
muscle B-NEG
dysfunction I-NEG
is O
caused O
more O
by O
atrophy B-NEG
than O
by O
altered O
acetylcholine O
receptor O
expression O
. O

large O
doses O
of O
glucocorticoids O
can O
alter O
muscle O
physiology O
and O
susceptibility O
to O
neuromuscular O
blocking O
drugs O
by O
mechanisms O
not O
clearly O
understood O
. O

we O
investigated O
the O
effects O
of O
moderate O
and O
large O
doses O
of O
prednisolone O
on O
muscle O
function O
and O
pharmacology O
, O
and O
their O
relationship O
to O
changes O
in O
muscle O
size O
and O
acetylcholine O
receptor O
( O
achr O
) O
expression O
. O

with O
institutional O
approval O
, O
35 O
sprague-dawley O
rats O
were O
randomly O
allocated O
to O
receive O
daily O
subcutaneous O
doses O
of O
10 O
mg/kg O
prednisolone O
( O
p10 O
group) O
, O
100 O
mg/kg O
prednisolone O
( O
p100 O
group) O
, O
or O
an O
equal O
volume O
of O
saline O
(s O
group O
) O
for O
7 O
days O
. O

a O
fourth O
group O
of O
rats O
was O
pair O
fed O
( O
food O
restricted O
) O
with O
the O
p100 O
rats O
for O
7 O
days O
( O
fr O
group) O
. O

on O
day O
8, O
the O
nerve-evoked O
peak O
twitch O
tensions O
, O
tetanic B-NEG
tensions O
, O
and O
fatigability O
, O
and O
the O
dose-response O
curves O
of O
d-tubocurarine O
in O
the O
tibialis O
cranialis O
muscle O
were O
measured O
in O
vivo O
and O
related O
to O
muscle O
mass O
or O
expression O
of O
achrs O
. O

rate O
of O
body O
weight O
gain O
was O
depressed O
in O
the O
p100 O
, O
fr O
, O
and O
p10 O
groups O
compared O
with O
the O
s O
group O
. O

tibialis O
muscle O
mass O
was O
smaller O
in O
the O
p100 O
group O
than O
in O
the O
p10 O
or O
s O
groups O
. O

the O
evoked O
peak O
twitch O
and O
tetanic B-NEG
tensions O
were O
less O
in O
the O
p100 O
group O
than O
in O
the O
p10 O
or O
s O
groups O
, O
however O
, O
tension O
per O
milligram O
of O
muscle O
mass O
was O
greater O
in O
the O
p100 O
group O
than O
in O
the O
s O
group O
. O

the O
50% O
effective O
dose O
of O
d-tubocurarine O
( O
microg/kg O
) O
in O
the O
tibialis O
muscle O
was O
smaller O
in O
the O
p10 O
( O
33.6 O
+/- O
5.4 O
) O
than O
in O
the O
s O
( O
61.9 O
+/- O
5.0 O
) O
or O
the O
p100 O
( O
71.3 O
+/- O
9.6 O
) O
groups O
. O

achr O
expression O
was O
less O
in O
the O
p10 O
group O
than O
in O
the O
s O
group O
. O

the O
evoked O
tensions O
correlated O
with O
muscle O
mass O
( O
r(2 O
) O
= O
0.32 O
, O
p O
< O
0.001) O
, O
however O
, O
not O
with O
expression O
of O
achr O
. O

the O
50% O
effective O
dose O
of O
d-tubocurarine O
did O
not O
correlate O
with O
muscle O
mass O
or O
achr O
expression O
. O

our O
results O
suggest O
that O
the O
neuromuscular B-NEG
dysfunction I-NEG
after O
prednisolone O
is O
dose-dependent O
, O
and O
derives O
primarily O
from O
muscle B-NEG
atrophy I-NEG
and O
derives O
less O
so O
from O
changes O
in O
achr O
expression O
. O

implications O
: O
the O
mechanisms O
by O
which O
chronic O
glucocorticoid O
therapy O
alters O
neuromuscular O
physiology O
and O
pharmacology O
are O
unclear O
. O

we O
suggest O
that O
the O
observed O
effects O
are O
dose-dependent O
and O
derive O
primarily O
from O
muscle B-NEG
atrophy I-NEG
and O
derive O
less O
from O
changes O
in O
acetylcholine O
receptor O
expression O
. O

-DOCSTART- O

rapid O
reversal O
of O
life-threatening O
diltiazem-induced O
tetany B-NEG
with O
calcium O
chloride O
. O

we O
describe O
a O
patient O
who O
developed O
tetany B-NEG
with O
sudden O
respiratory B-NEG
arrest I-NEG
after O
the O
infusion O
of O
intravenous O
diltiazem O
. O

the O
administration O
of O
calcium O
chloride O
rapidly O
resolved O
the O
patient's O
tetany B-NEG
with O
prompt O
recovery O
of O
respiratory O
function O
, O
averting O
the O
need O
for O
more O
aggressive O
airway O
management O
and O
ventilatory O
support O
. O

the O
emergency O
physician O
should O
be O
aware O
that O
life-threatening O
tetany B-NEG
may O
accompany O
the O
administration O
of O
intravenous O
diltiazem O
and O
that O
calcium O
chloride O
may O
be O
a O
rapid O
and O
effective O
remedy O
. O

-DOCSTART- O

effects O
of O
nonsteroidal O
anti-inflammatory O
drugs O
on O
hemostasis O
in O
patients O
with O
aneurysmal B-NEG
subarachnoid I-NEG
hemorrhage I-NEG
. O

platelet O
function O
is O
impaired O
by O
nonsteroidal O
anti-inflammatory O
drugs O
( O
nsaids O
) O
with O
prominent O
anti-inflammatory O
properties O
. O

their O
safety O
in O
patients O
undergoing O
intracranial O
surgery O
is O
under O
debate O
. O

patients O
with O
aneurysmal B-NEG
subarachnoid I-NEG
hemorrhage I-NEG
( O
sah B-NEG
) O
were O
randomized O
to O
receive O
either O
ketoprofen O
, O
100 O
mg O
, O
three O
times O
a O
day O
( O
ketoprofen O
group O
, O
n O
= O
9) O
or O
a O
weak O
nsaid O
, O
acetaminophen O
, O
1 O
g, O
three O
times O
a O
day O
( O
acetaminophen O
group O
, O
n O
= O
9) O
starting O
immediately O
after O
the O
diagnosis O
of O
aneurysmal B-NEG
sah B-NEG
. O

treatment O
was O
continued O
for O
3 O
days O
postoperatively O
. O

test O
blood O
samples O
were O
taken O
before O
treatment O
and O
surgery O
as O
well O
as O
on O
the O
first O
, O
third O
, O
and O
fifth O
postoperative O
mornings O
. O

maximal O
platelet B-NEG
aggregation I-NEG
induced O
by O
6 O
microm O
of O
adenosine O
diphosphate O
decreased O
after O
administration O
of O
ketoprofen O
. O

aggregation O
was O
lower O
(p O
< O
.05 O
) O
in O
the O
ketoprofen O
group O
than O
in O
the O
acetaminophen O
group O
just O
before O
surgery O
and O
on O
the O
third O
postoperative O
day O
. O

in O
contrast O
, O
maximal O
platelet B-NEG
aggregation I-NEG
increased O
in O
the O
acetaminophen O
group O
on O
the O
third O
postoperative O
day O
as O
compared O
with O
the O
pretreatment O
platelet B-NEG
aggregation I-NEG
results O
(p O
< O
.05) O
. O

one O
patient O
in O
the O
ketoprofen O
group O
developed O
a O
postoperative O
intracranial O
hematoma B-NEG
. O

coagulation O
( O
prothrombin O
time O
[pt] O
, O
activated O
partial O
thromboplastin O
time O
[appt] O
, O
fibrinogen O
concentration O
, O
and O
antithrombin O
iii O
[at O
iii] O
) O
was O
comparable O
between O
the O
two O
groups O
. O

ketoprofen O
but O
not O
acetaminophen O
impaired O
platelet O
function O
in O
patients O
with O
sah B-NEG
. O

if O
ketoprofen O
is O
used O
before O
surgery O
on O
cerebral O
artery B-NEG
aneurysms I-NEG
, O
it O
may O
pose O
an O
additional O
risk O
factor O
for O
hemorrhage B-NEG
. O

-DOCSTART- O

value O
of O
methylprednisolone O
in O
prevention O
of O
the O
arthralgia B-NEG
- O
myalgia B-NEG
syndrome O
associated O
with O
the O
total O
dose O
infusion O
of O
iron O
dextran O
: O
a O
double O
blind O
randomized O
trial O
. O

the O
safety O
and O
efficacy O
of O
total O
dose O
infusion O
( O
tdi O
) O
of O
iron O
dextran O
has O
been O
well O
documented O
. O

in O
40% O
of O
treated O
patients O
, O
an O
arthralgia B-NEG
- O
myalgia B-NEG
syndrome O
develops O
. O

the O
purpose O
of O
this O
randomized O
, O
double-blind O
, O
prospective O
study O
was O
to O
investigate O
whether O
intravenous O
( O
i.v. O
) O
administration O
of O
methylprednisolone O
( O
mp O
) O
prevents O
this O
complication O
. O

sixty-five O
patients O
, O
34 O
women O
and O
31 O
men O
, O
ages O
36 O
to O
80 O
years O
, O
received O
either O
normal O
saline O
before O
and O
after O
tdi O
( O
group O
1) O
, O
125 O
mg O
i.v O
. O

mp O
before O
and O
saline O
after O
tdi O
( O
group O
2) O
, O
or O
125 O
mg O
i.v O
. O

mp O
before O
and O
after O
tdi O
( O
group O
3) O
. O

patients O
were O
observed O
for O
72 O
hours O
and O
reactions O
were O
recorded O
and O
graded O
according O
to O
severity O
. O

fifty-eight O
percent O
of O
group O
1 O
patients O
, O
33% O
of O
group O
2, O
and O
26% O
of O
group O
3 O
had O
reactions O
to O
tdi O
. O

the O
severity O
of O
reactions O
(minimal O
, O
mild O
, O
and O
moderate O
, O
respectively O
) O
was O
as O
follows O
: O
group O
1--6 O
, O
6, O
and O
2; O
group O
2--1 O
, O
5, O
and O
0; O
group O
3--5 O
, O
1, O
and O
0. O

data O
were O
analyzed O
by O
the O
two-sided O
fisher's O
exact O
test O
using O
95% O
confidence O
intervals O
with O
the O
approximation O
of O
woolf O
. O

these O
data O
demonstrate O
that O
administration O
of O
mp O
before O
and O
after O
tdi O
reduces O
the O
frequency O
and O
severity O
of O
the O
arthralgia B-NEG
- O
myalgia B-NEG
syndrome O
. O

we O
conclude O
that O
125 O
mg O
i.v O
. O

mp O
should O
be O
given O
routinely O
before O
and O
after O
tdi O
of O
iron O
dextran O
. O

-DOCSTART- O

long-term O
effects O
of O
vincristine O
on O
the O
peripheral O
nervous O
system O
. O

forty O
patients O
with O
non-hodgkin's B-NEG
lymphoma I-NEG
treated O
with O
vincristine O
between O
1984 O
and O
1990 O
( O
cumulative O
dose O
12 O
mg O
in O
18-24 O
weeks O
) O
were O
investigated O
in O
order O
to O
evaluate O
the O
long O
term O
effects O
of O
vincristine O
on O
the O
peripheral O
nervous O
system O
. O

the O
patients O
were O
interviewed O
with O
emphasis O
on O
neuropathic B-NEG
symptoms I-NEG
. O

physical O
and O
quantitative O
sensory O
examination O
with O
determination O
of O
vibratory O
perception O
and O
thermal O
discrimination O
thresholds O
were O
performed O
, O
four O
to O
77 O
months O
( O
median O
34 O
months O
) O
after O
vincristine O
treatment O
. O

twenty-seven O
patients O
reported O
neuropathic B-NEG
symptoms I-NEG
. O

in O
13 O
of O
these O
27 O
patients O
symptoms O
were O
still O
present O
at O
the O
time O
of O
examination O
. O

in O
these O
patients O
sensory O
signs O
and O
symptoms O
predominated O
. O

in O
the O
other O
14 O
patients O
symptoms O
had O
been O
present O
in O
the O
past O
. O

symptoms O
persisted O
maximally O
40 O
months O
since O
cessation O
of O
therapy O
. O

there O
was O
no O
age O
difference O
between O
patients O
with O
and O
without O
complaints O
at O
the O
time O
of O
examination O
. O

normal O
reflexes O
were O
found O
in O
two O
third O
of O
patients O
. O

neuropathic O
complaints O
were O
not O
very O
troublesome O
on O
the O
long O
term O
. O

it O
is O
concluded O
that O
with O
the O
above O
mentioned O
vincristine O
dose O
schedule O
signs O
and O
symptoms O
of O
vincristine O
neuropathy B-NEG
are O
reversible O
for O
a O
great O
deal O
and O
prognosis O
is O
fairly O
good O
. O

-DOCSTART- O

a O
case O
of O
polymyositis B-NEG
in O
a O
patient O
with O
primary B-NEG
biliary I-NEG
cirrhosis I-NEG
treated O
with O
d-penicillamine O
. O

although O
d-penicillamine O
has O
been O
used O
for O
many O
rheumatologic B-NEG
diseases I-NEG
, O
toxicity B-NEG
limits O
its O
usefulness O
in O
many O
patients O
. O
polymyositis B-NEG
/ O
dermatomyositis B-NEG
can O
develop O
as O
one O
of O
the O
autoimmune O
complications O
of O
d-penicillamine O
treatment O
, O
but O
its O
exact O
pathogenesis O
remains O
unclear O
. O

we O
report O
a O
patient O
with O
primary B-NEG
biliary I-NEG
cirrhosis I-NEG
, O
who O
developed O
polymyositis B-NEG
while O
receiving O
d-penicillamine O
therapy O
. O

we O
described O
the O
special O
clinical O
course O
of O
the O
patient O
. O

patients O
receiving O
d-penicillamine O
therapy O
should O
be O
followed O
carefully O
for O
the O
development O
of O
autoimmune O
complications O
like O
polymyositis B-NEG
/ O
dermatomyositis B-NEG
. O

-DOCSTART- O

photodistributed O
nifedipine-induced O
facial O
telangiectasia B-NEG
. O

five O
months O
after O
starting O
nifedipine O
(adalat) O
, O
two O
patients O
developed O
photodistributed O
facial O
telangiectasia B-NEG
, O
which O
became O
more O
noticeable O
with O
time O
. O

neither O
patient O
complained O
of O
photosensitivity O
or O
flushing B-NEG
. O

both O
patients O
reported O
a O
significant O
cosmetic O
improvement O
after O
discontinuing O
the O
drug O
. O

one O
commenced O
the O
closely O
related O
drug O
amlodipine O
3 O
years O
later O
, O
with O
recurrence O
of O
telangiectasia B-NEG
. O

the O
photodistribution O
of O
the O
telangiectasia B-NEG
suggests O
a O
significant O
drug/light O
interaction O
. O

-DOCSTART- O

nephrotoxicity B-NEG
of O
cyclosporin O
a O
and O
fk506 O
: O
inhibition O
of O
calcineurin O
phosphatase O
. O

cyclosporin O
a O
(csa O
; O
50 O
mg/kg O
) O
and O
fujimycine O
(fk506 O
; O
5 O
mg/kg) O
, O
but O
not O
the O
related O
macrolide O
immunosuppressant O
rapamycin O
(5 O
mg/kg) O
, O
caused O
a O
reduction O
of O
glomerular O
filtration O
rate O
, O
degenerative O
changes O
of O
proximal O
tubular O
epithelium O
, O
and O
hypertrophy B-NEG
of O
the O
juxtaglomerular O
apparatus O
in O
male O
wistar O
rats O
when O
given O
for O
10 O
days O
. O

the O
molecular O
mechanisms O
of O
csa O
and O
fk506 O
toxicity B-NEG
were O
investigated O
. O

cyclophilin O
a O
and O
fk506-binding O
protein O
, O
the O
main O
intracytoplasmic O
receptors O
for O
csa O
and O
fk506 O
, O
respectively O
, O
were O
each O
detected O
in O
renal O
tissue O
extract O
. O

in O
the O
kidney O
, O
high O
levels O
of O
immunoreactive O
and O
enzymatically O
active O
calcineurin O
were O
found O
which O
were O
inhibited O
by O
the O
immunosuppressants O
csa O
and O
fk506 O
, O
but O
not O
by O
rapamycin O
. O

finally O
, O
specific O
immunophilin-drug-calcineurin O
complexes O
formed O
only O
in O
the O
presence O
of O
csa O
and O
fk506 O
, O
but O
not O
rapamycin O
. O

these O
results O
suggest O
that O
the O
nephrotoxic B-NEG
effects O
of O
csa O
and O
fk506 O
is O
likely O
mediated O
through O
binding O
to O
renal O
immunophilin O
and O
inhibiting O
calcineurin O
phosphatase O
. O

-DOCSTART- O

massive O
cerebral B-NEG
edema I-NEG
associated O
with O
fulminant O
hepatic B-NEG
failure I-NEG
in O
acetaminophen O
overdose B-NEG
: O
possible O
role O
of O
cranial O
decompression O
. O
cerebral B-NEG
edema I-NEG
may O
complicate O
the O
course O
of O
fulminant B-NEG
hepatic I-NEG
failure I-NEG
. O

response O
to O
conventional O
therapy O
has O
been O
disappointing O
. O

we O
present O
a O
patient O
with O
fatal O
acetaminophen-induced O
fulminant B-NEG
hepatic I-NEG
failure I-NEG
, O
with O
signs O
and O
symptoms O
of O
cerebral B-NEG
edema I-NEG
, O
unresponsive O
to O
conventional O
medical O
therapy O
. O

cranial O
decompression O
was O
carried O
out O
. O

a O
justification O
of O
the O
need O
for O
further O
evaluation O
of O
cranial O
decompression O
in O
such O
patients O
is O
presented O
. O

-DOCSTART- O

gentamicin O
nephropathy B-NEG
in O
a O
neonate O
. O

the O
clinical O
and O
autopsy O
findings O
in O
a O
premature O
baby O
who O
died O
of O
acute B-NEG
renal I-NEG
failure I-NEG
after O
therapy O
with O
gentamicin O
(5 O
mg/kg/day O
) O
and O
penicillin O
are O
presented O
. O

the O
serum O
gentamicin O
concentration O
had O
reached O
toxic O
levels O
when O
anuria B-NEG
developed O
. O

numerous O
periodic O
acid O
schiff O
( O
pas O
) O
positive O
, O
diastase O
resistant O
cytoplasmic O
inclusion O
bodies O
which O
appeared O
as O
myelin O
figures O
in O
cytosegresomes O
under O
the O
electron O
microscope O
were O
identified O
in O
the O
proximal O
convoluted O
tubules O
. O

the O
pathological O
changes O
induced O
by O
gentamicin O
in O
the O
human O
neonatal O
kidneys O
have O
not O
been O
previously O
reported O
. O

-DOCSTART- O

anti- O
carcinogenic B-NEG
action O
of O
phenobarbital O
given O
simultaneously O
with O
diethylnitrosamine O
in O
the O
rat O
. O

the O
present O
work O
has O
been O
planned O
in O
order O
to O
elucidate O
the O
effect O
of O
phenobarbital O
(pb O
: O
15 O
mg O
per O
rat O
of O
ingested O
dose O
) O
on O
carcinogenesis B-NEG
when O
it O
is O
administered O
simultaneously O
with O
diethylnitrosamine O
(den O
: O
10 O
mg/kg/day) O
. O

wistar O
rats O
( O
180 O
g) O
were O
treated O
by O
den O
alone O
or O
by O
den O
+ O
pb O
during O
2, O
4 O
and O
6 O
weeks O
according O
to O
our O
schedule O
for O
hepatocarcinogenesis B-NEG
. O

after O
the O
end O
of O
the O
treatment O
, O
the O
number O
and O
the O
size O
of O
induced O
pas O
positive O
preneoplastic B-NEG
foci I-NEG
was O
significantly O
reduced O
when O
pb O
was O
given O
simultaneously O
with O
den O
for O
4 O
and O
6 O
weeks O
. O

the O
mitotic O
inhibition O
and O
the O
production O
of O
micronuclei O
normally O
observed O
after O
partial O
hepatectomy O
in O
den O
treated O
rats O
were O
also O
significantly O
decreased O
in O
den O
+ O
pb O
treated O
rats O
. O

when O
the O
treatment O
last O
only O
2 O
weeks O
, O
the O
presence O
of O
pb O
did O
not O
change O
significantly O
the O
last O
parameters O
. O

in O
den O
+ O
pb O
treated O
rats O
, O
the O
survival O
was O
prolonged O
and O
the O
tumor B-NEG
incidence O
decreased O
as O
compared O
with O
the O
results O
obtained O
by O
den O
alone O
. O

it O
is O
concluded O
that O
pb O
, O
which O
promotes O
carcinogenesis B-NEG
when O
administered O
after O
the O
den O
treatment O
, O
reduces O
the O
carcinogen O
effect O
when O
given O
simultaneously O
with O
den O
. O

this O
'anti-carcinogen' O
effect O
acts O
on O
the O
initiation O
as O
well O
as O
on O
the O
promotion O
of O
the O
precancerous B-NEG
lesions I-NEG
. O

biochemical O
investigations O
are O
in O
progress O
to O
obtain O
more O
information O
about O
this O
'paradoxical' O
pb O
effect O
. O

-DOCSTART- O

post-operative O
rigidity B-NEG
after O
fentanyl O
administration O
. O

a O
case O
of O
thoraco-abdominal O
rigidity B-NEG
leading O
to O
respiratory B-NEG
failure I-NEG
is O
described O
in O
the O
post-operative O
period O
in O
an O
elderly O
patient O
who O
received O
a O
moderate O
dose O
of O
fentanyl O
. O

this O
was O
successfully O
reversed O
by O
naloxone O
. O

the O
mechanisms O
possibly O
implicated O
in O
this O
accident O
are O
discussed O
. O

-DOCSTART- O

postpartum O
psychosis B-NEG
induced O
by O
bromocriptine O
. O

two O
multigravida O
patients O
with O
no O
prior O
psychiatric B-NEG
history O
were O
seen O
with O
postpartum O
psychosis B-NEG
, O
having O
received O
bromocriptine O
for O
inhibition B-NEG
of I-NEG
lactation I-NEG
. O

bromocriptine O
given O
in O
high O
doses O
has O
been O
associated O
with O
psychosis B-NEG
in O
patients O
receiving O
the O
drug O
for O
parkinson's B-NEG
disease I-NEG
. O

these O
cases O
demonstrate O
that O
bromocriptine O
may O
cause O
psychosis B-NEG
even O
when O
given O
in O
low O
doses O
. O

-DOCSTART- O

a O
prospective O
study O
on O
the O
dose O
dependency O
of O
cardiotoxicity B-NEG
induced O
by O
mitomycin O
c. O

since O
1975 O
mitomycin O
c O
( O
mmc O
) O
has O
been O
suggested O
to O
be O
cardiotoxic B-NEG
, O
especially O
when O
combined O
with O
or O
given O
following O
doxorubicin O
. O

data O
on O
dose O
dependency O
or O
incidence O
concerning O
this O
side O
effect O
were O
not O
known O
. O

we O
have O
initiated O
a O
prospective O
study O
to O
obtain O
some O
more O
data O
on O
these O
subjects O
. O

forty-four O
mmc-treated O
patients O
were O
studied O
, O
37 O
of O
them O
could O
be O
evaluated O
. O

all O
patients O
were O
studied O
by O
repeated O
physical O
examinations O
, O
chest O
x-rays O
, O
electro- O
and O
echocardiography O
and O
radionuclide O
left O
ventricular O
ejection O
fraction O
( O
ef O
) O
determinations O
. O

the O
results O
were O
evaluated O
per O
cumulative O
dose O
level O
. O

one O
of O
the O
patients O
developed O
cardiac B-NEG
failure I-NEG
after O
30 O
mg O
m-2 O
mmc O
and O
only O
150 O
mg O
m-2 O
doxorubicin O
. O

the O
cardiac B-NEG
failure I-NEG
was O
predicted O
by O
a O
drop O
in O
ef O
determined O
during O
a O
cold O
pressor O
test O
. O

none O
of O
the O
other O
patients O
developed O
clinical O
cardiotoxicity B-NEG
, O
nor O
did O
the O
studied O
parameters O
change O
. O

the O
literature O
on O
this O
subject O
was O
also O
reviewed O
. O

based O
on O
the O
combined O
data O
from O
the O
present O
study O
and O
the O
literature O
, O
we O
suggest O
that O
mmc-related O
cardiotoxicity B-NEG
is O
dose O
dependent O
, O
occurring O
at O
cumulative O
dose O
levels O
of O
30 O
mg O
m-2 O
or O
more O
, O
mainly O
in O
patients O
also O
( O
previously O
or O
simultaneously O
) O
treated O
with O
doxorubicin O
. O

the O
incidence O
is O
likely O
to O
be O
less O
than O
10% O
even O
for O
this O
risk O
group O
. O

-DOCSTART- O

phlorizin-induced O
glycosuria B-NEG
does O
not O
prevent O
gentamicin O
nephrotoxicity B-NEG
in O
rats O
. O

because O
rats O
with O
streptozotocin-induced O
diabetes B-NEG
mellitus I-NEG
( O
dm B-NEG
) O
have O
a O
high O
solute O
diuresis O
( O
glycosuria B-NEG
of O
10 O
to O
12 O
g/day) O
, O
we O
have O
suggested O
that O
this O
may O
in O
part O
be O
responsible O
for O
their O
resistance O
to O
gentamicin-induced O
acute B-NEG
renal I-NEG
failure I-NEG
( O
arf B-NEG
). O

the O
protection O
from O
gentamicin O
nephrotoxicity B-NEG
was O
studied O
in O
non- O
diabetic B-NEG
rats O
with O
chronic O
solute O
diuresis O
induced O
by O
blockage O
of O
tubular O
glucose O
reabsorption O
with O
phlorizin O
(p) O
. O
dm B-NEG
rats O
with O
mild O
glycosuria B-NEG
( O
similar O
in O
degree O
to O
that O
of O
the O
p O
treated O
animals O
) O
were O
also O
studied O
. O

unanesthetized O
adult O
female O
, O
sprague-dawley O
rats O
were O
divided O
in O
four O
groups O
and O
studied O
for O
15 O
days O
. O

group O
1 O
(p O
alone O
) O
received O
p, O
360 O
mg/day O
, O
for O
15 O
days O
; O
group O
ii O
(p O
+ O
gentamicin) O
; O
group O
iii O
( O
gentamicin O
alone O
) O
and O
group O
iv O
( O
mild O
dm B-NEG
+ O
gentamicin) O
. O
nephrotoxic B-NEG
doses O
( O
40 O
mg/kg O
body O
wt/day O
) O
of O
gentamicin O
were O
injected O
during O
the O
last O
nine O
days O
of O
study O
to O
the O
animals O
of O
groups O
ii O
to O
iv O
. O

in O
group O
i, O
p O
induced O
a O
moderate O
and O
stable O
glycosuria B-NEG
( O
3.9 O
+/- O
0.1 O
g/day O
, O
se) O
, O
and O
no O
functional O
or O
morphologic O
evidence O
of O
renal B-NEG
dysfunction I-NEG
( O
baseline O
ccr O
2.1 O
+/- O
0.1 O
ml/min O
, O
undetectable O
lysozymuria O
) O
or O
damage O
( O
tubular B-NEG
necrosis I-NEG
score O
[maximum O
4] O
, O
zero) O
. O

in O
group O
ii O
, O
p O
did O
not O
prevent O
gentamicin- O
arf B-NEG
( O
maximal O
decrease O
in O
ccr O
at O
day O
9.89% O
, O
p O
less O
than O
0.001 O
; O
peak O
lysozymuria O
, O
1863 O
+/- O
321 O
micrograms/day O
; O
and O
tubular B-NEG
necrosis I-NEG
score O
, O
3.9 O
+/- O
0.1) O
. O

these O
values O
were O
not O
different O
from O
those O
of O
group O
iii O
: O
maximal O
decrease O
in O
ccr O
73% O
(p O
less O
than O
0.001) O
; O
lysozymuria O
, O
2147 O
+/- O
701 O
micrograms/day O
; O
tubular B-NEG
necrosis I-NEG
score O
, O
3.8 O
+/- O
0.1.(abstract O
truncated O
at O
250 O
words O
) O

-DOCSTART- O

tiapride O
in O
levodopa-induced O
involuntary B-NEG
movements I-NEG
. O

tiapride O
, O
a O
substituted O
benzamide O
derivative O
closely O
related O
to O
metoclopramide O
, O
reduced O
levodopa-induced O
peak O
dose O
involuntary B-NEG
movements I-NEG
in O
16 O
patients O
with O
idiopathic B-NEG
parkinson's I-NEG
disease I-NEG
. O

however O
, O
an O
unacceptable O
increase O
in O
disability O
from O
parkinsonism B-NEG
with O
aggravation O
of O
end-of-dose O
akinesia B-NEG
led O
to O
its O
cessation O
in O
14 O
patients O
. O

tiapride O
had O
no O
effect O
on O
levodopa-induced O
early O
morning O
of O
off-period O
segmental O
dystonia B-NEG
. O

these O
results O
fail O
to O
support O
the O
notion O
that O
levodopa-induced O
dyskinesias B-NEG
are O
caused O
by O
overstimulation O
of O
a O
separate O
group O
of O
dopamine O
receptors O
. O

-DOCSTART- O

effects O
of O
the O
hippocampal O
deep O
brain O
stimulation O
on O
cortical O
epileptic B-NEG
discharges O
in O
penicillin O
- O
induced O
epilepsy B-NEG
model O
in O
rats O
. O

aim O
: O
experimental O
and O
clinical O
studies O
have O
revealed O
that O
hippocampal O
dbs O
can O
control O
epileptic B-NEG
activity O
, O
but O
the O
mechanism O
of O
action O
is O
obscure O
and O
optimal O
stimulation O
parameters O
are O
not O
clearly O
defined O
. O

the O
aim O
was O
to O
evaluate O
the O
effects O
of O
high O
frequency O
hippocampal O
stimulation O
on O
cortical O
epileptic B-NEG
activity O
in O
penicillin-induced O
epilepsy B-NEG
model O
. O

material O
and O
methods O
: O
twenty-five O
sprague-dawley O
rats O
were O
implanted O
dbs O
electrodes O
. O

in O
group-1 O
( O
n=10 O
) O
hippocampal O
dbs O
was O
off O
and O
in O
the O
group-2 O
( O
n=10 O
) O
hippocampal O
dbs O
was O
on O
( O
185 O
hz O
, O
0.5v O
, O
1v O
, O
2v O
, O
and O
5v O
for O
60 O
sec O
) O
following O
penicillin O
g O
injection O
intracortically O
. O

in O
the O
control O
group O
hippocampal O
dbs O
was O
on O
following O
8 O
l O
saline O
injection O
intracortically O
. O

eeg O
recordings O
were O
obtained O
before O
and O
15 O
minutes O
following O
penicillin-g O
injection O
, O
and O
at O
10th O
minutes O
following O
each O
stimulus O
for O
analysis O
in O
terms O
of O
frequency O
, O
amplitude O
, O
and O
power O
spectrum O
. O

results O
: O
high O
frequency O
hippocampal O
dbs O
suppressed O
the O
acute O
penicillin-induced O
cortical O
epileptic B-NEG
activity O
independent O
from O
stimulus O
intensity O
. O

in O
the O
control O
group O
, O
hippocampal O
stimulation O
alone O
lead O
only O
to O
diffuse O
slowing O
of O
cerebral O
bioelectrical O
activity O
at O
5v O
stimulation O
. O

conclusion O
: O
our O
results O
revealed O
that O
continuous O
high O
frequency O
stimulation O
of O
the O
hippocampus O
suppressed O
acute O
cortical O
epileptic B-NEG
activity O
effectively O
without O
causing O
secondary O
epileptic B-NEG
discharges O
. O

these O
results O
are O
important O
in O
terms O
of O
defining O
the O
optimal O
parameters O
of O
hippocampal O
dbs O
in O
patients O
with O
epilepsy B-NEG
. O

-DOCSTART- O

neural O
correlates O
of O
s-ketamine O
induced O
psychosis B-NEG
during O
overt O
continuous O
verbal O
fluency O
. O

the O
glutamatergic O
n-methyl-d-aspartate O
( O
nmda O
) O
receptor O
has O
been O
implicated O
in O
the O
pathophysiology O
of O
schizophrenia B-NEG
. O

administered O
to O
healthy O
volunteers O
, O
a O
subanesthetic O
dose O
of O
the O
non-competitive O
nmda O
receptor O
antagonist O
ketamine O
leads O
to O
psychopathological O
symptoms O
similar O
to O
those O
observed O
in O
schizophrenia B-NEG
. O

in O
patients O
with O
schizophrenia B-NEG
, O
ketamine O
exacerbates O
the O
core O
symptoms O
of O
illness O
, O
supporting O
the O
hypothesis O
of O
a O
glutamatergic B-NEG
dysfunction I-NEG
. O

in O
a O
counterbalanced O
, O
placebo-controlled O
, O
double-blind O
study O
design O
, O
healthy O
subjects O
were O
administered O
a O
continuous O
subanesthetic O
s-ketamine O
infusion O
while O
differences O
in O
bold O
responses O
measured O
with O
fmri O
were O
detected O
. O

during O
the O
scanning O
period O
, O
subjects O
performed O
continuous O
overt O
verbal O
fluency O
tasks O
(phonological O
, O
lexical O
and O
semantic) O
. O

ketamine-induced O
psychopathological O
symptoms O
were O
assessed O
with O
the O
positive O
and O
negative O
syndrome O
scale O
(panss) O
. O

ketamine O
elicited O
psychosis B-NEG
like O
psychopathology O
. O

post-hoc O
t-tests O
revealed O
significant O
differences O
between O
placebo O
and O
ketamine O
for O
the O
amounts O
of O
words O
generated O
during O
lexical O
and O
semantic O
verbal O
fluency O
, O
while O
the O
phonological O
domain O
remained O
unaffected O
. O

ketamine O
led O
to O
enhanced O
cortical O
activations O
in O
supramarginal O
and O
frontal O
brain O
regions O
for O
phonological O
and O
lexical O
verbal O
fluency O
, O
but O
not O
for O
semantic O
verbal O
fluency O
. O

ketamine O
induces O
activation O
changes O
in O
healthy O
subjects O
similar O
to O
those O
observed O
in O
patients O
with O
schizophrenia B-NEG
, O
particularly O
in O
frontal O
and O
temporal O
brain O
regions O
. O

our O
results O
provide O
further O
support O
for O
the O
hypothesis O
of O
an O
nmda O
receptor O
dysfunction O
in O
the O
pathophysiology O
of O
schizophrenia B-NEG
. O

-DOCSTART- O

dopamine O
is O
not O
essential O
for O
the O
development O
of O
methamphetamine-induced O
neurotoxicity B-NEG
. O

it O
is O
widely O
believed O
that O
dopamine O
( O
da O
) O
mediates O
methamphetamine O
( O
meth)-induced O
toxicity B-NEG
to O
brain O
dopaminergic O
neurons O
, O
because O
drugs O
that O
interfere O
with O
da O
neurotransmission O
decrease O
toxicity B-NEG
, O
whereas O
drugs O
that O
increase O
da O
neurotransmission O
enhance O
toxicity B-NEG
. O

however O
, O
temperature O
effects O
of O
drugs O
that O
have O
been O
used O
to O
manipulate O
brain O
da O
neurotransmission O
confound O
interpretation O
of O
the O
data O
. O

here O
we O
show O
that O
the O
recently O
reported O
ability O
of O
l-dihydroxyphenylalanine O
to O
reverse O
the O
protective O
effect O
of O
alpha-methyl-para-tyrosine O
on O
meth-induced O
da O
neurotoxicity B-NEG
is O
also O
confounded O
by O
drug O
effects O
on O
body O
temperature O
. O

further O
, O
we O
show O
that O
mice O
genetically O
engineered O
to O
be O
deficient O
in O
brain O
da O
develop O
meth O
neurotoxicity B-NEG
, O
as O
long O
as O
the O
thermic O
effects O
of O
meth O
are O
preserved O
. O

in O
addition O
, O
we O
demonstrate O
that O
mice O
genetically O
engineered O
to O
have O
unilateral O
brain O
da O
deficits O
develop O
meth-induced O
dopaminergic B-NEG
deficits I-NEG
that O
are O
of O
comparable O
magnitude O
on O
both O
sides O
of O
the O
brain O
. O

taken O
together O
, O
these O
findings O
demonstrate O
that O
da O
is O
not O
essential O
for O
the O
development O
of O
meth-induced O
dopaminergic O
neurotoxicity B-NEG
and O
suggest O
that O
mechanisms O
independent O
of O
da O
warrant O
more O
intense O
investigation O
. O

-DOCSTART- O

brainstem B-NEG
dysgenesis I-NEG
in O
an O
infant O
prenatally O
exposed O
to O
cocaine O
. O

many O
authors O
described O
the O
effects O
on O
the O
fetus O
of O
maternal O
cocaine B-NEG
abuse I-NEG
during O
pregnancy O
. O

vasoconstriction O
appears O
to O
be O
the O
common O
mechanism O
of O
action O
leading O
to O
a O
wide O
range O
of O
fetal B-NEG
anomalies I-NEG
. O

we O
report O
on O
an O
infant O
with O
multiple B-NEG
cranial-nerve I-NEG
involvement I-NEG
attributable O
to O
brainstem B-NEG
dysgenesis I-NEG
, O
born O
to O
a O
cocaine-addicted B-NEG
mother O
. O

-DOCSTART- O

the O
protective O
role O
of O
nrf2 O
in O
streptozotocin-induced O
diabetic B-NEG
nephropathy I-NEG
. O

objective O
: O
diabetic B-NEG
nephropathy I-NEG
is O
one O
of O
the O
major O
causes O
of O
renal B-NEG
failure I-NEG
, O
which O
is O
accompanied O
by O
the O
production O
of O
reactive O
oxygen O
species O
(ros) O
. O

nrf2 O
is O
the O
primary O
transcription O
factor O
that O
controls O
the O
antioxidant O
response O
essential O
for O
maintaining O
cellular O
redox O
homeostasis O
. O

here O
, O
we O
report O
our O
findings O
demonstrating O
a O
protective O
role O
of O
nrf2 O
against O
diabetic B-NEG
nephropathy I-NEG
. O

research O
design O
and O
methods O
: O
we O
explore O
the O
protective O
role O
of O
nrf2 O
against O
diabetic B-NEG
nephropathy I-NEG
using O
human O
kidney O
biopsy O
tissues O
from O
diabetic B-NEG
nephropathy I-NEG
patients O
, O
a O
streptozotocin-induced O
diabetic B-NEG
nephropathy I-NEG
model O
in O
nrf2(-/- O
) O
mice O
, O
and O
cultured O
human O
mesangial O
cells O
. O

results O
: O
the O
glomeruli O
of O
human O
diabetic B-NEG
nephropathy I-NEG
patients O
were O
under O
oxidative O
stress O
and O
had O
elevated O
nrf2 O
levels O
. O

in O
the O
animal O
study O
, O
nrf2 O
was O
demonstrated O
to O
be O
crucial O
in O
ameliorating O
streptozotocin-induced O
renal B-NEG
damage I-NEG
. O

this O
is O
evident O
by O
nrf2(-/- O
) O
mice O
having O
higher O
ros O
production O
and O
suffering O
from O
greater O
oxidative O
dna O
damage O
and O
renal B-NEG
injury I-NEG
compared O
with O
nrf2(+/+ O
) O
mice O
. O

mechanistic O
studies O
in O
both O
in O
vivo O
and O
in O
vitro O
systems O
showed O
that O
the O
nrf2-mediated O
protection O
against O
diabetic B-NEG
nephropathy I-NEG
is O
, O
at O
least O
, O
partially O
through O
inhibition O
of O
transforming O
growth O
factor-beta1 O
( O
tgf-beta1 O
) O
and O
reduction O
of O
extracellular O
matrix O
production O
. O

in O
human O
renal O
mesangial O
cells O
, O
high O
glucose O
induced O
ros O
production O
and O
activated O
expression O
of O
nrf2 O
and O
its O
downstream O
genes O
. O

furthermore O
, O
activation O
or O
overexpression O
of O
nrf2 O
inhibited O
the O
promoter O
activity O
of O
tgf-beta1 O
in O
a O
dose-dependent O
manner O
, O
whereas O
knockdown O
of O
nrf2 O
by O
sirna O
enhanced O
tgf-beta1 O
transcription O
and O
fibronectin O
production O
. O

conclusions O
: O
this O
work O
clearly O
indicates O
a O
protective O
role O
of O
nrf2 O
in O
diabetic B-NEG
nephropathy I-NEG
, O
suggesting O
that O
dietary O
or O
therapeutic O
activation O
of O
nrf2 O
could O
be O
used O
as O
a O
strategy O
to O
prevent O
or O
slow O
down O
the O
progression O
of O
diabetic B-NEG
nephropathy I-NEG
. O

-DOCSTART- O

high-dose O
tranexamic O
acid O
is O
associated O
with O
nonischemic O
clinical O
seizures B-NEG
in O
cardiac O
surgical O
patients O
. O

background O
: O
in O
2 O
separate O
centers O
, O
we O
observed O
a O
notable O
increase O
in O
the O
incidence O
of O
postoperative O
convulsive B-NEG
seizures B-NEG
from O
1.3% O
to O
3.8% O
in O
patients O
having O
undergone O
major O
cardiac O
surgical O
procedures O
. O

these O
events O
were O
temporally O
coincident O
with O
the O
initial O
use O
of O
high-dose O
tranexamic O
acid O
( O
txa O
) O
therapy O
after O
withdrawal O
of O
aprotinin O
from O
general O
clinical O
usage O
. O

the O
purpose O
of O
this O
review O
was O
to O
perform O
a O
retrospective O
analysis O
to O
examine O
whether O
there O
was O
a O
relation O
between O
txa O
usage O
and O
seizures B-NEG
after O
cardiac O
surgery O
. O

methods O
: O
an O
in-depth O
chart O
review O
was O
undertaken O
in O
all O
24 O
patients O
who O
developed O
perioperative O
seizures B-NEG
. O

electroencephalographic O
activity O
was O
recorded O
in O
11 O
of O
these O
patients O
, O
and O
all O
patients O
had O
a O
formal O
neurological O
evaluation O
and O
brain O
imaging O
studies O
. O

results O
: O
twenty-one O
of O
the O
24 O
patients O
did O
not O
have O
evidence O
of O
new O
cerebral B-NEG
ischemic I-NEG
injury I-NEG
, O
but O
seizures B-NEG
were O
likely O
due O
to O
ischemic B-NEG
brain I-NEG
injury I-NEG
in O
3 O
patients O
. O

all O
patients O
with O
seizures B-NEG
did O
not O
have O
permanent O
neurological B-NEG
abnormalities I-NEG
. O

all O
24 O
patients O
with O
seizures B-NEG
received O
high O
doses O
of O
txa O
intraoperatively O
ranging O
from O
61 O
to O
259 O
mg/kg O
, O
had O
a O
mean O
age O
of O
69.9 O
years O
, O
and O
21 O
of O
24 O
had O
undergone O
open O
chamber O
rather O
than O
coronary O
bypass O
procedures O
. O

all O
but O
one O
patient O
were O
managed O
using O
cardiopulmonary O
bypass O
. O

no O
evidence O
of O
brain B-NEG
ischemic I-NEG
, O
metabolic O
, O
or O
hyperthermia B-NEG
-induced O
causes O
for O
their O
seizures B-NEG
was O
apparent O
. O

conclusion O
: O
our O
results O
suggest O
that O
use O
of O
high-dose O
txa O
in O
older O
patients O
in O
conjunction O
with O
cardiopulmonary O
bypass O
and O
open-chamber O
cardiac O
surgery O
is O
associated O
with O
clinical O
seizures B-NEG
in O
susceptible O
patients O
. O

-DOCSTART- O

recurrent O
dysosmia B-NEG
induced O
by O
pyrazinamide O
. O

pyrazinamide O
can O
have O
adverse O
effects O
such O
as O
hepatic B-NEG
toxicity I-NEG
, O
hyperuricemia B-NEG
or O
digestive O
disorders O
. O

in O
rare O
cases O
, O
alterations O
in O
taste O
and O
smell O
function O
have O
been O
reported O
for O
pyrazinamide O
when O
combined O
with O
other O
drugs O
. O

we O
report O
a O
case O
of O
reversible O
olfactory B-NEG
disorder I-NEG
related O
to O
pyrazinamide O
in O
a O
woman O
, O
with O
a O
positive O
rechallenge O
. O

the O
patient O
presented O
every O
day O
a O
sensation O
of O
smelling O
something O
burning O
15 O
min O
after O
drug O
intake O
. O
dysosmia B-NEG
disappeared O
completely O
after O
pyrazinamide O
withdrawal O
and O
recurred O
after O
its O
rechallenge O
. O

the O
case O
was O
reported O
to O
the O
tunisian O
centre O
of O
pharmacovigilance O
. O

-DOCSTART- O

longitudinal O
assessment O
of O
air O
conduction O
audiograms O
in O
a O
phase O
iii O
clinical O
trial O
of O
difluoromethylornithine O
and O
sulindac O
for O
prevention O
of O
sporadic O
colorectal B-NEG
adenomas I-NEG
. O

a O
phase O
iii O
clinical O
trial O
assessed O
the O
recurrence O
of O
adenomatous B-NEG
polyps I-NEG
after O
treatment O
for O
36 O
months O
with O
difluoromethylornithine O
( O
dfmo O
) O
plus O
sulindac O
or O
matched O
placebos O
. O

temporary O
hearing B-NEG
loss I-NEG
is O
a O
known O
toxicity B-NEG
of O
treatment O
with O
dfmo O
, O
thus O
a O
comprehensive O
approach O
was O
developed O
to O
analyze O
serial O
air O
conduction O
audiograms O
. O

the O
generalized O
estimating O
equation O
method O
estimated O
the O
mean O
difference O
between O
treatment O
arms O
with O
regard O
to O
change O
in O
air O
conduction O
pure O
tone O
thresholds O
while O
accounting O
for O
within-subject O
correlation O
due O
to O
repeated O
measurements O
at O
frequencies O
. O

based O
on O
290 O
subjects O
, O
there O
was O
an O
average O
difference O
of O
0.50 O
db O
between O
subjects O
treated O
with O
dfmo O
plus O
sulindac O
compared O
with O
those O
treated O
with O
placebo O
( O
95% O
confidence O
interval O
, O
-0.64 O
to O
1.63 O
db O
; O
p O
= O
0.39) O
, O
adjusted O
for O
baseline O
values O
, O
age O
, O
and O
frequencies O
. O

in O
the O
normal O
speech O
range O
of O
500 O
to O
3,000 O
hz O
, O
an O
estimated O
difference O
of O
0.99 O
db O
( O
-0.17 O
to O
2.14 O
db O
; O
p O
= O
0.09 O
) O
was O
detected O
. O

dose O
intensity O
did O
not O
add O
information O
to O
models O
. O

there O
were O
14 O
of O
151 O
( O
9.3% O
) O
in O
the O
dfmo O
plus O
sulindac O
group O
and O
4 O
of O
139 O
( O
2.9% O
) O
in O
the O
placebo O
group O
who O
experienced O
at O
least O
15 O
db O
hearing O
reduction O
from O
baseline O
in O
2 O
or O
more O
consecutive O
frequencies O
across O
the O
entire O
range O
tested O
(p O
= O
0.02) O
. O

follow-up O
air O
conduction O
done O
at O
least O
6 O
months O
after O
end O
of O
treatment O
showed O
an O
adjusted O
mean O
difference O
in O
hearing O
thresholds O
of O
1.08 O
db O
( O
-0.81 O
to O
2.96 O
db O
; O
p O
= O
0.26 O
) O
between O
treatment O
arms O
. O

there O
was O
no O
significant O
difference O
in O
the O
proportion O
of O
subjects O
in O
the O
dfmo O
plus O
sulindac O
group O
who O
experienced O
clinically O
significant O
hearing B-NEG
loss I-NEG
compared O
with O
the O
placebo O
group O
. O

the O
estimated O
attributable O
risk O
of O
ototoxicity B-NEG
from O
exposure O
to O
the O
drug O
is O
8.4% O
( O
95% O
confidence O
interval O
, O
-2.0% O
to O
18.8% O
; O
p O
= O
0.12) O
. O

there O
is O
a O
<2 O
db O
difference O
in O
mean O
threshold O
for O
patients O
treated O
with O
dfmo O
plus O
sulindac O
compared O
with O
those O
treated O
with O
placebo O
. O

-DOCSTART- O

increased O
mental B-NEG
slowing I-NEG
associated O
with O
the O
apoe O
epsilon4 O
allele O
after O
trihexyphenidyl O
oral O
anticholinergic O
challenge O
in O
healthy O
elderly O
. O

objectives O
: O
the O
objectives O
of O
this O
study O
were O
to O
examine O
the O
relationship O
between O
apoe O
epsilon4 O
and O
subjective O
effects O
of O
trihexyphenidyl O
on O
measures O
reflecting O
sedation O
and O
confusion B-NEG
and O
to O
investigate O
the O
relationship O
between O
trihexyphenidyl-induced O
subjective O
effects O
and O
objective O
memory O
performance O
. O

methods O
: O
this O
study O
comprised O
24 O
cognitively O
intact O
, O
health O
elderly O
adults O
( O
12 O
apoe O
epsilon4 O
carriers O
) O
at O
an O
outpatient O
geriatric O
psychiatry O
research O
clinic O
. O

this O
was O
a O
randomized O
, O
double O
blind O
, O
placebo-controlled O
, O
three-way O
, O
crossover O
experimental O
design O
. O

all O
participants O
received O
1.0 O
mg O
or O
2.0 O
mg O
trihexyphenidyl O
or O
placebo O
administered O
in O
counterbalanced O
sequences O
over O
a O
period O
of O
three O
consecutive O
weeks O
. O

bond O
and O
lader's O
visual O
analog O
scales O
and O
alternate O
versions O
of O
the O
buschke O
selective O
reminding O
test O
were O
administered O
in O
a O
repeated O
measures O
design O
at O
baseline O
, O
1, O
2.5 O
, O
and O
5 O
hours O
postdrug O
administration O
. O

results O
: O
a O
2.0-mg O
oral O
dose O
of O
trihexyphenidyl O
resulted O
in O
increased O
subjective O
ratings O
of O
mental B-NEG
slowness I-NEG
in O
carriers O
of O
the O
apoe O
epsilon4 O
allele O
only O
. O

drug O
effects O
as O
determined O
by O
difference O
scores O
between O
2.0 O
mg O
trihexyphenidyl O
and O
placebo O
on O
ratings O
of O
mental B-NEG
slowness I-NEG
significantly O
correlated O
with O
total O
and O
delayed O
recall O
on O
the O
buschke O
selective O
reminding O
test O
in O
carriers O
of O
the O
apoe O
epsilon4 O
allele O
only O
. O

however O
, O
no O
significant O
effects O
were O
found O
with O
other O
visual O
analog O
scales O
reflecting O
subjective O
sedation O
and O
clear-headedness O
. O

conclusion O
: O
the O
epsilon4 O
allele O
in O
healthy O
elderly O
was O
associated O
with O
increased O
subjective O
mental B-NEG
slowing I-NEG
after O
trihexyphenidyl O
anticholinergic O
challenge O
. O

-DOCSTART- O

behavioral O
effects O
of O
pubertal O
anabolic O
androgenic O
steroid O
exposure O
in O
male O
rats O
with O
low O
serotonin O
. O

the O
goal O
of O
this O
study O
was O
to O
assess O
the O
interactive O
effects O
of O
chronic O
anabolic O
androgenic O
steroid O
( O
aas O
) O
exposure O
and O
brain O
serotonin O
(5-hydroxytryptamine O
, O
5-ht O
) O
depletion O
on O
behavior O
of O
pubertal O
male O
rats O
. O

serotonin O
was O
depleted O
beginning O
on O
postnatal O
day O
26 O
with O
parachlorophenylalanine O
( O
pcpa O
100 O
mg/kg O
, O
every O
other O
day) O
; O
controls O
received O
saline O
. O

at O
puberty O
(p40) O
, O
half O
the O
pcpa-treated O
rats O
and O
half O
the O
saline-treated O
rats O
began O
treatment O
with O
testosterone O
(t O
, O
5 O
mg/kg O
, O
5 O
days/week) O
. O

behavioral O
measures O
included O
locomotion O
, O
irritability B-NEG
, O
copulation O
, O
partner O
preference O
, O
and O
aggression B-NEG
. O

animals O
were O
tested O
for O
aggression B-NEG
in O
their O
home O
cage O
, O
both O
with O
and O
without O
physical O
provocation O
( O
mild O
tail O
pinch) O
. O

brain O
levels O
of O
5-ht O
and O
its O
metabolite O
, O
5-hydroxyindoleacetic O
acid O
(5-hiaa) O
, O
were O
determined O
using O
hplc O
. O

pcpa O
significantly O
and O
substantially O
depleted O
5-ht O
and O
5-hiaa O
in O
all O
brain O
regions O
examined O
. O

chronic O
t O
treatment O
significantly O
decreased O
5-ht O
and O
5-hiaa O
in O
certain O
brain O
areas O
, O
but O
to O
a O
much O
lesser O
extent O
than O
pcpa O
. O

chronic O
exposure O
to O
pcpa O
alone O
significantly O
decreased O
locomotor O
activity O
and O
increased O
irritability B-NEG
but O
had O
no O
effect O
on O
sexual O
behavior O
, O
partner O
preference O
, O
or O
aggression B-NEG
. O

t O
alone O
had O
no O
effect O
on O
locomotion O
, O
irritability B-NEG
, O
or O
sexual O
behavior O
but O
increased O
partner O
preference O
and O
aggression B-NEG
. O

the O
most O
striking O
effect O
of O
combining O
t+pcpa O
was O
a O
significant O
increase O
in O
attack O
frequency O
as O
well O
as O
a O
significant O
decrease O
in O
the O
latency O
to O
attack O
, O
particularly O
following O
physical O
provocation O
. O

based O
on O
these O
data O
, O
it O
can O
be O
speculated O
that O
pubertal O
aas O
users O
with O
low O
central O
5-ht O
may O
be O
especially O
prone O
to O
exhibit O
aggressive B-NEG
behavior I-NEG
. O

-DOCSTART- O

intracavitary O
chemotherapy O
( O
paclitaxel/carboplatin O
liquid O
crystalline O
cubic O
phases O
) O
for O
recurrent O
glioblastoma B-NEG
-- O
clinical O
observations O
. O

human O
malignant O
brain B-NEG
tumors I-NEG
have O
a O
poor O
prognosis O
in O
spite O
of O
surgery O
and O
radiation O
therapy O
. O

cubic O
phases O
consist O
of O
curved O
biocontinuous O
lipid O
bilayers O
, O
separating O
two O
congruent O
networks O
of O
water O
channels O
. O

used O
as O
a O
host O
for O
cytotoxic O
drugs O
, O
the O
gel-like O
matrix O
can O
easily O
be O
applied O
to O
the O
walls O
of O
a O
surgical O
resection O
cavity O
. O

for O
human O
glioblastoma B-NEG
recurrences O
, O
the O
feasibility O
, O
safety O
, O
and O
short-term O
effects O
of O
a O
surgical O
intracavitary O
application O
of O
paclitaxel O
and O
carboplatin O
encapsulated O
by O
liquid O
crystalline O
cubic O
phases O
are O
examined O
in O
a O
pilot O
study O
. O

a O
total O
of O
12 O
patients O
with O
a O
recurrence O
of O
a O
glioblastoma B-NEG
multiforme O
underwent O
re-resection O
and O
received O
an O
intracavitary O
application O
of O
paclitaxel O
and O
carboplatin O
cubic O
phases O
in O
different O
dosages O
. O

six O
of O
the O
patients O
received O
more O
than O
15 O
mg O
paclitaxel O
and O
suffered O
from O
moderate O
to O
severe O
brain B-NEG
edema I-NEG
, O
while O
the O
remaining O
patients O
received O
only O
a O
total O
of O
15 O
mg O
paclitaxel O
. O

in O
the O
latter O
group O
, O
brain B-NEG
edema I-NEG
was O
markedly O
reduced O
and O
dealt O
medically O
. O

intracavitary O
chemotherapy O
in O
recurrent O
glioblastoma B-NEG
using O
cubic O
phases O
is O
feasible O
and O
safe O
, O
yet O
the O
clinical O
benefit O
remains O
to O
be O
examined O
in O
a O
clinical O
phase O
ii O
study O
. O

-DOCSTART- O

methylphenidate-induced O
obsessive-compulsive B-NEG
symptoms I-NEG
in O
an O
elderly O
man O
. O

an O
82-year-old O
man O
with O
treatment-resistant B-NEG
depression I-NEG
and O
early O
alzheimer's B-NEG
disease I-NEG
was O
started O
on O
methylphenidate O
. O

significant O
obsessive-compulsive B-NEG
behavior I-NEG
ensued O
but O
diminished O
over O
several O
weeks O
when O
methylphenidate O
was O
replaced O
by O
fluvoxamine O
. O

the O
patient O
had O
no O
prior O
psychiatric B-NEG
history O
, O
but O
he O
had O
a O
sister O
with O
obsessive-compulsive B-NEG
disorder I-NEG
. O

it O
appears O
that O
methylphenidate O
precipitated O
the O
patient's O
pathological O
behavior O
. O

-DOCSTART- O

cardiac B-NEG
arrest I-NEG
after O
intravenous O
metoclopramide O
- O
a O
case O
of O
five O
repeated O
injections O
of O
metoclopramide O
causing O
five O
episodes O
of O
cardiac B-NEG
arrest I-NEG
. O

we O
describe O
a O
patient O
where O
intravenous O
injection O
of O
metoclopramide O
was O
immediately O
followed O
by O
asystole B-NEG
repeatedly O
. O

the O
patient O
received O
metoclopramide O
10 O
mg O
i.v O
. O
five O
times O
during O
48 O
h. O

after O
interviewing O
the O
attending O
nurses O
and O
reviewing O
the O
written O
documentation O
, O
it O
is O
clear O
that O
every O
administration O
of O
metoclopramide O
was O
immediately O
( O
within O
s) O
followed O
by O
asystole B-NEG
. O

the O
asystole B-NEG
lasted O
15-30 O
s O
on O
four O
occasions O
, O
on O
one O
occasion O
it O
lasted O
2 O
min O
. O

the O
patient O
received O
atropine O
0.5-1 O
mg O
and O
chest O
compressions O
, O
before O
sinus O
rhythm O
again O
took O
over O
. O

we O
interpret O
this O
as O
episodes O
of O
cardiac B-NEG
arrest I-NEG
caused O
by O
metoclopramide O
. O

the O
rapid O
injection O
via O
the O
central O
venous O
route O
and O
the O
concomitant O
tapering O
of O
dopamine O
infusion O
might O
have O
contributed O
in O
precipitating O
the O
adverse O
drug O
reaction O
. O

-DOCSTART- O

severe O
immune O
hemolytic B-NEG
anemia I-NEG
associated O
with O
prophylactic O
use O
of O
cefotetan O
in O
obstetric O
and O
gynecologic O
procedures O
. O

second- O
and O
third-generation O
cephalosporins O
, O
especially O
cefotetan O
, O
are O
increasingly O
associated O
with O
severe O
, O
sometimes O
fatal O
immune O
hemolytic B-NEG
anemia I-NEG
. O

we O
noticed O
that O
10 O
of O
our O
35 O
cases O
of O
cefotetan-induced O
hemolytic B-NEG
anemias I-NEG
were O
in O
patients O
who O
had O
received O
cefotetan O
prophylactically O
for O
obstetric O
and O
gynecologic O
procedures O
. O

eight O
of O
these O
cases O
of O
severe O
immune O
hemolytic B-NEG
anemia I-NEG
are O
described O
. O

-DOCSTART- O

cauda B-NEG
equina I-NEG
syndrome I-NEG
after O
spinal O
anaesthesia O
with O
hyperbaric O
5% O
lignocaine O
: O
a O
review O
of O
six O
cases O
of O
cauda B-NEG
equina I-NEG
syndrome I-NEG
reported O
to O
the O
swedish O
pharmaceutical O
insurance O
1993-1997 O
. O

six O
cases O
of O
cauda B-NEG
equina I-NEG
syndrome I-NEG
with O
varying O
severity O
were O
reported O
to O
the O
swedish O
pharmaceutical O
insurance O
during O
the O
period O
1993-1997 O
. O

all O
were O
associated O
with O
spinal O
anaesthesia O
using O
hyperbaric O
5% O
lignocaine O
. O

five O
cases O
had O
single-shot O
spinal O
anaesthesia O
and O
one O
had O
a O
repeat O
spinal O
anaesthetic O
due O
to O
inadequate O
block O
. O

the O
dose O
of O
hyperbaric O
5% O
lignocaine O
administered O
ranged O
from O
60 O
to O
120 O
mg O
. O

three O
of O
the O
cases O
were O
most O
likely O
caused O
by O
direct O
neurotoxicity B-NEG
of O
hyperbaric O
5% O
lignocaine O
. O

in O
the O
other O
3 O
cases O
, O
direct O
neurotoxicity B-NEG
was O
also O
probable O
, O
but O
unfortunately O
radiological O
investigations O
were O
not O
done O
to O
definitely O
exclude O
a O
compressive O
aetiology O
. O

all O
cases O
sustained O
permanent O
neurological B-NEG
deficits I-NEG
. O

we O
recommend O
that O
hyperbaric O
lignocaine O
should O
be O
administered O
in O
concentrations O
not O
greater O
than O
2% O
and O
at O
a O
total O
dose O
preferably O
not O
exceeding O
60 O
mg O
. O

-DOCSTART- O

cortical O
motor O
overactivation O
in O
parkinsonian B-NEG
patients O
with O
l-dopa-induced O
peak-dose O
dyskinesia B-NEG
. O

we O
have O
studied O
the O
regional O
cerebral O
blood O
flow O
( O
rcbf O
) O
changes O
induced O
by O
the O
execution O
of O
a O
finger-to-thumb O
opposition O
motor O
task O
in O
the O
supplementary O
and O
primary O
motor O
cortex O
of O
two O
groups O
of O
parkinsonian B-NEG
patients O
on O
l-dopa O
medication O
, O
the O
first O
one O
without O
l-dopa O
induced O
dyskinesia B-NEG
(n O
= O
23 O
) O
and O
the O
other O
with O
moderate O
peak-dose O
dyskinesia B-NEG
(n O
= O
15) O
, O
and O
of O
a O
group O
of O
14 O
normal O
subjects O
. O

single O
photon O
emission O
tomography O
with O
i.v O
. O

133xe O
was O
used O
to O
measure O
the O
rcbf O
changes O
. O

the O
dyskinetic B-NEG
parkinsonian B-NEG
patients O
exhibited O
a O
pattern O
of O
response O
which O
was O
markedly O
different O
from O
those O
of O
the O
normal O
subjects O
and O
non- O
dyskinetic B-NEG
parkinsonian B-NEG
patients O
, O
with O
a O
significant O
overactivation O
in O
the O
supplementary O
motor O
area O
and O
the O
ipsi- O
and O
contralateral O
primary O
motor O
areas O
. O

these O
results O
are O
compatible O
with O
the O
hypothesis O
that O
an O
hyperkinetic B-NEG
abnormal B-NEG
involuntary I-NEG
movement I-NEG
, O
like O
l-dopa-induced O
peak O
dose O
dyskinesia B-NEG
, O
is O
due O
to O
a O
disinhibition O
of O
the O
primary O
and O
associated O
motor O
cortex O
secondary O
to O
an O
excessive O
outflow O
of O
the O
pallidothalamocortical O
motor O
loop O
. O

-DOCSTART- O

dexamethasone-induced O
ocular B-NEG
hypertension I-NEG
in O
perfusion-cultured O
human O
eyes O
. O

purpose O
: O
glucocorticoid O
administration O
can O
lead O
to O
the O
development O
of O
ocular B-NEG
hypertension I-NEG
and O
corticosteroid B-NEG
glaucoma I-NEG
in O
a O
subset O
of O
the O
population O
through O
a O
decrease O
in O
the O
aqueous O
humor O
outflow O
facility O
. O

the O
purpose O
of O
this O
study O
was O
to O
determine O
whether O
glucocorticoid O
treatment O
can O
directly O
affect O
the O
outflow O
facility O
of O
isolated O
, O
perfusion-cultured O
human O
eyes O
. O

methods O
: O
the O
anterior O
segments O
of O
human O
donor O
eyes O
from O
regional O
eye O
banks O
were O
placed O
in O
a O
constant O
flow O
, O
variable O
pressure O
perfusion O
culture O
system O
. O

paired O
eyes O
were O
perfused O
in O
serum-free O
media O
with O
or O
without O
10(-7 O
) O
m O
dexamethasone O
for O
12 O
days O
. O

intraocular O
pressure O
was O
monitored O
daily O
. O

after O
incubation O
, O
the O
eyes O
were O
morphologically O
characterized O
by O
light O
microscopy O
, O
transmission O
and O
scanning O
electron O
microscopy O
, O
and O
scanning O
laser O
confocal O
microscopy O
. O

results O
: O
a O
significant O
increase O
in O
intraocular O
pressure O
developed O
in O
13 O
of O
the O
44 O
pairs O
of O
eyes O
perfused O
with O
dexamethasone O
with O
an O
average O
pressure O
rise O
of O
17.5 O
+/- O
3.8 O
mm O
hg O
after O
12 O
days O
of O
dexamethasone O
exposure O
. O

the O
contralateral O
control O
eyes O
, O
which O
did O
not O
receive O
dexamethasone O
, O
maintained O
a O
stable O
intraocular O
pressure O
during O
the O
same O
period O
. O

the O
outflow O
pathway O
of O
the O
untreated O
eyes O
appeared O
morphologically O
normal O
. O

in O
contrast O
, O
the O
dexamethasone-treated O
hypertensive B-NEG
eyes I-NEG
had O
thickened O
trabecular O
beams O
, O
decreased O
intertrabecular O
spaces O
, O
thickened O
juxtacanalicular O
tissue O
, O
activated O
trabecular O
meshwork O
cells O
, O
and O
increased O
amounts O
of O
amorphogranular O
extracellular O
material O
, O
especially O
in O
the O
juxtacanalicular O
tissue O
and O
beneath O
the O
endothelial O
lining O
of O
the O
canal O
of O
schlemm O
. O

the O
dexamethasone-treated O
nonresponder O
eyes O
appeared O
to O
be O
morphologically O
similar O
to O
the O
untreated O
eyes O
, O
although O
several O
subtle O
dexamethasone-induced O
morphologic O
changes O
were O
evident O
. O

conclusion O
: O
dexamethasone O
treatment O
of O
isolated O
, O
perfusion-cultured O
human O
eyes O
led O
to O
the O
generation O
of O
ocular B-NEG
hypertension I-NEG
in O
approximately O
30% O
of O
the O
dexamethasone-treated O
eyes O
. O

steroid O
treatment O
resulted O
in O
morphologic O
changes O
in O
the O
trabecular O
meshwork O
similar O
to O
those O
reported O
for O
corticosteroid B-NEG
glaucoma I-NEG
and O
open B-NEG
angle I-NEG
glaucoma I-NEG
. O

this O
system O
may O
provide O
an O
acute O
model O
in O
which O
to O
study O
the O
pathogenic O
mechanisms O
involved O
in O
steroid B-NEG
glaucoma I-NEG
and O
primary B-NEG
open I-NEG
angle I-NEG
glaucoma I-NEG
. O

-DOCSTART- O

cognitive B-NEG
deterioration I-NEG
from O
long-term O
abuse O
of O
dextromethorphan O
: O
a O
case O
report O
. O

dextromethorphan O
(dm) O
, O
the O
dextrorotatory O
isomer O
of O
3-hydroxy-n-methylmorphinan O
, O
is O
the O
main O
ingredient O
in O
a O
number O
of O
widely O
available O
, O
over-the-counter O
antitussives O
. O

initial O
studies O
( O
bornstein O
1968 O
) O
showed O
that O
it O
possessed O
no O
respiratory O
suppressant O
effects O
and O
no O
addiction O
liability O
. O

subsequently O
, O
however O
, O
several O
articles O
reporting O
abuse O
of O
this O
drug O
have O
appeared O
in O
the O
literature O
. O

the O
drug O
is O
known O
to O
cause O
a O
variety O
of O
acute O
toxic O
effects O
, O
ranging O
from O
nausea B-NEG
, O
restlessness B-NEG
, O
insomnia B-NEG
, O
ataxia B-NEG
, O
slurred O
speech O
and O
nystagmus B-NEG
to O
mood O
changes O
, O
perceptual O
alterations O
, O
inattention O
, O
disorientation O
and O
aggressive B-NEG
behavior I-NEG
( O
rammer O
et O
al O
1988 O
; O
katona O
and O
watson O
1986 O
; O
isbell O
and O
fraser O
1953 O
; O
devlin O
et O
al O
1985 O
; O
mccarthy O
1971 O
; O
dodds O
and O
revai O
1967 O
; O
degkwitz O
1964 O
; O
hildebrand O
et O
al O
1989) O
. O

there O
have O
also O
been O
two O
reported O
fatalities O
from O
dm O
overdoses O
( O
fleming O
1986) O
. O

however O
, O
there O
are O
no O
reports O
describing O
the O
effects O
of O
chronic O
abuse O
. O

this O
report O
describes O
a O
case O
of O
cognitive B-NEG
deterioration I-NEG
resulting O
from O
prolonged O
use O
of O
dm O
. O

-DOCSTART- O

long-term O
lithium O
treatment O
and O
the O
kidney O
. O

interim O
report O
on O
fifty O
patients O
. O

this O
is O
a O
report O
on O
the O
first O
part O
of O
our O
study O
of O
the O
effects O
of O
long-term O
lithium O
treatment O
on O
the O
kidney O
. O

creatinine O
clearance O
, O
maximum O
urinary O
osmolality O
and O
24 O
hour O
urine O
volume O
have O
been O
tested O
in O
50 O
affectively O
ill O
patients O
who O
have O
been O
on O
long-term O
lithium O
for O
more O
than O
one O
year O
. O

these O
findings O
have O
been O
compared O
with O
norms O
and O
with O
values O
of O
the O
same O
tests O
from O
screening O
prior O
to O
lithium O
, O
available O
for O
most O
of O
our O
patients O
. O

no O
evidence O
was O
found O
for O
any O
reduction O
of O
glomerular O
filtration O
during O
lithium O
treatment O
. O

low O
clearance O
values O
found O
in O
several O
patients O
could O
be O
accounted O
for O
by O
their O
age O
and O
their O
pre-lithium O
values O
. O

urinary O
concentration O
defect O
appeared O
frequent O
but O
the O
extent O
of O
the O
impairment O
is O
difficult O
to O
assess O
because O
of O
the O
uncertainty O
about O
the O
norms O
applicable O
to O
this O
group O
of O
patients O
. O

the O
concentration O
defect O
appeared O
reversible O
, O
at O
least O
in O
part O
. O
polyuria B-NEG
above O
3 O
litres/24 O
hours O
was O
found O
in O
10% O
of O
patients O
. O

an O
attempt O
is O
made O
to O
draw O
practical O
conclusions O
from O
the O
preliminary O
findings O
. O

-DOCSTART- O

complete O
heart B-NEG
block I-NEG
following O
a O
single O
dose O
of O
trazodone O
. O

forty O
minutes O
after O
receiving O
a O
single O
starting O
dose O
of O
trazodone O
, O
a O
patient O
developed O
complete O
heart B-NEG
block I-NEG
. O

the O
case O
illustrates O
that O
, O
despite O
the O
results O
of O
earlier O
studies O
, O
trazodone's O
effect O
on O
cardiac O
conduction O
may O
be O
severe O
in O
individuals O
at O
risk O
for O
conduction O
delay O
. O

-DOCSTART- O

quinidine O
phenylethylbarbiturate-induced O
fulminant O
hepatitis B-NEG
in O
a O
pregnant O
woman O
. O

a O
case O
report O
. O

we O
report O
the O
case O
of O
a O
19-year-old O
laotian O
patient O
affected O
by O
fulminant O
hepatitis B-NEG
during O
the O
third O
trimester O
of O
her O
pregnancy O
after O
a O
1-month O
administration O
of O
quinidine O
phenylethylbarbiturate O
. O

after O
delivery O
, O
the O
patient O
underwent O
orthotopic O
liver O
transplantation O
. O

the O
patient O
was O
in O
good O
condition O
16 O
months O
after O
liver O
transplantation O
. O

quinidine O
itself O
or O
phenylethylbarbiturate O
may O
be O
responsible O
for O
fulminant O
hepatitis B-NEG
in O
this O
patient O
. O

-DOCSTART- O

the O
epidemiology O
of O
the O
acute O
flank B-NEG
pain I-NEG
syndrome O
from O
suprofen O
. O

suprofen O
, O
a O
new O
nonsteroidal O
anti-inflammatory O
drug O
, O
was O
marketed O
in O
early O
1986 O
as O
an O
analgesic O
agent O
. O

until O
physicians O
began O
reporting O
an O
unusual O
acute O
flank B-NEG
pain I-NEG
syndrome O
to O
the O
spontaneous O
reporting O
system O
, O
700,000 O
persons O
used O
the O
drug O
in O
the O
united O
states O
. O

through O
august O
1986 O
, O
a O
total O
of O
163 O
cases O
of O
this O
syndrome O
were O
reported O
. O

to O
elucidate O
the O
epidemiology O
of O
the O
syndrome O
, O
a O
case-control O
study O
was O
performed O
, O
comparing O
62 O
of O
the O
case O
patients O
who O
had O
been O
reported O
to O
the O
spontaneous O
reporting O
system O
to O
185 O
suprofen-exposed O
control O
subjects O
who O
did O
not O
have O
the O
syndrome O
. O

case O
patients O
were O
more O
likely O
to O
be O
men O
( O
odds O
ratio O
, O
3.8 O
; O
95% O
confidence O
interval O
, O
1.2-12.1) O
, O
suffer O
from O
hay B-NEG
fever I-NEG
and O
asthma B-NEG
( O
odds O
ratio O
, O
3.4 O
; O
95% O
confidence O
interval O
, O
1.0-11.9) O
; O
to O
participate O
in O
regular O
exercise O
( O
odds O
ratio O
, O
5.9 O
; O
95% O
confidence O
interval O
, O
1.1-30.7) O
, O
especially O
in O
the O
use O
of O
nautilus O
equipment O
(p O
= O
0.02) O
; O
and O
to O
use O
alcohol O
( O
odds O
ratio O
, O
4.4 O
; O
95% O
confidence O
interval O
, O
1.1-17.5) O
. O

possible O
risk O
factors O
included O
young O
age O
, O
concurrent O
use O
of O
other O
analgesic O
agents O
( O
especially O
ibuprofen) O
, O
preexisting O
renal B-NEG
disease I-NEG
, O
a O
history O
of O
kidney B-NEG
stones I-NEG
, O
a O
history O
of O
gout B-NEG
, O
a O
recent O
increase O
in O
activity O
, O
a O
recent O
increase O
in O
sun O
exposure O
, O
and O
residence O
in O
the O
sunbelt O
. O

these O
were O
findings O
that O
were O
suggestive O
but O
did O
not O
reach O
conventional O
statistical O
significance O
. O

these O
findings O
are O
consistent O
with O
the O
postulated O
mechanism O
for O
this O
unusual O
syndrome O
: O
acute O
diffuse O
crystallization O
of O
uric O
acid O
in O
renal O
tubules O
. O

-DOCSTART- O

hemolytic-uremic B-NEG
syndrome I-NEG
associated O
with O
ingestion O
of O
quinine O
. O
hemolytic-uremic B-NEG
syndrome I-NEG
following O
quinine O
ingestion O
is O
a O
newly O
described O
phenomenon O
, O
with O
just O
two O
previous O
descriptions O
of O
4 O
cases O
in O
the O
literature O
. O

we O
describe O
a O
5th O
case O
. O

the O
reaction O
may O
be O
mediated O
by O
the O
presence O
of O
antibodies O
reactive O
against O
platelets O
in O
the O
presence O
of O
quinine O
. O

treatment O
has O
included O
use O
of O
plasma O
exchange O
, O
prednisone O
, O
aspirin O
, O
and O
dipyridamole O
. O

the O
patients O
have O
all O
regained O
some O
degree O
of O
renal O
function O
. O

however O
, O
it O
is O
unclear O
whether O
pharmacological O
treatment O
or O
spontaneous O
resolution O
is O
responsible O
for O
the O
improvement O
. O

quinine-associated O
hemolytic-uremic B-NEG
syndrome I-NEG
probably O
occurs O
more O
often O
than O
is O
recognized O
. O

it O
is O
important O
to O
recognize O
this O
reaction O
when O
it O
occurs O
and O
to O
avoid O
further O
quinine O
exposure O
, O
since O
the O
reaction O
seems O
to O
be O
recurrent O
. O

-DOCSTART- O

pyeloureteral O
filling O
defects O
associated O
with O
systemic O
anticoagulation O
: O
a O
case O
report O
. O

the O
etiology O
of O
pyeloureteritis B-NEG
cystica I-NEG
has O
long O
been O
attributed O
to O
chronic O
infection B-NEG
and O
inflammation B-NEG
. O

a O
case O
is O
presented O
that O
is O
unique O
in O
that O
the O
acute O
onset O
and O
the O
rapid O
resolution O
of O
pyeloureteral O
filling O
defects O
in O
this O
patient O
were O
documented O
by O
radiography O
. O

there O
is O
no O
evidence O
of O
antecedent O
or O
concurrent O
infection B-NEG
in O
this O
patient O
. O

the O
disease O
occurred O
subsequent O
to O
the O
initiation O
of O
heparin O
therapy O
for O
suspected O
pelvic O
thrombophlebitis B-NEG
and O
cleared O
rapidly O
subsequent O
to O
its O
discontinuation O
. O

the O
rate O
of O
resolution O
of O
the O
radiographic O
findings O
may O
be O
helpful O
in O
distinguishing O
between O
true O
pyeloureteritis B-NEG
cystica I-NEG
and O
submucosal B-NEG
hemorrhage I-NEG
. O

-DOCSTART- O

changes O
in O
peroxisomes O
in O
preneoplastic O
liver O
and O
hepatoma B-NEG
of O
mice O
induced O
by O
alpha-benzene O
hexachloride O
. O

peroxisomes O
in O
hepatomas B-NEG
and O
hyperplastic O
preneoplastic O
liver B-NEG
lesions I-NEG
induced O
in O
mice O
by O
500 O
ppm O
alpha-benzene O
hexachloride O
were O
examined O
histochemically O
and O
electron O
microscopically O
. O

although O
most O
of O
the O
hepatomas B-NEG
were O
well-differentiated O
tumors B-NEG
and O
contained O
a O
considerable O
number O
of O
peroxisomes O
, O
the O
tumor B-NEG
cells O
did O
not O
respond O
to O
ethyl-alpha-p-chlorophenoxyisobutyrate O
with O
proliferation O
of O
peroxisomes O
. O

at O
the O
16th O
week O
of O
carcinogen O
feeding O
, O
hyperplastic O
nodules O
appeared O
and O
advanced O
to O
further O
stages O
. O

a O
majority O
of O
the O
nodules O
showed O
a O
considerable O
number O
of O
peroxisomes O
and O
the O
inductive O
proliferation O
of O
peroxisomes O
. O

within O
the O
nodules O
, O
foci O
of O
proliferation O
of O
the O
cells O
that O
showed O
no O
inducibility O
of O
proliferation O
of O
peroxisomes O
appeared O
. O

these O
cells O
proliferated O
further O
, O
replacing O
the O
most O
part O
of O
the O
nodules O
, O
and O
with O
this O
process O
hepatomas B-NEG
appeared O
to O
have O
been O
formed O
. O

no O
abnormal O
matrical O
inclusions O
of O
peroxisomes O
were O
formed O
in O
the O
cells O
of O
hyperplastic O
nodules O
by O
ethyl-alpha-p-chlorophenoxyisobutyrate O
unlike O
in O
the O
case O
of O
rats O
. O

-DOCSTART- O

quinidine O
hepatitis B-NEG
. O

long-term O
administration O
of O
quinidine O
was O
associated O
with O
persistent O
elevation O
of O
serum O
concentrations O
of O
sgot O
, O
lactic O
acid O
dehydrogenase O
, O
and O
alkaline O
phosphatase O
. O

liver O
biopsy O
showed O
active O
hepatitis B-NEG
. O

discontinuance O
of O
quinidine O
therapy O
led O
to O
normalization O
of O
liver O
function O
tests O
. O

a O
challenge O
dose O
of O
quinidine O
caused O
clinical O
symptoms O
and O
abrupt O
elevation O
of O
sgot O
, O
alkaline O
phosphatase O
, O
and O
lactic O
acid O
dehydrogenase O
values O
. O

we O
concluded O
that O
this O
patient O
had O
quinidine O
hepatotoxicity B-NEG
and O
believe O
that O
this O
is O
the O
first O
case O
reported O
with O
liver O
biopsy O
documentation O
. O

this O
report O
also O
suggests O
that O
, O
even O
after O
long-term O
administration O
, O
the O
hepatic B-NEG
toxicity I-NEG
is O
reversible O
. O

-DOCSTART- O

cholesteryl O
hemisuccinate O
treatment O
protects O
rodents O
from O
the O
toxic O
effects O
of O
acetaminophen O
, O
adriamycin O
, O
carbon O
tetrachloride O
, O
chloroform O
and O
galactosamine O
. O

in O
addition O
to O
its O
use O
as O
a O
stabilizer/rigidifier O
of O
membranes O
, O
cholesteryl O
hemisuccinate O
, O
tris O
salt O
( O
cs O
) O
administration O
has O
also O
been O
shown O
to O
protect O
rats O
from O
the O
hepatotoxic B-NEG
effects O
of O
carbon O
tetrachloride O
(ccl4) O
. O

to O
further O
our O
understanding O
of O
the O
mechanism O
of O
cs O
cytoprotection O
, O
we O
examined O
in O
rats O
and O
mice O
the O
protective O
abilities O
of O
cs O
and O
the O
non-hydrolyzable O
ether O
form O
of O
cs O
, O
gamma-cholesteryloxybutyric O
acid O
, O
tris O
salt O
( O
cse O
) O
against O
acetaminophen- O
, O
adriamycin- O
, O
carbon O
tetrachloride- O
, O
chloroform- O
and O
galactosamine-induced O
toxicity B-NEG
. O

the O
results O
of O
these O
studies O
demonstrated O
that O
cs-mediated O
protection O
is O
not O
selective O
for O
a O
particular O
species O
, O
organ O
system O
or O
toxic O
chemical O
. O

a O
24-h O
pretreatment O
of O
both O
rats O
and O
mice O
with O
a O
single O
dose O
of O
cs O
(100mg/kg O
, O
i.p.) O
, O
resulted O
in O
significant O
protection O
against O
the O
hepatotoxic B-NEG
effects O
of O
ccl4 O
, O
chcl3 O
, O
acetaminophen O
and O
galactosamine O
and O
against O
the O
lethal O
( O
and O
presumably O
cardiotoxic B-NEG
) O
effect O
of O
adriamycin O
administration O
. O

maximal O
cs-mediated O
protection O
was O
observed O
in O
experimental O
animals O
pretreated O
24 O
h O
prior O
to O
the O
toxic O
insult O
. O

these O
data O
suggest O
that O
cs O
intervenes O
in O
a O
critical O
cellular O
event O
that O
is O
an O
important O
common O
pathway O
to O
toxic O
cell O
death O
. O

the O
mechanism O
of O
cs O
protection O
does O
not O
appear O
to O
be O
dependent O
on O
the O
inhibition O
of O
chemical O
bioactivation O
to O
a O
toxic O
reactive O
intermediate O
( O
in O
light O
of O
the O
protection O
observed O
against O
galactosamine O
hepatotoxicity B-NEG
). O

however O
, O
based O
on O
the O
data O
presented O
, O
we O
can O
not O
exclude O
the O
possibility O
that O
cs O
administration O
inhibits O
chemical O
bioactivation O
. O

our O
findings O
do O
suggest O
that O
cs-mediated O
protection O
is O
dependent O
on O
the O
action O
of O
the O
intact O
anionic O
cs O
molecule O
( O
non-hydrolyzable O
cse O
was O
as O
protective O
as O
cs) O
, O
whose O
mechanism O
has O
yet O
to O
be O
defined O
. O

-DOCSTART- O

dsmm O
xi O
study O
: O
dose O
definition O
for O
intravenous O
cyclophosphamide O
in O
combination O
with O
bortezomib/dexamethasone O
for O
remission O
induction O
in O
patients O
with O
newly O
diagnosed O
myeloma B-NEG
. O

a O
clinical O
trial O
was O
initiated O
to O
evaluate O
the O
recommended O
dose O
of O
cyclophosphamide O
in O
combination O
with O
bortezomib O
and O
dexamethasone O
as O
induction O
treatment O
before O
stem O
cell O
transplantation O
for O
younger O
patients O
with O
newly O
diagnosed O
multiple B-NEG
myeloma I-NEG
( O
mm B-NEG
). O

thirty O
patients O
were O
treated O
with O
three O
21-day O
cycles O
of O
bortezomib O
1.3 O
mg/m(2 O
) O
on O
days O
1, O
4, O
8, O
and O
11 O
plus O
dexamethasone O
40 O
mg O
on O
the O
day O
of O
bortezomib O
injection O
and O
the O
day O
after O
plus O
cyclophosphamide O
at O
900 O
, O
1,200 O
, O
or O
1,500 O
mg/m(2 O
) O
on O
day O
1. O

the O
maximum O
tolerated O
dose O
of O
cyclophosphamide O
was O
defined O
as O
900 O
mg/m(2) O
. O

at O
this O
dose O
level O
, O
92% O
of O
patients O
achieved O
at O
least O
a O
partial O
response O
. O

the O
overall O
response O
rate O
[complete O
response O
( O
cr O
) O
plus O
partial O
response O
( O
pr)] O
across O
all O
dose O
levels O
was O
77% O
, O
with O
a O
10% O
cr O
rate O
. O

no O
patient O
experienced O
progressive O
disease O
. O

the O
most O
frequent O
adverse O
events O
were O
hematological B-NEG
and I-NEG
gastrointestinal I-NEG
toxicities I-NEG
as O
well O
as O
neuropathy B-NEG
. O

the O
results O
suggest O
that O
bortezomib O
in O
combination O
with O
cyclophosphamide O
at O
900 O
mg/m(2 O
) O
and O
dexamethasone O
is O
an O
effective O
induction O
treatment O
for O
patients O
with O
newly O
diagnosed O
mm B-NEG
that O
warrants O
further O
investigation O
. O

-DOCSTART- O

results O
of O
a O
comparative O
, O
phase O
iii O
, O
12-week O
, O
multicenter O
, O
prospective O
, O
randomized O
, O
double-blind O
assessment O
of O
the O
efficacy O
and O
tolerability O
of O
a O
fixed-dose O
combination O
of O
telmisartan O
and O
amlodipine O
versus O
amlodipine O
monotherapy O
in O
indian O
adults O
with O
stage O
ii O
hypertension B-NEG
. O

objective O
: O
the O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
efficacy O
and O
tolerability O
of O
a O
new O
fixed-dose O
combination O
( O
fdc O
) O
of O
telmisartan O
40 O
mg O
+ O
amlodipine O
5 O
mg O
( O
t+a O
) O
compared O
with O
amlodipine O
5-mg O
monotherapy O
( O
a O
) O
in O
adult O
indian O
patients O
with O
stage O
ii O
hypertension B-NEG
. O

methods O
: O
this O
comparative O
, O
phase O
iii O
, O
12-week O
, O
multicenter O
, O
prospective O
, O
randomized O
, O
double-blind O
study O
was O
conducted O
in O
indian O
patients O
aged O
18 O
to O
65 O
years O
with O
established O
stage O
ii O
hypertension B-NEG
. O

patients O
were O
treated O
with O
oral O
fdc O
of O
t+a O
or O
a O
qd O
before O
breakfast O
for O
12 O
weeks O
; O
blood O
pressure O
( O
bp O
) O
and O
heart O
rate O
were O
measured O
in O
the O
sitting O
position O
. O

primary O
efficacy O
end O
points O
were O
reduction O
in O
clinical O
systolic O
bp O
( O
sbp)/ O
diastolic O
bp O
( O
dbp O
) O
from O
baseline O
to O
study O
end O
and O
number O
of O
responders O
(ie O
, O
patients O
who O
achieved O
target O
sbp/ O
dbp O
<130/<80 O
mm O
hg O
) O
at O
end O
of O
study O
. O

tolerability O
was O
assessed O
by O
treatment-emergent O
adverse O
events O
, O
identified O
using O
physical O
examination O
, O
laboratory O
analysis O
, O
and O
electrocardiography O
. O

results O
: O
a O
total O
of O
210 O
patients O
were O
enrolled O
in O
the O
study O
; O
203 O
patients O
( O
143 O
men O
, O
60 O
women O
) O
completed O
the O
study O
while O
7 O
were O
lost O
to O
follow-up O
(4 O
patients O
in O
the O
t+a O
group O
and O
3 O
in O
the O
a O
group O
) O
and O
considered O
with-drawn O
. O

at O
study O
end O
, O
statistically O
significant O
percentage O
reductions O
from O
baseline O
within O
groups O
and O
between O
groups O
were O
observed O
in O
sbp O
( O
t+a O
[-27.4%] O
; O
a O
[-16.6%] O
) O
and O
dbp O
( O
t+a O
[-20.1%] O
; O
a O
[-13.3%] O
) O
(all O
, O
p O
< O
0.05) O
. O

response O
rates O
were O
87.3% O
( O
89/102 O
) O
in O
the O
t+a O
group O
and O
69.3% O
( O
70/101 O
) O
in O
the O
a O
group O
(p O
< O
0.05) O
. O

the O
prevalences O
of O
adverse O
events O
were O
not O
significantly O
different O
between O
the O
2 O
treatment O
groups O
(t+a O
, O
16.0% O
[17/106] O
; O
a, O
15.4% O
[16/104]) O
. O

peripheral O
edema B-NEG
was O
reported O
in O
8.5% O
patients O
( O
9/106 O
) O
in O
the O
t+a O
group O
compared O
with O
13.5% O
( O
14/104 O
) O
in O
the O
a O
group O
, O
and O
cough B-NEG
was O
reported O
in O
3.8% O
patients O
( O
4/106 O
) O
in O
the O
t+a O
group O
and O
1.0% O
( O
1/104 O
) O
patients O
in O
the O
a O
group O
; O
these O
differences O
did O
not O
reach O
statistical O
significance O
. O

the O
incidences O
of O
headache B-NEG
, O
dizziness B-NEG
, O
and O
diarrhea B-NEG
were O
similar O
between O
the O
2 O
groups O
. O

conclusions O
: O
among O
these O
indian O
patients O
with O
stage O
ii O
hypertension B-NEG
, O
the O
fdc O
of O
t+a O
was O
found O
to O
be O
significantly O
more O
effective O
, O
with O
regard O
to O
bp O
reductions O
, O
than O
a, O
and O
both O
treatments O
were O
well O
tolerated O
. O

-DOCSTART- O

cutaneous B-NEG
leucocytoclastic I-NEG
vasculitis I-NEG
associated O
with O
oxacillin O
. O

a O
67-year-old O
man O
who O
was O
treated O
with O
oxacillin O
for O
one O
week O
because O
of O
staphylococcus B-NEG
aureus I-NEG
bacteremia I-NEG
, O
developed O
renal B-NEG
failure I-NEG
and O
diffuse O
, O
symmetric O
, O
palpable O
purpuric B-NEG
lesions I-NEG
on O
his O
feet O
. O
necrotic B-NEG
blisters I-NEG
were O
noted O
on O
his O
fingers O
. O

skin O
biopsies O
showed O
findings O
diagnostic O
of O
leucocytoclastic B-NEG
vasculitis I-NEG
. O

oxacillin O
was O
discontinued O
and O
patient O
was O
treated O
with O
corticosteroids O
. O

the O
rash B-NEG
disappeared O
after O
three O
weeks O
and O
renal O
function O
returned O
to O
normal O
. O
leucocytoclastic B-NEG
vasculitis I-NEG
presents O
as O
palpable O
purpura B-NEG
of O
the O
lower O
extremities O
often O
accompanied O
by O
abdominal B-NEG
pain I-NEG
, O
arthralgia B-NEG
, O
and O
renal B-NEG
involvement I-NEG
. O

etiologic O
factors O
or O
associated O
disorders O
include O
infections B-NEG
, O
medications O
, O
collagen B-NEG
vascular I-NEG
disease I-NEG
and O
neoplasia B-NEG
. O

however O
, O
in O
half O
of O
the O
cases O
no O
etiologic O
factor O
is O
identified O
. O

usually O
it O
is O
a O
self-limited O
disorder O
, O
but O
corticosteroid O
therapy O
may O
be O
needed O
in O
life-threatening O
cases O
since O
early O
treatment O
with O
corticosteroids O
in O
severe O
cases O
can O
prevent O
complications O
. O

oxacillin O
should O
be O
included O
among O
the O
drugs O
that O
can O
cause O
leucocytoclastic B-NEG
vasculitis I-NEG
. O

-DOCSTART- O

naloxazone O
pretreatment O
modifies O
cardiorespiratory O
, O
temperature O
, O
and O
behavioral O
effects O
of O
morphine O
. O

behavioral O
and O
cardiorespiratory O
responses O
to O
a O
lethal O
dose O
of O
morphine O
were O
evaluated O
in O
rats O
pretreated O
with O
saline O
or O
naloxazone O
, O
an O
antagonist O
of O
high-affinity O
mu O
1 O
opioid O
receptors O
. O

pretreatment O
with O
naloxazone O
significantly O
blocked O
morphine O
analgesia B-NEG
, O
catalepsy B-NEG
and O
hypothermia B-NEG
at O
a O
dose O
which O
completely O
eliminated O
high-affinity O
binding O
in O
brain O
membranes O
. O

moreover O
, O
naloxazone O
significantly O
attenuated O
the O
morphine-induced O
hypotension B-NEG
and O
respiratory B-NEG
depression I-NEG
, O
whereas O
morphine-induced O
bradycardia B-NEG
was O
less O
affected O
. O

results O
indicate O
that O
subpopulations O
of O
mu O
receptors O
may O
mediate O
selective O
behavioral O
and O
cardiorespiratory O
responses O
to O
morphine O
. O

-DOCSTART- O

dexrazoxane O
protects O
against O
myelosuppression B-NEG
from O
the O
dna O
cleavage-enhancing O
drugs O
etoposide O
and O
daunorubicin O
but O
not O
doxorubicin O
. O

purpose O
: O
the O
anthracyclines O
daunorubicin O
and O
doxorubicin O
and O
the O
epipodophyllotoxin O
etoposide O
are O
potent O
dna O
cleavage-enhancing O
drugs O
that O
are O
widely O
used O
in O
clinical O
oncology O
; O
however O
, O
myelosuppression B-NEG
and O
cardiac B-NEG
toxicity I-NEG
limit O
their O
use O
. O

dexrazoxane O
( O
icrf-187 O
) O
is O
recommended O
for O
protection O
against O
anthracycline-induced O
cardiotoxicity B-NEG
. O

experimental O
design O
: O
because O
of O
their O
widespread O
use O
, O
the O
hematologic B-NEG
toxicity I-NEG
following O
coadministration O
of O
dexrazoxane O
and O
these O
three O
structurally O
different O
dna O
cleavage O
enhancers O
was O
investigated O
: O
sensitivity O
of O
human O
and O
murine O
blood O
progenitor O
cells O
to O
etoposide O
, O
daunorubicin O
, O
and O
doxorubicin O
+/- O
dexrazoxane O
was O
determined O
in O
granulocyte-macrophage O
colony O
forming O
assays O
. O

likewise O
, O
in O
vivo O
, O
b6d2f1 O
mice O
were O
treated O
with O
etoposide O
, O
daunorubicin O
, O
and O
doxorubicin O
, O
with O
or O
without O
dexrazoxane O
over O
a O
wide O
range O
of O
doses O
: O
posttreatment O
, O
a O
full O
hematologic O
evaluation O
was O
done O
. O

results O
: O
nontoxic O
doses O
of O
dexrazoxane O
reduced O
myelosuppression B-NEG
and O
weight B-NEG
loss I-NEG
from O
daunorubicin O
and O
etoposide O
in O
mice O
and O
antagonized O
their O
antiproliferative O
effects O
in O
the O
colony O
assay O
; O
however O
, O
dexrazoxane O
neither O
reduced O
myelosuppression B-NEG
, O
weight B-NEG
loss I-NEG
, O
nor O
the O
in O
vitro O
cytotoxicity B-NEG
from O
doxorubicin O
. O

conclusion O
: O
although O
our O
findings O
support O
the O
observation O
that O
dexrazoxane O
reduces O
neither O
hematologic O
activity O
nor O
antitumor O
activity O
from O
doxorubicin O
clinically O
, O
the O
potent O
antagonism O
of O
daunorubicin O
activity O
raises O
concern O
; O
a O
possible O
interference O
with O
anticancer O
efficacy O
certainly O
would O
call O
for O
renewed O
attention O
. O

our O
data O
also O
suggest O
that O
significant O
etoposide O
dose O
escalation O
is O
perhaps O
possible O
by O
the O
use O
of O
dexrazoxane O
. O

clinical O
trials O
in O
patients O
with O
brain O
metastases B-NEG
combining O
dexrazoxane O
and O
high O
doses O
of O
etoposide O
is O
ongoing O
with O
the O
aim O
of O
improving O
efficacy O
without O
aggravating O
hematologic B-NEG
toxicity I-NEG
. O

if O
successful O
, O
this O
represents O
an O
exciting O
mechanism O
for O
pharmacologic O
regulation O
of O
side O
effects O
from O
cytotoxic O
chemotherapy O
. O

-DOCSTART- O

effects O
of O
the O
novel O
compound O
aniracetam O
( O
ro O
13-5057 O
) O
upon O
impaired B-NEG
learning I-NEG
and I-NEG
memory I-NEG
in O
rodents O
. O

the O
effect O
of O
aniracetam O
( O
ro O
13-5057 O
, O
1-anisoyl-2-pyrrolidinone O
) O
was O
studied O
on O
various O
forms O
of O
experimentally O
impaired B-NEG
cognitive I-NEG
functions I-NEG
( O
learning O
and O
memory O
) O
in O
rodents O
and O
produced O
the O
following O
effects O
: O
( O
1 O
) O
almost O
complete O
prevention O
of O
the O
incapacity O
to O
learn O
a O
discrete O
escape O
response O
in O
rats O
exposed O
to O
sublethal O
hypercapnia B-NEG
immediately O
before O
the O
acquisition O
session O
; O
( O
2 O
) O
partial O
( O
rats O
) O
or O
complete O
( O
mice O
) O
prevention O
of O
the O
scopolamine-induced O
short-term O
amnesia B-NEG
for O
a O
passive O
avoidance O
task O
; O
( O
3 O
) O
complete O
protection O
against O
amnesia B-NEG
for O
a O
passive O
avoidance O
task O
in O
rats O
submitted O
to O
electroconvulsive O
shock O
immediately O
after O
avoidance O
acquisition O
; O
( O
4 O
) O
prevention O
of O
the O
long-term O
retention- O
or O
retrieval-deficit O
for O
a O
passive O
avoidance O
task O
induced O
in O
rats O
and O
mice O
by O
chloramphenicol O
or O
cycloheximide O
administered O
immediately O
after O
acquisition O
; O
( O
5 O
) O
reversal O
, O
when O
administered O
as O
late O
as O
1 O
h O
before O
the O
retention O
test O
, O
of O
the O
deficit O
in O
retention O
or O
retrieval O
of O
a O
passive O
avoidance O
task O
induced O
by O
cycloheximide O
injected O
2 O
days O
previously O
; O
( O
6 O
) O
prevention O
of O
the O
deficit O
in O
the O
retrieval O
of O
an O
active O
avoidance O
task O
induced O
in O
mice O
by O
subconvulsant O
electroshock O
or O
hypercapnia B-NEG
applied O
immediately O
before O
retrieval O
testing O
( O
24 O
h O
after O
acquisition) O
. O

these O
improvements O
or O
normalizations O
of O
impaired B-NEG
cognitive I-NEG
functions I-NEG
were O
seen O
at O
oral O
aniracetam O
doses O
of O
10-100 O
mg/kg O
. O

generally O
, O
the O
dose-response O
curves O
were O
bell-shaped O
. O

the O
mechanisms O
underlying O
the O
activity O
of O
aniracetam O
and O
its O
'therapeutic O
window' O
are O
unknown O
. O

piracetam O
, O
another O
pyrrolidinone O
derivative O
was O
used O
for O
comparison O
. O

it O
was O
active O
only O
in O
six O
of O
nine O
tests O
and O
had O
about O
one-tenth O
the O
potency O
of O
aniracetam O
. O

the O
results O
indicate O
that O
aniracetam O
improves O
cognitive O
functions O
which O
are O
impaired O
by O
different O
procedure O
and O
in O
different O
phases O
of O
the O
learning O
and O
memory O
process O
. O

-DOCSTART- O

nicotine O
potentiation O
of O
morphine-induced O
catalepsy B-NEG
in O
mice O
. O

in O
the O
present O
study O
, O
effects O
of O
nicotine O
on O
catalepsy B-NEG
induced O
by O
morphine O
in O
mice O
have O
been O
investigated O
. O

morphine O
but O
not O
nicotine O
induced O
a O
dose-dependent O
catalepsy B-NEG
. O

the O
response O
of O
morphine O
was O
potentiated O
by O
nicotine O
. O

intraperitoneal O
administration O
of O
atropine O
, O
naloxone O
, O
mecamylamine O
, O
and O
hexamethonium O
to O
mice O
reduced O
catalepsy B-NEG
induced O
by O
a O
combination O
of O
morphine O
with O
nicotine O
. O

intracerebroventricular O
injection O
of O
atropine O
, O
hexamethonium O
, O
and O
naloxone O
also O
decreased O
catalepsy B-NEG
induced O
by O
morphine O
plus O
nicotine O
. O

intraperitoneal O
administration O
of O
atropine O
, O
but O
not O
intraperitoneal O
or O
intracerebroventricular O
injection O
of O
hexamethonium O
, O
decreased O
the O
effect O
of O
a O
single O
dose O
of O
morphine O
. O

it O
was O
concluded O
that O
morphine O
catalepsy B-NEG
can O
be O
elicited O
by O
opioid O
and O
cholinergic O
receptors O
, O
and O
the O
potentiation O
of O
morphine O
induced O
by O
nicotine O
may O
also O
be O
mediated O
through O
cholinergic O
receptor O
mechanisms O
. O

-DOCSTART- O

reduced O
cardiotoxicity B-NEG
and O
preserved O
antitumor O
efficacy O
of O
liposome-encapsulated O
doxorubicin O
and O
cyclophosphamide O
compared O
with O
conventional O
doxorubicin O
and O
cyclophosphamide O
in O
a O
randomized O
, O
multicenter O
trial O
of O
metastatic O
breast B-NEG
cancer I-NEG
. O

purpose O
: O
to O
determine O
whether O
myocet O
( O
liposome-encapsulated O
doxorubicin O
; O
the O
liposome O
company O
, O
elan O
corporation O
, O
princeton O
, O
nj O
) O
in O
combination O
with O
cyclophosphamide O
significantly O
reduces O
doxorubicin O
cardiotoxicity B-NEG
while O
providing O
comparable O
antitumor O
efficacy O
in O
first-line O
treatment O
of O
metastatic O
breast B-NEG
cancer I-NEG
( O
mbc B-NEG
). O

patients O
and O
methods O
: O
two O
hundred O
ninety-seven O
patients O
with O
mbc B-NEG
and O
no O
prior O
chemotherapy O
for O
metastatic O
disease O
were O
randomized O
to O
receive O
either O
60 O
mg/m(2 O
) O
of O
myocet O
( O
m O
) O
or O
conventional O
doxorubicin O
(a) O
, O
in O
combination O
with O
600 O
mg/m(2 O
) O
of O
cyclophosphamide O
(c) O
, O
every O
3 O
weeks O
until O
disease O
progression O
or O
unacceptable O
toxicity B-NEG
. O
cardiotoxicity B-NEG
was O
defined O
by O
reductions O
in O
left-ventricular O
ejection O
fraction O
, O
assessed O
by O
serial O
multigated O
radionuclide O
angiography O
scans O
, O
or O
congestive B-NEG
heart I-NEG
failure I-NEG
( O
chf B-NEG
). O

antitumor O
efficacy O
was O
assessed O
by O
objective O
tumor B-NEG
response O
rates O
( O
world O
health O
organization O
criteria) O
, O
time O
to O
progression O
, O
and O
survival O
. O

results O
: O
six O
percent O
of O
mc O
patients O
versus O
21% O
( O
including O
five O
cases O
of O
chf B-NEG
) O
of O
ac O
patients O
developed O
cardiotoxicity B-NEG
(p O
=.0002) O
. O

median O
cumulative O
doxorubicin O
dose O
at O
onset O
was O
more O
than O
2,220 O
mg/m(2 O
) O
for O
mc O
versus O
480 O
mg/m(2 O
) O
for O
ac O
(p O
=.0001 O
, O
hazard O
ratio O
, O
5.04) O
. O

mc O
patients O
also O
experienced O
less O
grade O
4 O
neutropenia B-NEG
. O

antitumor O
efficacy O
of O
mc O
versus O
ac O
was O
comparable O
: O
objective O
response O
rates O
, O
43% O
versus O
43% O
; O
median O
time O
to O
progression O
, O
5.1% O
versus O
5.5 O
months O
; O
median O
time O
to O
treatment O
failure O
, O
4.6 O
versus O
4.4 O
months O
; O
and O
median O
survival O
, O
19 O
versus O
16 O
months O
. O

conclusion O
: O
myocet O
improves O
the O
therapeutic O
index O
of O
doxorubicin O
by O
significantly O
reducing O
cardiotoxicity B-NEG
and O
grade O
4 O
neutropenia B-NEG
and O
provides O
comparable O
antitumor O
efficacy O
, O
when O
used O
in O
combination O
with O
cyclophosphamide O
as O
first-line O
therapy O
for O
mbc B-NEG
. O

-DOCSTART- O

protective O
effect O
of O
a O
specific O
platelet-activating O
factor O
antagonist O
, O
bn O
52021 O
, O
on O
bupivacaine-induced O
cardiovascular B-NEG
impairments I-NEG
in O
rats O
. O

administration O
of O
the O
local O
anaesthetic O
bupivacaine O
( O
1.5 O
or O
2 O
mg/kg O
, O
i.v. O
) O
to O
rats O
elicited O
a O
marked O
decrease B-NEG
of I-NEG
mean I-NEG
arterial I-NEG
blood I-NEG
pressure I-NEG
( O
mbp I-NEG
) O
and I-NEG
heart I-NEG
rate I-NEG
( O
hr I-NEG
) O
leading O
to O
death O
( O
in O
67% O
or O
90% O
of O
animals O
respectively) O
. O

intravenous O
injection O
of O
the O
specific O
platelet-activating O
factor O
( O
paf O
) O
antagonist O
bn O
52021 O
( O
10 O
mg/kg) O
, O
30 O
min O
before O
bupivacaine O
administration O
(2 O
mg/kg O
i.v. O
) O
suppressed O
both O
the O
decrease B-NEG
of I-NEG
mbp I-NEG
and I-NEG
hr I-NEG
. O

in O
contrast O
, O
doses O
of O
1 O
mg/kg O
bn O
52021 O
given O
30 O
min O
before O
or O
10 O
mg/kg O
administered O
5 O
min O
before O
i.v O
. O
injection O
of O
bupivacaine O
were O
ineffective O
. O

when O
bn O
52021 O
( O
20 O
mg/kg O
i.v. O
) O
was O
injected O
immediately O
after O
bupivacaine O
(2 O
mg/kg) O
, O
a O
partial O
reversion O
of O
the O
decrease B-NEG
of I-NEG
mbp I-NEG
and I-NEG
hr I-NEG
was O
observed O
, O
whereas O
the O
dose O
of O
10 O
mg/kg O
was O
ineffective O
. O

a O
partial O
recovery O
of O
bupivacaine-induced O
ecg O
alterations O
was O
observed O
after O
pretreatment O
of O
the O
rats O
with O
bn O
52021 O
. O

since O
the O
administration O
of O
bn O
52021 O
, O
at O
all O
doses O
studied O
, O
did O
not O
alter O
mbp O
and O
hr O
at O
the O
doses O
used O
, O
the O
bulk O
of O
these O
results O
clearly O
demonstrate O
a O
protective O
action O
of O
bn O
52021 O
, O
a O
specific O
antagonist O
of O
paf O
, O
against O
bupivacaine-induced O
cardiovascular B-NEG
toxicity I-NEG
. O

thus O
, O
consistent O
with O
its O
direct O
effect O
on O
heart O
, O
paf O
appears O
to O
be O
implicated O
in O
bupivacaine-induced O
cardiovascular B-NEG
alterations I-NEG
. O

-DOCSTART- O

benzylacyclouridine O
reverses O
azidothymidine-induced O
marrow B-NEG
suppression I-NEG
without O
impairment O
of O
anti-human O
immunodeficiency B-NEG
virus O
activity O
. O

increased O
extracellular O
concentrations O
of O
uridine O
( O
urd O
) O
have O
been O
reported O
to O
reduce O
, O
in O
vitro O
, O
azidothymidine O
( O
azt)-induced O
inhibition O
of O
human O
granulocyte-macrophage O
progenitor O
cells O
without O
impairment O
of O
its O
antihuman O
immunodeficiency B-NEG
virus O
( O
hiv O
) O
activity O
. O

because O
of O
the O
clinical O
toxicities B-NEG
associated O
with O
chronic O
urd O
administration O
, O
the O
ability O
of O
benzylacyclouridine O
( O
bau O
) O
to O
effect O
, O
in O
vivo O
, O
azt-induced O
anemia B-NEG
and O
leukopenia B-NEG
was O
assessed O
. O

this O
agent O
inhibits O
urd O
catabolism O
and O
, O
in O
vivo O
, O
increases O
the O
plasma O
concentration O
of O
urd O
in O
a O
dose-dependent O
manner O
, O
without O
urd-related O
toxicity B-NEG
. O

in O
mice O
rendered O
anemic B-NEG
and O
leukopenic B-NEG
by O
the O
administration O
of O
azt O
for O
28 O
days O
in O
drinking O
water O
( O
1.5 O
mg/ml) O
, O
the O
continued O
administration O
of O
azt O
plus O
daily O
bau O
( O
300 O
mg/kg O
, O
orally O
) O
partially O
reversed O
azt-induced O
anemia B-NEG
and O
leukopenia B-NEG
(p O
less O
than O
.05) O
, O
increased O
peripheral O
reticulocytes O
( O
to O
4.9% O
, O
p O
less O
than O
.01) O
, O
increased O
cellularity O
in O
the O
marrow O
, O
and O
improved O
megaloblastosis B-NEG
. O

when O
coadministered O
with O
azt O
from O
the O
onset O
of O
drug O
administration O
, O
bau O
reduced O
azt-induced O
marrow B-NEG
toxicity I-NEG
. O

in O
vitro O
, O
at O
a O
concentration O
of O
100 O
mumol/l O
, O
bau O
possesses O
minimal O
anti-hiv O
activity O
and O
has O
no O
effect O
on O
the O
ability O
of O
azt O
to O
reverse O
the O
hiv-induced O
cytopathic O
effect O
in O
mt4 O
cells O
. O

the O
clinical O
and O
biochemical O
implications O
of O
these O
findings O
are O
discussed O
. O

-DOCSTART- O

cyclophosphamide-induced O
cystitis B-NEG
in O
freely-moving O
conscious O
rats O
: O
behavioral O
approach O
to O
a O
new O
model O
of O
visceral B-NEG
pain I-NEG
. O

purpose O
: O
to O
develop O
a O
model O
of O
visceral B-NEG
pain I-NEG
in O
rats O
using O
a O
behavioral O
approach O
. O

cyclophosphamide O
(cp) O
, O
an O
antitumoral O
agent O
known O
to O
produce O
toxic O
effects O
on O
the O
bladder O
wall O
through O
its O
main O
toxic O
metabolite O
acrolein O
, O
was O
used O
to O
induce O
cystitis B-NEG
. O

materials O
and O
methods O
: O
cp O
was O
administered O
at O
doses O
of O
50 O
, O
100 O
and O
200 O
mg./kg O
. O

i.p O
. O
to O
male O
rats O
, O
and O
their O
behavior O
observed O
and O
scored O
. O

the O
effects O
of O
morphine O
( O
0.5 O
to O
4 O
mg./kg O
. O
i.v. O
) O
on O
cp-induced O
behavioral O
modifications O
were O
tested O
administered O
alone O
and O
after O
naloxone O
(1 O
mg./kg O
. O
s.c.) O
. O

in O
addition O
, O
90 O
minutes O
after O
cp O
injection O
, O
that O
is O
, O
at O
the O
time O
of O
administration O
of O
morphine O
, O
the O
bladder O
was O
removed O
in O
some O
rats O
for O
histological O
examination O
. O

finally O
, O
to O
show O
that O
the O
bladder O
is O
essential O
for O
the O
cp-induced O
behavioral O
modifications O
, O
female O
rats O
also O
received O
cp O
at O
doses O
of O
200 O
mg./kg O
. O

i.p O
. O
and O
of O
20 O
mg O
. O
by O
the O
intravesical O
route O
, O
and O
acrolein O
at O
doses O
of O
0.5 O
mg O
. O
by O
the O
intravesical O
route O
and O
of O
5 O
mg./kg O
. O

i.v O
. O

results O
: O
cp O
dose-relatedly O
induced O
marked O
behavioral O
modifications O
in O
male O
rats O
: O
breathing O
rate O
decrease O
, O
closing O
of O
the O
eyes O
and O
occurrence O
of O
specific O
postures O
. O

morphine O
dose-dependently O
reversed O
these O
behavioral B-NEG
disorders I-NEG
. O

a O
dose O
of O
0.5 O
mg./kg O
. O
produced O
a O
reduction O
of O
almost O
50% O
of O
the O
behavioral O
score O
induced O
by O
cp O
200 O
mg./kg O
. O

this O
effect O
was O
completely O
prevented O
by O
pretreatment O
with O
naloxone O
. O

at O
the O
time O
of O
administration O
of O
morphine O
, O
histological O
modifications O
of O
the O
bladder O
wall O
, O
such O
as O
chorionic O
and O
muscle O
layer O
edema B-NEG
, O
were O
observed O
. O

in O
female O
rats O
, O
cp O
200 O
mg./kg O
. O

i.p O
. O
produced O
the O
same O
marked O
behavioral O
modifications O
as O
those O
observed O
in O
male O
rats O
. O

administered O
at O
the O
dose O
of O
20 O
mg O
. O
intravesically O
, O
cp O
did O
not O
produce O
any O
behavioral O
effects O
, O
whereas O
acrolein O
at O
0.5 O
mg O
. O
intravesically O
induced O
behavioral O
modifications O
identical O
to O
those O
under O
cp O
200 O
mg./kg O
. O

i.p. O
, O
with O
the O
same O
maximal O
levels O
. O

conversely O
, O
acrolein O
5 O
mg./kg O
. O

i.v O
. O
did O
not O
produce O
any O
behavioral O
effects O
at O
all O
. O

conclusions O
: O
overall O
, O
these O
results O
indicate O
that O
this O
experimental O
model O
of O
cp-induced O
cystitis B-NEG
may O
be O
an O
interesting O
new O
behavioral O
model O
of O
inflammatory O
visceral B-NEG
pain I-NEG
, O
allowing O
a O
better O
understanding O
of O
these O
painful B-NEG
syndromes I-NEG
and O
thus O
a O
better O
therapeutic O
approach O
to O
them O
. O

-DOCSTART- O

hyperalgesia B-NEG
and O
myoclonus B-NEG
in O
terminal O
cancer B-NEG
patients O
treated O
with O
continuous O
intravenous O
morphine O
. O

eight O
cancer B-NEG
patients O
in O
the O
terminal O
stages O
of O
the O
disease O
treated O
with O
high O
doses O
of O
intravenous O
morphine O
developed O
hyperalgesia B-NEG
. O

all O
cases O
were O
retrospectively O
sampled O
from O
three O
different O
hospitals O
in O
copenhagen O
. O

five O
patients O
developed O
universal O
hyperalgesia B-NEG
and O
hyperesthesia B-NEG
which O
in O
2 O
cases O
were O
accompanied O
by O
myoclonus B-NEG
. O

in O
3 O
patients O
a O
pre-existing O
neuralgia B-NEG
increased O
to O
excruciating O
intensity O
and O
in O
2 O
of O
these O
cases O
myoclonus B-NEG
occurred O
simultaneously O
. O

although O
only O
few O
clinical O
descriptions O
of O
the O
relationship O
between O
hyperalgesia B-NEG
/ O
myoclonus B-NEG
and O
high O
doses O
of O
morphine O
are O
available O
, O
experimental O
support O
from O
animal O
studies O
indicates O
that O
morphine O
, O
or O
its O
metabolites O
, O
plays O
a O
causative O
role O
for O
the O
observed O
behavioural O
syndrome O
. O

the O
possible O
mechanisms O
are O
discussed O
and O
treatment O
proposals O
given O
suggesting O
the O
use O
of O
more O
efficacious O
opioids O
with O
less O
excitatory O
potency O
in O
these O
situations O
. O

-DOCSTART- O

a O
prospective O
study O
of O
adverse O
reactions O
associated O
with O
vancomycin O
therapy O
. O

a O
prospective O
evaluation O
of O
the O
efficacy O
and O
safety O
of O
vancomycin O
was O
conducted O
in O
54 O
consecutive O
patients O
over O
a O
16-month O
period O
. O

vancomycin O
was O
curative O
in O
95% O
of O
43 O
patients O
with O
proven O
infection B-NEG
. O

drugs O
were O
ceased O
in O
six O
patients O
because O
of O
adverse O
reactions O
; O
in O
three O
of O
these O
vancomycin O
was O
considered O
the O
likely O
cause O
. O

reactions O
included O
thrombophlebitis B-NEG
( O
20 O
of O
54 O
patients) O
, O
rash B-NEG
(4 O
of O
54) O
, O
nephrotoxicity B-NEG
(4 O
of O
50) O
, O
proteinuria B-NEG
(1 O
of O
50 O
) O
and O
ototoxicity B-NEG
(1 O
of O
11 O
patients O
tested O
by O
audiometry) O
. O
thrombophlebitis B-NEG
occurred O
only O
with O
infusion O
through O
peripheral O
cannulae O
; O
nephrotoxicity B-NEG
and O
ototoxicity B-NEG
were O
confined O
to O
patients O
receiving O
an O
aminoglycoside O
plus O
vancomycin O
. O

we O
conclude O
that O
vancomycin O
, O
administered O
appropriately O
, O
constitutes O
safe O
, O
effective O
therapy O
for O
infections B-NEG
caused O
by O
susceptible O
bacteria O
. O

-DOCSTART- O

blockade O
of O
both O
d-1 O
and O
d-2 O
dopamine O
receptors O
may O
induce O
catalepsy B-NEG
in O
mice O
. O

1. O

the O
catalepsy B-NEG
induced O
by O
dopamine O
antagonists O
has O
been O
tested O
and O
the O
possible O
dopamine O
subtypes O
involved O
in O
catalepsy B-NEG
was O
determined O
. O

2. O

dopamine O
antagonist O
fluphenazine O
, O
d-1 O
antagonist O
sch O
23390 O
or O
d-2 O
antagonist O
sulpiride O
induced O
catalepsy B-NEG
. O

the O
effect O
of O
fluphenazine O
and O
sulpiride O
was O
dose-dependent O
. O

combination O
of O
sch O
23390 O
with O
sulpiride O
did O
not O
induce O
catalepsy B-NEG
potentiation O
. O

3. O

d-1 O
agonist O
skf O
38393 O
or O
d-2 O
agonist O
quinpirole O
decreased O
the O
catalepsy B-NEG
induced O
by O
fluphenazine O
, O
sch O
23390 O
or O
sulpiride O
. O

4. O

combination O
of O
skf O
38393 O
with O
quinpirole O
did O
not O
cause O
potentiated O
inhibitory O
effect O
on O
catalepsy B-NEG
induced O
by O
dopamine O
antagonists O
. O

5. O

the O
data O
may O
indicate O
that O
although O
d-2 O
receptor O
blockade O
is O
involved O
in O
catalepsy B-NEG
, O
the O
d-1 O
receptor O
may O
plan O
a O
role O
. O

-DOCSTART- O

dextran-etodolac O
conjugates O
: O
synthesis O
, O
in O
vitro O
and O
in O
vivo O
evaluation O
. O

etodolac O
(e) O
, O
is O
a O
non-narcotic O
analgesic O
and O
antiinflammatory O
drug O
. O

a O
biodegradable O
polymer O
dextran O
has O
been O
utilized O
as O
a O
carrier O
for O
synthesis O
of O
etodolac-dextran O
conjugates O
( O
ed O
) O
to O
improve O
its O
aqueous O
solubility O
and O
reduce O
gastrointestinal O
side O
effects O
. O

an O
activated O
moiety O
, O
i.e O
. O

n-acylimidazole O
derivative O
of O
etodolac O
(eai) O
, O
was O
condensed O
with O
the O
polysaccharide O
polymer O
dextran O
of O
different O
molecular O
weights O
(40000 O
, O
60000 O
, O
110000 O
and O
200000) O
. O

ir O
spectral O
data O
confirmed O
formation O
of O
ester O
bonding O
in O
the O
conjugates O
. O

etodolac O
contents O
were O
evaluated O
by O
uv-spectrophotometric O
analysis O
. O

the O
molecular O
weights O
were O
determined O
by O
measuring O
viscosity O
using O
the O
mark-howink-sakurada O
equation O
. O

in O
vitro O
hydrolysis O
of O
ed O
was O
done O
in O
aqueous O
buffers O
( O
ph O
1.2 O
, O
7.4 O
, O
9) O
and O
in O
80% O
( O
v/v O
) O
human O
plasma O
( O
ph O
7.4) O
. O

at O
ph O
9, O
a O
higher O
rate O
of O
etodolac O
release O
from O
ed O
was O
observed O
as O
compared O
to O
aqueous O
buffer O
of O
ph O
7.4 O
and O
80% O
human O
plasma O
( O
ph O
7.4) O
, O
following O
first-order O
kinetics O
. O

in O
vivo O
investigations O
were O
performed O
in O
animals O
. O

acute O
analgesic O
and O
antiinflammatory O
activities O
were O
ascertained O
using O
acetic O
acid O
induced O
writhing B-NEG
model O
( O
mice O
) O
and O
carrageenan-induced O
rat O
paw O
edema B-NEG
model O
, O
respectively O
. O

in O
comparison O
to O
control O
, O
e O
and O
ed1-ed4 O
showed O
highly O
significant O
analgesic O
and O
antiinflammatory O
activities O
(p O
<0.001) O
. O

biological O
evaluation O
suggested O
that O
conjugates O
( O
ed1-ed4 O
) O
retained O
comparable O
analgesic O
and O
antiinflammatory O
activities O
with O
remarkably O
reduced O
ulcerogenicity O
as O
compared O
to O
their O
parent O
drug--etodolac O
. O

-DOCSTART- O

hypersensitivity B-NEG
myocarditis B-NEG
complicating O
hypertrophic B-NEG
cardiomyopathy I-NEG
heart O
. O

the O
present O
report O
describes O
a O
case O
of O
eosinophilic B-NEG
myocarditis I-NEG
complicating O
hypertrophic B-NEG
cardiomyopathy I-NEG
. O

the O
47-year-old O
female O
patient O
, O
known O
to O
have O
hypertrophic B-NEG
cardiomyopathy I-NEG
, O
was O
admitted O
with O
biventricular B-NEG
failure I-NEG
and O
managed O
aggressively O
with O
dobutamine O
infusion O
and O
other O
drugs O
while O
being O
assessed O
for O
heart O
transplantation O
. O

on O
transthoracic O
echocardiogram O
, O
she O
had O
moderate O
left B-NEG
ventricular I-NEG
dysfunction I-NEG
with O
regional O
variability O
and O
moderate O
mitral B-NEG
regurgitation I-NEG
. O

the O
recipient's O
heart O
showed O
the O
features O
of O
apical O
hypertrophic B-NEG
cardiomyopathy I-NEG
and O
myocarditis B-NEG
with O
abundant O
eosinophils O
. O
myocarditis B-NEG
is O
rare O
and O
eosinophilic B-NEG
myocarditis I-NEG
is O
rarer O
. O

it O
is O
likely O
that O
the O
hypersensitivity B-NEG
( O
eosinophilic B-NEG
) O
myocarditis B-NEG
was O
related O
to O
dobutamine O
infusion O
therapy O
. O
eosinophilic B-NEG
myocarditis I-NEG
has O
been O
reported O
with O
an O
incidence O
of O
2.4% O
to O
7.2% O
in O
explanted O
hearts O
and O
may O
be O
related O
to O
multidrug O
therapy O
. O

-DOCSTART- O

all- O
trans-retinoic O
acid-induced O
erythema B-NEG
nodosum I-NEG
in O
patients O
with O
acute B-NEG
promyelocytic I-NEG
leukemia I-NEG
. O
erythema B-NEG
nodosum I-NEG
associated O
with O
all- O
trans-retinoic O
acid O
( O
atra O
) O
for O
acute B-NEG
promyelocytic I-NEG
leukemia I-NEG
( O
apl B-NEG
) O
is O
very O
rare O
. O

we O
describe O
four O
patients O
with O
classic O
apl B-NEG
who O
developed O
erythema B-NEG
nodosum I-NEG
during O
atra O
therapy O
. O
fever B-NEG
and O
subsequent O
multiple O
painful B-NEG
erythematous B-NEG
nodules I-NEG
over O
extremities O
developed O
on O
d11 O
, O
d16 O
, O
d17 O
, O
and O
d19 O
, O
respectively O
, O
after O
atra O
therapy O
. O

the O
skin O
biopsy O
taken O
from O
each O
patient O
was O
consistent O
with O
erythema B-NEG
nodosum I-NEG
. O

all O
patients O
received O
short O
course O
of O
steroids O
. O
fever B-NEG
subsided O
rapidly O
and O
the O
skin O
lesions O
regressed O
completely O
. O

all O
patients O
achieved O
complete O
remission O
without O
withdrawal O
of O
atra O
. O

atra O
seemed O
to O
be O
the O
most O
possible O
etiology O
of O
erythema B-NEG
nodosum I-NEG
in O
our O
patients O
. O

short-term O
use O
of O
steroid O
is O
very O
effective O
in O
atra-induced O
erythema B-NEG
nodosum I-NEG
. O

-DOCSTART- O

delayed-onset O
heparin-induced O
thrombocytopenia B-NEG
. O

background O
: O
heparin-induced O
thrombocytopenia B-NEG
presents O
5 O
to O
12 O
days O
after O
heparin O
exposure O
, O
with O
or O
without O
arterial B-NEG
or I-NEG
venous I-NEG
thromboemboli I-NEG
. O

delayed O
recognition O
and O
treatment O
of O
heparin-induced O
thrombocytopenia B-NEG
contribute O
to O
poor O
patient O
outcomes O
. O

objective O
: O
to O
describe O
and O
increase O
awareness O
of O
a O
clinical O
scenario O
in O
which O
the O
onset O
or O
manifestations O
of O
heparin-induced O
thrombocytopenia B-NEG
are O
delayed O
. O

design O
: O
retrospective O
case O
series O
. O

setting O
: O
three O
large O
urban O
hospitals O
( O
with O
active O
cardiovascular O
surgery O
programs) O
. O

patients O
: O
14 O
patients O
seen O
over O
a O
3-year O
period O
in O
whom O
heparin-induced O
thrombocytopenia B-NEG
became O
apparent O
on O
delayed O
presentation O
with O
thromboembolic B-NEG
complications O
. O

measurements O
: O
platelet O
counts O
, O
onset O
of O
objectively O
determined O
thromboembolism B-NEG
, O
results O
of O
heparin-induced O
platelet O
factor O
4 O
antibody O
tests O
, O
and O
outcomes O
. O

results O
: O
patients O
went O
home O
after O
hospitalizations O
that O
had O
included O
heparin O
exposure--in O
most O
cases O
, O
with O
no O
thrombocytopenia B-NEG
recognized--only O
to O
return O
to O
the O
hospital O
(median O
, O
day O
14 O
) O
with O
thromboembolic B-NEG
complications O
. O
thromboemboli B-NEG
were O
venous O
( O
12 O
patients O
, O
7 O
with O
pulmonary B-NEG
emboli I-NEG
) O
or O
arterial O
(4 O
patients O
) O
or O
both O
. O

platelet O
counts O
were O
mildly O
decreased O
in O
all O
but O
2 O
patients O
on O
second O
presentation O
. O

on O
readmission O
, O
11 O
patients O
received O
therapeutic O
heparin O
, O
which O
worsened O
the O
patients' O
clinical O
condition O
and O
, O
in O
all O
11 O
cases O
, O
decreased O
the O
platelet O
count O
( O
mean O
at O
readmission O
, O
143 O
x O
10(9 O
) O
cells/l O
; O
mean O
nadir O
after O
heparin O
re-exposure O
, O
39 O
x O
10(9 O
) O
cells/l) O
. O

results O
of O
serologic O
tests O
for O
heparin-induced O
antibodies O
were O
positive O
in O
all O
patients O
. O

subsequent O
treatments O
included O
alternative O
anticoagulants O
( O
11 O
patients) O
, O
thrombolytic O
drugs O
(3 O
patients) O
, O
inferior O
vena O
cava O
filters O
(3 O
patients O
) O
and O
, O
eventually O
, O
warfarin O
( O
11 O
patients) O
. O

three O
patients O
died O
. O

conclusions O
: O
delayed-onset O
heparin-induced O
thrombocytopenia B-NEG
is O
increasingly O
being O
recognized O
. O

to O
avoid O
disastrous O
outcomes O
, O
physicians O
must O
consider O
heparin-induced O
thrombocytopenia B-NEG
whenever O
a O
recently O
hospitalized O
patient O
returns O
with O
thromboembolism B-NEG
; O
therapy O
with O
alternative O
anticoagulants O
, O
not O
heparin O
, O
should O
be O
initiated O
. O

-DOCSTART- O

valsartan O
, O
a O
new O
angiotensin O
ii O
antagonist O
for O
the O
treatment O
of O
essential O
hypertension B-NEG
: O
a O
comparative O
study O
of O
the O
efficacy O
and O
safety O
against O
amlodipine O
. O

objective O
: O
to O
compare O
the O
antihypertensive O
efficacy O
of O
a O
new O
angiotensin O
ii O
antagonist O
, O
valsartan O
, O
with O
a O
reference O
therapy O
, O
amlodipine O
. O

methods O
: O
one O
hundred O
sixty-eight O
adult O
outpatients O
with O
mild O
to O
moderate O
hypertension B-NEG
were O
randomly O
allocated O
in O
double-blind O
fashion O
and O
equal O
number O
to O
receive O
80 O
mg O
valsartan O
or O
5 O
mg O
amlodipine O
for O
12 O
weeks O
. O

after O
8 O
weeks O
of O
therapy O
, O
in O
patients O
whose O
blood O
pressure O
remained O
uncontrolled O
, O
5 O
mg O
amlodipine O
was O
added O
to O
the O
initial O
therapy O
. O

patients O
were O
assessed O
at O
4, O
8, O
and O
12 O
weeks O
. O

the O
primary O
efficacy O
variable O
was O
change O
from O
baseline O
in O
mean O
sitting O
diastolic O
blood O
pressure O
at O
8 O
weeks O
. O

secondary O
variables O
included O
change O
in O
sitting O
systolic O
blood O
pressure O
and O
responder O
rates O
. O

results O
: O
both O
valsartan O
and O
amlodipine O
were O
effective O
at O
lowering O
blood O
pressure O
at O
4, O
8, O
and O
12 O
weeks O
. O

similar O
decreases O
were O
observed O
in O
both O
groups O
, O
with O
no O
statistically O
significant O
differences O
between O
the O
groups O
for O
any O
variable O
analyzed O
. O

for O
the O
primary O
variable O
the O
difference O
was O
0.5 O
mm O
hg O
in O
favor O
of O
valsartan O
(p O
= O
0.68 O
; O
95% O
confidence O
interval O
, O
-2.7 O
to O
1.7) O
. O

responder O
rates O
at O
8 O
weeks O
were O
66.7% O
for O
valsartan O
and O
60.2% O
for O
amlodipine O
(p O
= O
0.39) O
. O

both O
treatments O
were O
well O
tolerated O
. O

the O
incidence O
of O
drug-related O
dependent O
edema B-NEG
was O
somewhat O
higher O
in O
the O
amlodipine O
group O
, O
particularly O
at O
a O
dose O
of O
10 O
mg O
per O
day O
( O
2.4% O
for O
80 O
mg O
valsartan O
; O
3.6% O
for O
5 O
mg O
amlodipine O
; O
0% O
for O
valsartan O
plus O
5 O
mg O
amlodipine O
; O
14.3% O
for O
10 O
mg O
amlodipine) O
. O

conclusions O
: O
the O
data O
show O
that O
valsartan O
is O
at O
least O
as O
effective O
as O
amlodipine O
in O
the O
treatment O
of O
mild O
to O
moderate O
hypertension B-NEG
. O

the O
results O
also O
show O
valsartan O
to O
be O
well O
tolerated O
and O
suggest O
that O
it O
is O
not O
associated O
with O
side O
effects O
characteristic O
of O
this O
comparator O
class O
, O
dihydropyridine O
calcium O
antagonists O
. O

-DOCSTART- O

kf17837 O
: O
a O
novel O
selective O
adenosine O
a2a O
receptor O
antagonist O
with O
anticataleptic O
activity O
. O

kf17837 O
is O
a O
novel O
selective O
adenosine O
a2a O
receptor O
antagonist O
. O

oral O
administration O
of O
kf17837 O
(2.5 O
, O
10.0 O
and O
30.0 O
mg/kg O
) O
significantly O
ameliorated O
the O
cataleptic B-NEG
responses O
induced O
by O
intracerebroventricular O
administration O
of O
an O
adenosine O
a2a O
receptor O
agonist O
, O
cgs O
21680 O
( O
10 O
micrograms) O
, O
in O
a O
dose-dependent O
manner O
. O

kf17837 O
also O
reduced O
the O
catalepsy B-NEG
induced O
by O
haloperidol O
(1 O
mg/kg O
i.p. O
) O
and O
by O
reserpine O
(5 O
mg/kg O
i.p.) O
. O

these O
anticataleptic O
effects O
were O
exhibited O
dose O
dependently O
at O
doses O
from O
0.625 O
and O
2.5 O
mg/kg O
p.o. O
, O
respectively O
. O

moreover O
, O
kf17837 O
( O
0.625 O
mg/kg O
p.o. O
) O
potentiated O
the O
anticataleptic O
effects O
of O
a O
subthreshold O
dose O
of O
l-3,4-dihydroxyphenylalanine O
(l-dopa O
; O
25 O
mg/kg O
i.p. O
) O
plus O
benserazide O
( O
6.25 O
mg/kg O
i.p.) O
. O

these O
results O
suggested O
that O
kf17837 O
is O
a O
centrally O
active O
adenosine O
a2a O
receptor O
antagonist O
and O
that O
the O
dopaminergic O
function O
of O
the O
nigrostriatal O
pathway O
is O
potentiated O
by O
adenosine O
a2a O
receptor O
antagonists O
. O

furthermore O
, O
kf17837 O
may O
be O
a O
useful O
drug O
in O
the O
treatment O
of O
parkinsonism B-NEG
. O

-DOCSTART- O

some O
central O
effects O
of O
repeated O
treatment O
with O
fluvoxamine O
. O

we O
investigated O
the O
effect O
of O
repeated O
treatment O
with O
fluvoxamine O
, O
a O
selective O
serotonin O
uptake O
inhibitor O
, O
on O
behavioral O
effects O
of O
dopaminomimetics O
and O
methoxamine O
and O
on O
the O
animal O
behavior O
in O
the O
behavioral O
despair O
test O
. O

a O
repeated O
treatment O
with O
fluvoxamine O
( O
twice O
daily O
for O
14 O
days O
) O
potentiated O
in O
mice O
and O
in O
rats O
( O
weaker O
) O
the O
amphetamine-induced O
hyperactivity B-NEG
. O

the O
hyperactivity B-NEG
induced O
by O
nomifensine O
in O
mice O
remained O
unaffected O
by O
fluvoxamine O
. O

the O
stimulation O
of O
locomotor O
activity O
by O
intracerebroventricularly O
administered O
methoxamine O
was O
not O
affected O
by O
repeated O
treatment O
with O
fluvoxamine O
. O

given O
three O
times O
fluvoxamine O
had O
no O
effect O
on O
the O
immobilization O
time O
in O
the O
behavioral O
despair O
test O
in O
rats O
. O

the O
results O
indicate O
that O
fluvoxamine O
given O
repeatedly O
acts O
differently O
than O
citalopram O
, O
another O
selective O
serotonin O
uptake O
inhibitor O
, O
and O
differs O
also O
from O
other O
antidepressant O
drugs O
. O

-DOCSTART- O

severe O
congestive B-NEG
heart I-NEG
failure I-NEG
patient O
on O
amiodarone O
presenting O
with O
myxedemic B-NEG
coma I-NEG
: O
a O
case O
report O
. O

this O
is O
a O
case O
report O
of O
myxedema B-NEG
coma I-NEG
secondary O
to O
amiodarone-induced O
hypothyroidism B-NEG
in O
a O
patient O
with O
severe O
congestive B-NEG
heart I-NEG
failure I-NEG
( O
chf B-NEG
). O

to O
our O
knowledge O
and O
after O
reviewing O
the O
literature O
there O
is O
one O
case O
report O
of O
myxedema B-NEG
coma I-NEG
during O
long O
term O
amiodarone O
therapy O
. O
myxedema B-NEG
coma I-NEG
is O
a O
life O
threatening O
condition O
that O
carries O
a O
mortality O
reaching O
as O
high O
as O
20% O
with O
treatment O
. O

the O
condition O
is O
treated O
with O
intravenous O
thyroxine O
( O
t4 O
) O
or O
intravenous O
tri-iodo-thyronine O
(t3) O
. O

patients O
with O
chf B-NEG
on O
amiodarone O
may O
suffer O
serious O
morbidity O
and O
mortality O
from O
hypothyroidism B-NEG
, O
and O
thus O
may O
deserve O
closer O
follow O
up O
for O
thyroid O
stimulating O
hormone O
( O
tsh O
) O
levels O
. O

this O
case O
report O
carries O
an O
important O
clinical O
application O
given O
the O
frequent O
usage O
of O
amiodarone O
among O
chf B-NEG
patients O
. O

the O
myriad O
clinical O
presentation O
of O
myxedema B-NEG
coma I-NEG
and O
its O
serious O
morbidity O
and O
mortality O
stresses O
the O
need O
to O
suspect O
this O
clinical O
syndrome O
among O
chf B-NEG
patients O
presenting O
with O
hypotension B-NEG
, O
weakness B-NEG
or O
other O
unexplained O
symptoms O
. O

-DOCSTART- O

fear-potentiated O
startle B-NEG
, O
but O
not O
light-enhanced O
startle B-NEG
, O
is O
enhanced O
by O
anxiogenic O
drugs O
. O

rationale O
and O
objectives O
: O
the O
light-enhanced O
startle B-NEG
paradigm O
( O
les O
) O
is O
suggested O
to O
model O
anxiety B-NEG
, O
because O
of O
the O
non-specific O
cue O
and O
the O
long-term O
effect O
. O

in O
contrast O
, O
the O
fear-potentiated O
startle B-NEG
( O
fps O
) O
is O
suggested O
to O
model O
conditioned O
fear O
. O

however O
, O
the O
pharmacological O
profiles O
of O
these O
two O
paradigms O
are O
very O
similar O
. O

the O
present O
study O
investigated O
the O
effects O
of O
putative O
anxiogenic O
drugs O
on O
les O
and O
fps O
and O
aimed O
at O
determining O
the O
sensitivity O
of O
les O
for O
anxiogenic O
drugs O
and O
to O
potentially O
showing O
a O
pharmacological O
differentiation O
between O
these O
two O
paradigms O
. O

methods O
: O
male O
wistar O
rats O
received O
each O
dose O
of O
the O
alpha(2)-adrenoceptor O
antagonist O
yohimbine O
(0.25-1.0mg/kg) O
, O
the O
5-ht(2c O
) O
receptor O
agonist O
m-chlorophenylpiperazine O
(mcpp O
, O
0.5-2.0mg/kg O
) O
or O
the O
gaba(a O
) O
inverse O
receptor O
agonist O
pentylenetetrazole O
(ptz O
, O
3-30mg/kg O
) O
and O
were O
subsequently O
tested O
in O
either O
les O
or O
fps O
. O

results O
: O
none O
of O
the O
drugs O
enhanced O
les O
, O
whereas O
mcpp O
increased O
percentage O
fps O
and O
yohimbine O
increased O
absolute O
fps O
values O
. O

furthermore O
, O
yohimbine O
increased O
baseline O
startle B-NEG
amplitude O
in O
the O
les O
, O
while O
mcpp O
suppressed O
baseline O
startle B-NEG
in O
both O
the O
les O
and O
fps O
and O
ptz O
suppressed O
baseline O
startle B-NEG
in O
the O
fps O
. O

conclusions O
: O
in O
contrast O
to O
findings O
in O
the O
fps O
paradigm O
, O
none O
of O
the O
drugs O
were O
able O
to O
exacerbate O
the O
les O
response O
. O

thus O
, O
a O
clear O
pharmacological O
differentiation O
was O
found O
between O
les O
and O
fps O
. O

-DOCSTART- O

proteinase O
3-antineutrophil O
cytoplasmic O
antibody-(pr3-anca O
) O
positive O
necrotizing O
glomerulonephritis B-NEG
after O
restarting O
sulphasalazine O
treatment O
. O

a O
59-year-old O
woman O
with O
ulcerative B-NEG
colitis I-NEG
developed O
red B-NEG
eyes I-NEG
, O
pleural B-NEG
effusion I-NEG
, O
eosinophilia B-NEG
and O
urinary B-NEG
abnormalities I-NEG
after O
restarting O
of O
sulphasalazine O
treatment O
. O

light O
microscopy O
of O
a O
kidney O
biopsy O
revealed O
segmental B-NEG
necrotizing I-NEG
glomerulonephritis I-NEG
without O
deposition O
of O
immunoglobulin O
or O
complement O
. O

proteinase O
3-antineutrophil O
cytoplasmic O
antibody O
( O
pr3-anca O
) O
titer O
was O
elevated O
at O
183 O
elisa O
units O
( O
eu O
) O
in O
sera O
( O
normal O
range O
less O
than O
10 O
eu) O
, O
myeloperoxidase-anca O
was O
negative O
. O

pr3-anca O
titer O
was O
250 O
and O
1,070 O
eu O
in O
pleural B-NEG
effusions I-NEG
on O
right O
and O
left O
side O
, O
respectively O
. O

although O
cessation O
of O
sulphasalazine O
treatment O
resulted O
in O
improvements O
in O
fever B-NEG
, O
red B-NEG
eyes I-NEG
, O
chest B-NEG
pain I-NEG
, O
titer O
of O
c-reactive O
protein O
and O
volume O
of O
the O
pleural B-NEG
effusions I-NEG
, O
we O
initiated O
steroid O
therapy O
, O
because O
pr3-anca O
titer O
rose O
to O
320 O
eu O
, O
eosinophil O
count O
increased O
to O
1,100 O
cells/microl O
, O
and O
the O
pleural B-NEG
effusion I-NEG
remained O
. O

one O
month O
after O
steroid O
therapy O
, O
the O
pleural B-NEG
effusion I-NEG
disappeared O
, O
and O
pr3-anca O
titer O
normalized O
3 O
months O
later O
. O

this O
case O
suggests O
that O
sulphasalazine O
can O
induce O
pr3-anca-positive O
necrotizing O
glomerulonephritis B-NEG
. O

-DOCSTART- O

is O
phenytoin O
administration O
safe O
in O
a O
hypothermic B-NEG
child? O

a O
male O
neonate O
with O
a O
chiari B-NEG
malformation I-NEG
and O
a O
leaking O
myelomeningocoele O
underwent O
ventriculoperitoneal O
shunt O
insertion O
followed O
by O
repair O
of O
myelomeningocoele O
. O

during O
anaesthesia O
and O
surgery O
, O
he O
inadvertently O
became O
moderately O
hypothermic B-NEG
. O

intravenous O
phenytoin O
was O
administered O
during O
the O
later O
part O
of O
the O
surgery O
for O
seizure B-NEG
prophylaxis O
. O

following O
phenytoin O
administration O
, O
the O
patient O
developed O
acute O
severe O
bradycardia B-NEG
, O
refractory O
to O
atropine O
and O
adrenaline O
. O

the O
cardiac O
depressant O
actions O
of O
phenytoin O
and O
hypothermia B-NEG
can O
be O
additive O
. O

administration O
of O
phenytoin O
in O
the O
presence O
of O
hypothermia B-NEG
may O
lead O
to O
an O
adverse O
cardiac O
event O
in O
children O
. O

as O
phenytoin O
is O
a O
commonly O
used O
drug O
, O
clinicians O
need O
to O
be O
aware O
of O
this O
interaction O
. O

-DOCSTART- O

amisulpride O
related O
tic-like B-NEG
symptoms I-NEG
in O
an O
adolescent O
schizophrenic B-NEG
. O
tic B-NEG
disorders I-NEG
can O
be O
effectively O
treated O
by O
atypical O
antipsychotics O
such O
as O
risperidone O
, O
olanzapine O
and O
ziprasidone O
. O

however O
, O
there O
are O
two O
case O
reports O
that O
show O
tic-like B-NEG
symptoms I-NEG
, O
including O
motor O
and O
phonic O
variants O
, O
occurring O
during O
treatment O
with O
quetiapine O
or O
clozapine O
. O

we O
present O
a O
15-year-old O
girl O
schizophrenic B-NEG
who O
developed O
frequent O
involuntary B-NEG
eye-blinking I-NEG
movements I-NEG
after O
5 O
months O
of O
amisulpride O
treatment O
( O
1000 O
mg O
per O
day) O
. O

the O
tic-like B-NEG
symptoms I-NEG
resolved O
completely O
after O
we O
reduced O
the O
dose O
of O
amisulpride O
down O
to O
800 O
mg O
per O
day O
. O

however O
, O
her O
psychosis B-NEG
recurred O
after O
the O
dose O
reduction O
. O

we O
then O
placed O
her O
on O
an O
additional O
100 O
mg O
per O
day O
of O
quetiapine O
. O

she O
has O
been O
in O
complete O
remission O
under O
the O
combined O
medications O
for O
more O
than O
one O
year O
and O
maintains O
a O
fair O
role O
function O
. O

no O
more O
tic-like B-NEG
symptoms I-NEG
or O
other O
side O
effects O
have O
been O
reported O
. O

together O
with O
previously O
reported O
cases O
, O
our O
patient O
suggests O
that O
tic-like B-NEG
symptoms I-NEG
might O
occur O
in O
certain O
vulnerable O
individuals O
during O
treatment O
with O
atypical O
antipsychotics O
such O
as O
quetiapine O
, O
clozapine O
, O
or O
amisulpride O
. O

-DOCSTART- O

comparison O
of O
developmental O
toxicology O
of O
aspirin O
( O
acetylsalicylic O
acid O
) O
in O
rats O
using O
selected O
dosing O
paradigms O
. O

background O
: O
analysis O
of O
the O
literature O
for O
nonsteroidal O
anti-inflammatory O
drugs O
( O
nsaids O
) O
suggests O
that O
a O
low O
incidence O
of O
developmental B-NEG
anomalies I-NEG
occurs O
in O
rats O
given O
nsaids O
on O
specific O
days O
during O
organogenesis O
. O

aspirin O
( O
acetylsalicylic O
acid O
[asa]) O
, O
an O
irreversible O
cyclooxygenase O
1 O
and O
2 O
inhibitor O
, O
induces O
developmental B-NEG
anomalies I-NEG
when O
administered O
to O
wistar O
rats O
on O
gestational O
day O
( O
gd O
) O
9, O
10 O
, O
or O
11 O
( O
kimmel O
ca O
, O
wilson O
jg O
, O
schumacher O
hj O
. O
teratology O
4:15-24 O
, O
1971) O
. O

there O
are O
no O
published O
asa O
studies O
using O
the O
multiple O
dosing O
paradigm O
of O
gds O
6 O
to O
17 O
. O

objectives O
of O
the O
current O
study O
were O
to O
compare O
results O
between O
sprague-dawley O
( O
sd O
) O
and O
wistar O
strains O
when O
asa O
is O
administered O
on O
gd O
9, O
10 O
, O
or O
11 O
; O
to O
compare O
the O
malformation O
patterns O
following O
single O
and O
multiple O
dosings O
during O
organogenesis O
in O
sd O
rats O
; O
and O
to O
test O
the O
hypothesis O
that O
maternal O
gastrointestinal B-NEG
toxicity I-NEG
confounds O
the O
detection O
of O
low O
incidence O
malformations B-NEG
with O
asa O
when O
a O
multiple O
dosing O
paradigm O
is O
used O
. O

methods O
: O
asa O
was O
administered O
as O
a O
single O
dose O
on O
gd O
9 O
(0 O
, O
250 O
, O
500 O
, O
or O
625 O
mg/kg) O
, O
10 O
(0 O
, O
500 O
, O
625 O
, O
or O
750 O
mg/kg) O
, O
or O
11 O
(0 O
, O
500 O
, O
750 O
, O
or O
1000 O
mg/kg O
) O
and O
from O
gd O
6 O
to O
gd O
17 O
(0 O
, O
50 O
, O
125 O
, O
or O
250 O
mg/kg O
a O
day O
) O
in O
the O
multiple O
dose O
study O
to O
sd O
rats O
. O

animals O
were O
killed O
on O
gd O
21 O
, O
and O
fetuses O
were O
examined O
viscerally O
. O

results O
: O
the O
literature O
evaluation O
suggested O
that O
nsaids O
induce O
ventricular B-NEG
septal I-NEG
defects I-NEG
( O
vsds B-NEG
) O
and O
midline B-NEG
defects I-NEG
( O
mds B-NEG
) O
in O
rats O
and O
diaphragmatic B-NEG
hernia I-NEG
( O
dh B-NEG
), O
mds B-NEG
, O
and O
vsds B-NEG
in O
rabbits O
( O
cook O
jc O
et O
al. O
, O
2003) O
; O
hence O
, O
the O
present O
study O
focused O
on O
these O
malformations B-NEG
, O
even O
though O
asa O
induces O
several O
other O
low-incidence O
malformations B-NEG
. O

in O
single O
dose O
studies O
, O
dh B-NEG
, O
md B-NEG
, O
and O
vsd B-NEG
were O
induced O
on O
gds O
9 O
and O
10 O
. O
vsd B-NEG
also O
was O
noted O
following O
treatment O
on O
gd O
11 O
. O

in O
contrast O
, O
dh B-NEG
and O
md B-NEG
were O
noted O
in O
the O
multiple O
dose O
study O
design O
only O
in O
the O
high-dose O
group O
, O
and O
vsd B-NEG
was O
noted O
across O
all O
dose O
groups O
. O

conclusions O
: O
high O
concordance O
in O
major O
developmental B-NEG
anomalies I-NEG
between O
wistar O
and O
sd O
rats O
were O
noted O
with O
the O
exception O
of O
vsd B-NEG
in O
the O
sd O
rats O
and O
hydrocephalus B-NEG
in O
the O
wistar O
rats O
. O

variations O
and O
malformations B-NEG
were O
similar O
when O
asa O
was O
administered O
as O
a O
single O
dose O
or O
during O
the O
period O
of O
organogenesis O
( O
gds O
6 O
to O
17) O
. O

it O
was O
also O
evident O
that O
, O
by O
titrating O
the O
dose O
to O
achieve O
a O
maximum O
tolerated O
dose O
, O
malformations B-NEG
that O
normally O
occur O
at O
low O
incidence O
, O
as O
reported O
from O
previous O
single O
dose O
studies O
, O
could O
also O
be O
induced O
with O
asa O
given O
at O
multiple O
doses O
. O

-DOCSTART- O

torsade B-NEG
de I-NEG
pointes I-NEG
induced O
by O
metoclopramide O
in O
an O
elderly O
woman O
with O
preexisting O
complete O
left B-NEG
bundle I-NEG
branch I-NEG
block I-NEG
. O

there O
is O
a O
growing O
list O
of O
drugs O
implicated O
in O
acquired O
long B-NEG
qt I-NEG
syndrome I-NEG
and O
torsade B-NEG
de I-NEG
pointes I-NEG
. O

however O
, O
the O
torsadogenic O
potential O
of O
metoclopramide O
, O
a O
commonly O
used O
antiemetic O
and O
prokinetic O
drug O
, O
has O
not O
been O
reported O
in O
the O
literature O
, O
despite O
its O
chemical O
similarity O
to O
procainamide O
. O

we O
report O
on O
a O
92-year-old O
woman O
with O
preexisting O
complete O
left B-NEG
bundle I-NEG
branch I-NEG
block I-NEG
who O
developed O
torsade B-NEG
de I-NEG
pointes I-NEG
after O
intravenous O
and O
oral O
administration O
of O
metoclopramide O
. O

this O
patient O
also O
developed O
torsade B-NEG
de I-NEG
pointes I-NEG
when O
cisapride O
and O
erythromycin O
were O
given O
simultaneously O
. O

these O
two O
episodes O
were O
suppressed O
successfully O
after O
discontinuing O
the O
offending O
drugs O
and O
administering O
class O
ib O
drugs O
. O

this O
is O
the O
first O
documentation O
that O
metoclopramide O
provokes O
torsade B-NEG
de I-NEG
pointes I-NEG
clinically O
. O

metoclopramide O
should O
be O
used O
cautiously O
in O
patients O
with O
a O
risk O
of O
torsade B-NEG
de I-NEG
pointes I-NEG
. O

-DOCSTART- O

apomorphine O
: O
an O
underutilized O
therapy O
for O
parkinson's B-NEG
disease I-NEG
. O

apomorphine O
was O
the O
first O
dopaminergic O
drug O
ever O
used O
to O
treat O
symptoms O
of O
parkinson's B-NEG
disease I-NEG
. O

while O
powerful O
antiparkinsonian O
effects O
had O
been O
observed O
as O
early O
as O
1951 O
, O
the O
potential O
of O
treating O
fluctuating O
parkinson's B-NEG
disease I-NEG
by O
subcutaneous O
administration O
of O
apomorphine O
has O
only O
recently O
become O
the O
subject O
of O
systematic O
study O
. O

a O
number O
of O
small O
scale O
clinical O
trials O
have O
unequivocally O
shown O
that O
intermittent O
subcutaneous O
apomorphine O
injections O
produce O
antiparkinsonian O
benefit O
close O
if O
not O
identical O
to O
that O
seen O
with O
levodopa O
and O
that O
apomorphine O
rescue O
injections O
can O
reliably O
revert O
off-periods O
even O
in O
patients O
with O
complex O
on-off O
motor O
swings O
. O

continuous O
subcutaneous O
apomorphine O
infusions O
can O
reduce O
daily O
off-time O
by O
more O
than O
50% O
in O
this O
group O
of O
patients O
, O
which O
appears O
to O
be O
a O
stronger O
effect O
than O
that O
generally O
seen O
with O
add-on O
therapy O
with O
oral O
dopamine O
agonists O
or O
comt O
inhibitors O
. O

extended O
follow-up O
studies O
of O
up O
to O
8 O
years O
have O
demonstrated O
long-term O
persistence O
of O
apomorphine O
efficacy O
. O

in O
addition O
, O
there O
is O
convincing O
clinical O
evidence O
that O
monotherapy O
with O
continuous O
subcutaneous O
apomorphine O
infusions O
is O
associated O
with O
marked O
reductions O
of O
preexisting O
levodopa-induced O
dyskinesias B-NEG
. O

the O
main O
side O
effects O
of O
subcutaneous O
apomorphine O
treatment O
are O
related O
to O
cutaneous O
tolerability O
problems O
, O
whereas O
sedation O
and O
psychiatric B-NEG
complications O
play O
a O
lesser O
role O
. O

given O
the O
marked O
degree O
of O
efficacy O
of O
subcutaneous O
apomorphine O
treatment O
in O
fluctuating O
parkinson's B-NEG
disease I-NEG
, O
this O
approach O
seems O
to O
deserve O
more O
widespread O
clinical O
use O
. O

-DOCSTART- O

fatal O
excited O
delirium B-NEG
following O
cocaine O
use O
: O
epidemiologic O
findings O
provide O
new O
evidence O
for O
mechanisms O
of O
cocaine O
toxicity B-NEG
. O

we O
describe O
an O
outbreak O
of O
deaths O
from O
cocaine-induced O
excited O
delirium B-NEG
( O
edds B-NEG
) O
in O
dade O
county O
, O
florida O
between O
1979 O
and O
1990 O
. O

from O
a O
registry O
of O
all O
cocaine-related O
deaths O
in O
dade O
county O
, O
florida O
, O
from O
1969-1990 O
, O
58 O
edds B-NEG
were O
compared O
with O
125 O
victims O
of O
accidental O
cocaine O
overdose B-NEG
without O
excited O
delirium B-NEG
. O

compared O
with O
controls O
, O
edds B-NEG
were O
more O
frequently O
black O
, O
male O
, O
and O
younger O
. O

they O
were O
less O
likely O
to O
have O
a O
low O
body O
mass O
index O
, O
and O
more O
likely O
to O
have O
died O
in O
police O
custody O
, O
to O
have O
received O
medical O
treatment O
immediately O
before O
death O
, O
to O
have O
survived O
for O
a O
longer O
period O
, O
to O
have O
developed O
hyperthermia B-NEG
, O
and O
to O
have O
died O
in O
summer O
months O
. O
edds B-NEG
had O
concentrations O
of O
cocaine O
and O
benzoylecgonine O
in O
autopsy O
blood O
that O
were O
similar O
to O
those O
for O
controls O
. O

the O
epidemiologic O
findings O
are O
most O
consistent O
with O
the O
hypothesis O
that O
chronic O
cocaine O
use O
disrupts O
dopaminergic O
function O
and O
, O
when O
coupled O
with O
recent O
cocaine O
use O
, O
may O
precipitate O
agitation B-NEG
, O
delirium B-NEG
, O
aberrant O
thermoregulation O
, O
rhabdomyolysis B-NEG
, O
and O
sudden B-NEG
death I-NEG
. O

-DOCSTART- O

heparin-induced O
thrombocytopenia B-NEG
, O
thrombosis B-NEG
, O
and O
hemorrhage B-NEG
. O

sixty-two O
patients O
with O
a O
heparin-induced O
thrombocytopenia B-NEG
are O
reported O
. O

clinical O
manifestations O
of O
this O
disorder O
include O
hemorrhage B-NEG
or O
, O
more O
frequently O
, O
thromboembolic B-NEG
events O
in O
patients O
receiving O
heparin O
. O

laboratory O
testing O
has O
revealed O
a B-NEG
falling I-NEG
platelet I-NEG
count I-NEG
, O
increased O
resistance O
to O
heparin O
, O
and O
aggregation O
of O
platelets O
by O
the O
patient's O
plasma O
when O
heparin O
is O
added O
. O

immunologic O
testing O
has O
demonstrated O
the O
presence O
of O
a O
heparin-dependent O
platelet O
membrane O
antibody O
. O

the O
20 O
deaths O
, O
52 O
hemorrhagic B-NEG
and I-NEG
thromboembolic I-NEG
complications I-NEG
, O
and O
21 O
surgical O
procedures O
to O
manage O
the O
complications O
confirm O
the O
seriousness O
of O
the O
disorder O
. O

specific O
risk O
factors O
have O
not O
been O
identified O
; O
therefore O
, O
all O
patients O
receiving O
heparin O
should O
be O
monitored O
. O

if O
the O
platelet O
count O
falls O
to O
less O
than O
100,000/mm3 O
, O
while O
the O
patient O
is O
receiving O
heparin O
, O
platelet B-NEG
aggregation I-NEG
testing O
, O
using O
the O
patient's O
plasma O
, O
is O
indicated O
. O

management O
consists O
of O
cessation O
of O
heparin O
, O
platelet O
anti-aggregating O
agents O
, O
and O
alternate O
forms O
of O
anticoagulation O
when O
indicated O
. O

-DOCSTART- O

cardiac B-NEG
toxicity I-NEG
of O
5-fluorouracil O
. O

report O
of O
a O
case O
of O
spontaneous O
angina B-NEG
. O

we O
report O
a O
case O
of O
a O
patient O
with O
colon B-NEG
carcinoma I-NEG
and O
liver O
metastasis B-NEG
who O
presented O
chest B-NEG
pain I-NEG
after O
5-fluorouracil O
( O
5-fu O
) O
administration O
. O

clinical O
electrocardiographic O
evolution O
was O
similar O
to O
that O
observed O
in O
prinzmetal's B-NEG
angina I-NEG
, O
and O
chest B-NEG
pain I-NEG
promptly O
resolved O
with O
nifedipine O
. O

these O
data O
suggest O
that O
coronary B-NEG
spasm I-NEG
may O
be O
the O
cause O
of O
cardiotoxicity B-NEG
due O
to O
5-fu O
, O
and O
that O
calcium O
antagonists O
may O
probably O
be O
used O
in O
the O
prevention O
or O
treatment O
of O
5-fu O
cardiotoxicity B-NEG
. O

-DOCSTART- O

toxicity B-NEG
due O
to O
remission O
inducing O
drugs O
in O
rheumatoid B-NEG
arthritis I-NEG
. O

association O
with O
hla-b35 O
and O
cw4 O
antigens O
. O

twenty-five O
patients O
with O
rheumatoid B-NEG
arthritis I-NEG
( O
ra B-NEG
) O
who O
developed O
toxicity B-NEG
while O
taking O
remission O
inducing O
drugs O
and O
30 O
without O
toxicity B-NEG
were O
studied O
for O
possible O
associations O
with O
class O
i O
and O
ii O
hla O
antigens O
. O

a O
strong O
association O
has O
been O
found O
between O
nephritis B-NEG
and O
dermatitis B-NEG
due O
to O
tiopronin O
(a O
d-penicillamine O
like O
compound O
) O
and O
class O
i O
antigens O
b35-cw4 O
, O
and O
between O
dermatitis B-NEG
due O
to O
gold O
thiosulphate O
and O
b35 O
. O

compared O
to O
healthy O
controls O
a O
lower O
dr5 O
frequency O
was O
observed O
in O
patients O
with O
ra B-NEG
except O
for O
the O
tiopronin O
related O
nephritis B-NEG
group O
. O

-DOCSTART- O

transient O
hemiparesis B-NEG
: O
a O
rare O
manifestation O
of O
diphenylhydantoin O
toxicity B-NEG
. O

report O
of O
two O
cases O
. O

among O
the O
common O
side O
effects O
of O
diphenylhydantoin O
( O
dph O
) O
overdose B-NEG
, O
the O
most O
frequently O
encountered O
neurological O
signs O
are O
those O
of O
cerebellar B-NEG
dysfunction I-NEG
. O

very O
rarely O
, O
the O
toxic O
neurological O
manifestations O
of O
this O
drug O
are O
of O
cerebral O
origin O
. O

two O
patients O
are O
presented O
who O
suffered O
progressive O
hemiparesis B-NEG
due O
to O
dph O
overdose B-NEG
. O

both O
had O
brain O
surgery O
before O
dph O
treatment O
. O

it O
is O
assumed O
that O
patients O
with O
some O
cerebral B-NEG
damage I-NEG
are O
liable O
to O
manifest O
dph O
toxicity B-NEG
as O
focal O
neurological O
signs O
. O

-DOCSTART- O

nerve O
growth O
factor O
and O
prostaglandins O
in O
the O
urine O
of O
female O
patients O
with O
overactive B-NEG
bladder I-NEG
. O

purpose O
: O
ngf O
and O
pgs O
in O
the O
bladder O
can O
be O
affected O
by O
pathological O
changes O
in O
the O
bladder O
and O
these O
changes O
can O
be O
detected O
in O
urine O
. O

we O
investigated O
changes O
in O
urinary O
ngf O
and O
pgs O
in O
women O
with O
oab B-NEG
. O

materials O
and O
methods O
: O
the O
study O
groups O
included O
65 O
women O
with O
oab B-NEG
and O
20 O
without O
bladder O
symptoms O
who O
served O
as O
controls O
. O

evaluation O
included O
patient O
history O
, O
urinalysis O
, O
a O
voiding O
diary O
and O
urodynamic O
studies O
. O

urine O
samples O
were O
collected O
. O

ngf O
, O
pge2 O
, O
pgf2alpha O
and O
pgi2 O
were O
measured O
using O
enzyme-linked O
immunosorbent O
assay O
and O
compared O
between O
the O
groups O
. O

in O
addition O
, O
correlations O
between O
urinary O
ngf O
and O
pg O
, O
and O
urodynamic O
parameters O
in O
patients O
with O
oab B-NEG
were O
examined O
. O

results O
: O
urinary O
ngf O
, O
pge2 O
and O
pgf2alpha O
were O
significantly O
increased O
in O
patients O
with O
oab B-NEG
compared O
with O
controls O
(p O
<0.05) O
. O

however O
, O
urinary O
pgi2 O
was O
not O
different O
between O
controls O
and O
patients O
with O
oab B-NEG
. O

in O
patients O
with O
oab B-NEG
urinary O
pge2 O
positively O
correlated O
with O
volume O
at O
first O
desire O
to O
void O
and O
maximum O
cystometric O
capacity O
(p O
<0.05) O
. O

urinary O
ngf O
, O
pgf2alpha O
and O
pgi2 O
did O
not O
correlate O
with O
urodynamic O
parameters O
in O
patients O
with O
oab B-NEG
. O

conclusions O
: O
ngf O
and O
pgs O
have O
important O
roles O
in O
the O
development O
of O
oab B-NEG
symptoms O
in O
female O
patients O
. O

urinary O
levels O
of O
these O
factors O
may O
be O
used O
as O
markers O
to O
evaluate O
oab B-NEG
symptoms O
. O

-DOCSTART- O

acute O
low B-NEG
back I-NEG
pain I-NEG
during O
intravenous O
administration O
of O
amiodarone O
: O
a O
report O
of O
two O
cases O
. O

amiodarone O
represents O
an O
effective O
antiarrhythmic O
drug O
for O
cardioversion O
of O
recent-onset O
atrial B-NEG
fibrillation I-NEG
( O
af B-NEG
) O
and O
maintenance O
of O
sinus O
rhythm O
. O

we O
briefly O
describe O
two O
patients O
suffering O
from O
recent-onset O
atrial B-NEG
fibrillation I-NEG
, O
who O
experienced O
an O
acute O
devastating O
low B-NEG
back I-NEG
pain I-NEG
a O
few O
minutes O
after O
initiation O
of O
intravenous O
amiodarone O
loading O
. O

notably O
, O
this O
side O
effect O
has O
not O
been O
ever O
reported O
in O
the O
medical O
literature O
. O

clinicians O
should O
be O
aware O
of O
this O
reaction O
since O
prompt O
termination O
of O
parenteral O
administration O
leads O
to O
complete O
resolution O
. O

-DOCSTART- O

postoperative B-NEG
myalgia I-NEG
after O
succinylcholine O
: O
no O
evidence O
for O
an O
inflammatory O
origin O
. O

a O
common O
side O
effect O
associated O
with O
succinylcholine O
is O
postoperative B-NEG
myalgia I-NEG
. O

the O
pathogenesis O
of O
this O
myalgia B-NEG
is O
still O
unclear O
; O
inflammation B-NEG
has O
been O
suggested O
but O
without O
convincing O
evidence O
. O

we O
designed O
the O
present O
study O
to O
investigate O
whether O
an O
inflammatory O
reaction O
contributes O
to O
this O
myalgia B-NEG
. O

the O
incidence O
and O
severity O
of O
succinylcholine-associated O
myalgia B-NEG
was O
determined O
in O
64 O
patients O
pretreated O
with O
saline O
or O
dexamethasone O
before O
succinylcholine O
(n O
= O
32 O
for O
each) O
. O

incidence O
and O
severity O
of O
myalgia B-NEG
did O
not O
differ O
significantly O
between O
the O
two O
groups O
: O
15 O
patients O
in O
the O
dexamethasone O
group O
complained O
of O
myalgia B-NEG
compared O
with O
18 O
patients O
in O
the O
saline O
group O
, O
and O
severe O
myalgia B-NEG
was O
reported O
by O
five O
patients O
and O
three O
patients O
, O
respectively O
( O
not O
significant) O
. O

at O
48 O
h O
after O
surgery O
, O
12 O
patients O
in O
both O
groups O
still O
suffered O
from O
myalgia B-NEG
( O
not O
significant) O
. O

in O
addition O
, O
interleukin-6 O
( O
il-6 O
) O
as O
an O
early O
marker O
of O
inflammation B-NEG
was O
assessed O
in O
a O
subgroup O
of O
10 O
patients O
pretreated O
with O
saline O
. O

we O
found O
an O
increase O
of O
il-6 O
for O
only O
three O
patients O
, O
but O
only O
one O
patient O
reported O
myalgia B-NEG
; O
no O
relationship O
between O
myalgia B-NEG
and O
the O
increase O
of O
il-6 O
was O
found O
. O

in O
conclusion O
, O
there O
is O
no O
evidence O
for O
an O
inflammatory O
origin O
of O
succinylcholine-associated O
myalgia B-NEG
. O

implications O
: O
administration O
of O
dexamethasone O
before O
succinylcholine O
was O
not O
effective O
in O
decreasing O
the O
incidence O
or O
the O
severity O
of O
succinylcholine-induced O
postoperative B-NEG
myalgia I-NEG
. O

furthermore O
, O
there O
was O
no O
significant O
relationship O
between O
postoperative B-NEG
myalgia I-NEG
and O
time O
course O
of O
interleukin-6 O
concentrations O
, O
a O
marker O
of O
inflammation B-NEG
. O

pretreatment O
with O
dexamethasone O
is O
not O
justified O
to O
prevent O
postoperative B-NEG
myalgia I-NEG
after O
succinylcholine O
. O

-DOCSTART- O

levodopa-induced O
oromandibular O
dystonia B-NEG
in O
progressive B-NEG
supranuclear I-NEG
palsy I-NEG
. O

levodopa-induced O
dyskinesias B-NEG
have O
been O
reported O
in O
parkinson's B-NEG
disease I-NEG
and O
multiple B-NEG
system I-NEG
atrophy I-NEG
. O

cranial O
dystonias B-NEG
are O
rare O
in O
patients O
with O
progressive B-NEG
supranuclear I-NEG
palsy I-NEG
( O
psp B-NEG
). O

in O
this O
report O
we O
describe O
an O
unusual O
case O
of O
reversible O
levodopa-induced O
oromandibular B-NEG
dystonia I-NEG
( O
omd B-NEG
) O
in O
a O
psp B-NEG
patient O
to O
highlight O
the O
importance O
of O
recognizing O
this O
drug O
related O
complication O
in O
the O
management O
of O
psp B-NEG
, O
and O
discuss O
the O
possible O
underlying O
pathophysiology O
. O

-DOCSTART- O

protective O
effect O
of O
edaravone O
against O
streptomycin-induced O
vestibulotoxicity B-NEG
in O
the O
guinea O
pig O
. O

this O
study O
investigated O
alleviation O
of O
streptomycin-induced O
vestibulotoxicity B-NEG
by O
edaravone O
in O
guinea O
pigs O
. O

edaravone O
, O
a O
free O
radical O
scavenger O
, O
has O
potent O
free O
radical O
quenching O
action O
and O
is O
used O
in O
clinical O
practice O
to O
treat O
cerebral B-NEG
infarction I-NEG
. O

streptomycin O
was O
administered O
to O
the O
inner O
ear O
by O
osmotic O
pump O
for O
24 O
h, O
and O
edaravone O
( O
n=8 O
) O
or O
saline O
( O
n=6 O
) O
was O
intraperitoneally O
injected O
once O
a O
day O
for O
7 O
days O
. O

we O
observed O
horizontal O
vestibulo-ocular O
reflex O
as O
a O
marker O
of O
postoperative O
vestibular O
function O
. O

animals O
injected O
with O
saline O
showed O
statistically O
smaller O
gains O
than O
those O
injected O
with O
edaravone O
. O

these O
results O
suggest O
that O
edaravone O
suppresses O
streptomycin-induced O
vestibulotoxicity B-NEG
. O

-DOCSTART- O

ketamine O
in O
war/tropical O
surgery O
(a O
final O
tribute O
to O
the O
racemic O
mixture) O
. O

a O
technique O
of O
continuous O
intravenous O
anaesthesia O
with O
ketamine O
was O
used O
successfully O
during O
the O
somalia O
civil O
war O
in O
1994 O
and O
in O
north O
uganda O
in O
1999 O
for O
64 O
operations O
in O
62 O
patients O
, O
aged O
from O
6 O
weeks O
to O
70 O
years O
, O
undergoing O
limb O
and O
abdominal O
surgery O
including O
caesarian O
sections O
and O
interventions O
in O
neonates O
. O

operations O
lasting O
up O
to O
2h O
could O
be O
performed O
in O
the O
absence O
of O
sophisticated O
equipment O
such O
as O
pulse O
oximeters O
or O
ventilators O
in O
patients O
on O
spontaneous O
ventilation O
breathing O
air/oxygen O
only O
. O

after O
premedication O
with O
diazepam O
, O
glycopyrrolate O
and O
local O
anaesthesia O
, O
and O
induction O
with O
standard O
doses O
of O
ketamine O
, O
a O
maintenance O
dose O
of O
10-20 O
microg/kg/min O
of O
ketamine O
proved O
safe O
and O
effective O
. O

emphasis O
was O
placed O
on O
bedside O
clinical O
monitoring O
, O
relying O
heavily O
on O
the O
heart O
rate O
. O

diazepam O
, O
unless O
contraindicated O
or O
risky O
, O
remains O
the O
only O
necessary O
complementary O
drug O
to O
ketamine O
as O
it O
buffers O
its O
cardiovascular O
response O
and O
decreases O
the O
duration O
and O
intensity O
of O
operative O
and O
postoperative O
hallucinations B-NEG
. O

local O
anaesthetic O
blocks O
were O
useful O
in O
decreasing O
the O
requirement O
for O
postoperative O
analgesia B-NEG
. O

an O
antisialogue O
was O
usually O
unnecessary O
in O
operations O
lasting O
up O
to O
2 O
h, O
glycopyrrolate O
being O
the O
best O
choice O
for O
its O
lowest O
psychotropic O
and O
chronotropic O
effects O
, O
especially O
in O
a O
hot O
climate O
. O

experience O
in O
war/tropical O
settings O
suggests O
this O
technique O
could O
be O
useful O
in O
civilian O
contexts O
such O
as O
outdoor O
life-saving O
emergency O
surgery O
or O
in O
mass O
casualties O
where O
, O
e.g O
. O
amputation O
and O
rapid O
extrication O
were O
required O
. O

-DOCSTART- O

steroid O
structure O
and O
pharmacological O
properties O
determine O
the O
anti- O
amnesic B-NEG
effects O
of O
pregnenolone O
sulphate O
in O
the O
passive O
avoidance O
task O
in O
rats O
. O

pregnenolone O
sulphate O
( O
pregs O
) O
has O
generated O
interest O
as O
one O
of O
the O
most O
potent O
memory-enhancing O
neurosteroids O
to O
be O
examined O
in O
rodent O
learning O
studies O
, O
with O
particular O
importance O
in O
the O
ageing O
process O
. O

the O
mechanism O
by O
which O
this O
endogenous O
steroid O
enhances O
memory O
formation O
is O
hypothesized O
to O
involve O
actions O
on O
glutamatergic O
and O
gabaergic O
systems O
. O

this O
hypothesis O
stems O
from O
findings O
that O
pregs O
is O
a O
potent O
positive O
modulator O
of O
n-methyl-d-aspartate O
receptors O
( O
nmdars O
) O
and O
a O
negative O
modulator O
of O
gamma-aminobutyric O
acid(a O
) O
receptors O
(gaba(a)rs) O
. O

moreover O
, O
pregs O
is O
able O
to O
reverse O
the O
amnesic B-NEG
-like O
effects O
of O
nmdar O
and O
gaba(a)r O
ligands O
. O

to O
investigate O
this O
hypothesis O
, O
the O
present O
study O
in O
rats O
examined O
the O
memory-altering O
abilities O
of O
structural O
analogs O
of O
pregs O
, O
which O
differ O
in O
their O
modulation O
of O
nmdar O
and/or O
gaba(a)r O
function O
. O

the O
analogs O
tested O
were O
: O
11-ketopregnenolone O
sulphate O
( O
an O
agent O
that O
is O
inactive O
at O
gaba(a)rs O
and O
nmdars) O
, O
epipregnanolone O
( O
[3beta-hydroxy-5beta-pregnan-20-one] O
sulphate O
, O
an O
inhibitor O
of O
both O
gaba(a)rs O
and O
nmdars) O
, O
and O
a O
newly O
synthesized O
( O
- O
) O
pregs O
enantiomer O
( O
which O
is O
identical O
to O
pregs O
in O
effects O
on O
gaba(a)rs O
and O
nmdars) O
. O

the O
memory-enhancing O
effects O
of O
pregs O
and O
its O
analogs O
were O
tested O
in O
the O
passive O
avoidance O
task O
using O
the O
model O
of O
scopolamine-induced O
amnesia B-NEG
. O

both O
pregs O
and O
its O
( O
- O
) O
enantiomer O
blocked O
the O
effects O
of O
scopolamine O
. O

the O
results O
show O
that O
, O
unlike O
pregs O
, O
11-ketopregnenolone O
sulphate O
and O
epipregnanolone O
sulphate O
failed O
to O
block O
the O
effect O
of O
scopolamine O
, O
suggesting O
that O
altering O
the O
modulation O
of O
nmda O
receptors O
diminishes O
the O
memory-enhancing O
effects O
of O
pregs O
. O

moreover O
, O
enantioselectivity O
was O
demonstrated O
by O
the O
ability O
of O
natural O
pregs O
to O
be O
an O
order O
of O
magnitude O
more O
effective O
than O
its O
synthetic O
enantiomer O
in O
reversing O
scopolamine-induced O
amnesia B-NEG
. O

these O
results O
identify O
a O
novel O
neuropharmacological O
site O
for O
the O
modulation O
of O
memory O
processes O
by O
neuroactive O
steroids O
. O

-DOCSTART- O

preliminary O
efficacy O
assessment O
of O
intrathecal O
injection O
of O
an O
american O
formulation O
of O
adenosine O
in O
humans O
. O

background O
: O
preclinical O
studies O
of O
intrathecal O
adenosine O
suggest O
it O
may O
be O
effective O
in O
the O
treatment O
of O
acute B-NEG
and I-NEG
chronic I-NEG
pain I-NEG
in O
humans O
, O
and O
preliminary O
studies O
in O
volunteers O
and O
patients O
with O
a O
swedish O
formulation O
of O
adenosine O
suggests O
it O
may O
be O
effective O
in O
hypersensitivity B-NEG
states O
but O
not O
with O
acute O
noxious O
stimulation O
. O

the O
purpose O
of O
this O
study O
was O
to O
screen O
for O
efficacy O
of O
a O
different O
formulation O
of O
adenosine O
marketed O
in O
the O
us O
, O
using O
both O
acute O
noxious O
stimulation O
and O
capsaicin-evoked O
mechanical O
hypersensitivity B-NEG
. O

methods O
: O
following O
food O
and O
drug O
administration O
and O
institutional O
review O
board O
approval O
and O
written O
informed O
consent O
, O
65 O
volunteers O
were O
studied O
in O
two O
trials O
: O
an O
open-label O
, O
dose-escalating O
trial O
with O
intrathecal O
adenosine O
doses O
of O
0.25-2.0 O
mg O
and O
a O
double-blind O
, O
placebo-controlled O
trial O
of O
adenosine O
, O
2 O
mg O
. O

cerebrospinal O
fluid O
was O
obtained O
for O
pharmacokinetic O
analysis O
, O
and O
pain B-NEG
ratings O
in O
response O
to O
acute O
heat O
stimuli O
and O
areas O
of O
mechanical B-NEG
hyperalgesia I-NEG
and O
allodynia B-NEG
after O
intradermal O
capsaicin O
injection O
were O
determined O
. O

results O
: O
adenosine O
produced O
no O
effect O
on O
pain B-NEG
report O
to O
acute O
noxious O
thermal O
or O
chemical O
stimulation O
but O
reduced O
mechanical B-NEG
hyperalgesia I-NEG
and O
allodynia B-NEG
from O
intradermal O
capsaicin O
injection O
for O
at O
least O
24 O
h. O

in O
contrast O
, O
residence O
time O
of O
adenosine O
in O
cerebrospinal O
fluid O
was O
short O
(< O
4 O
h) O
. O

conclusions O
: O
these O
results O
show O
selective O
inhibition O
by O
intrathecal O
adenosine O
of O
hypersensitivity B-NEG
, O
presumed O
to O
reflect O
central O
sensitization O
in O
humans O
after O
peripheral O
capsaicin O
injection O
. O

the O
long-lasting O
effect O
is O
consistent O
with O
that O
observed O
in O
preliminary O
reports O
of O
patients O
with O
chronic O
neuropathic B-NEG
pain I-NEG
and O
is O
not O
due O
to O
prolonged O
residence O
of O
adenosine O
in O
cerebrospinal O
fluid O
. O

-DOCSTART- O

effect O
of O
lithium O
maintenance O
therapy O
on O
thyroid O
and O
parathyroid O
function O
. O

objectives O
: O
to O
assess O
changes O
induced O
by O
lithium O
maintenance O
therapy O
on O
the O
incidence O
of O
thyroid O
, O
parathyroid O
and O
ion O
alterations O
. O

these O
were O
evaluated O
with O
respect O
to O
the O
duration O
of O
lithium O
therapy O
, O
age O
, O
sex O
, O
and O
family O
history O
( O
whether O
or O
not O
the O
patient O
had O
a O
first-degree O
relative O
with O
thyroid B-NEG
disease I-NEG
). O

design O
: O
prospective O
study O
. O

setting O
: O
affective O
disorders O
clinic O
at O
st O
. O
mary's O
hospital O
, O
montreal O
. O

patients O
: O
one O
hundred O
and O
one O
patients O
( O
28 O
men O
and O
73 O
women O
) O
with O
bipolar B-NEG
disorder I-NEG
receiving O
lithium O
maintenance O
therapy O
ranging O
from O
1 O
year's O
to O
32 O
years' O
duration O
. O

the O
control O
group O
consisted O
of O
82 O
patients O
with O
no O
psychiatric B-NEG
or O
endocrinological O
diagnoses O
from O
the O
hospital's O
out-patient O
clinics O
. O

outcome O
measures O
: O
laboratory O
analyses O
of O
calcium O
, O
magnesium O
and O
thyroid-stimulating O
hormone O
levels O
performed O
before O
beginning O
lithium O
therapy O
and O
at O
biannual O
follow-up O
. O

results O
: O
hypothyroidism B-NEG
developed O
in O
40 O
patients O
, O
excluding O
8 O
patients O
who O
were O
hypothyroid B-NEG
at O
baseline O
. O

all O
patients O
having O
first-degree O
relatives O
affected O
by O
thyroid B-NEG
illness I-NEG
had O
accelerated O
onset O
of O
hypothyroidism B-NEG
( O
3.7 O
years O
after O
onset O
of O
lithium O
therapy O
) O
compared O
with O
patients O
without O
a O
family O
history O
( O
8.6 O
years O
after O
onset O
of O
lithium O
therapy) O
. O

women O
over O
60 O
years O
of O
age O
were O
more O
often O
affected O
by O
hypothyroidism B-NEG
than O
women O
under O
60 O
years O
of O
age O
( O
34.6% O
versus O
31.9%) O
. O

magnesium O
levels O
in O
patients O
on O
lithium O
treatment O
were O
unchanged O
from O
baseline O
levels O
. O

after O
lithium O
treatment O
, O
calcium O
levels O
were O
higher O
than O
either O
baseline O
levels O
or O
control O
levels O
. O

thus O
, O
lithium O
treatment O
counteracted O
the O
decrease O
in O
plasma O
calcium O
levels O
associated O
with O
aging O
. O

conclusions O
: O
familial O
thyroid B-NEG
illness I-NEG
is O
a O
risk O
factor O
for O
hypothyroidism B-NEG
and O
hypercalcemia B-NEG
during O
lithium O
therapy O
. O

-DOCSTART- O

systemic O
toxicity B-NEG
following O
administration O
of O
sirolimus O
( O
formerly O
rapamycin O
) O
for O
psoriasis B-NEG
: O
association O
of O
capillary B-NEG
leak I-NEG
syndrome I-NEG
with O
apoptosis O
of O
lesional O
lymphocytes O
. O

background O
: O
sirolimus O
( O
formerly O
rapamycin O
) O
is O
an O
immunosuppressive O
agent O
that O
interferes O
with O
t-cell O
activation O
. O

after O
2 O
individuals O
with O
psoriasis B-NEG
developed O
a O
capillary B-NEG
leak I-NEG
syndrome I-NEG
following O
treatment O
with O
oral O
sirolimus O
lesional O
skin O
cells O
and O
activated O
peripheral O
blood O
cells O
were O
analyzed O
for O
induction O
of O
apoptosis O
. O

observations O
: O
a O
keratome O
skin O
specimen O
from O
1 O
patient O
with O
sirolimus-induced O
capillary B-NEG
leak I-NEG
syndrome I-NEG
had O
a O
2.3-fold O
increase O
in O
percentage O
of O
apoptotic O
cells O
( O
to O
48% O
) O
compared O
with O
an O
unaffected O
sirolimus-treated O
patient O
with O
psoriasis B-NEG
(21%) O
. O

activated O
peripheral O
blood O
t O
cells O
from O
patients O
with O
psoriasis B-NEG
tended O
to O
exhibit O
greater O
spontaneous O
or O
dexamethasone-induced O
apoptosis O
than O
did O
normal O
t O
cells O
, O
particularly O
in O
the O
presence O
of O
sirolimus O
. O

conclusions O
: O
severe O
adverse O
effects O
of O
sirolimus O
include O
fever B-NEG
, O
anemia B-NEG
, O
and O
capillary B-NEG
leak I-NEG
syndrome I-NEG
. O

these O
symptoms O
may O
be O
the O
result O
of O
drug-induced O
apoptosis O
of O
lesional O
leukocytes O
, O
especially O
activated O
t O
lymphocytes O
, O
and O
possibly O
release O
of O
inflammatory O
mediators O
. O

because O
patients O
with O
severe O
psoriasis B-NEG
may O
develop O
capillary B-NEG
leak I-NEG
from O
various O
systemic O
therapies O
, O
clinical O
monitoring O
is O
advisable O
for O
patients O
with O
inflammatory B-NEG
diseases I-NEG
who O
are O
treated O
with O
immune O
modulators O
. O

-DOCSTART- O

contribution O
of O
the O
glycine O
site O
of O
nmda O
receptors O
in O
rostral O
and O
intermediate-caudal O
parts O
of O
the O
striatum O
to O
the O
regulation O
of O
muscle O
tone O
in O
rats O
. O

the O
aim O
of O
the O
present O
study O
was O
to O
assess O
the O
contribution O
of O
the O
glycine O
site O
of O
nmda O
receptors O
in O
the O
striatum O
to O
the O
regulation O
of O
muscle O
tone O
. O

muscle O
tone O
was O
examined O
using O
a O
combined O
mechanoand O
electromyographic O
method O
, O
which O
measured O
simultaneously O
the O
muscle O
resistance O
( O
mmg O
) O
of O
the O
rat's O
hind O
foot O
to O
passive O
extension O
and O
flexion O
in O
the O
ankle O
joint O
and O
the O
electromyographic O
activity O
( O
emg O
) O
of O
the O
antagonistic O
muscles O
of O
that O
joint O
: O
gastrocnemius O
and O
tibialis O
anterior O
. O
muscle B-NEG
rigidity I-NEG
was O
induced O
by O
haloperidol O
( O
2.5 O
mg/kg O
i.p.) O
. O

5,7-dichlorokynurenic O
acid O
(5,7-dcka) O
, O
a O
selective O
glycine O
site O
antagonist O
, O
injected O
in O
doses O
of O
2.5 O
and O
4.5 O
microg/0.5 O
microl O
bilaterally O
, O
into O
the O
rostral O
region O
of O
the O
striatum O
, O
decreased O
both O
the O
haloperidol-induced O
muscle B-NEG
rigidity I-NEG
( O
mmg O
) O
and O
the O
enhanced O
electromyographic O
activity O
(emg) O
. O

5,7-dcka O
injected O
bilaterally O
in O
a O
dose O
of O
4.5 O
microg/0.5 O
microl O
into O
the O
intermediate-caudal O
region O
of O
the O
striatum O
of O
rats O
not O
pretreated O
with O
haloperidol O
had O
no O
effect O
on O
the O
muscle O
tone O
. O

the O
present O
results O
suggest O
that O
blockade O
of O
the O
glycine O
site O
of O
nmda O
receptors O
in O
the O
rostral O
part O
of O
the O
striatum O
may O
be O
mainly O
responsible O
for O
the O
antiparkinsonian O
action O
of O
this O
drug O
. O

-DOCSTART- O

efficacy O
and O
tolerability O
of O
lovastatin O
in O
3390 O
women O
with O
moderate O
hypercholesterolemia B-NEG
. O

objective O
: O
to O
evaluate O
the O
efficacy O
and O
safety O
of O
lovastatin O
in O
women O
with O
moderate O
hypercholesterolemia B-NEG
. O

design O
: O
the O
expanded O
clinical O
evaluation O
of O
lovastatin O
( O
excel O
) O
study O
, O
a O
multicenter O
, O
double-blind O
, O
diet- O
and O
placebo-controlled O
trial O
, O
in O
which O
participants O
were O
randomly O
assigned O
to O
receive O
placebo O
or O
lovastatin O
at O
doses O
of O
20 O
or O
40 O
mg O
once O
daily O
, O
or O
20 O
or O
40 O
mg O
twice O
daily O
for O
48 O
weeks O
. O

setting O
: O
ambulatory O
patients O
recruited O
by O
362 O
participating O
centers O
throughout O
the O
united O
states O
. O

patients O
: O
women O
(n O
= O
3390 O
) O
from O
the O
total O
cohort O
of O
8245 O
volunteers O
. O

measurements O
: O
plasma O
total O
, O
low-density O
lipoprotein O
(ldl) O
, O
and O
high-density O
lipoprotein O
( O
hdl O
) O
cholesterol O
, O
and O
triglycerides O
; O
and O
laboratory O
and O
clinical O
evidence O
of O
adverse O
events O
monitored O
periodically O
throughout O
the O
study O
. O

results O
: O
among O
women O
, O
lovastatin O
( O
20 O
to O
80 O
mg/d O
) O
produced O
sustained O
( O
12- O
to O
48-week) O
, O
dose-related O
changes O
(p O
< O
0.001) O
: O
decreases O
in O
ldl O
cholesterol O
( O
24% O
to O
40% O
) O
and O
triglycerides O
( O
9% O
to O
18%) O
, O
and O
increases O
in O
hdl O
cholesterol O
( O
6.7% O
to O
8.6%) O
. O

depending O
on O
the O
dose O
, O
from O
82% O
to O
95% O
of O
lovastatin-treated O
women O
achieved O
the O
national O
cholesterol O
education O
program O
goal O
of O
ldl O
cholesterol O
levels O
less O
than O
4.14 O
mmol/l O
( O
160 O
mg/dl) O
, O
and O
40% O
to O
87% O
achieved O
the O
goal O
of O
3.36 O
mmol/l O
( O
130 O
mg/dl) O
. O

successive O
transaminase O
elevations O
greater O
than O
three O
times O
the O
upper O
limit O
of O
normal O
occurred O
in O
0.1% O
of O
women O
and O
were O
dose O
dependent O
above O
the O
20-mg O
dose O
. O
myopathy B-NEG
, O
defined O
as O
muscle O
symptoms O
with O
creatine O
kinase O
elevations O
greater O
than O
10 O
times O
the O
upper O
limit O
of O
normal O
, O
was O
rare O
and O
associated O
with O
the O
highest O
recommended O
daily O
dose O
of O
lovastatin O
( O
80 O
mg) O
. O

estrogen-replacement O
therapy O
appeared O
to O
have O
no O
effect O
on O
either O
the O
efficacy O
or O
safety O
profile O
of O
lovastatin O
. O

conclusion O
: O
lovastatin O
is O
highly O
effective O
and O
generally O
well O
tolerated O
as O
therapy O
for O
primary O
hypercholesterolemia B-NEG
in O
women O
. O

-DOCSTART- O

rem B-NEG
sleep I-NEG
deprivation I-NEG
changes O
behavioral O
response O
to O
catecholaminergic O
and O
serotonergic O
receptor O
activation O
in O
rats O
. O

the O
effects O
of O
rem B-NEG
sleep I-NEG
deprivation I-NEG
( O
remd B-NEG
) O
on O
apomorphine-induced O
aggressiveness B-NEG
and O
quipazine-induced O
head B-NEG
twitches I-NEG
in O
rats O
were O
determined O
. O

forty-eight O
hr O
of O
remd B-NEG
increased O
apomorphine-induced O
aggressiveness B-NEG
, O
and O
reduced O
( O
immediately O
after O
completing O
of O
remd B-NEG
) O
or O
increased O
( O
96 O
hr O
after O
completing O
of O
remd B-NEG
) O
quipazine-induced O
head B-NEG
twitches I-NEG
. O

results O
are O
discussed O
in O
terms O
of O
similarity O
to O
pharmacological O
effects O
of O
other O
antidepressive O
treatments O
. O

-DOCSTART- O

extrapyramidal O
side O
effects O
and O
oral O
haloperidol O
: O
an O
analysis O
of O
explanatory O
patient O
and O
treatment O
characteristics O
. O

the O
incidence O
of O
extrapyramidal O
side O
effects O
( O
eps O
) O
was O
evaluated O
in O
98 O
patients O
treated O
with O
haloperidol O
. O

the O
incidence O
of O
parkinsonism B-NEG
was O
higher O
at O
higher O
doses O
of O
haloperidol O
and O
in O
younger O
patients O
. O

prophylactic O
antiparkinsonian O
medication O
was O
effective O
in O
younger O
but O
not O
in O
older O
patients O
. O

however O
, O
these O
medications O
were O
more O
effective O
in O
both O
young O
and O
old O
patients O
when O
given O
after O
parkinsonism B-NEG
developed O
. O
akathisia B-NEG
was O
controlled O
by O
the O
benzodiazepine O
lorazepam O
in O
14 O
out O
of O
16 O
patients O
, O
while O
prophylactic O
antiparkinsonians O
were O
ineffective O
. O

the O
present O
study O
points O
to O
patient O
characteristics O
that O
may O
be O
of O
significance O
in O
the O
development O
of O
eps O
due O
to O
haloperidol O
. O

-DOCSTART- O

hepatic B-NEG
veno-occlusive I-NEG
disease I-NEG
caused O
by O
6-thioguanine O
. O

clinically O
reversible O
veno-occlusive B-NEG
disease I-NEG
of I-NEG
the I-NEG
liver I-NEG
developed O
in O
a O
23-year-old O
man O
with O
acute B-NEG
lymphocytic I-NEG
leukemia I-NEG
after O
10 O
months O
of O
maintenance O
therapy O
with O
6-thioguanine O
. O

serial O
liver O
biopsies O
showed O
the O
development O
and O
resolution O
of O
intense O
sinusoidal O
engorgement O
. O

although O
this O
disease O
was O
clinically O
reversible O
, O
some O
subintimal O
fibrosis B-NEG
about O
the O
terminal O
hepatic O
veins O
persisted O
. O

this O
case O
presented O
a O
unique O
opportunity O
to O
observe O
the O
histologic O
features O
of O
clinically O
reversible O
hepatic B-NEG
veno-occlusive I-NEG
disease I-NEG
over O
time O
, O
and O
may O
be O
the O
first O
case O
of O
veno-occlusive O
related O
solely O
to O
6-thioguanine O
. O

-DOCSTART- O

treatment O
of O
ifosfamide-induced O
urothelial B-NEG
toxicity I-NEG
by O
oral O
administration O
of O
sodium O
2-mercaptoethane O
sulphonate O
( O
mesna O
) O
to O
patients O
with O
inoperable O
lung B-NEG
cancer I-NEG
. O

the O
protective O
effect O
of O
oral O
administration O
of O
the O
thiol O
compound O
sodium O
2-mercaptoethane O
sulphonate O
( O
mesna O
) O
against O
urothelial B-NEG
toxicity I-NEG
induced O
by O
ifosfamide O
( O
if O
) O
was O
tested O
in O
a O
group O
of O
45 O
patients O
with O
inoperable O
lung B-NEG
cancer I-NEG
under O
treatment O
with O
if O
( O
2250 O
mg/m2 O
on O
days O
2-5 O
) O
as O
part O
of O
a O
polychemotherapy O
regimen O
repeated O
in O
a O
4-week O
cycle O
. O

mesna O
was O
given O
orally O
on O
the O
days O
of O
treatment O
with O
if O
in O
3 O
doses O
of O
840 O
mg/m2 O
, O
each O
administered O
at O
0 O
hr O
(= O
injection O
of O
if) O
, O
4 O
hr O
and O
8 O
hr O
p.i O
. O

out O
of O
a O
total O
of O
88 O
courses O
of O
this O
treatment O
we O
observed O
10 O
episodes O
of O
asymptomatic O
microscopic O
haematuria B-NEG
and O
no O
episodes O
of O
gross O
haematuria B-NEG
. O

in O
this O
group O
of O
45 O
patients O
under O
protection O
with O
mesna O
there O
were O
5 O
complete O
remissions O
and O
9 O
partial O
remissions O
( O
total O
31%) O
. O

a O
further O
group O
of O
25 O
patients O
under O
polychemotherapy O
with O
if O
were O
treated O
by O
conventional O
prophylactic O
measures O
( O
raised O
fluid O
intake O
and O
forced O
diuresis) O
. O

in O
this O
group O
there O
were O
1 O
complete O
and O
5 O
partial O
remissions O
( O
total O
24%) O
, O
but O
nearly O
all O
patients O
developed O
either O
gross O
haematuria B-NEG
and/or O
symptoms O
of O
bladder B-NEG
irritation I-NEG
( O
cystitis B-NEG
and O
pollakisuria B-NEG
). O

there O
were O
no O
appreciable O
differences O
between O
the O
mesna O
series O
and O
the O
conventional O
prophylaxis O
series O
with O
respect O
to O
either O
haematological O
or O
systemic O
toxicity B-NEG
of O
the O
cytostatic O
treatment O
. O

our O
results O
support O
the O
view O
that O
mesna O
, O
given O
orally O
in O
conjunction O
with O
combined O
cytostatic O
regimens O
which O
include O
if O
, O
simplifies O
the O
treatment O
and O
provides O
optimum O
protection O
for O
the O
urinary O
epithelium O
. O

protection O
with O
oral O
mesna O
is O
particularly O
suitable O
for O
outpatients O
. O

-DOCSTART- O

time O
course O
alterations O
of O
qtc O
interval O
due O
to O
hypaque O
76 O
. O

sequential O
measurement O
of O
qt O
interval O
during O
left O
ventricular O
angiography O
was O
made O
30 O
seconds O
and O
one O
, O
three O
, O
five O
and O
ten O
minutes O
after O
injection O
of O
hypaque O
76 O
. O

the O
subjects O
were O
ten O
patients O
found O
to O
have O
normal O
left O
ventricles O
and O
coronary O
arteries O
. O

significant O
qtc B-NEG
prolongation I-NEG
occurred O
in O
30 O
seconds O
to O
one O
minute O
in O
association O
with O
marked O
hypotension B-NEG
and O
elevation O
of O
cardiac O
output O
. O

-DOCSTART- O

production O
of O
autochthonous O
prostate B-NEG
cancer I-NEG
in O
lobund-wistar O
rats O
by O
treatments O
with O
n-nitroso-n-methylurea O
and O
testosterone O
. O

more O
than O
50% O
of O
lobund-wistar O
( O
l-w O
) O
strain O
rats O
developed O
large O
, O
palpable O
prostate B-NEG
adenocarcinomas I-NEG
( O
pas B-NEG
) O
following O
treatments O
with O
n-nitroso-n-methylurea O
(cas O
: O
684-93-5 O
) O
and O
testosterone O
propionate O
[(tp O
) O
cas O
: O
57-85-2] O
, O
and O
most O
of O
the O
tumor B-NEG
-bearing O
rats O
manifested O
metastatic O
lesions O
. O

the O
incubation O
periods O
averaged O
10.6 O
months O
. O

within O
the O
same O
timeframe O
, O
no O
l-w O
rat O
developed O
a O
similar O
palpable O
pa B-NEG
when O
treated O
only O
with O
tp O
. O

in O
l-w O
rats O
, O
tp O
acted O
as O
a O
tumor B-NEG
enhancement O
agent O
, O
with O
primary O
emphasis O
on O
the O
development O
of O
prostate B-NEG
cancer I-NEG
. O

-DOCSTART- O

a O
dystonia B-NEG
-like O
syndrome O
after O
neuropeptide O
( O
msh/acth O
) O
stimulation O
of O
the O
rat O
locus O
ceruleus O
. O

the O
movement B-NEG
disorder I-NEG
investigated O
in O
these O
studies O
has O
some O
features O
in O
common O
with O
human O
idiopathic O
dystonia B-NEG
, O
and O
information O
obtained O
in O
these O
studies O
may O
be O
of O
potential O
clinical O
benefit O
. O

the O
present O
experimental O
results O
indicated O
that O
peptidergic O
stimulation O
of O
the O
lc O
resulted O
in O
a O
ne-mediated O
inhibition O
of O
cerebellar O
purkinje O
cells O
located O
at O
terminals O
of O
the O
ceruleo-cerebellar O
pathway O
. O

however O
, O
it O
is O
not O
certain O
as O
to O
the O
following O
: O
( O
a O
) O
what O
receptors O
were O
stimulated O
by O
the O
acth O
n-terminal O
fragments O
at O
the O
lc O
that O
resulted O
in O
this O
disorder O
; O
( O
b O
) O
whether O
ne O
, O
released O
onto O
purkinje O
cell O
synapses O
located O
at O
terminals O
of O
the O
ceruleo-cerebellar O
pathway O
, O
did O
indeed O
cause O
the O
long-term O
depression B-NEG
at O
purkinje O
cell O
synapses O
( O
previously O
described O
by O
others O
) O
that O
resulted O
in O
the O
long O
duration O
of O
the O
movement B-NEG
disorder I-NEG
; O
( O
c O
) O
whether O
the O
inhibition O
of O
inhibitory O
purkinje O
cells O
resulted O
in O
disinhibition O
or O
increased O
excitability O
of O
the O
unilateral O
cerebellar O
fastigial O
or O
interpositus O
nuclei O
, O
the O
output O
targets O
of O
the O
purkinje O
cell O
axons O
, O
that O
may O
have O
been O
an O
important O
contributing O
factor O
to O
this O
disorder O
. O

these O
questions O
are O
currently O
being O
investigated O
. O

-DOCSTART- O

dexmedetomidine O
, O
acting O
through O
central O
alpha-2 O
adrenoceptors O
, O
prevents O
opiate-induced O
muscle B-NEG
rigidity I-NEG
in O
the O
rat O
. O

the O
highly-selective O
alpha-2 O
adrenergic O
agonist O
dexmedetomidine O
( O
d-med O
) O
is O
capable O
of O
inducing O
muscle B-NEG
flaccidity I-NEG
and O
anesthesia O
in O
rats O
and O
dogs O
. O

intense O
generalized O
muscle B-NEG
rigidity I-NEG
is O
an O
undesirable O
side O
effect O
of O
potent O
opiate O
agonists O
. O

although O
the O
neurochemistry O
of O
opiate-induced O
rigidity B-NEG
has O
yet O
to O
be O
fully O
elucidated O
, O
recent O
work O
suggests O
a O
role O
for O
a O
central O
adrenergic O
mechanism O
. O

in O
the O
present O
study O
, O
the O
authors O
determined O
if O
treatment O
with O
d-med O
prevents O
the O
muscle B-NEG
rigidity I-NEG
caused O
by O
high-dose O
alfentanil O
anesthesia O
in O
the O
rat O
. O

animals O
(n O
= O
42 O
) O
were O
treated O
intraperitoneally O
with O
one O
of O
the O
following O
six O
regimens O
: O
1) O
l-med O
( O
the O
inactive O
l-isomer O
of O
medetomidine) O
, O
30 O
micrograms/kg O
; O
2) O
d-med O
, O
10 O
micrograms/kg O
; O
3) O
d-med O
, O
30 O
micrograms/kg O
; O
4) O
d-med O
[30 O
micrograms/kg] O
and O
the O
central-acting O
alpha-2 O
antagonist O
, O
idazoxan O
[10 O
mg/kg] O
; O
5) O
d-med O
[30 O
micrograms/kg] O
and O
the O
peripheral-acting O
alpha-2 O
antagonist O
dg-5128 O
[10 O
mg/kg] O
, O
or O
; O
6) O
saline O
. O

baseline O
electromyographic O
activity O
was O
recorded O
from O
the O
gastrocnemius O
muscle O
before O
and O
after O
drug O
treatment O
. O

each O
rat O
was O
then O
injected O
with O
alfentanil O
(alf O
, O
0.5 O
mg/kg O
sc) O
. O

alf O
injection O
resulted O
in O
a O
marked O
increase O
in O
hindlimb O
emg O
activity O
in O
the O
l-med O
treatment O
group O
which O
was O
indistinguishable O
from O
that O
seen O
in O
animals O
treated O
with O
saline O
. O

in O
contrast O
, O
d-med O
prevented O
alfentanil-induced O
muscle B-NEG
rigidity I-NEG
in O
a O
dose-dependent O
fashion O
. O

the O
small O
emg O
values O
obtained O
in O
the O
high-dose O
d-med O
group O
were O
comparable O
with O
those O
recorded O
in O
earlier O
studies O
from O
control O
animals O
not O
given O
any O
opiate O
. O

the O
high-dose O
d-med O
animals O
were O
flaccid O
, O
akinetic B-NEG
, O
and O
lacked O
a O
startle B-NEG
response O
during O
the O
entire O
experimental O
period.(abstract O
truncated O
at O
250 O
words O
) O

-DOCSTART- O

seizure B-NEG
activity O
with O
imipenem O
therapy O
: O
incidence O
and O
risk O
factors O
. O

two O
elderly O
patients O
with O
a O
history O
of O
either O
cerebral B-NEG
vascular I-NEG
accident I-NEG
( O
cva B-NEG
) O
or O
head B-NEG
trauma I-NEG
and O
no O
evidence O
of O
renal B-NEG
disease I-NEG
developed O
seizures B-NEG
while O
receiving O
maximum O
doses O
of O
imipenem/cilastatin O
. O

neither O
patient O
had O
reported O
previous O
seizures B-NEG
or O
seizure B-NEG
-like O
activity O
nor O
was O
receiving O
anticonvulsant O
agents O
. O

all O
seizures B-NEG
were O
controlled O
with O
therapeutic O
doses O
of O
phenytoin O
. O

both O
patients O
had O
received O
maximum O
doses O
of O
other O
beta-lactam O
antibiotics O
without O
evidence O
of O
seizure B-NEG
activity O
. O

-DOCSTART- O

the O
ability O
of O
insulin O
treatment O
to O
reverse O
or O
prevent O
the O
changes O
in O
urinary O
bladder O
function O
caused O
by O
streptozotocin-induced O
diabetes B-NEG
mellitus I-NEG
. O

1. O

the O
effects O
of O
insulin O
treatment O
on O
in O
vivo O
and O
in O
vitro O
urinary O
bladder O
function O
in O
streptozotocin- O
diabetic B-NEG
rats O
were O
investigated O
. O

2. O
diabetes B-NEG
of O
2 O
months O
duration O
resulted O
in O
decreases O
in O
body O
weight O
and O
increases O
in O
fluid O
consumption O
, O
urine O
volume O
, O
frequency O
of O
micturition O
, O
and O
average O
volume O
per O
micturition O
; O
effects O
which O
were O
prevented O
by O
insulin O
treatment O
. O

3. O

insulin O
treatment O
also O
prevented O
the O
increases O
in O
contractile O
responses O
of O
bladder O
body O
strips O
from O
diabetic B-NEG
rats O
to O
nerve O
stimulation O
, O
atp O
, O
and O
bethanechol O
. O

4. O
diabetes B-NEG
of O
4 O
months O
duration O
also O
resulted O
in O
decreases O
in O
body O
weight O
, O
and O
increases O
in O
fluid O
consumption O
, O
urine O
volume O
, O
frequency O
of O
micturition O
, O
and O
average O
volume O
per O
micturition O
, O
effects O
which O
were O
reversed O
by O
insulin O
treatment O
for O
the O
final O
2 O
months O
of O
the O
study O
. O

5. O

insulin O
treatment O
reversed O
the O
increases O
in O
contractile O
responses O
of O
bladder O
body O
strips O
from O
diabetic B-NEG
rats O
to O
nerve O
stimulation O
, O
atp O
, O
and O
bethanechol O
. O

6. O

the O
data O
indicate O
that O
the O
effects O
of O
streptozotocin-induced O
diabetes B-NEG
on O
urinary O
bladder O
function O
are O
both O
prevented O
and O
reversed O
by O
insulin O
treatment O
. O

-DOCSTART- O

delayed O
institution O
of O
hypertension B-NEG
during O
focal O
cerebral B-NEG
ischemia I-NEG
: O
effect O
on O
brain B-NEG
edema I-NEG
. O

the O
effect O
of O
induced O
hypertension B-NEG
instituted O
after O
a O
2-h O
delay O
following O
middle B-NEG
cerebral I-NEG
artery I-NEG
occlusion I-NEG
( O
mcao B-NEG
) O
on O
brain B-NEG
edema I-NEG
formation O
and O
histochemical O
injury O
was O
studied O
. O

under O
isoflurane O
anesthesia O
, O
the O
mca O
of O
14 O
spontaneously O
hypertensive B-NEG
rats O
was O
occluded O
. O

in O
the O
control O
group O
(n O
= O
7) O
, O
the O
mean O
arterial O
pressure O
( O
map O
) O
was O
not O
manipulated O
. O

in O
the O
hypertensive B-NEG
group O
(n O
= O
7) O
, O
the O
map O
was O
elevated O
by O
25-30 O
mm O
hg O
beginning O
2 O
h O
after O
mcao B-NEG
. O

four O
hours O
after O
mcao B-NEG
, O
the O
rats O
were O
killed O
and O
the O
brains O
harvested O
. O

the O
brains O
were O
sectioned O
along O
coronal O
planes O
spanning O
the O
distribution O
of O
ischemia B-NEG
produced O
by O
mcao B-NEG
. O

specific O
gravity O
( O
sg O
) O
was O
determined O
in O
the O
subcortex O
and O
in O
two O
sites O
in O
the O
cortex O
( O
core O
and O
periphery O
of O
the O
ischemic B-NEG
territory) O
. O

the O
extent O
of O
neuronal B-NEG
injury I-NEG
was O
determined O
by O
2,3,5-triphenyltetrazolium O
staining O
. O

in O
the O
ischemic B-NEG
core O
, O
there O
was O
no O
difference O
in O
sg O
in O
the O
subcortex O
and O
cortex O
in O
the O
two O
groups O
. O

in O
the O
periphery O
of O
the O
ischemic B-NEG
territory O
, O
sg O
in O
the O
cortex O
was O
greater O
( O
less O
edema B-NEG
accumulation O
) O
in O
the O
hypertensive B-NEG
group O
( O
1.041 O
+/- O
0.001 O
vs O
1.039 O
+/- O
0.001 O
, O
p O
less O
than O
0.05) O
. O

the O
area O
of O
histochemical O
injury O
( O
as O
a O
percent O
of O
the O
cross-sectional O
area O
of O
the O
hemisphere O
) O
was O
less O
in O
the O
hypertensive B-NEG
group O
( O
33 O
+/- O
3% O
vs O
21 O
+/- O
2% O
, O
p O
less O
than O
0.05) O
. O

the O
data O
indicate O
that O
phenylephrine-induced O
hypertension B-NEG
instituted O
2 O
h O
after O
mcao B-NEG
does O
not O
aggravate O
edema B-NEG
in O
the O
ischemic B-NEG
core O
, O
that O
it O
improves O
edema B-NEG
in O
the O
periphery O
of O
the O
ischemic B-NEG
territory O
, O
and O
that O
it O
reduces O
the O
area O
of O
histochemical O
neuronal B-NEG
dysfunction I-NEG
. O

-DOCSTART- O

amiodarone O
pulmonary B-NEG
toxicity I-NEG
. O

amiodarone O
is O
an O
effective O
antiarrhythmic O
agent O
whose O
utility O
is O
limited O
by O
many O
side-effects O
, O
the O
most O
problematic O
being O
pneumonitis B-NEG
. O

the O
pulmonary B-NEG
toxicity I-NEG
of O
amiodarone O
is O
thought O
to O
result O
from O
direct O
injury O
related O
to O
the O
intracellular O
accumulation O
of O
phospholipid O
and O
t O
cell-mediated O
hypersensitivity B-NEG
pneumonitis I-NEG
. O

the O
clinical O
and O
radiographic O
features O
of O
amiodarone-induced O
pulmonary B-NEG
toxicity I-NEG
are O
characteristic O
but O
nonspecific O
. O

the O
diagnosis O
depends O
on O
exclusion O
of O
other O
entities O
, O
such O
as O
heart B-NEG
failure I-NEG
, O
infection B-NEG
, O
and O
malignancy B-NEG
. O

while O
withdrawal O
of O
amiodarone O
leads O
to O
clinical O
improvement O
in O
majority O
of O
cases O
, O
this O
is O
not O
always O
possible O
or O
advisable O
. O

dose O
reduction O
or O
concomitant O
steroid O
therapy O
may O
have O
a O
role O
in O
selected O
patients O
. O

-DOCSTART- O

light O
chain O
proteinuria B-NEG
and O
cellular O
mediated O
immunity O
in O
rifampin O
treated O
patients O
with O
tuberculosis B-NEG
. O

light O
chain O
proteinuria B-NEG
was O
found O
in O
9 O
of O
17 O
tuberculosis B-NEG
patients O
treated O
with O
rifampin O
. O

concomitant O
assay O
of O
cellular O
mediated O
immunity O
in O
these O
patients O
using O
skin O
test O
antigen O
and O
a O
lymphokine O
in O
vitro O
test O
provided O
results O
that O
were O
different O
. O

response O
to O
varidase O
skin O
test O
antigen O
was O
negative O
for O
all O
eight O
tuberculosis B-NEG
patients O
tested O
, O
but O
there O
occurred O
a O
hyper-responsiveness O
of O
the O
lymphocytes O
of O
these O
eight O
patients O
to O
phytomitogen O
(pha-p) O
. O
as O
well O
as O
of O
those O
of O
seven O
other O
tuberculous B-NEG
patients O
. O

this O
last O
finding O
may O
be O
related O
to O
time O
of O
testing O
and/or O
endogenous O
serum O
binding O
of O
rifampin O
which O
could O
have O
inhibited O
mitogen O
activity O
for O
the O
lymphocyte O
. O

-DOCSTART- O

initial O
potassium O
loss O
and O
hypokalaemia B-NEG
during O
chlorthalidone O
administration O
in O
patients O
with O
essential O
hypertension B-NEG
: O
the O
influence O
of O
dietary O
sodium O
restriction O
. O

to O
investigate O
the O
initial O
potassium O
loss O
and O
development O
of O
hypokalaemia B-NEG
during O
the O
administration O
of O
an O
oral O
diuretic O
, O
metabolic O
balance O
studies O
were O
performed O
in O
ten O
patients O
with O
essential O
hypertension B-NEG
who O
had O
shown O
hypokalaemia B-NEG
under O
prior O
oral O
diuretic O
treatment O
. O

chlorthalidone O
( O
50 O
mg O
daily O
) O
was O
given O
for O
14 O
days O
. O

six O
patients O
received O
a O
normal-sodium O
diet O
and O
four O
a O
low-sodium O
( O
17 O
mmol/day O
) O
diet O
. O

all O
patients O
had O
a O
normal O
initial O
total O
body O
potassium O
(40k) O
. O

the O
electrolyte O
balances O
, O
weight O
, O
bromide O
space O
, O
plasma O
renin O
activity O
, O
and O
aldosterone O
secretion O
rate O
were O
measured O
. O

in O
both O
groups O
a O
potassium O
deficit O
developed O
, O
with O
proportionally O
larger O
losses O
from O
the O
extracellular O
than O
from O
the O
intracellular O
compartment O
. O

in O
the O
normal-sodium O
group O
the O
highest O
mean O
potassium O
deficit O
was O
176 O
mmol O
on O
day O
9, O
after O
which O
some O
potassium O
was O
regained O
; O
in O
the O
low-sodium O
group O
the O
highest O
deficit O
was O
276 O
mmol O
on O
day O
13 O
. O

the O
normal-sodium O
group O
showed O
an O
immediate O
but O
temporary O
rise O
of O
the O
renin O
and O
aldosterone O
levels O
; O
in O
the O
low-sodium O
group O
renin O
and O
aldosterone O
increased O
more O
slowly O
but O
remained O
elevated O
. O

it O
is O
concluded O
that O
dietary O
sodium O
restriction O
increases O
diuretic-induced O
potassium O
loss O
, O
presumably O
by O
an O
increased O
activity O
of O
the O
renin-angiotensin-aldosterone O
system O
, O
while O
sodium O
delivery O
to O
the O
distal O
renal O
tubules O
remains O
sufficiently O
high O
to O
allow O
increased O
potassium O
secretion O
. O

-DOCSTART- O

dynamic O
response O
of O
blood O
vessel O
in O
acute B-NEG
renal I-NEG
failure I-NEG
. O

in O
this O
study O
we O
postulated O
that O
during O
acute B-NEG
renal I-NEG
failure I-NEG
induced O
by O
gentamicin O
the O
transient O
or O
dynamic O
response O
of O
blood O
vessels O
could O
be O
affected O
, O
and O
that O
antioxidants O
can O
prevent O
the O
changes O
in O
dynamic O
responses O
of O
blood O
vessels O
. O

the O
new O
approach O
to O
ex O
vivo O
blood O
vessel O
experiments O
in O
which O
not O
only O
the O
end O
points O
of O
vessels O
response O
within O
the O
time O
interval O
is O
considered O
, O
but O
also O
dynamics O
of O
this O
response O
, O
was O
used O
in O
this O
paper O
. O

our O
results O
confirm O
the O
alteration O
in O
dynamic O
response O
of O
blood O
vessels O
during O
the O
change O
of O
pressure O
in O
gentamicin-treated O
animals O
. O

the O
beneficial O
effects O
of O
vitamin O
c O
administration O
to O
gentamicin-treated O
animals O
are O
also O
confirmed O
through O
: O
lower O
level O
of O
blood O
urea O
and O
creatinine O
and O
higher O
level O
of O
potassium O
. O

the O
pressure O
dynamic O
responses O
of O
isolated O
blood O
vessels O
show O
a O
faster O
pressure O
change O
in O
gentamicin-treated O
animals O
( O
8.07 O
+/- O
1.7 O
s O
vs O
. O
5.64 O
+/- O
0.18 O
s) O
. O

vitamin O
c O
administration O
induced O
slowdown O
of O
pressure O
change O
back O
to O
the O
control O
values O
. O

the O
pressure O
dynamic O
properties O
, O
quantitatively O
defined O
by O
comparative O
pressure O
dynamic O
and O
total O
pressure O
dynamic O
, O
confirm O
the O
alteration O
in O
dynamic O
response O
of O
blood O
vessels O
during O
the O
change O
of O
pressure O
in O
gentamicin-treated O
animals O
and O
beneficial O
effects O
of O
vitamin O
c O
administration O
. O

-DOCSTART- O

the O
hemodynamics O
of O
oxytocin O
and O
other O
vasoactive O
agents O
during O
neuraxial O
anesthesia O
for O
cesarean O
delivery O
: O
findings O
in O
six O
cases O
. O

oxytocin O
is O
a O
commonly O
used O
uterotonic O
that O
can O
cause O
significant O
and O
even O
fatal O
hypotension B-NEG
, O
particularly O
when O
given O
as O
a O
bolus O
. O

the O
resulting O
hypotension B-NEG
can O
be O
produced O
by O
a O
decrease O
in O
systemic O
vascular O
resistance O
or O
cardiac O
output O
through O
a O
decrease O
in O
venous O
return O
. O

parturients O
with O
normal O
volume O
status O
, O
heart O
valves O
and O
pulmonary O
vasculature O
most O
often O
respond O
to O
this O
hypotension B-NEG
with O
a O
compensatory O
increase O
in O
heart O
rate O
and O
stroke B-NEG
volume O
. O

oxytocin-induced O
hypotension B-NEG
at O
cesarean O
delivery O
may O
be O
incorrectly O
attributed O
to O
blood B-NEG
loss I-NEG
. O

pulse O
power O
analysis O
( O
also O
called O
pulse O
contour O
analysis O
) O
of O
an O
arterial O
pressure O
wave O
form O
allows O
continuous O
evaluation O
of O
systemic O
vascular O
resistance O
and O
cardiac O
output O
in O
real O
time O
, O
thereby O
elucidating O
the O
causative O
factors O
behind O
changes O
in O
blood O
pressure O
. O

pulse O
power O
analysis O
was O
conducted O
in O
six O
cases O
of O
cesarean O
delivery O
performed O
under O
neuraxial O
anesthesia O
. O
hypotension B-NEG
in O
response O
to O
oxytocin O
was O
associated O
with O
a O
decrease O
in O
systemic O
vascular O
resistance O
and O
a O
compensatory O
increase O
in O
stroke B-NEG
volume O
, O
heart O
rate O
and O
cardiac O
output O
. O

pulse O
power O
analysis O
may O
be O
helpful O
in O
determining O
the O
etiology O
of O
and O
treating O
hypotension B-NEG
during O
cesarean O
delivery O
under O
neuraxial O
anesthesia O
. O

-DOCSTART- O

exaggerated O
expression O
of O
inflammatory O
mediators O
in O
vasoactive O
intestinal O
polypeptide O
knockout O
( O
vip-/- O
) O
mice O
with O
cyclophosphamide O
( O
cyp)-induced O
cystitis B-NEG
. O

vasoactive O
intestinal O
polypeptide O
( O
vip O
) O
is O
an O
immunomodulatory O
neuropeptide O
distributed O
in O
micturition O
pathways O
. O

vip(-/- O
) O
mice O
exhibit O
altered O
bladder O
function O
and O
neurochemical O
properties O
in O
micturition O
pathways O
after O
cyclophosphamide O
( O
cyp)-induced O
cystitis B-NEG
. O

given O
vip's O
role O
as O
an O
anti-inflammatory O
mediator O
, O
we O
hypothesized O
that O
vip(-/- O
) O
mice O
would O
exhibit O
enhanced O
inflammatory O
mediator O
expression O
after O
cystitis B-NEG
. O

a O
mouse O
inflammatory O
cytokine O
and O
receptor O
rt2 O
profiler O
array O
was O
used O
to O
determine O
regulated O
transcripts O
in O
the O
urinary O
bladder O
of O
wild O
type O
( O
wt O
) O
and O
vip(-/- O
) O
mice O
with O
or O
without O
cyp-induced O
cystitis B-NEG
( O
150 O
mg/kg O
; O
i.p. O
; O
48 O
h) O
. O

four O
binary O
comparisons O
were O
made O
: O
wt O
control O
versus O
cyp O
treatment O
( O
48 O
h) O
, O
vip(-/- O
) O
control O
versus O
cyp O
treatment O
( O
48 O
h) O
, O
wt O
control O
versus O
vip(-/- O
) O
control O
, O
and O
wt O
with O
cyp O
treatment O
( O
48 O
h) O
versus O
vip(-/- O
) O
with O
cyp O
treatment O
( O
48 O
h) O
. O

the O
genes O
presented O
represent O
( O
1 O
) O
greater O
than O
1.5-fold O
change O
in O
either O
direction O
and O
( O
2 O
) O
the O
p O
value O
is O
less O
than O
0.05 O
for O
the O
comparison O
being O
made O
. O

several O
regulated O
genes O
were O
validated O
using O
enzyme-linked O
immunoassays O
including O
il-1beta O
and O
cxcl1 O
. O

cyp O
treatment O
significantly O
(p O
< O
or O
= O
0.001 O
) O
increased O
expression O
of O
cxcl1 O
and O
il-1beta O
in O
the O
urinary O
bladder O
of O
wt O
and O
vip(-/- O
) O
mice O
, O
but O
expression O
in O
vip(-/- O
) O
mice O
with O
cyp O
treatment O
was O
significantly O
(p O
< O
or O
= O
0.001 O
) O
greater O
( O
4.2- O
to O
13-fold O
increase O
) O
than O
that O
observed O
in O
wt O
urinary O
bladder O
( O
3.6- O
to O
5-fold O
increase) O
. O

the O
data O
suggest O
that O
in O
vip(-/- O
) O
mice O
with O
bladder B-NEG
inflammation I-NEG
, O
inflammatory O
mediators O
are O
increased O
above O
that O
observed O
in O
wt O
with O
cyp O
. O

this O
shift O
in O
balance O
may O
contribute O
to O
increased O
bladder B-NEG
dysfunction I-NEG
in O
vip(-/- O
) O
mice O
with O
bladder B-NEG
inflammation I-NEG
and O
altered O
neurochemical O
expression O
in O
micturition O
pathways O
. O

-DOCSTART- O

intraocular O
pressure O
in O
patients O
with O
uveitis B-NEG
treated O
with O
fluocinolone O
acetonide O
implants O
. O

objective O
: O
to O
report O
the O
incidence O
and O
management O
of O
elevated B-NEG
intraocular I-NEG
pressure I-NEG
( O
iop O
) O
in O
patients O
with O
uveitis B-NEG
treated O
with O
the O
fluocinolone O
acetonide O
( O
fa O
) O
intravitreal O
implant O
. O

design O
: O
pooled O
data O
from O
3 O
multicenter O
, O
double-masked O
, O
randomized O
, O
controlled O
, O
phase O
2b/3 O
clinical O
trials O
evaluating O
the O
safety O
and O
efficacy O
of O
the O
0.59-mg O
or O
2.1-mg O
fa O
intravitreal O
implant O
or O
standard O
therapy O
were O
analyzed O
. O

results O
: O
during O
the O
3-year O
follow-up O
, O
71.0% O
of O
implanted O
eyes O
had O
an O
iop O
increase O
of O
10 O
mm O
hg O
or O
more O
than O
baseline O
and O
55.1% O
, O
24.7% O
, O
and O
6.2% O
of O
eyes O
reached O
an O
iop O
of O
30 O
mm O
hg O
or O
more O
, O
40 O
mm O
hg O
or O
more O
, O
and O
50 O
mm O
hg O
or O
more O
, O
respectively O
. O

topical O
iop-lowering O
medication O
was O
administered O
in O
74.8% O
of O
implanted O
eyes O
, O
and O
iop-lowering O
surgeries O
, O
most O
of O
which O
were O
trabeculectomies O
(76.2%) O
, O
were O
performed O
on O
36.6% O
of O
implanted O
eyes O
. O

intraocular O
pressure-lowering O
surgeries O
were O
considered O
a O
success O
( O
postoperative O
iop O
of O
6-21 O
mm O
hg O
with O
or O
without O
additional O
iop-lowering O
medication O
) O
in O
85.1% O
of O
eyes O
at O
1 O
year O
. O

the O
rate O
of O
hypotony B-NEG
( O
iop O
</= O
5 O
mm O
hg O
) O
following O
iop-lowering O
surgery O
( O
42.5% O
) O
was O
not O
different O
from O
that O
of O
implanted O
eyes O
not O
subjected O
to O
surgery O
( O
35.4% O
) O
(p O
= O
.09) O
. O

conclusion O
: O
elevated O
iop O
is O
a O
significant O
complication O
with O
the O
fa O
intravitreal O
implant O
but O
may O
be O
controlled O
with O
medication O
and O
surgery O
. O

-DOCSTART- O

pallidal O
stimulation O
: O
an O
alternative O
to O
pallidotomy? O

a O
resurgence O
of O
interest O
in O
the O
surgical O
treatment O
of O
parkinson's B-NEG
disease I-NEG
( O
pd B-NEG
) O
came O
with O
the O
rediscovery O
of O
posteroventral O
pallidotomy O
by O
laitinen O
in O
1985 O
. O

laitinen's O
procedure O
improved O
most O
symptoms O
in O
drug-resistant O
pd B-NEG
, O
which O
engendered O
wide O
interest O
in O
the O
neurosurgical O
community O
. O

another O
lesioning O
procedure O
, O
ventrolateral O
thalamotomy O
, O
has O
become O
a O
powerful O
alternative O
to O
stimulate O
the O
nucleus O
ventralis O
intermedius O
, O
producing O
high O
long-term O
success O
rates O
and O
low O
morbidity O
rates O
. O

pallidal O
stimulation O
has O
not O
met O
with O
the O
same O
success O
. O

according O
to O
the O
literature O
pallidotomy O
improves O
the O
on O
symptoms O
of O
pd B-NEG
, O
such O
as O
dyskinesias B-NEG
, O
as O
well O
as O
the O
off O
symptoms O
, O
such O
as O
rigidity B-NEG
, O
bradykinesia B-NEG
, O
and O
on-off O
fluctuations O
. O

pallidal O
stimulation O
improves O
bradykinesia B-NEG
and O
rigidity B-NEG
to O
a O
minor O
extent O
; O
however O
, O
its O
strength O
seems O
to O
be O
in O
improving O
levodopa-induced O
dyskinesias B-NEG
. O

stimulation O
often O
produces O
an O
improvement O
in O
the O
hyper- B-NEG
or I-NEG
dyskinetic I-NEG
upper O
limbs O
, O
but O
increases O
the O
freezing O
phenomenon O
in O
the O
lower O
limbs O
at O
the O
same O
time O
. O

considering O
the O
small O
increase O
in O
the O
patient's O
independence O
, O
the O
high O
costs O
of O
bilateral O
implants O
, O
and O
the O
difficulty O
most O
patients O
experience O
in O
handling O
the O
devices O
, O
the O
question O
arises O
as O
to O
whether O
bilateral O
pallidal O
stimulation O
is O
a O
real O
alternative O
to O
pallidotomy O
. O

-DOCSTART- O

case O
report O
: O
dexatrim O
( O
phenylpropanolamine O
) O
as O
a O
cause O
of O
myocardial B-NEG
infarction I-NEG
. O

phenylpropanolamine O
( O
ppa O
) O
is O
a O
sympathetic O
amine O
used O
in O
over-the-counter O
cold O
remedies O
and O
weight-control O
preparations O
worldwide O
. O

its O
use O
has O
been O
associated O
with O
hypertensive B-NEG
episodes O
and O
hemorrhagic B-NEG
strokes I-NEG
in O
younger O
women O
. O

several O
reports O
have O
linked O
the O
abuse O
of O
ppa O
with O
myocardial B-NEG
injury I-NEG
, O
especially O
when O
overdose B-NEG
is O
involved O
. O

we O
report O
here O
the O
first O
case O
of O
dexatrim O
( O
ppa)-induced O
myocardial B-NEG
injury I-NEG
in O
a O
young O
woman O
who O
was O
using O
it O
at O
recommended O
doses O
for O
weight O
control O
. O

in O
addition O
, O
we O
review O
the O
7 O
other O
cases O
of O
ppa O
related O
myocardial B-NEG
injury I-NEG
that O
have O
been O
reported O
so O
far O
. O

physicians O
and O
patients O
should O
be O
alert O
to O
the O
potential O
cardiac O
risk O
associated O
with O
the O
use O
of O
ppa O
, O
even O
at O
doses O
generally O
considered O
to O
be O
safe O
. O

-DOCSTART- O

risperidone-associated O
, O
benign O
transient O
visual B-NEG
disturbances I-NEG
in O
schizophrenic B-NEG
patients O
with O
a O
past O
history O
of O
lsd O
abuse O
. O

two O
schizophrenic B-NEG
patients O
, O
who O
had O
a O
prior O
history O
of O
lsd O
abuse O
and O
who O
had O
previously O
developed O
eps B-NEG
with O
classic O
antipsychotics O
, O
were O
successfully O
treated O
with O
risperidone O
. O

they O
both O
reported O
short O
episodes O
of O
transient O
visual B-NEG
disturbances I-NEG
, O
which O
appeared O
immediately O
after O
starting O
treatment O
with O
risperidone O
. O

this O
imagery O
resembled O
visual B-NEG
disturbances I-NEG
previously O
experienced O
as O
flashbacks O
related O
to O
prior O
lsd O
consumption O
. O

risperidone O
administration O
was O
continued O
and O
the O
visual B-NEG
disturbances I-NEG
gradually O
wore O
off O
. O

during O
a O
six-month O
follow-up O
period O
, O
there O
was O
no O
recurrence O
of O
visual B-NEG
disturbances I-NEG
. O

this O
phenomenon O
may O
be O
interpreted O
as O
a O
benign O
, O
short-term O
and O
self-limiting O
side O
effect O
which O
does O
not O
contraindicate O
the O
use O
of O
risperidone O
or O
interfere O
with O
treatment O
. O

conclusions O
based O
on O
two O
case O
reports O
should O
be O
taken O
with O
appropriate O
caution O
. O

-DOCSTART- O

activation O
of O
poly(adp-ribose O
) O
polymerase O
contributes O
to O
development O
of O
doxorubicin-induced O
heart B-NEG
failure I-NEG
. O

activation O
of O
the O
nuclear O
enzyme O
poly(adp-ribose O
) O
polymerase O
( O
parp O
) O
by O
oxidant-mediated O
dna O
damage O
is O
an O
important O
pathway O
of O
cell O
dysfunction O
and O
tissue O
injury O
in O
conditions O
associated O
with O
oxidative O
stress O
. O

increased O
oxidative O
stress O
is O
a O
major O
factor O
implicated O
in O
the O
cardiotoxicity B-NEG
of O
doxorubicin O
(dox) O
, O
a O
widely O
used O
antitumor O
anthracycline O
antibiotic O
. O

thus O
, O
we O
hypothesized O
that O
the O
activation O
of O
parp O
may O
contribute O
to O
the O
dox-induced O
cardiotoxicity B-NEG
. O

using O
a O
dual O
approach O
of O
parp-1 O
suppression O
, O
by O
genetic O
deletion O
or O
pharmacological O
inhibition O
with O
the O
phenanthridinone O
parp O
inhibitor O
pj34 O
, O
we O
now O
demonstrate O
the O
role O
of O
parp O
in O
the O
development O
of O
cardiac B-NEG
dysfunction I-NEG
induced O
by O
dox O
. O

parp-1+/+ O
and O
parp-1-/- O
mice O
received O
a O
single O
injection O
of O
dox O
( O
25 O
mg/kg O
i.p) O
. O

five O
days O
after O
dox O
administration O
, O
left O
ventricular O
performance O
was O
significantly O
depressed O
in O
parp-1+/+ O
mice O
, O
but O
only O
to O
a O
smaller O
extent O
in O
parp-1-/- O
ones O
. O

similar O
experiments O
were O
conducted O
in O
balb/c O
mice O
treated O
with O
pj34 O
or O
vehicle O
. O

treatment O
with O
a O
pj34 O
significantly O
improved O
cardiac B-NEG
dysfunction I-NEG
and O
increased O
the O
survival O
of O
the O
animals O
. O

in O
addition O
pj34 O
significantly O
reduced O
the O
dox-induced O
increase O
in O
the O
serum O
lactate O
dehydrogenase O
and O
creatine O
kinase O
activities O
but O
not O
metalloproteinase O
activation O
in O
the O
heart O
. O

thus O
, O
parp O
activation O
contributes O
to O
the O
cardiotoxicity B-NEG
of O
dox O
. O

parp O
inhibitors O
may O
exert O
protective O
effects O
against O
the O
development O
of O
severe O
cardiac B-NEG
complications I-NEG
associated O
with O
the O
dox O
treatment O
. O

-DOCSTART- O

fluconazole-induced O
torsade B-NEG
de I-NEG
pointes I-NEG
. O

objective O
: O
to O
present O
a O
case O
of O
fluconazole-associated O
torsade B-NEG
de I-NEG
pointes I-NEG
( O
tdp B-NEG
) O
and O
discuss O
fluconazole's O
role O
in O
causing O
tdp B-NEG
. O

case O
summary O
: O
a O
68-year-old O
white O
woman O
with O
candida O
glabrata O
isolated O
from O
a O
presacral O
abscess O
developed O
tdp B-NEG
eight O
days O
after O
commencing O
oral O
fluconazole O
the O
patient O
had O
no O
other O
risk O
factors O
for O
tdp B-NEG
, O
including O
coronary B-NEG
artery I-NEG
disease I-NEG
, O
cardiomyopathy B-NEG
, O
congestive B-NEG
heart I-NEG
failure I-NEG
, O
and O
electrolyte O
abnormalities O
there O
was O
a O
temporal O
association O
between O
the O
initiation O
of O
fluconazole O
and O
tdp B-NEG
. O

the O
tdp B-NEG
resolved O
when O
fluconazole O
was O
discontinued O
; O
however O
, O
the O
patient O
continued O
to O
have O
premature B-NEG
ventricular I-NEG
contractions I-NEG
and O
nonsustained O
ventricular B-NEG
tachycardia I-NEG
( O
nsvt B-NEG
) O
until O
six O
days O
after O
drug O
cessation O
discussion O
: O
use O
of O
the O
naranjo O
probability O
scale O
indicates O
a O
probable O
relationship O
between O
the O
use O
of O
fluconazole O
and O
the O
development O
of O
tdp B-NEG
. O

the O
possible O
mechanism O
is O
depression B-NEG
of O
rapidly O
activating O
delayed O
rectifier O
potassium O
currents O
. O

in O
our O
patient O
, O
there O
was O
no O
other O
etiology O
identified O
that O
could O
explain O
qt B-NEG
prolongation I-NEG
or O
tdp B-NEG
the O
complete O
disappearance O
of O
nsvt B-NEG
and O
premature B-NEG
ventricular I-NEG
contractions I-NEG
followed O
by O
normalization O
of O
qt O
interval O
after O
the O
drug O
was O
stopped O
strongly O
suggests O
fluconazole O
as O
the O
etiology O
. O

conclusions O
: O
clinicians O
should O
be O
aware O
that O
fluconazole O
, O
even O
at O
low O
doses O
, O
may O
cause O
prolongation B-NEG
of I-NEG
the I-NEG
qt I-NEG
interval I-NEG
, O
leading O
to O
tdp B-NEG
. O

serial O
electrocardiographic O
monitoring O
may O
be O
considered O
when O
fluconazole O
is O
administered O
in O
patients O
who O
are O
at O
risk O
for O
ventricular B-NEG
arrhythmias I-NEG
. O

-DOCSTART- O

high-dose O
methylprednisolone O
may O
do O
more O
harm O
for O
spinal B-NEG
cord I-NEG
injury I-NEG
. O

because O
of O
the O
national O
acute O
spinal B-NEG
cord I-NEG
injury I-NEG
studies O
(nascis) O
, O
high-dose O
methylprednisolone O
became O
the O
standard O
of O
care O
for O
the O
acute O
spinal B-NEG
cord I-NEG
injury I-NEG
. O

in O
the O
nascis O
, O
there O
was O
no O
mention O
regarding O
the O
possibility O
of O
acute O
corticosteroid O
myopathy B-NEG
that O
high-dose O
methylprednisolone O
may O
cause O
. O

the O
dosage O
of O
methylprednisolone O
recommended O
by O
the O
nascis O
3 O
is O
the O
highest O
dose O
of O
steroids O
ever O
being O
used O
during O
a O
2-day O
period O
for O
any O
clinical O
condition O
. O

we O
hypothesize O
that O
it O
may O
cause O
some O
damage B-NEG
to I-NEG
the I-NEG
muscle I-NEG
of O
spinal B-NEG
cord I-NEG
injury I-NEG
patients O
. O

further O
, O
steroid O
myopathy B-NEG
recovers O
naturally O
and O
the O
neurological O
improvement O
shown O
in O
the O
nascis O
may O
be O
just O
a O
recording O
of O
this O
natural O
motor O
recovery O
from O
the O
steroid O
myopathy B-NEG
, O
instead O
of O
any O
protection O
that O
methylprednisolone O
offers O
to O
the O
spinal B-NEG
cord I-NEG
injury I-NEG
. O

to O
our O
knowledge O
, O
this O
is O
the O
first O
discussion O
considering O
the O
possibility O
that O
the O
methylprednisolone O
recommended O
by O
nascis O
may O
cause O
acute O
corticosteroid O
myopathy B-NEG
. O

-DOCSTART- O

probing O
peripheral O
and O
central O
cholinergic O
system O
responses O
. O

objective O
: O
the O
pharmacological O
response O
to O
drugs O
that O
act O
on O
the O
cholinergic O
system O
of O
the O
iris O
has O
been O
used O
to O
predict O
deficits O
in O
central O
cholinergic O
functioning O
due O
to O
diseases O
such O
as O
alzheimer's B-NEG
disease I-NEG
, O
yet O
correlations O
between O
central O
and O
peripheral O
responses O
have O
not O
been O
properly O
studied O
. O

this O
study O
assessed O
the O
effect O
of O
normal O
aging O
on O
( O
1 O
) O
the O
tropicamide-induced O
increase O
in O
pupil O
diameter O
, O
and O
( O
2 O
) O
the O
reversal O
of O
this O
effect O
with O
pilocarpine O
. O

scopolamine O
was O
used O
as O
a O
positive O
control O
to O
detect O
age-dependent O
changes O
in O
central O
cholinergic O
functioning O
in O
the O
elderly O
. O

design O
: O
randomized O
double-blind O
controlled O
trial O
. O

participants O
: O
ten O
healthy O
elderly O
( O
mean O
age O
70 O
) O
and O
9 O
young O
( O
mean O
age O
33 O
) O
volunteers O
. O

interventions O
: O
pupil O
diameter O
was O
monitored O
using O
a O
computerized O
infrared O
pupillometer O
over O
4 O
hours O
. O

the O
study O
involved O
4 O
sessions O
. O

in O
1 O
session O
, O
tropicamide O
( O
20 O
microl O
, O
0.01% O
) O
was O
administered O
to O
one O
eye O
and O
placebo O
to O
the O
other O
. O

in O
another O
session O
, O
tropicamide O
( O
20 O
microl O
, O
0.01% O
) O
was O
administered O
to O
both O
eyes O
, O
followed O
23 O
minutes O
later O
by O
the O
application O
of O
pilocarpine O
( O
20 O
microl O
, O
0.1% O
) O
to O
one O
eye O
and O
placebo O
to O
the O
other O
. O

all O
eye O
drops O
were O
given O
in O
a O
randomized O
order O
. O

in O
2 O
separate O
sessions O
, O
a O
single O
dose O
of O
scopolamine O
( O
0.5 O
mg O
, O
intravenously O
) O
or O
placebo O
was O
administered O
, O
and O
the O
effects O
on O
word O
recall O
were O
measured O
using O
the O
buschke O
selective O
reminding O
test O
over O
2 O
hours O
. O

outcome O
measures O
: O
pupil O
size O
at O
time O
points O
after O
administration O
of O
tropicamide O
and O
pilocarpine O
; O
scopolamine-induced O
impairment B-NEG
in I-NEG
word I-NEG
recall I-NEG
. O

results O
: O
there O
was O
no O
significant O
difference O
between O
elderly O
and O
young O
volunteers O
in O
pupillary O
response O
to O
tropicamide O
at O
any O
time O
point O
(p O
> O
0.05) O
. O

the O
elderly O
group O
had O
a O
significantly O
greater O
pilocarpine-induced O
net O
decrease O
in O
pupil O
size O
85 O
, O
125 O
, O
165 O
and O
215 O
minutes O
after O
administration O
, O
compared O
with O
the O
young O
group O
(p O
< O
0.05) O
. O

compared O
with O
the O
young O
group O
, O
the O
elderly O
group O
had O
greater O
scopolamine-induced O
impairment B-NEG
in I-NEG
word I-NEG
recall I-NEG
60 O
, O
90 O
and O
120 O
minutes O
after O
administration O
(p O
< O
0.05) O
. O

conclusion O
: O
there O
is O
an O
age-related O
pupillary O
response O
to O
pilocarpine O
that O
is O
not O
found O
with O
tropicamide O
. O

thus O
, O
pilocarpine O
may O
be O
useful O
to O
assess O
variations O
in O
central O
cholinergic O
function O
in O
elderly O
patients O
. O

-DOCSTART- O

acetazolamide-induced O
gerstmann B-NEG
syndrome I-NEG
. O

acute O
confusion B-NEG
induced O
by O
acetazolamide O
is O
a O
well O
known O
adverse O
drug O
reaction O
in O
patients O
with O
renal B-NEG
impairment I-NEG
. O

we O
report O
a O
case O
of O
acetazolamide-induced O
gerstmann B-NEG
syndrome I-NEG
in O
a O
patient O
with O
normal O
renal O
function O
, O
to O
highlight O
predisposing O
factors O
that O
are O
frequently O
overlooked O
. O

-DOCSTART- O

hypomania B-NEG
-like O
syndrome O
induced O
by O
olanzapine O
. O

we O
report O
a O
female O
patient O
with O
a O
diagnosis O
of O
a O
not O
otherwise O
specified O
psychotic B-NEG
disorder I-NEG
( O
dsm-iv O
) O
who O
developed O
hypomania B-NEG
shortly O
after O
the O
introduction O
of O
olanzapine O
treatment O
. O

-DOCSTART- O

neutrophil O
superoxide O
and O
hydrogen O
peroxide O
production O
in O
patients O
with O
acute B-NEG
liver I-NEG
failure I-NEG
. O

defects O
in O
superoxide O
and O
hydrogen O
peroxide O
production O
may O
be O
implicated O
in O
the O
high O
incidence O
of O
bacterial B-NEG
infections I-NEG
in O
patients O
with O
acute B-NEG
liver I-NEG
failure I-NEG
( O
alf B-NEG
). O

in O
the O
present O
study O
, O
oxygen O
radical O
production O
in O
patients O
with O
alf B-NEG
due O
to O
paracetamol O
overdose B-NEG
was O
compared O
with O
that O
of O
healthy O
volunteers O
. O

neutrophils O
from O
14 O
alf B-NEG
patients O
were O
stimulated O
via O
the O
complement O
receptors O
using O
zymosan O
opsonized O
with O
alf B-NEG
or O
control O
serum O
. O

superoxide O
and O
hydrogen O
peroxide O
production O
by O
alf B-NEG
neutrophils O
stimulated O
with O
zymosan O
opsonized O
with O
alf B-NEG
serum O
was O
significantly O
reduced O
compared O
with O
the O
control O
subjects O
(p O
< O
0.01) O
. O

this O
defect O
persisted O
when O
zymosan O
opsonized O
by O
control O
serum O
was O
used O
(p O
< O
0.05) O
. O

superoxide O
and O
hydrogen O
peroxide O
production O
in O
neutrophils O
stimulated O
with O
formyl-methionyl-leucyl-phenylalanine O
( O
fmlp O
) O
from O
a O
further O
18 O
alf B-NEG
patients O
was O
unaffected O
compared O
with O
control O
neutrophils O
. O

serum O
c3 O
complement O
levels O
were O
significantly O
reduced O
in O
alf B-NEG
patients O
compared O
with O
control O
subjects O
(p O
< O
0.0005) O
. O

these O
results O
demonstrate O
a O
neutrophil O
defect O
in O
alf B-NEG
due O
to O
paracetamol O
overdose B-NEG
, O
that O
is O
complement O
dependent O
but O
independent O
of O
serum O
complement O
, O
possibly O
connected O
to O
the O
complement O
receptor O
. O

-DOCSTART- O

absence O
of O
effect O
of O
sertraline O
on O
time-based O
sensitization O
of O
cognitive B-NEG
impairment I-NEG
with O
haloperidol O
. O

this O
double-blind O
, O
randomized O
, O
placebo-controlled O
study O
evaluated O
the O
effects O
of O
haloperidol O
alone O
and O
haloperidol O
plus O
sertraline O
on O
cognitive O
and O
psychomotor O
function O
in O
24 O
healthy O
male O
subjects O
. O

method O
: O
all O
subjects O
received O
placebo O
on O
day O
1 O
and O
haloperidol O
2 O
mg O
on O
days O
2 O
and O
25 O
. O

from O
days O
9 O
to O
25 O
, O
subjects O
were O
randomly O
assigned O
to O
either O
sertraline O
( O
12 O
subjects O
) O
or O
placebo O
( O
12 O
subjects) O
; O
the O
sertraline O
dose O
was O
titrated O
from O
50 O
to O
200 O
mg/day O
from O
days O
9 O
to O
16 O
, O
and O
remained O
at O
200 O
mg/day O
for O
the O
final O
10 O
days O
of O
the O
drug O
administration O
period O
. O

cognitive O
function O
testing O
was O
performed O
before O
dosing O
and O
over O
a O
24-hour O
period O
after O
dosing O
on O
days O
1, O
2, O
and O
25 O
. O

results O
: O
impairment B-NEG
of I-NEG
cognitive I-NEG
function I-NEG
was O
observed O
6 O
to O
8 O
hours O
after O
administration O
of O
haloperidol O
on O
day O
2 O
but O
was O
not O
evident O
23 O
hours O
after O
dosing O
. O

when O
single-dose O
haloperidol O
was O
given O
again O
25 O
days O
later O
, O
greater O
impairment O
with O
earlier O
onset O
was O
noted O
in O
several O
tests O
in O
both O
treatment O
groups O
, O
suggesting O
enhancement O
of O
this O
effect O
. O

there O
was O
no O
indication O
that O
sertraline O
exacerbated O
the O
impairment O
produced O
by O
haloperidol O
since O
an O
equivalent O
effect O
also O
occurred O
in O
the O
placebo O
group O
. O

three O
subjects O
(2 O
on O
sertraline O
and O
1 O
on O
placebo O
) O
withdrew O
from O
the O
study O
because O
of O
side O
effects O
. O

ten O
subjects O
in O
each O
group O
reported O
side O
effects O
related O
to O
treatment O
. O

the O
side O
effect O
profiles O
of O
sertraline O
and O
of O
placebo O
were O
similar O
. O

conclusion O
: O
haloperidol O
produced O
a O
clear O
profile O
of O
cognitive B-NEG
impairment I-NEG
that O
was O
not O
worsened O
by O
concomitant O
sertraline O
administration O
. O

-DOCSTART- O

ciprofloxacin-induced O
nephrotoxicity B-NEG
in O
patients O
with O
cancer B-NEG
. O
nephrotoxicity B-NEG
associated O
with O
ciprofloxacin O
is O
uncommon O
. O

five O
patients O
with O
cancer B-NEG
who O
developed O
acute B-NEG
renal I-NEG
failure I-NEG
that O
followed O
treatment O
with O
ciprofloxacin O
are O
described O
and O
an O
additional O
15 O
cases O
reported O
in O
the O
literature O
are O
reviewed O
. O

other O
than O
elevation O
of O
serum O
creatinine O
levels O
, O
characteristic O
clinical O
manifestations O
and O
abnormal O
laboratory O
findings O
are O
not O
frequently O
present O
. O

allergic O
interstitial B-NEG
nephritis I-NEG
is O
believed O
to O
be O
the O
underlying O
pathological-process O
. O

definitive O
diagnosis O
requires O
performance O
of O
renal O
biopsy O
, O
although O
this O
is O
not O
always O
feasible O
. O

an O
improvement O
in O
renal O
function O
that O
followed O
the O
discontinuation O
of O
the O
offending O
antibiotic O
supports O
the O
presumptive O
diagnosis O
of O
ciprofloxacin-induced O
acute B-NEG
renal I-NEG
failure I-NEG
. O

-DOCSTART- O

case O
report O
: O
pentamidine O
and O
polymorphic O
ventricular B-NEG
tachycardia I-NEG
revisited O
. O

pentamidine O
isethionate O
has O
been O
associated O
with O
ventricular B-NEG
tachyarrhythmias I-NEG
, O
including O
torsade B-NEG
de I-NEG
pointes I-NEG
. O

this O
article O
reports O
two O
cases O
of O
this O
complication O
and O
reviews O
all O
reported O
cases O
to O
date O
. O

pentamidine-induced O
torsade B-NEG
de I-NEG
pointes I-NEG
may O
be O
related O
to O
serum O
magnesium O
levels O
and O
hypomagnesemia B-NEG
may O
synergistically O
induce O
torsade O
. O
torsade B-NEG
de I-NEG
pointes I-NEG
occurred O
after O
an O
average O
of O
10 O
days O
of O
treatment O
with O
pentamidine O
. O

in O
these O
patients O
, O
no O
other O
acute O
side O
effects O
of O
pentamidine O
were O
observed O
. O
torsade B-NEG
de I-NEG
pointes I-NEG
can O
be O
treated O
when O
recognized O
early O
, O
possibly O
without O
discontinuation O
of O
pentamidine O
. O

when O
qtc B-NEG
interval I-NEG
prolongation I-NEG
is O
observed O
, O
early O
magnesium O
supplementation O
is O
advocated O
. O

-DOCSTART- O

time O
dependence O
of O
plasma O
malondialdehyde O
, O
oxypurines O
, O
and O
nucleosides O
during O
incomplete O
cerebral B-NEG
ischemia I-NEG
in O
the O
rat O
. O

incomplete O
cerebral B-NEG
ischemia I-NEG
( O
30 O
min O
) O
was O
induced O
in O
the O
rat O
by O
bilaterally O
clamping O
the O
common O
carotid O
arteries O
. O

peripheral O
venous O
blood O
samples O
were O
withdrawn O
from O
the O
femoral O
vein O
four O
times O
( O
once O
every O
5 O
min O
) O
before O
ischemia B-NEG
(0 O
time O
) O
and O
5, O
15 O
, O
and O
30 O
min O
after O
ischemia B-NEG
. O

plasma O
extracts O
were O
analyzed O
by O
a O
highly O
sensitive O
high-performance O
liquid O
chromatographic O
method O
for O
the O
direct O
determination O
of O
malondialdehyde O
, O
oxypurines O
, O
and O
nucleosides O
. O

during O
ischemia B-NEG
, O
a O
time-dependent O
increase O
of O
plasma O
oxypurines O
and O
nucleosides O
was O
observed O
. O

plasma O
malondialdehyde O
, O
which O
was O
present O
in O
minimal O
amount O
at O
zero O
time O
( O
0.058 O
mumol/liter O
plasma O
; O
sd O
0.015) O
, O
increased O
after O
5 O
min O
of O
ischemia B-NEG
, O
resulting O
in O
a O
fivefold O
increase O
after O
30 O
min O
of O
carotid O
occlusion O
( O
0.298 O
mumol/liter O
plasma O
; O
sd O
0.078) O
. O

increased O
plasma O
malondialdehyde O
was O
also O
recorded O
in O
two O
other O
groups O
of O
animals O
subjected O
to O
the O
same O
experimental O
model O
, O
one O
receiving O
20 O
mg/kg O
b.w O
. O
of O
the O
cyclooxygenase O
inhibitor O
acetylsalicylate O
intravenously O
immediately O
before O
ischemia B-NEG
, O
the O
other O
receiving O
650 O
micrograms/kg O
b.w O
. O
of O
the O
hypotensive B-NEG
drug O
nitroprusside O
at O
a O
flow O
rate O
of O
103 O
microliters/min O
intravenously O
during O
ischemia B-NEG
, O
although O
in O
this O
latter O
group O
malondialdehyde O
was O
significantly O
higher O
. O

the O
present O
data O
indicate O
that O
the O
determination O
of O
malondialdehyde O
, O
oxypurines O
, O
and O
nucleosides O
in O
peripheral O
blood O
, O
may O
be O
used O
to O
monitor O
the O
metabolic O
alterations O
of O
tissues O
occurring O
during O
ischemic B-NEG
phenomena.(abstract O
truncated O
at O
250 O
words O
) O

-DOCSTART- O

cholinergic O
toxicity B-NEG
resulting O
from O
ocular O
instillation O
of O
echothiophate O
iodide O
eye O
drops O
. O

a O
patient O
developed O
a O
severe O
cholinergic O
syndrome O
from O
the O
use O
of O
echothiophate O
iodide O
ophthalmic O
drops O
, O
presented O
with O
profound O
muscle B-NEG
weakness I-NEG
and O
was O
initially O
given O
the O
diagnosis O
of O
myasthenia B-NEG
gravis I-NEG
. O

red O
blood O
cell O
and O
serum O
cholinesterase O
levels O
were O
severely O
depressed O
and O
symptoms O
resolved O
spontaneously O
following O
discontinuation O
of O
the O
eye O
drops O
. O

-DOCSTART- O

acute B-NEG
renal I-NEG
failure I-NEG
in O
high O
dose O
carboplatin O
chemotherapy O
. O

carboplatin O
has O
been O
reported O
to O
cause O
acute B-NEG
renal I-NEG
failure I-NEG
when O
administered O
in O
high O
doses O
to O
adult O
patients O
. O

we O
report O
a O
4 O
1/2-year-old O
girl O
who O
was O
treated O
with O
high-dose O
carboplatin O
for O
metastatic O
parameningeal O
embryonal B-NEG
rhabdomyosarcoma I-NEG
. O
acute B-NEG
renal I-NEG
failure I-NEG
developed O
followed O
by O
a O
slow O
partial O
recovery O
of O
renal O
function O
. O

possible O
contributing O
factors O
are O
discussed O
. O

-DOCSTART- O

endometrial B-NEG
carcinoma I-NEG
after O
hodgkin B-NEG
disease I-NEG
in O
childhood O
. O

a O
34-year-old O
patient O
developed O
metastic O
endometrial B-NEG
carcinoma I-NEG
after O
hodgkin B-NEG
disease I-NEG
in O
childhood O
. O

she O
had O
ovarian B-NEG
failure I-NEG
after O
abdominal O
irradiation O
and O
chemotherapy O
for O
hodgkin B-NEG
disease I-NEG
, O
and O
received O
exogenous O
estrogens O
, O
a O
treatment O
implicated O
in O
the O
development O
of O
endometrial B-NEG
cancer I-NEG
in O
menopausal O
women O
. O

young O
women O
on O
replacement O
estrogens O
for O
ovarian B-NEG
failure I-NEG
after O
cancer B-NEG
therapy O
may O
also O
have O
increased O
risk O
of O
endometrial B-NEG
carcinoma I-NEG
and O
should O
be O
examined O
periodically O
. O

-DOCSTART- O

induction O
of O
the O
obstructive B-NEG
sleep I-NEG
apnea I-NEG
syndrome I-NEG
in O
a O
woman O
by O
exogenous O
androgen O
administration O
. O

we O
documented O
airway O
occlusion O
during O
sleep O
and O
an O
abnormally O
high O
supraglottic O
resistance O
while O
awake O
in O
a O
54-yr-old O
woman O
who O
had O
developed O
physical O
changes O
and O
the O
syndrome B-NEG
of I-NEG
obstructive I-NEG
sleep I-NEG
apnea I-NEG
while O
being O
administered O
exogenous O
androgens O
. O

when O
the O
androgens O
were O
withdrawn O
, O
the O
patient's O
physical O
changes O
, O
symptoms O
, O
sleep O
study O
, O
and O
supraglottic O
resistance O
all O
returned O
to O
normal O
. O

a O
rechallenge O
with O
androgen O
produced O
symptoms O
of O
obstructive B-NEG
sleep I-NEG
apnea I-NEG
that O
abated O
upon O
withdrawal O
of O
the O
hormone O
. O

previous O
reports O
have O
favored O
a O
role O
of O
androgens O
in O
the O
pathogenesis O
of O
sleep B-NEG
apnea I-NEG
. O

our O
report O
provides O
direct O
evidence O
for O
this O
role O
. O

structural O
and O
functional O
measurements O
indicate O
that O
androgens O
exert O
a O
permissive O
or O
necessary O
action O
on O
the O
structural O
configuration O
of O
the O
oropharynx O
that O
predisposes O
to O
obstruction O
during O
sleep O
. O

development O
of O
the O
obstructive B-NEG
sleep I-NEG
apnea I-NEG
syndrome I-NEG
must O
be O
considered O
a O
possible O
side O
effect O
of O
androgen O
therapy O
. O

-DOCSTART- O

effect O
of O
captopril O
on O
pre-existing O
and O
aminonucleoside-induced O
proteinuria B-NEG
in O
spontaneously O
hypertensive B-NEG
rats O
. O
proteinuria B-NEG
is O
a O
side O
effect O
of O
captopril O
treatment O
in O
hypertensive B-NEG
patients O
. O

the O
possibility O
of O
reproducing O
the O
same O
renal B-NEG
abnormality I-NEG
with O
captopril O
was O
examined O
in O
shr O
. O

oral O
administration O
of O
captopril O
at O
100 O
mg/kg O
for O
14 O
days O
failed O
to O
aggravate O
proteinuria B-NEG
pre-existing O
in O
shr O
. O

also O
, O
captopril O
treatment O
failed O
to O
potentiate O
or O
facilitate O
development O
of O
massive O
proteinuria B-NEG
invoked O
by O
puromycin O
aminonucleoside O
in O
shr O
. O

captopril O
had O
little O
or O
no O
demonstrable O
effects O
on O
serum O
electrolyte O
concentrations O
, O
excretion O
of O
urine O
, O
sodium O
and O
potassium O
, O
endogenous O
creatinine O
clearance O
, O
body O
weight O
, O
and O
food O
and O
water O
consumption O
. O

however O
, O
ketone O
bodies O
were O
consistently O
present O
in O
urine O
and O
several O
lethalities O
occurred O
during O
multiple O
dosing O
of O
captopril O
in O
shr O
. O

-DOCSTART- O

epileptogenic O
properties O
of O
enflurane O
and O
their O
clinical O
interpretation O
. O

three O
cases O
of O
eeg O
changes O
induced O
by O
single O
exposure O
to O
enflurane O
anesthesia O
are O
reported O
. O

in O
one O
patient O
, O
enflurane O
administered O
during O
a O
donor O
nephrectomy O
resulted O
in O
unexpected O
partial O
motor O
seizures B-NEG
. O

until O
the O
cause O
of O
the O
seizures B-NEG
was O
correctly O
identified O
, O
the O
patient O
was O
inappropriately O
treated O
with O
anticonvulsants O
. O

two O
other O
patients O
suffered O
from O
partial O
, O
complex O
and O
generalized O
seizures B-NEG
uncontrolled O
by O
medication O
. O
epileptic B-NEG
foci O
delineated O
and O
activated O
by O
enflurane O
were O
surgically O
ablated O
and O
the O
patients O
are O
now O
seizure B-NEG
-free O
. O

previous O
exposures O
to O
enflurane O
have O
to O
be O
disclosed O
to O
avoid O
mistakes O
in O
clinical O
interpretation O
of O
the O
eeg O
. O

on O
the O
other O
hand O
, O
enflurane O
may O
prove O
to O
be O
a O
safe O
fast O
acting O
activator O
of O
epileptic B-NEG
foci O
during O
corticography O
or O
depth O
electrode O
intraoperative O
recordings O
. O

-DOCSTART- O

reversible O
cerebral B-NEG
lesions I-NEG
associated O
with O
tiazofurin O
usage O
: O
mr O
demonstration O
. O

tiazofurin O
is O
an O
experimental O
chemotherapeutic O
agent O
currently O
undergoing O
clinical O
evaluation O
. O

we O
report O
our O
results O
with O
magnetic O
resonance O
( O
mr O
) O
in O
demonstrating O
reversible O
cerebral B-NEG
abnormalities I-NEG
concurrent O
with O
the O
use O
of O
this O
drug O
. O

the O
abnormalities O
on O
mr O
were O
correlated O
with O
findings O
on O
ct O
as O
well O
as O
with O
cerebral O
angiography O
. O

the O
utility O
of O
mr O
in O
the O
evaluation O
of O
patients O
receiving O
this O
new O
agent O
is O
illustrated O
. O

-DOCSTART- O

antagonism O
of O
diazepam-induced O
sedative O
effects O
by O
ro15-1788 O
in O
patients O
after O
surgery O
under O
lumbar O
epidural O
block O
. O

a O
double-blind O
placebo-controlled O
investigation O
of O
efficacy O
and O
safety O
. O

the O
aim O
of O
this O
study O
was O
to O
assess O
the O
efficacy O
of O
ro15-1788 O
and O
a O
placebo O
in O
reversing O
diazepam-induced O
effects O
after O
surgery O
under O
epidural O
block O
, O
and O
to O
evaluate O
the O
local O
tolerance O
and O
general O
safety O
of O
ro15-1788 O
. O

fifty-seven O
patients O
were O
sedated O
with O
diazepam O
for O
surgery O
under O
epidural O
anaesthesia O
. O

antagonism O
of O
diazepam-induced O
effects O
by O
ro15-1788 O
was O
investigated O
postoperatively O
in O
a O
double-blind O
placebo-controlled O
trial O
. O

the O
patient's O
subjective O
assessment O
of O
mood O
rating O
, O
an O
objective O
test O
of O
performance O
, O
a O
test O
for O
amnesia B-NEG
, O
and O
vital O
signs O
were O
recorded O
for O
up O
to O
300 O
min O
after O
administration O
of O
the O
trial O
drug O
. O

no O
significant O
differences O
between O
the O
two O
groups O
were O
observed O
for O
mood O
rating O
, O
amnesia B-NEG
, O
or O
vital O
signs O
. O

the O
ro15-1788 O
group O
showed O
a O
significant O
improvement O
in O
the O
performance O
test O
up O
to O
120 O
min O
after O
administration O
of O
the O
drug O
. O

there O
was O
no O
evidence O
of O
reaction O
at O
the O
injection O
site O
. O

-DOCSTART- O

enhanced O
stimulus-induced O
neurotransmitter O
overflow O
in O
epinephrine-induced O
hypertensive B-NEG
rats O
is O
not O
mediated O
by O
prejunctional O
beta-adrenoceptor O
activation O
. O

the O
present O
study O
examines O
the O
effect O
of O
6-day O
epinephrine O
treatment O
( O
100 O
micrograms/kg O
per O
h, O
s.c. O
) O
on O
stimulus-induced O
(1 O
hz O
) O
endogenous O
neurotransmitter O
overflow O
from O
the O
isolated O
perfused O
kidney O
of O
vehicle- O
and O
epinephrine-treated O
rats O
. O

renal O
catecholamine O
stores O
and O
stimulus-induced O
overflow O
in O
the O
vehicle-treated O
group O
consisted O
of O
norepinephrine O
only O
. O

however O
, O
epinephrine O
treatment O
resulted O
in O
the O
incorporation O
of O
epinephrine O
into O
renal O
catecholamine O
stores O
such O
that O
approximately O
40% O
of O
the O
catecholamine O
present O
was O
epinephrine O
while O
the O
norepinephrine O
content O
was O
reduced O
by O
a O
similar O
degree O
. O

total O
tissue O
catecholamine O
content O
of O
the O
kidney O
on O
a O
molar O
basis O
was O
unchanged O
. O

stimulus-induced O
fractional O
overflow O
of O
neurotransmitter O
from O
the O
epinephrine-treated O
kidneys O
was O
approximately O
twice O
normal O
and O
consisted O
of O
both O
norepinephrine O
and O
epinephrine O
in O
proportions O
similar O
to O
those O
found O
in O
the O
kidney O
. O

this O
difference O
in O
fractional O
overflow O
between O
groups O
was O
not O
affected O
by O
neuronal O
and O
extraneuronal O
uptake O
blockade O
. O

propranolol O
had O
no O
effect O
on O
stimulus-induced O
overflow O
in O
either O
group O
. O

phentolamine O
increased O
stimulus-induced O
overflow O
in O
both O
groups O
although O
the O
increment O
in O
overflow O
was O
greater O
in O
the O
epinephrine-treated O
group O
. O

in O
conclusion O
, O
chronic O
epinephrine O
treatment O
results O
in O
enhanced O
fractional O
neurotransmitter O
overflow O
. O

however O
, O
neither O
alterations O
in O
prejunctional O
beta-adrenoceptor O
influences O
nor O
alterations O
in O
neuronal O
and O
extraneuronal O
uptake O
mechanisms O
appear O
to O
be O
responsible O
for O
this O
alteration O
. O

furthermore O
, O
data O
obtained O
with O
phentolamine O
alone O
do O
not O
suggest O
alpha-adrenoceptor O
desensitization O
as O
the O
cause O
of O
the O
enhanced O
neurotransmitter O
overflow O
after O
epinephrine O
treatment O
. O

-DOCSTART- O

ocular O
manifestations O
of O
juvenile B-NEG
rheumatoid I-NEG
arthritis I-NEG
. O

we O
followed O
210 O
cases O
of O
juvenile B-NEG
rheumatoid I-NEG
arthritis I-NEG
closely O
for O
eleven O
years O
. O

thirty-six O
of O
the O
210 O
patients O
( O
17.2% O
) O
developed O
iridocyclitis B-NEG
. O
iridocyclitis B-NEG
was O
seen O
most O
frequently O
in O
young O
female O
patients O
(0 O
to O
4 O
years O
) O
with O
the O
monoarticular O
or O
pauciatricular O
form O
of O
the O
arthritis B-NEG
. O

however O
, O
30% O
of O
the O
patients O
developed O
uveitis B-NEG
after O
16 O
years O
of O
age O
. O

although O
61% O
of O
patients O
had O
a O
noncontributory O
ocular O
history O
on O
entry O
, O
42% O
had O
active O
uveitis B-NEG
on O
entry O
. O

our O
approach O
was O
effective O
in O
detecting O
uveitis B-NEG
in O
new O
cases O
and O
exacerbations O
of O
uveitis B-NEG
in O
established O
cases O
. O

forty-four O
percent O
of O
patients O
with O
uveitis B-NEG
had O
one O
or O
more O
identifiable O
signs O
or O
symptoms O
, O
such O
as O
red O
eye O
, O
ocular B-NEG
pain I-NEG
, O
decreased B-NEG
visual I-NEG
acuity I-NEG
, O
or O
photophobia B-NEG
, O
in O
order O
of O
decreasing O
frequency O
. O

even O
after O
early O
detection O
and O
prompt O
treatment O
, O
41% O
of O
cases O
of O
uveitis B-NEG
did O
not O
respond O
to O
more O
than O
six O
months O
of O
intensive O
topical O
treatment O
with O
corticosteroids O
and O
mydriatics O
. O

despite O
this O
, O
there O
was O
a O
dramatic O
decrease O
in O
the O
50% O
incidence O
of O
blinding O
complications O
of O
uveitis B-NEG
cited O
in O
earlier O
studies O
. O
cataract B-NEG
and O
band B-NEG
keratopathy I-NEG
occurred O
in O
only O
22 O
and O
13% O
of O
our O
group O
, O
respectively O
. O

we O
used O
chloroquine O
or O
hydroxychloroquine O
in O
173 O
of O
210 O
cases O
and O
found O
only O
one O
case O
of O
chorioretinopathy B-NEG
attributable O
to O
these O
drugs O
. O

systemically O
administered O
corticosteroids O
were O
used O
in O
75 O
of O
210 O
cases O
; O
a O
significant O
number O
of O
posterior O
subcapsular O
cataracts B-NEG
was O
found O
. O

typical O
keratoconjunctivitis B-NEG
sicca O
developed O
in O
three O
of O
the O
uveitis B-NEG
cases O
. O

this O
association O
with O
uveitis B-NEG
and O
jra O
was O
not O
noted O
previously O
. O

surgical O
treatment O
of O
cataracts B-NEG
, O
band B-NEG
keratopathy I-NEG
, O
and O
glaucoma B-NEG
achieved O
uniformly O
discouraging O
results O
. O

-DOCSTART- O

water B-NEG
intoxication I-NEG
associated O
with O
oxytocin O
administration O
during O
saline-induced O
abortion B-NEG
. O

four O
cases O
of O
water B-NEG
intoxication I-NEG
in O
connection O
with O
oxytocin O
administration O
during O
saline-induced O
abortions B-NEG
are O
described O
. O

the O
mechanism O
of O
water B-NEG
intoxication I-NEG
is O
discussed O
in O
regard O
to O
these O
cases O
. O

oxytocin O
administration O
during O
midtrimester-induced O
abortions B-NEG
is O
advocated O
only O
if O
it O
can O
be O
carried O
out O
under O
careful O
observations O
of O
an O
alert O
nursing O
staff O
, O
aware O
of O
the O
symptoms O
of O
water B-NEG
intoxication I-NEG
and O
instructed O
to O
watch O
the O
diuresis O
and O
report O
such O
early O
signs O
of O
the O
syndrome O
as O
asthenia B-NEG
, O
muscular O
irritability B-NEG
, O
or O
headaches B-NEG
. O

the O
oxytocin O
should O
be O
given O
only O
in O
ringers O
lactate O
or O
, O
alternately O
, O
in O
ringers O
lactate O
and O
a O
5 O
per O
cent O
dextrose O
and O
water O
solutions O
. O

the O
urinary O
output O
should O
be O
monitored O
and O
the O
oxytocin O
administration O
discontinued O
and O
the O
serum O
electrolytes O
checked O
if O
the O
urinary O
output O
decreases O
. O

the O
oxytocin O
should O
not O
be O
administered O
in O
excess O
of O
36 O
hours O
. O

if O
the O
patient O
has O
not O
aborted O
by O
then O
the O
oxytocin O
should O
be O
discontinued O
for O
10 O
to O
12 O
hours O
in O
order O
to O
perform O
electrolyte O
determinations O
and O
correct O
any O
electrolyte O
imbalance O
. O

-DOCSTART- O

omeprazole O
is O
a O
proton O
pump O
inhibitor O
that O
suppresses O
gastric B-NEU
acid I-NEU
secretion I-NEU
by O
specific O
inhibition O
of O
the O
h+/k+-atpase O
in O
the O
gastric O
parietal O
cell O
. O

by O
acting O
specifically O
on O
the O
proton O
pump O
, O
omeprazole O
blocks O
the O
final O
step O
in O
acid O
production O
, O
thus O
reducing O
gastric B-NEU
acidity I-NEU
. O

-DOCSTART- O

wind-toxic B-NEG
pathogen O

-DOCSTART- O

to O
diffuse O
lung O
qi O
, O
dispel O
wind-damp B-NEG
, O
disperse O
swelling B-NEG
toxin I-NEG
. O

-DOCSTART- O

other O
nutritional B-NEG
deficiencies I-NEG

-DOCSTART- O

treatment O
of O
bdominal O
pain B-NEG
and O
constipation B-NEG
due O
to O
cold B-NEG
or O
retention B-NEG
of I-NEG
food I-NEG
in O
the O
intestines O
. O

-DOCSTART- O

hiv-1 B-NEG
infection I-NEG

-DOCSTART- O

this O
means O
no O
rash B-NEG
formation O
after O
days O
of O
fever B-NEG
. O

-DOCSTART- O

to O
cause O
catharsis O
and O
purge O
away O
heat B-NEU
, O
to O
reduce O
heat B-NEU
in O
blood B-DNP
and O
counteract O
toxicity B-NEG
, O
and O
to O
eliminate O
blood B-DNP
stasis I-DNP
and O
stimulate O
menstrual B-DNP
discharge I-DNP
. O

-DOCSTART- O

weak B-NEG
and I-NEG
reduced I-NEG
yin I-NEG
blood I-NEG
after O
treatment O
, O
exterior B-NEG
evil I-NEG
, O
loss B-NEG
of I-NEG
blood I-NEG
, O
cold B-NEG
and O
period O
, O
headache B-NEG
, O
hot B-NEU
body I-NEU
, O
feeling O
slightly O
cold B-NEG
, O
no B-NEG
sweating I-NEG
. O

-DOCSTART- O

quality O
of O
life O
, O
others O

-DOCSTART- O

a O
high O
performance O
liquid O
chromatography-hydride O
generation-atomic O
fluorescence O
spectrometry O
( O
hplc-hg-afs O
) O
method O
was O
developed O
for O
the O
simultaneous O
determination O
of O
four O
arsenic O
species O
( O
as(iii) O
) O
, O
dimethylarsinic O
acid O
( O
dma O
) O
, O
monomethylarsonic O
acid O
( O
mma O
) O
and O
arsenate O
as(v) O
in O
dog O
plasma O
. O

good O
separation O
of O
the O
four O
arsenic O
species O
was O
achieved O
within O
15min O
on O
an O
anion-exchange O
column O
with O
isocratic O
elution O
using O
15mmol/l O
kh(2)po(4 O
) O
( O
ph O
5.9 O
) O
as O
eluent O
at O
a O
flow O
rate O
of O
1.0ml/min O
. O

the O
assay O
was O
linear O
over O
the O
range O
of O
1.25-200 O
, O
1.56-200 O
, O
1.34-172 O
, O
and O
2.50-200ng/ml O
with O
the O
detection O
limits O
of O
0.8 O
, O
1 O
, O
0.86 O
and O
2.00ng/ml O
for O
as O
( O
iii O
) O
, O
dma O
, O
mma O
and O
as O
( O
v O
) O
, O
respectively O
. O

the O
method O
was O
validated O
for O
selectivity O
, O
precision O
, O
accuracy O
and O
recovery O
and O
then O
applied O
to O
a O
comparative O
pharmacokinetic O
study O
of O
the O
arsenic O
species O
in O
beagle O
dogs O
after O
a O
single O
oral O
administration O
of O
realgar O
( O
24.32mg/kg O
, O
equivalent O
to O
11.31mgas/kg O
) O
alone O
or O
niu O
huang O
jie O
du O
pian O
(a O
patent O
traditional O
chinese O
medicine O
( O
tcm O
) O
, O
380mg/kg O
, O
equivalent O
to O
28.45mgas/kg O
) O
, O
respectively O
. O

dma O
was O
found O
to O
be O
the O
predominant O
species O
in O
the O
dog O
plasma O
after O
dosing O
, O
with O
as(v O
) O
appeared O
as O
the O
quickly O
eliminating O
one O
. O

no O
traces O
of O
mma O
and O
as(iii O
) O
were O
detected O
at O
any O
sampling O
time O
points O
. O

the O
main O
pharmacokinetic O
parameters O
found O
for O
dma O
p.o O
. O
administration O
of O
realgar O
and O
niu O
huang O
jie O
du O
pian O
were O
as O
follows O
: O
c(max O
) O
( O
14.7 O
4.2 O
) O
and O
( O
57 O
32.0)ng/ml O
, O
t(max O
) O
( O
2.4 O
0.5 O
) O
and O
( O
2.5 O
0.5)h O
, O
auc(0-36 O
) O
( O
151.1 O
12.9 O
) O
and O
( O
635.9 O
418.2)ngh/ml O
, O
auc(0- O
) O
( O
206 O
44.5 O
) O
and O
( O
687.2 O
425.1)ngh/ml O
, O
t(1/2 O
) O
( O
16.2 O
7.9 O
) O
and O
( O
9.4 O
2.2)h O
, O
respectively O
. O

the O
influence O
of O
compounding O
in O
niu O
huang O
jie O
du O
pian O
on O
the O
pharmacokinetics O
of O
arsenics O
was O
shown O
with O
increased O
transformation O
of O
dma O
and O
its O
faster O
elimination O
rate O
. O

-DOCSTART- O

to O
dispel O
wind-damp B-NEG
, O
quicken O
blood B-DNP
and O
relieve O
pain B-NEG
, O
resolve O
toxin B-NEG
. O

-DOCSTART- O

stage O
ii O
childhood B-NEG
lymphoblastic I-NEG
lymphoma I-NEG

-DOCSTART- O

treatment O
of O
ulcer B-NEG
difficulty O
to O
heal O
, O
wounds B-NEG
, O
burns B-NEG
and O
scalds B-NEG
. O

-DOCSTART- O

to O
replenish O
the O
liver B-DNP
and O
the O
kidney B-DNP
, O
and O
to O
arrest O
bleeding B-NEG
by O
removing O
heat B-NEU
from I-NEU
blood I-NEU
. O

-DOCSTART- O

treatment O
of O
cough B-NEG
, O
asthma B-NEG
and O
distending B-NEG
pain I-NEG
of O
the O
chest O
caused O
by O
cold B-NEG
phlegm I-NEG
, O
arthralgia B-NEG
accompanied O
by O
numbness B-NEG
due O
to O
obstruction O
of O
collaterals O
by O
phlegm B-NEG
, O
deep O
abscess B-NEG
. O

-DOCSTART- O

endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
reproductive B-DNP
systems I-DNP
, O
strength B-POS
and O
power B-POS
, O
physical B-DNP
performance I-DNP
and O
fitness B-POS

-DOCSTART- O

1 O
to O
dispel O
cold B-NEG
and O
stop O
pain B-NEG
; O
2 O
to O
regulate O
qi O
and O
harmonize O
the O
stomach B-DNP

-DOCSTART- O

abortion B-NEG

-DOCSTART- O

neck B-NEG
stiffness I-NEG
; O
neck B-NEG
rigidity I-NEG
; O
rigidity B-NEG
of I-NEG
the I-NEG
neck I-NEG
; O
rigid B-NEG
neck I-NEG

-DOCSTART- O

anticancer B-POS

-DOCSTART- O

arrhythmia B-NEG

-DOCSTART- O

arthralgia B-NEG
; O
pi B-NEG
syndrome I-NEG

-DOCSTART- O

sumatriptan O
is O
a O
serotonin O
agonist O
that O
acts O
selectively O
at O
5ht1 O
receptors O
. O

naproxen O
inhibits O
the O
activity B-DNP
of I-DNP
the I-DNP
enzymes I-DNP
cyclo-oxygenase I-DNP
i I-DNP
and I-DNP
ii I-DNP
, O
resulting O
in O
a O
decreased O
formation B-DNP
of I-DNP
precursors I-DNP
of I-DNP
prostaglandins I-DNP
and I-DNP
thromboxanes I-DNP
. O

-DOCSTART- O

invigorate O
the O
spleen B-DNP
and O
resolve O
accumulation O

-DOCSTART- O

warm O
the O
lumbus B-DNP
and O
knees B-DNP

-DOCSTART- O

fever B-NEG
of O
juvenile O
gamjeck O

-DOCSTART- O

1 O
its O
decoction O
is O
a O
broad-spectrum O
bacteriostatic O
. O

2 O
stimulating O
the O
mucosa O
of O
respiratory O
tract O
directly O
, O
promoting O
secretion O
and O
expectoration O
. O

3 O
its O
volatile O
oil O
kills O
trichomonas B-NEG
vaginalis I-NEG
in O
vitro O
. O

4 O
its O
volatile O
oil O
is O
also O
an O
analgesic O
. O

-DOCSTART- O

endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
reproductive B-DNP
systems I-DNP
, O
blood B-NEU
pressure I-NEU
, O
lipid B-NEU
profile I-NEU
, O
overall O
cvd B-NEG
, O
diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
others O
, O
hemostatic B-DNP
function I-DNP
, O
protective O
immunity B-NEU

-DOCSTART- O

eum O
deficiency O
of O
liver O
and O
kidney O
; O
deficiency O
of O
eum(vital O
essence O
) O
of O
the O
liver O
and O
kidney O

-DOCSTART- O

sudden O
turmoil B-NEG
; O

cholera B-NEG
disease I-NEG
; O

acute B-NEG
gastroenteritis I-NEG
; O

acute B-NEG
vomiting I-NEG
and O
diarrhea B-NEG
a O
group O
of O
diseases B-NEG
including O
cholera B-NEG
, O
characterized O
by O
sudden B-NEG
and I-NEG
drastic I-NEG
vomiting I-NEG
and I-NEG
diarrhea I-NEG
. O

-DOCSTART- O

eum O
in O
its O
extreme O
rise O
to O
agitation O

-DOCSTART- O

disperse O
cold B-NEG
and O
eliminate O
dampness B-NEG

-DOCSTART- O

treatment O
of O
chronic B-NEG
rheumatiod I-NEG
arthritis I-NEG
with O
numbness B-NEG
and O
ankylosis B-NEG
, O
hemiplegia B-NEG
in O
stroke O
, O
convulsion B-NEG
, O
tetanus B-NEG
, O
leprosy B-NEG
, O
scabies B-NEG
, O
scrofula B-NEG
with O
suppuration B-NEG
. O

-DOCSTART- O

dispel O
wind-damp B-NEG

-DOCSTART- O

nine O
kinds O
of O
illness B-NEG
due O
to O
disturbance O
of O
gi O

-DOCSTART- O

settle O
the O
pain B-NEG
and O
tranquilize O

-DOCSTART- O

infertility B-NEG

-DOCSTART- O

breast B-NEG
abscess I-NEG
; O
acute B-NEG
mastitis I-NEG

-DOCSTART- O

wind-damp B-NEG
impediment O
pain B-NEG
, O
taxation O
damage O
in O
lumbar B-DNP
muscle I-DNP
, O
knocks O
and O
falls O
. O

-DOCSTART- O

numbness B-NEG
of I-NEG
the I-NEG
extremities I-NEG
, O
aching B-NEG
of O
the O
joints O
and O
menstrual B-NEG
disorders I-NEG
due O
to O
deficiency B-NEG
of I-NEG
blood I-NEG
. O

-DOCSTART- O

croton O
seed O
( O
badou O
) O
is O
used O
externally O
. O

-DOCSTART- O

stage O
ii O
contiguous O
adult B-NEG
lymphoblastic I-NEG
lymphoma I-NEG

-DOCSTART- O

this O
is O
bleeding B-NEG
due O
to O
an O
external B-NEG
wound I-NEG
. O

-DOCSTART- O

wind-damp B-NEG
impediment I-NEG
pain I-NEG
, O
knocks B-NEG
and O
falls B-NEG
, O
pain B-NEG
in O
stomach O
duct O
, O
hemiplegia B-NEG
, O
gan B-NEG
accumulation I-NEG
, O
dysentery B-NEG
. O

-DOCSTART- O

to O
relax O
the O
bowels B-DNP
( O
sthenia-syndrome B-NEG
with O
constipation B-NEG
due O
to O
accumulation O
of O
cold B-NEG
, O
dysentery B-NEG
of I-NEG
cold I-NEG
type O
) O
. O

-DOCSTART- O

metastatic B-NEG
cancer I-NEG

-DOCSTART- O

pralnacasan O
inhibits O
interleukin-1beta B-DNP
converting I-DNP
enzyme I-DNP
( O
ice B-DNP
) O
, O
an O
enzyme B-DNP
that O
regulates O
the O
production B-NEU
of I-NEU
il-1 I-NEU
and I-NEU
ifn I-NEU
gamma I-NEU
- I-NEU
intercellular I-NEU
mediators I-NEU
that O
initiate O
and O
sustain O
the O
process O
of O
inflammation B-NEG
. O

inhibiting O
ice B-DNP
may O
be O
an O
effective O
strategy O
for O
curtailing O
damaging O
inflammatory O
processes O
common O
to O
a O
number O
of O
acute O
and O
chronic O
conditions O
, O
such O
as O
rheumatoid B-NEG
arthritis I-NEG
( O
ra B-NEG
) O
and O
osteoarthritis B-NEG
. O

-DOCSTART- O

boils B-NEG
and O
carbuncles B-NEG
. O

-DOCSTART- O

kallmann B-NEG
syndrome I-NEG

-DOCSTART- O

kworeum O
headache B-NEG
caused O
by O
disorders O
of O
kworeum O
channel O
and O
aching B-NEG
along O
the O
kworeum O
channel O
over O
the O
head O

-DOCSTART- O

this O
is O
a O
syndrome O
that O
the O
both O
cheeks O
of O
children O
turn O
red O
. O

-DOCSTART- O

invigorate O
blood B-DNP
and O
regulate O
menstruation B-NEU

-DOCSTART- O

second-degree B-NEG
burn I-NEG

-DOCSTART- O

disperse O
carbuncle B-NEG
swelling B-NEG

-DOCSTART- O

chlorambucil O
alkylates O
and O
cross-links O
dna O
during O
all O
phases O
of O
the O
cell O
cycle O
, O
resulting O
in O
disruption B-NEG
of I-NEG
dna I-NEG
function I-NEG
, O
cell B-NEU
cycle I-NEU
arrest I-NEU
, O
and O
apoptosis O
. O

-DOCSTART- O

dispel O
cold B-NEG
and O
relieve O
pain B-NEG

-DOCSTART- O

diagnostic O
agent O
for O
radionuclide O
myocardial O
perfusion O
imaging O
( O
mpi O
) O

-DOCSTART- O

unblock O
the O
network B-DNP
vessels I-DNP

-DOCSTART- O

swelling B-NEG
and O
pain B-NEG
of O
the O
anus O

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
digestion B-NEU
, O
absorption B-NEU
, O
improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
body B-NEU
weight I-NEU
regulation I-NEU
, O
motility B-NEU
, O
others O

-DOCSTART- O

woman O
, O
eldery O
, O
menopausal B-NEG
woman I-NEG
, O
others O

-DOCSTART- O

treatment O
of O
: O
1 O
deficient O
yin O
of O
the O
lungs B-DNP
with O
heat B-NEU
manifested O
as O
dry B-NEG
cough I-NEG
or O
cough B-NEG
with O
scanty O
sputum B-NEG
, O
hoarse B-NEG
voice I-NEG
from O
a O
chronic B-NEG
cough I-NEG
, O
dry B-NEU
throat I-NEU
and O
thirst B-NEU
. O

glehnia O
root O
( O
shashen O
) O
is O
used O
with O
ophiopogon O
root O
( O
maidong O
) O
and O
tendrilled O
fritillary O
bulb O
( O
chuanbeimu O
) O
. O

2 O
body O
fluids O
consumed O
by O
febrile B-NEG
diseases I-NEG
manifested O
as O
dry B-NEG
tongue I-NEG
and O
poor B-NEG
appetite I-NEG
. O

glehnia O
root O
( O
shashen O
) O
is O
used O
with O
ophiopogon O
root O
( O
maidong O
) O
, O
fresh O
rehmannia O
root O
( O
shengdihuang O
) O
and O
fragrant O
solomonseal O
rhizome O
( O
yuzhu O
) O
in O
the O
formula O
yiwei O
tang O
. O

-DOCSTART- O

spasmodic B-NEG
contraction I-NEG
of I-NEG
tendons I-NEG
and I-NEG
meridian I-NEG

-DOCSTART- O

white B-NEG
turbid I-NEG
urine I-NEG

-DOCSTART- O

bone B-NEG
marrow I-NEG
suppression I-NEG

-DOCSTART- O

inhibiting O
the O
growth O
of O
various O
kinds O
of O
dermatomyces B-DNP
. O

-DOCSTART- O

disperse O
stasis B-NEG

-DOCSTART- O

latent O
summer B-NEG
heat I-NEG
syndrome I-NEG

-DOCSTART- O

1 O
application O
to O
cass O
of O
early O
stage O
of O
superficial O
pyogenic O
infection O
with O
local O
signs O
of O
inflammation B-NEG
, O
chilliness B-NEG
, O
fever B-NEG
, O
bitter B-NEG
mouth I-NEG
, O
constipation B-NEG
, O
oliguria B-NEG
, O
red B-NEG
tongue I-NEG
with O
white O
fur O
and O
rapid B-NEU
pulse I-NEU
. O
2 O
also O
indicated O
for O
cases O
of O
urticaria B-NEG
and O
e O

-DOCSTART- O

edema B-NEG
edema B-NEG
, O
pathogenesis O
of O
which O
is O
associated O
with O
dysfunction B-NEG
of I-NEG
the I-NEG
lung I-NEG
, I-NEG
spleen I-NEG
and I-NEG
kidney I-NEG
. O

-DOCSTART- O

myelomeningocele B-NEG

-DOCSTART- O

adult B-NEG
acute I-NEG
myelomonocytic I-NEG
leukemia I-NEG

-DOCSTART- O

the O
precise O
mechanism O
of O
action O
has O
not O
been O
fully O
determined O
, O
but O
the O
main O
mechanism O
of O
fluorouracil O
is O
thought O
to O
be O
the O
binding O
of O
the O
deoxyribonucleotide O
of O
the O
drug O
( O
fdump O
) O
and O
the O
folate O
cofactor O
, O
n50-methylenetetrahydrofolate O
, O
to O
thymidylate O
synthase O
( O
ts O
) O
to O
form O
a O
covalently O
bound O
ternary O
complex O
. O

this O
results O
in O
the O
inhibition O
of O
the O
formation B-NEU
of I-NEU
thymidylate I-NEU
from O
uracil O
, O
which O
leads O
to O
the O
inhibition O
of O
dna B-NEU
and I-NEU
rna I-NEU
synthesis I-NEU
and O
cell B-NEU
death I-NEU
. O

fluorouracil O
can O
also O
be O
incorporated O
into O
rna B-DNP
in O
place O
of O
uridine O
triphosphate O
( O
utp O
) O
, O
producing O
a O
fraudulent B-DNP
rna I-DNP
and O
interfering O
with O
rna B-NEU
processing I-NEU
and O
protein B-NEU
synthesis I-NEU
. O

-DOCSTART- O

gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
inflammation B-NEG
, O
other O
system O
health O
, O
others O

-DOCSTART- O

red B-NEG
eyes I-NEG
with O
gall O
, O
pulmonary O
welling O
abscess B-NEG
, O
diarrhea B-NEG
, O
dysentery B-NEG
, O
leukorrhea B-NEG
, O
postpartum O
blood B-NEG
stasis I-NEG
abdominal B-NEG
pain I-NEG
, O
indigestion B-NEG
, O
nephritis B-NEG
with O
edema B-NEG
, O
cirrhosis B-NEG
with O
ascites B-NEG
, O
swelling B-NEG
toxin O
of O
welling B-NEG
abscess I-NEG
and O
sore B-NEG
. O

-DOCSTART- O

hemodialysis B-NEG

-DOCSTART- O

penbutolol O
is O
indicated O
in O
the O
treatment O
of O
mild O
to O
moderate B-NEG
arterial I-NEG
hypertension I-NEG
. O

it O
may O
be O
used O
alone O
or O
in O
combination O
with O
other O
antihypertensive O
agents O
, O
especially O
thiazide-type O
diuretics O
. O

penbutolol O
is O
contraindicated O
in O
patients O
with O
cardiogenic B-NEG
shock I-NEG
, O
sinus B-NEG
bradycardia I-NEG
, O
second B-NEG
and I-NEG
third I-NEG
degree I-NEG
atrioventricular I-NEG
conduction I-NEG
block I-NEG
, O
bronchial B-NEG
asthma I-NEG
, O
and O
those O
with O
known O
hypersensitivity B-NEG
. O

-DOCSTART- O

to O
arrest O
bleeding B-NEG
by O
reducing O
heat B-NEU
in O
blood O
, O
to O
remove O
heat B-NEU
, O
and O
to O
cause O
diuresis B-NEU
. O

-DOCSTART- O

stop O
sweating B-NEU

-DOCSTART- O

beta-thalassemia B-NEG

-DOCSTART- O

to O
dispel O
wind B-NEG
and O
eliminate O
damp B-NEU
, O
disinhibit O
water O
and O
harmonize O
center O
, O
quicken O
blood B-DNP
and O
resolve O
toxin B-NEG
. O

-DOCSTART- O

to O
nourish O
yin O
and O
clear O
away O
heat B-NEU
, O
relieve O
restlessness B-NEG
and O
tranquilize O
the O
mind B-DNP
, O
regulate O
the O
equilibrium O
of O
the O
human B-DNP
body I-DNP
, O
improve O
health B-DNP
and O
prolong B-POS
life I-POS
. O

-DOCSTART- O

( O
1 O
) O
hematochezia B-NEG
( O
2 O
) O
viginal B-NEG
bleeding I-NEG

-DOCSTART- O

melphalan O
alkylates O
dna B-DNP
at O
the O
n7 O
position O
of O
guanine O
and O
induces O
dna B-NEU
inter-strand I-NEU
cross-linkages I-NEU
, O
resulting O
in O
the O
inhibition O
of O
dna B-NEU
and I-NEU
rna I-NEU
synthesis I-NEU
and O
cytotoxicity B-NEG
against O
both O
dividing O
and O
non-dividing O
tumor B-NEG
cells I-NEG
. O

-DOCSTART- O

irritability B-NEG
and O
restlessness B-NEG
; O

dysphoria B-NEG

-DOCSTART- O

harmonize O
acute B-NEG
and I-NEG
chronic I-NEG
disease I-NEG
of O
center O

-DOCSTART- O

hernioplasty O

-DOCSTART- O

dispel O
wind B-NEG

-DOCSTART- O

the O
coldness B-NEG
of O
hands O
and O
feet O

-DOCSTART- O

encainide O
is O
a O
sodium O
channel O
blocker O
, O
binding O
to O
voltage B-DNP
gated I-DNP
sodium I-DNP
channels I-DNP
. O

it O
stabilizes O
the O
neuronal B-DNP
membrane I-DNP
by O
inhibiting O
the O
ionic B-NEU
fluxes I-NEU
required O
for O
the O
initiation O
and O
conduction O
of O
impulses O
. O

ventricular O
excitability O
is O
depressed O
and O
the O
stimulation O
threshold O
of O
the O
ventricle B-DNP
is O
increased O
during O
diastole O
. O

-DOCSTART- O

to O
strengthen O
spleen B-DNP
and O
benefit O
qi O
; O
to O
soothe O
liver B-DNP
and O
modulate O
qi O
; O
to O
revitalize O
blood B-DNP
and O
desolve O
stagnation B-NEG

-DOCSTART- O

strengthen O
sinews B-DNP
and O
bones B-DNP

-DOCSTART- O

it O
is O
designed O
to O
mimic O
the O
molecular O
shape O
of O
adrenaline O
. O

it O
binds O
to O
alpha-adrenergic O
receptors O
in O
the O
nasal O
mucosa O
. O

here O
it O
can O
, O
therefore O
, O
cause O
vasoconstriction B-NEU

-DOCSTART- O

urinary B-DNP
systems I-DNP
, O
urinary B-DNP
system I-DNP
health I-DNP

-DOCSTART- O

phlegmy B-NEG
fire O
a O
morbid O
condition O
produced O
by O
long-standing O
depression B-NEG
of O
gi O
which O
turns O
into O
fire O
and O
changes O
the O
body O
fluid O
into O
phlegm B-NEG
, O
usually O
causing B-NEG
mental I-NEG
disturbances O
such O
as O
hysteria B-NEG
, O
mania B-NEG
. O

-DOCSTART- O

adult B-NEG
acute I-NEG
megakaryoblastic I-NEG
leukemia I-NEG

-DOCSTART- O

rigidity B-NEG
of O
the O
limbs O
; O

contracture B-NEG
; O

subjective B-NEU
sensation I-NEU
of O
contraction O

-DOCSTART- O

menstrual B-NEG
disorder I-NEG
, O
postpartum B-NEG
abdominal I-NEG
pain I-NEG
due O
to O
stasis B-NEG
obstruction I-NEG
, O
knocks B-NEG
and O
falls B-NEG
, O
wind-damp B-NEG
impediment I-NEG
pain I-NEG
. O

-DOCSTART- O

1 O
treatment O
of O
rheumatism B-NEG
, O
trauma B-NEG
, O
headache B-NEG
, O
and O
other O
pains B-NEG
. O
recently O
, O
also O
used O
for O
abdominal B-NEG
and I-NEG
biliary I-NEG
colics I-NEG
, O
and O
trigeminal B-NEG
neuralgia I-NEG
. O
2. O
treatment O
of O
bronchial B-NEG
asthma I-NEG
and O
asthmatic B-NEG
bronchitis I-NEG
. O

-DOCSTART- O

the O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
effects O
of O
the O
water O
extract O
of O
samultang O
( O
smt O
) O
, O
a O
chinese O
herb O
, O
on O
apoptotic B-NEG
cell I-NEG
death I-NEG
by O
h(2)o(2)-induced O
oxidative B-NEG
stress I-NEG
in O
sk-n-mc O
cells O
. O

a O
nuclear O
fragmentation O
was O
observed O
via O
fluorescence O
imaging O
12 O
h O
after O
exposure O
to O
30 O
microm O
h(2)o(2 O
) O
and O
dna O
laddering O
was O
detected O
via O
agarose O
electrophoresis O
gel O
. O

in O
addition O
, O
increases O
in O
sub-g1 O
phase O
and O
cleavage O
of O
the O
parp O
protein O
were O
observed O
. O

however O
, O
treatment O
with O
smt O
for O
2 O
h O
prior O
to O
h(2)o(2 O
) O
exposure O
significantly O
reduced O
apoptotic B-NEG
cell I-NEG
death I-NEG
induced O
by O
incubation O
with O
30 O
microm O
h(2)o(2 O
) O
in O
sk-n-mc O
cells O
. O

pre-incubation O
with O
water O
extract O
of O
smt O
for O
2 O
h O
prevented O
the O
h(2)o(2)-induced O
decrease O
in O
mitochondrial O
transmembrane O
potential O
. O

smt O
also O
attenuated O
the O
increase O
in O
caspase-3 B-NEU
activity I-NEU
and O
the O
breakdown O
of O
parp B-DNP
protein I-DNP
caused O
by O
h(2)o(2)-induced O
oxidative O
stress O
. O

these O
results O
suggest O
that O
the O
water O
extract O
of O
smt O
provides O
inhibition O
of O
apoptotic B-NEG
cell I-NEG
death I-NEG
against O
oxidative B-NEG
injury I-NEG
in O
sk-n-mc O
cells O
. O

-DOCSTART- O

relieve O
cough B-NEG
and O
dispel O
phlegm B-NEG

-DOCSTART- O

prolonged O
chronic B-NEG
headache I-NEG

dead B-NEG
coldness I-NEG
of O
the O
extremities O

morbid B-NEG
condition I-NEG
of O
intense B-NEG
pain I-NEG
in O
the O
chest O
and O
abdomen O
, O
sudden O
coldness B-NEG
of O
the O
two O
feet O
, O
restlessness B-NEG
with O
disinclination B-NEG
ti O
eat O
and O
unsmooth O
pulse B-DNP

-DOCSTART- O

to O
promote O
blood B-NEU
circulation I-NEU
to O
remove O
blood B-NEG
stasis I-NEG
, O
soothe O
the O
liver B-DNP
and O
remove O
the O
obstruction B-NEG
in O
the O
channels O
. O

-DOCSTART- O

oxcarbazepine O
produces O
blockade B-DNP
of I-DNP
voltage-sensitive I-DNP
sodium I-DNP
channels I-DNP
, O
resulting O
in O
stabilization O
of O
hyperexcited O
neural B-DNP
membranes I-DNP
, O
inhibition O
of O
repetitive B-NEU
neuronal I-NEU
firing I-NEU
, O
and O
diminution O
of O
propagation B-NEU
of I-NEU
synaptic I-NEU
impulses I-NEU
. O

these O
actions O
are O
thought O
to O
be O
important O
in O
the O
prevention O
of O
seizure B-NEG
spread I-NEG
in O
the O
intact O
brain O
. O

gabapentin's O
therapeutic O
action O
on O
neuropathic B-NEG
pain I-NEG
is O
thought O
to O
involve O
voltage-gated B-DNP
n-type I-DNP
calcium I-DNP
ion I-DNP
channels I-DNP
. O

it O
is O
thought O
to O
bind O
to O
the O
subunit O
(1 O
and O
2) O
of O
the O
voltage-dependent B-DNP
calcium I-DNP
channel I-DNP
in O
the O
central O
nervous O
system O
. O

-DOCSTART- O

used O
in O
surgical O
procedures O
where O
a O
rapid O
onset O
and O
brief O
duration O
of O
muscle B-POS
relaxation I-POS
is O
needed O
( O
includes O
intubation O
, O
endoscopies O
, O
and O
ect O
) O

-DOCSTART- O

to O
eliminate O
blood B-NEG
stasis I-NEG
with O
strong O
effect O
, O
promote O
the O
flow O
of O
qi O
, O
remove O
the O
retention O
of O
undigested O
food O
, O
and O
relieve O
pain B-NEG
. O

-DOCSTART- O

dizziness B-NEG
and O
vertigo B-NEG

-DOCSTART- O

ceftazidime O
inhibits O
the O
bacteria B-NEU
cell I-NEU
wall I-NEU
synthesis I-NEU
via O
affinity O
for O
penicillin B-DNP
- I-DNP
binding I-DNP
proteins I-DNP
( O
pbps B-DNP
) O
. O

the O
reduced O
metronidazole O
then O
covalently O
binds O
to O
dna O
, O
disrupt O
its O
helical O
structure O
, O
inhibiting O
bacterial B-NEU
nucleic I-NEU
acid I-NEU
synthesis I-NEU
and O
resulting O
in O
bacterial B-NEU
cell I-NEU
death I-NEU
. O

-DOCSTART- O

alleviate O
edema B-NEG

-DOCSTART- O

like O
other O
macrolides O
, O
it O
then O
penetrates O
bacteria O
cell O
wall O
and O
reversibly O
binds O
to O
domain O
v O
of O
the O
23s O
ribosomal O
rna O
of O
the O
50s O
subunit O
of O
the O
bacterial O
ribosome O
, O
blocking O
translocation B-NEU
of I-NEU
aminoacyl I-NEU
transfer-rna I-NEU
and I-NEU
polypeptide I-NEU
synthesis I-NEU
. O

-DOCSTART- O

its O
leaf O
infusion O
from O
nacl O
solution O
inhibits O
the O
growth O
of O
bacillus B-NEG
coli I-NEG
. O

-DOCSTART- O

upper O
diabetes B-NEG

-DOCSTART- O

to O
clear O
heat B-NEG
and O
resolve O
toxin B-NEG
, O
dry O
damp B-NEU
and O
kill O
worms B-NEG
. O

-DOCSTART- O

infant B-NEG
, I-NEG
diabetic I-NEG
mother I-NEG

-DOCSTART- O

investigated O
for O
use O
/ O
treatment O
in O
benign B-NEG
prostatic I-NEG
hyperplasia I-NEG
. O

-DOCSTART- O

hepatitis B-NEG
b I-NEG
, I-NEG
chronic I-NEG

-DOCSTART- O

gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
woman O
, O
absorption B-NEU
, O
digestion B-NEU
, O
motility B-NEU
, O
others O
, O
general O
woman O

-DOCSTART- O

childhood B-NEG
acute I-NEG
megakaryoblastic I-NEG
leukemia I-NEG

-DOCSTART- O

to O
resolve O
phlegm B-NEG
and O
benefit O
throat B-DNP

-DOCSTART- O

hypochondriac B-NEG
pain I-NEG

-DOCSTART- O

infertility B-NEG

-DOCSTART- O

external O
use O
for O
vitiligo B-NEG
and O
alpecia B-NEG
areata I-NEG
. O

-DOCSTART- O

photoaging B-NEG

-DOCSTART- O

infantile B-NEG
convulsion I-NEG
; O
child O
fright O
epilepsy B-NEG

-DOCSTART- O

hiv-1 B-NEG
infections I-NEG

-DOCSTART- O

to O
clear O
away O
heat B-NEU
and O
toxic B-NEG
materials I-NEG
, O
relieve O
cough B-NEG
and O
eliminate O
phlegm B-NEG
. O

-DOCSTART- O

myelodysplastic B-NEG
syndrome I-NEG

-DOCSTART- O

relieve O
lactation O
and O
disperse O
edema B-NEG

-DOCSTART- O

wind-heat B-NEG
; O
wind B-NEG
and O
heat B-NEU
; O
wind-heat B-NEG
pathogene I-NEG
wind I-NEG
and O
heat B-NEG
blended O
as O
a O
pathogenic O
factor O
. O

-DOCSTART- O

good O
evidence O
exists O
that O
this O
drug O
bind O
strongly O
, O
but O
reversibly O
, O
to O
dna B-DNP
, O
interfering O
with O
synthesis B-NEU
of I-NEU
rna I-NEU
( O
prevention O
of O
rna B-NEU
polymerase I-NEU
elongation I-NEU
) O
and O
, O
consequently O
, O
with O
protein B-NEU
synthesis I-NEU
. O

-DOCSTART- O

gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk O
, O
body B-NEU
weight I-NEU
regulation I-NEU
, O
others O
, O
overall O
cvd O
, O
diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
body B-NEU
weight I-NEU
, O
evacuation B-NEU
, O
hemostatic B-NEU
function I-NEU
. O

-DOCSTART- O

the O
authors O
report O
the O
3 O
months O
treatment O
of O
51 O
cases O
of O
breast B-NEG
proliferation I-NEG
disease I-NEG
with O
modified O
xiao O
yao O
san O
and O
er O
chen O
decoction O
, O
an O
effective O
rate O
being O
0.961 O
. O

in O
each O
patient O
before O
and O
after O
treatment O
, O
saliva B-DNP
estradiol I-DNP
( O
se2 B-DNP
) O
, O
saliva B-DNP
progesterone I-DNP
( O
sp B-DNP
) O
, O
saliva B-DNP
testosterone I-DNP
( O
st B-DNP
) O
and O
plasma B-DNP
prolactin I-DNP
( O
prl B-DNP
) O
concentrations O
were O
monitored O
and O
breast O
molybdenum O
- O
target O
x O
- O
ray O
films O
were O
taken O
. O

the O
results O
showed O
that O
after O
treatment O
, O
se2 B-NEU
concentrations I-NEU
declined O
very O
significantly O
( O
p O
less O
than O
0.001 O
) O
; O
sp B-NEU
concentrations I-NEU
declined O
significantly O
( O
p O
less O
than O
0.05 O
) O
; O
prl B-NEU
concentrations I-NEU
declined O
very O
significantly O
( O
p O
less O
than O
0.005 O
) O
, O
but O
st B-NEU
concentrations I-NEU
did O
not O
change O
significantly O
. O

breast O
molybdenum O
- O
target O
x O
- O
ray O
films O
showed O
absorption O
of O
proliferation O
masses O
in O
21 O
cases O
. O

these O
indicated O
that O
the O
medicine O
could O
regulate O
endocrine B-DNP
system I-DNP
, O
perhaps O
through O
suppressing O
secretion B-NEU
of I-NEU
prl I-NEU
, O
decreasing O
prolactin B-NEU
antagonist I-NEU
action I-NEU
to O
follicular B-DNP
stimulating I-DNP
hormone I-DNP
so O
as O
to O
restore O
follicle B-NEU
function I-NEU
, O
and O
could O
regulate O
pituitary O
- O
follicle O
axis O
and O
make O
the O
axis O
normal O
. O

-DOCSTART- O

to O
regulate O
the O
flow O
of O
qi O
and O
blood B-DNP
, O
to O
relieve O
cough B-NEG
, O
and O
to O
induce O
tranquilization B-POS
. O

-DOCSTART- O

a O
continuum O
of O
pus B-NEG
and O
blood B-NEG
due O
to O
the O
parasite O
in O
the O
ear O

-DOCSTART- O

endocrine B-DNP
system I-DNP
, O
endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
eldery O
, O
woman O
, O
menopausal B-NEG
woman I-NEG

-DOCSTART- O

psoriatic B-NEG
arthritis I-NEG

-DOCSTART- O

for O
relieving O
exterior B-NEG
syndrome I-NEG

-DOCSTART- O

endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
reproductive B-DNP
systems I-DNP
, O
physical B-DNP
performance I-DNP
and O
fitness B-POS
, O
endocrine B-DNP
system I-DNP
, O
diet O
related O
cardiovascular B-NEG
disease I-NEG
, O
strength O
and O
power O
, O
others O
, O
protective O
immunity B-NEU
, O
hemostatic B-POS
function I-POS
, O
metabolism B-NEU
, O
man O

-DOCSTART- O

damp-heat B-NEG
diarrhea I-NEG
, O
vaginal B-NEU
discharge I-NEU
, O
hemorrhoids B-NEG
, O
pain B-NEG
from O
swollen O
welling O
abscess B-NEG
, O
scrofula B-NEG
. O

-DOCSTART- O

eyebrow B-NEG
hypotrichosis I-NEG

-DOCSTART- O

to O
clear O
liver B-DNP
and O
brighten O
eyes B-DNP
. O

-DOCSTART- O

to O
cool O
lung B-DNP
, O
release O
discomfort B-NEG
in O
pharynx O
, O
remove O
epidemic O
evils O
, O
and O
to O
relieve O
cough B-NEG
. O

-DOCSTART- O

complicated O
skin O
and O
skin B-NEG
structure I-NEG
infections I-NEG

-DOCSTART- O

to O
clear O
heat B-NEU
and O
dry O
damp B-NEU
, O
check O
dysentery B-NEG
. O

-DOCSTART- O

chlorothiazide O
is O
indicated O
as O
adjunctive O
therapy O
in O
edema B-NEG
associated O
with O
congestive B-NEG
heart I-NEG
failure I-NEG
, O
hepatic B-NEG
cirrhosis I-NEG
, O
and O
corticosteroid O
and O
estrogen O
therapy O
. O

it O
is O
also O
indicated O
in O
the O
management O
of O
hypertension B-NEG
either O
as O
the O
sole O
therapeutic O
agent O
or O
to O
enhance O
the O
effectiveness O
of O
other O
antihypertensive O
drugs O
in O
the O
more O
severe O
forms O
of O
hypertension B-NEG
. O

-DOCSTART- O

treatment O
of O
deficiency B-NEG
of I-NEG
spleen I-NEG
and I-NEG
stomach I-NEG
, O
lassitude B-NEG
, O
palpitation B-NEG
, O
arrhythmia B-NEG
. O

-DOCSTART- O

neostigmine O
is O
used O
for O
the O
symptomatic O
treatment O
of O
myasthenia B-NEG
gravis I-NEG
by O
improving O
muscle B-NEU
tone I-NEU
. O

-DOCSTART- O

1 O
byak-angelicin O
contained O
in O
its O
root O
can O
dilate O
the O
coronary B-NEG
arteries I-NEG
. O
2 O
stimulating O
the O
respiratory B-DNP
center I-DNP
, O
vasomotor B-DNP
center I-DNP
and O
nervus B-DNP
vagus I-DNP
. O
3 O
its O
decoction O
exerts O
bacteriostatic B-POS
effect I-POS
. O
4 O
imperatorin O
, O
another O
active O
component O
, O
is O
effective O
for O
psoriasis B-NEG
. O

-DOCSTART- O

stage O
iv O
childhood B-NEG
lymphoblastic I-NEG
lymphoma I-NEG

-DOCSTART- O

new O
and O
old O
cough B-NEG

-DOCSTART- O

sparrow B-NEG
vision I-NEG
; O
night B-NEG
blindness I-NEG

-DOCSTART- O

adult B-NEG
b I-NEG
acute I-NEG
lymphoblastic I-NEG
leukemia I-NEG
with O
t(9;22)(q34;q11.2 O
) O
; O
bcr-abl1 O

-DOCSTART- O

tiagabine O
blocks O
gaba O
uptake O
into O
presynaptic O
neurons O
, O
permitting O
more O
gaba O
to O
be O
available O
for O
receptor O
binding O
on O
the O
surfaces O
of O
post-synaptic O
cells O
. O

gabapentin's O
therapeutic O
action O
on O
neuropathic B-NEG
pain I-NEG
is O
thought O
to O
involve O
voltage-gated O
n-type O
calcium O
ion O
channels O
. O

it O
is O
thought O
to O
bind O
to O
the O
subunit O
(1 O
and O
2) O
of O
the O
voltage-dependent O
calcium O
channel O
in O
the O
central B-DNP
nervous I-DNP
system I-DNP
. O

-DOCSTART- O

rituximab O
binds O
to O
the O
cd20 O
antigen O
on O
b O
lymphocytes O
, O
while O
the O
fc O
domain O
recruits O
antibodies B-DNP
and O
complements O
to O
mediate O
cell B-NEU
lysis I-NEU
and O
interferes O
with O
the O
growth O
and O
spread O
of O
cancer B-NEG
cells I-NEG
in O
the O
body O
. O

-DOCSTART- O

urinary B-NEG
bladder I-NEG
, I-NEG
overactive I-NEG

-DOCSTART- O

refers O
to O
the O
heavy B-NEG
coughing I-NEG
and O
shortness B-NEG
of I-NEG
breath I-NEG
due O
to O
the O
heat B-NEU
in I-NEU
the I-NEU
lung I-NEU

-DOCSTART- O

diarrhea B-NEG

-DOCSTART- O

clear O
the O
head B-DNP
and O
eyes B-DNP

-DOCSTART- O

to O
regulate O
the O
qi O
of O
the O
liver B-DNP
and O
stomach B-DNP
, O
and O
relieve O
pain B-NEG
. O

-DOCSTART- O

kidney B-NEG
disease I-NEG
of O
diabetes B-NEG
type O

-DOCSTART- O

stroke B-NEG

-DOCSTART- O

all O
kinds O
of O
disease O
due O
to O
wind B-NEG

-DOCSTART- O

treatment O
of O
impotence B-NEG
, O
seminal B-NEU
emission I-NEU
, O
enuresis B-NEG
, O
frequent B-NEG
urination I-NEG
, O
aching B-NEG
of I-NEG
the I-NEG
loins I-NEG
and I-NEG
knees I-NEG
with O
cold B-NEG
sensation O
, O
asthma B-NEG
in O
deficiency B-NEG
syndromes I-NEG
of O
the O
kidney O
, O
diarrhea B-NEG
occurring O
before O
dawn O
daily O
. O

-DOCSTART- O

tretinoin O
binds O
to O
and O
activates O
retinoic O
acid O
receptors O
( O
rars O
) O
, O
thereby O
inducing O
changes O
in O
gene B-NEU
expression I-NEU
that O
lead O
to O
cell B-NEU
differentiation I-NEU
, O
decreased B-NEU
cell I-NEU
proliferation I-NEU
, O
and O
inhibition B-POS
of I-POS
tumorigenesis I-POS
. O

-DOCSTART- O

ocular B-NEG
hypertension I-NEG

-DOCSTART- O

prolapse B-NEG
of I-NEG
the I-NEG
rectum I-NEG

-DOCSTART- O

imc-a12 O
is O
a O
fully O
human O
monoclonal O
antibody O
that O
specifically O
targets O
the O
type O
1 O
human O
insulin-like O
growth O
factor O
receptor O
( O
igf-ir O
) O
. O

tumors B-NEG
have O
receptors O
for O
the O
insulin-like O
growth O
factor-1 O
( O
igf-i O
) O
, O
and O
it O
is O
thought O
that O
the O
presence O
of O
these O
receptors O
cause O
tumors B-NEG
to O
grow O
. O

imc-a12 O
attaches O
to O
the O
receptors O
and O
may O
inhibit O
the O
growth B-NEG
of I-NEG
cancer I-NEG
cells I-NEG
. O

-DOCSTART- O

shosaikoto O
, O
which O
is O
one O
of O
the O
japanese O
and O
chinese O
traditional O
herbal O
medicine O
mixtures O
, O
has O
several O
immunomodulating B-NEU
activities I-NEU
. O

especially O
, O
shosaikoto O
is O
a O
potent O
polyclonal O
b O
cell O
mitogen O
in O
vivo O
and O
in O
vitro O
. O

in O
order O
to O
characterize O
the O
active O
substances O
for O
mitogenic B-NEU
activity I-NEU
, O
shosaikoto O
was O
fractionated O
by O
means O
of O
ethanol O
precipitation O
to O
give O
two O
fractions O
, O
called O
ethanol-precipitate O
( O
ep O
) O
fraction O
and O
ethanol-soluble O
( O
es O
) O
fraction O
. O

the O
ep O
fraction O
consisted O
mainly O
of O
polysaccharides O
and O
showed O
significant O
mitogenic B-NEU
activity I-NEU
. O

the O
es O
fraction O
consisted O
of O
low O
molecular O
compounds O
and O
did O
not O
show O
the O
activity O
in O
vitro O
. O

the O
ep O
fraction O
of O
hot O
water O
extracts O
of O
glycyrrhizae O
radix O
and O
bupureuri O
radix O
showed O
the O
activities O
, O
and O
the O
es O
fraction O
of O
a O
hot O
water O
extract O
of O
glycyrrhizae O
radix O
and O
all O
fractions O
of O
hot O
water O
extract O
of O
scutellariae O
radix O
showed O
the O
cytotoxicity O
. O

these O
results O
suggested O
that O
the O
crude O
polysaccharide O
fractions O
could O
play O
an O
important O
role O
in O
the O
mitogenic B-NEU
activity I-NEU
by O
shosaikoto O
. O

-DOCSTART- O

to O
kill O
roundworms B-NEG
; O

to O
kill O
worms B-NEG
; O

to O
move O
qi O
; O

to O
stop O
pain B-NEG

-DOCSTART- O

sore B-NEG
of I-NEG
scrotum I-NEG

-DOCSTART- O

epistaxis B-NEG
; O
nosebleed B-NEG

-DOCSTART- O

methdilazine O
binds O
to O
the O
histamine O
h O
1 O
receptor O
. O

-DOCSTART- O

promote O
sweating B-NEU

-DOCSTART- O

growth B-NEU

-DOCSTART- O

secretin O
binds O
to O
the O
secretin O
receptor O
found O
on O
the O
lining O
of O
s O
cells O
in O
the O
duodenum O
and O
g O
cells O
in O
the O
stomach O
. O
binding O
leads O
to O
the O
secrection O
of O
bicarbonate O
or O
the O
reduction O
of O
the O
secretion O
of O
gastrin O
. O
properly O
functioning O
organs O
( O
duodenum O
, O
pancreas O
and O
stomach O
) O
should O
be O
responsive O
to O
this O
hormone O

-DOCSTART- O

to O
calm O
asthma B-NEG
, O
dispel O
wind B-NEG
, O
relieve O
pain B-NEG
. O

-DOCSTART- O

the O
heat B-NEU
from O
bones O
without O
sweating B-NEU

-DOCSTART- O

to O
contract O
uterus O
and O
stanch O
bleeding O
, O
relieve O
pain O
. O

-DOCSTART- O

a O
disease O
with O
pain B-NEG
in I-NEG
the I-NEG
joints I-NEG

-DOCSTART- O

to O
arrest O
spontaneous O
emission O
, O
to O
reduce O
excessive B-NEG
urination I-NEG
, O
and O
to O
cure O
turbid B-NEG
discharge I-NEG
from O
the O
urethra O
. O
cturnal B-NEG
emission I-NEG
, O
spermatorrhea B-NEG
, O
enuresis B-NEG
, O
frequent B-NEG
urination I-NEG
, O
turbid B-NEG
discharge I-NEG
with O
urine O
. O

-DOCSTART- O

to O
dispel O
phlegm B-NEG
, O
to O
restore O
consciousness B-NEU
, O
and O
to O
reduce O
modulation B-NEU
and O
cause O
the O
subsidence B-NEU
of I-NEU
swelling I-NEU
. O

-DOCSTART- O

blood B-NEG
vacuity I-NEG
, O
septicemia B-NEG
, O
menstrual B-NEG
disorder I-NEG
, O
numbness B-NEG
and O
paralysis B-NEG
, O
aching B-NEG
in O
lumbus O
and O
legs O
. O

-DOCSTART- O

for O
calming O
liver B-DNP
and O
containing O
wind B-NEG

-DOCSTART- O

harmonize O
the O
stomach B-DNP

-DOCSTART- O

to O
drain O
accumulated O
cold B-NEG
downward O

-DOCSTART- O

stage O
iv O
adult B-NEG
t-cell I-NEG
leukemia/lymphoma I-NEG

-DOCSTART- O

yokukansan O
inhibits O
morphine O
tolerance O
and O
physical O
dependence O
in O
mice O
: O
the O
role O
of O
a O
a-adrenoceptor B-DNP
. O

-DOCSTART- O

for O
use O
in O
the O
treatment O
of O
symptomatic O
anaemia B-NEG
associated O
with O
chronic B-NEG
renal I-NEG
failure I-NEG
( O
crf B-NEG
) O
in O
adult O
and O
paediatric O
patients O
. O

also O
for O
use O
in O
the O
treatment O
of O
anaemia B-NEG
and O
reduction B-NEG
of I-NEG
transfusion I-NEG
requirements O
in O
adult O
patients O
receiving O
chemotherapy O
for O
solid B-NEG
tumours I-NEG
, O
malignant B-NEG
lymphoma I-NEG
or O
multiple B-NEG
myeloma I-NEG
, O
and O
at O
risk O
of O
transfusion O
as O
assessed O
by O
the O
patient's O
general O
status O
( O
e.g O
. O
cardiovascular O
status O
, O
pre-existing O
anaemia B-NEG
at O
the O
start O
of O
chemotherapy O
) O
. O

also O
for O
used O
to O
increase O
the O
yield O
of O
autologous B-DNP
blood I-DNP
from O
patients O
in O
a O
predonation O
program O
. O

when O
administered O
subcutaneously O
, O
epoetin O
zeta O
is O
equivalent O
to O
epoetin O
alfa O
in O
terms O
of O
clinical O
effectiveness O
. O

-DOCSTART- O

a O
disease O
that O
tendons B-DNP
and O
bones B-DNP
become O
dry O

-DOCSTART- O

treatment O
of O
stagnation B-NEG
of I-NEG
undigested I-NEG
meat I-NEG
with O
epigastric B-NEG
distension I-NEG
, O
diarrhea B-NEG
and O
abdominal B-NEG
pain I-NEG
, O
amenorrhea B-NEG
due O
to O
blood B-NEG
stasis I-NEG
, O
epigastric B-NEG
pain I-NEG
or O
abdominal B-NEG
colic I-NEG
, O
after O
childbirth O
, O
heraial O
pain B-NEG
, O
hyperlipemia B-NEG
. O

-DOCSTART- O

pain B-NEG
of O
genitals O
among O
men O
and O
women O

-DOCSTART- O

knee B-NEG
osteoarthritis I-NEG

-DOCSTART- O

abdominal B-NEG
pain I-NEG
due O
to O
stagnation O
of O
gi O

-DOCSTART- O

to O
remove O
damp-heat B-NEG
, O
quench O
fire B-NEU
and O
counteract O
toxicity B-NEG
. O

-DOCSTART- O

to O
promote O
blood B-NEU
circulation I-NEU
, O
strengthen O
the O
muscles B-DNP
and O
tendon B-DNP
, O
regulate O
the O
function O
between O
qi O
and O
blood O
. O

-DOCSTART- O

psychomotor B-NEG
agitation I-NEG

-DOCSTART- O

menstrual B-NEG
irregularities I-NEG
; O
menstrual B-NEG
disorders I-NEG
; O
abnormal B-NEG
menstruation I-NEG

-DOCSTART- O

dizziness B-NEG

-DOCSTART- O

soften O
hard B-NEG
mass I-NEG

-DOCSTART- O

its O
volatile O
oil O
is O
an O
expectorant O
and O
antiasthmatic. O
. O

-DOCSTART- O

juzentaihoto O
( O
jtt O
) O
is O
a O
well-known O
japanese O
herbal O
medicine O
, O
which O
has O
been O
reported O
to O
modulate O
immune B-NEU
responses I-NEU
and O
enhance O
antitumor B-POS
immunity I-POS
in O
animal O
models O
. O

however O
, O
it O
is O
not O
clear O
whether O
jtt O
has O
similar O
effects O
on O
humans O
. O

in O
particular O
, O
there O
is O
little O
information O
on O
the O
effects O
of O
jtt O
in O
antigen-specific B-NEU
immunity I-NEU
in O
cancer B-NEG
patients O
. O

here O
we O
conducted O
a O
randomized O
clinical O
study O
to O
investigate O
whether O
combined O
usage O
of O
jtt O
could O
affect O
antigen-specific B-NEU
immunity I-NEU
and O
clinical O
findings O
in O
advanced O
pancreatic B-NEG
cancer I-NEG
patients O
undergoing O
personalized O
peptide O
vaccination O
( O
ppv O
) O
, O
in O
which O
hla-matched O
vaccine O
antigens O
were O
selected O
based O
on O
the O
preexisting B-NEU
host I-NEU
immunity I-NEU
. O

fifty-seven O
patients O
were O
randomly O
assigned O
to O
receive O
ppv O
with O
(n O
= O
28 O
) O
or O
without O
(n O
= O
29 O
) O
jtt O
. O

unexpectedly O
, O
jtt O
did O
not O
significantly O
affect O
cellular B-NEU
or I-NEU
humoral I-NEU
immune I-NEU
responses I-NEU
specific O
to O
the O
vaccine O
antigens O
, O
which O
were O
determined O
by O
antigen B-NEU
- I-NEU
specific I-NEU
interferon I-NEU
- I-NEU
y I-NEU
secretion I-NEU
in O
t B-DNP
cells I-DNP
and O
antigen B-DNP
- I-DNP
specific I-DNP
igg I-DNP
titers I-DNP
in O
plasma O
, O
respectively O
. O

nevertheless O
, O
jtt O
prevented O
deterioration O
of O
patients' O
conditions O
, O
such O
as O
anemia B-NEG
, O
lymphopenia B-NEG
, O
hypoalbuminemia B-NEG
, O
plasma B-NEU
il-6 I-NEU
elevation I-NEU
, O
and O
reduction O
of O
performance O
status O
, O
which O
are O
frequently O
observed O
in O
advanced O
cancers B-NEG
. O

to O
our O
knowledge O
, O
this O
is O
the O
first O
clinical O
study O
that O
examined O
the O
immunological O
and O
clinical O
effects O
of O
jtt O
in O
cancer B-NEG
patients O
undergoing O
immunotherapy O
in O
humans O
. O

-DOCSTART- O

neoplasms B-NEG
, I-NEG
breast I-NEG

-DOCSTART- O

to O
nourish O
vital O
energy O
, O
strengthen O
spleen B-DNP
, O
invigorate O
the O
heart B-DNP
and O
nourish O
blood B-DNP
. O

-DOCSTART- O

stop O
bleeding B-NEG

-DOCSTART- O

prevent O
pregnancy B-NEU

-DOCSTART- O

abdominal B-NEG
distension I-NEG
; O
distension B-NEG
of I-NEG
abdomen I-NEG
with O
a O
gas O
or O
fluid O

-DOCSTART- O

furuncle B-NEG
and O
swelling B-NEG
of I-NEG
carbuncle I-NEG

-DOCSTART- O

hoarseness B-NEG
due O
to O
singing O

-DOCSTART- O

for O
the O
treatment O
of O
mild O
to O
moderate O
infections B-NEG
in O
adults O
and O
adolescents O
( O
12 O
years O
of O
age O
or O
older O
) O
which O
are O
caused O
by O
susceptible O
strains B-NEG
of O
microorganisms O
in O
acute B-NEG
bacterial I-NEG
exacerbation I-NEG
of O
chronic B-NEG
bronchitis I-NEG
, O
community-acquired B-NEG
pneumonia I-NEG
, O
pharyngitis/tonsillitis B-NEG
, O
and O
uncomplicated O
skin O
and O
skin-structure B-NEG
infections I-NEG
. O

-DOCSTART- O

for O
the O
symptomatic B-POS
relief I-POS
of O
pain B-NEG
, O
burning B-NEG
, O
urgency B-NEG
, O
frequency O
, O
and O
other O
discomforts B-NEG
arising O
from O
irritation B-NEG
of O
the O
lower B-NEU
urinary I-NEU
tract I-NEU
mucosa I-NEU
caused O
by O
infection B-NEG
, O
trauma B-NEG
, O
surgery O
, O
endoscopic O
procedures O
, O
or O
the O
passage O
of O
sounds O
or O
catheters O
. O

-DOCSTART- O

s B-NEG
. I-NEG
aureus I-NEG
bacteremia I-NEG

-DOCSTART- O

five O
kinds O
of O
fluid-retention B-NEG
syndromes I-NEG

-DOCSTART- O

cyt006-angqb O
is O
a O
therapeutic O
vaccine O
designed O
to O
instruct O
the O
patient's O
immune B-DNP
system I-DNP
to O
produce O
a O
specific O
anti-angiotensin B-NEU
ii I-NEU
antibody I-NEU
response I-NEU
. O

-DOCSTART- O

paclitaxel O
interferes O
with O
the O
normal O
function B-NEU
of I-NEU
microtubule I-NEU
growth I-NEU
. O

whereas O
drugs O
like O
colchicine O
cause O
the O
depolymerization B-NEU
of I-NEU
microtubules I-NEU
in O
vivo O
, O
paclitaxel O
arrests O
their O
function O
by O
having O
the O
opposite O
effect O
; O

it O
hyper-stabilizes O
their O
structure O
. O

this O
destroys O
the O
cell's O
ability O
to O
use O
its O
cytoskeleton B-DNP
in O
a O
flexible O
manner O
. O

specifically O
, O
paclitaxel O
binds O
to O
the O
; O

subunit B-DNP
of I-DNP
tubulin I-DNP
. O

tubulin O
is O
the O
building O
block O
of O
mictotubules O
, O
and O
the O
binding O
of O
paclitaxel B-DNP
locks O
these O
building O
blocks O
in O
place O
. O

the O
resulting O
microtubule B-DNP
/ I-DNP
paclitaxel I-DNP
complex I-DNP
does O
not O
have O
the O
ability O
to O
disassemble O
. O

this O
adversely O
affects O
cell O
function O
because O
the O
shortening O
and O
lengthening O
of O
microtubules B-DNP
( O
termed O
dynamic O
instability O
) O
is O
necessary O
for O
their O
function O
as O
a O
transportation O
highway O
for O
the O
cell O
. O

chromosomes B-DNP
, O
for O
example O
, O
rely O
upon O
this O
property O
of O
microtubules B-DNP
during O
mitosis O
. O

further O
research O
has O
indicated O
that O
paclitaxel O
induces O
programmed O
cell B-POS
death I-POS
( I-POS
apoptosis I-POS
) I-POS
in I-POS
cancer I-POS
cells I-POS
by O
binding O
to O
an O
apoptosis B-NEU
stopping O
protein O
called O
bcl-2 O
( O
b-cell O
leukemia O
2 O
) O
and O
thus O
arresting O
its O
function O
. O

-DOCSTART- O

dispel O
wind B-NEG
and O
eliminate O
dampness B-NEG

-DOCSTART- O

a O
disease O
with O
dry B-NEG
cough I-NEG
with O
little O
amount O
of O
phlegm B-NEG

-DOCSTART- O

carbuncle B-NEG
and O
cellulitis B-NEG

-DOCSTART- O

therapeutic O
effect O
of O
kakkonto O
in O
a O
mouse O
model O
of O
food B-NEG
allergy I-NEG
with O
gastrointestinal O
symptoms O
. O

-DOCSTART- O

to O
pacify O
the O
liver B-DNP
and O
subdue O
the O
yang O
; O

to O
conduct O
rebellious O
qi O
downward O
and O
stop O
vomiting B-NEG
; O

to O
stop O
bleeding B-NEG

-DOCSTART- O

treament O
of O
unprocessed O
fructus O
hordei O
germinatus O
: O

anorexia B-NEG
due O
to O
diminished B-NEG
function I-NEG
of I-NEG
the I-NEG
spleen I-NEG
, O
galactostasis B-NEG
. O

fructus O
hordei O
germinatus O
( O
stir-fried O
) O
: O

indigestion B-NEG
, O
weaning O
a O
baby O
. O

fructus O
hordei O
germinatus O
( O
charred O
) O
: O

retention B-NEG
of I-NEG
undigested I-NEG
food I-NEG
with O
epigastric B-NEG
distension I-NEG
and O
pain B-NEG
. O

-DOCSTART- O

cough B-NEG
due O
to O
lung B-NEU
subcutaneous I-NEU
nodes I-NEU

-DOCSTART- O

enduring O
cough B-NEG
and O
asthma B-NEG
, O
bronchitis B-NEG
, O
lumbago B-NEG
and O
limp O
leg B-DNP
, O
frequent O
urination B-NEU
, O
enuresis B-NEG
, O
impotence B-NEG
, O
emission B-NEU
, O
intestinal B-NEG
dry I-NEG
and O
constipation B-NEG
, O
stone B-NEG
strangury I-NEG
, O
sores B-NEG
and O
scrofula B-NEG
. O

-DOCSTART- O

gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
protective B-NEU
immunity I-NEU
, O
others O

-DOCSTART- O

hematemesis B-NEG
and O
epistaxis B-NEG

-DOCSTART- O

unconsciousness B-NEG

-DOCSTART- O

treatment O
of O
toothache B-NEG
due O
to O
caries B-NEG
, O
sores B-NEG
, O
ulcers B-NEG
, O
mastitis B-NEG
, O
scrofula B-NEG
, O
ringworm B-NEG
, O
tinea B-NEG
unguium I-NEG
. O

-DOCSTART- O

treatment O
of O
sore B-NEG
throat I-NEG
and O
hoarseness B-NEG
of I-NEG
voice I-NEG
, O
cough B-NEG
with O
yellow B-NEG
sticky I-NEG
sputum I-NEG
, O
dysuria B-NEG
, O
external O
use O
for O
pemphigus B-NEG
and O
eczema B-NEG
. O

-DOCSTART- O

behavioral B-NEG
and I-NEG
psychological I-NEG
symptoms I-NEG
of I-NEG
dementia I-NEG
( O
bpsd B-NEG
) O
are O
commonly O
seen O
in O
patients O
with O
alzheimer's B-NEG
disease I-NEG
( O
ad B-NEG
) O
and O
other O
forms O
of O
senile B-NEG
dementia I-NEG
. O

bpsd B-NEG
have O
a O
serious O
impact O
on O
the O
quality O
of O
life O
of O
dementia B-NEG
patients O
, O
as O
well O
as O
their O
caregivers O
. O

however O
, O
an O
effective O
drug O
therapy O
for O
bpsd B-NEG
has O
not O
been O
established O
. O

recently O
, O
the O
traditional O
japanese O
medicine O
yokukansan O
( O
yks O
, O
yi-gan O
san O
in O
chinese O
) O
has O
been O
reported O
to O
improve O
bpsd B-NEG
in O
a O
randomized O
, O
single-blind O
, O
placebo-controlled O
study O
. O

moreover O
, O
abnormalities B-NEG
of I-NEG
the I-NEG
serotonin I-NEG
( O
5-ht B-DNP
) O
system O
such O
as O
5-ht2a O
receptors O
have O
been O
reported O
to O
be O
associated O
with O
bpsd B-NEG
of O
ad B-NEG
patients O
. O

in O
the O
present O
study O
, O
we O
investigated O
the O
effect O
of O
yks O
on O
head-twitch O
response O
induced O
by O
2,5-dimethoxy-4-iodoamphetamine O
( O
doi O
, O
5 O
mg/kg O
, O
i.p O
. O
) O
in O
mice O
, O
a O
behavioral O
response O
that O
is O
mediated O
, O
in O
part O
, O
by O
5-ht2a O
receptors O
. O

acute O
treatment O
with O
yks O
( O
100 O
and O
300 O
mg/kg O
, O
p.o O
. O
) O
had O
no O
effect O
on O
the O
doi-induced B-NEG
head-twitch I-NEG
response I-NEG
, O
whilst O
14 O
days O
repeated O
treatment O
with O
yks O
( O
300 O
mg/kg O
, O
p.o O
. O
) O
significantly O
inhibited O
this O
response O
. O

moreover O
, O
repeated O
treatment O
with O
yks O
( O
300 O
mg/kg O
, O
p.o O
. O
) O
decreased O
expression O
of O
5-ht2a O
receptors O
in O
the O
prefrontal O
cortex O
, O
which O
is O
part O
of O
the O
circuitry O
mediating O
the O
head-twitch B-NEG
response I-NEG
. O

these O
findings O
suggest O
that O
the O
inhibition O
of O
doi-induced B-NEG
head-twitch I-NEG
response O
by O
yks O
may O
be O
mediated O
, O
in O
part O
, O
by O
altered O
expression O
of O
5-ht2a O
receptors O
in O
the O
prefrontal O
cortex O
, O
which O
suggests O
the O
involvement O
of O
the O
5-ht B-DNP
system I-DNP
in O
psychopharmacological O
effects O
of O
yks O
. O

-DOCSTART- O

to O
regulate O
the O
flow O
of O
qi O
in O
the O
chest O
, O
to O
eliminate O
the O
retention B-NEG
of I-NEG
undigested I-NEG
food I-NEG
, O
relieve O
vomiting B-NEG
. O

-DOCSTART- O

1 O
its O
decoction O
acts O
as O
an O
antitussive O
and O
expectorant O
in O
mice O
. O

2 O
inhibiting O
the O
growth O
of O
pneumococcus B-NEG
and O
beta-streptococcus B-NEG
in O
vitro O
. O

-DOCSTART- O

invigorate O
blood B-DNP
and O
relieve O
pain B-NEG

-DOCSTART- O

swelling B-NEG
of O
the O
lips O
; O
swollen B-NEG
lips I-NEG

-DOCSTART- O

steaming B-NEG
bone I-NEG
disorder I-NEG

-DOCSTART- O

inflammation B-NEG
of O
the O
throat O
; O
sore B-NEG
throat I-NEG
; O
hoarse B-NEG
voice I-NEG
; O
aphonia B-NEG

-DOCSTART- O

malignancy B-NEG

-DOCSTART- O

for O
promoting O
diuresis B-NEU
and O
desolving O
inflammation B-NEG

-DOCSTART- O

fever B-NEG
with O
overstrain B-NEG

-DOCSTART- O

treament O
of O
looseness B-NEG
of I-NEG
teeth I-NEG
, O
premature B-NEG
greying I-NEG
of I-NEG
hair I-NEG
and I-NEG
beard I-NEG
, O
dizziness B-NEG
, O
tinnitus B-NEG
, O
aching B-NEG
and I-NEG
weakness I-NEG
of I-NEG
the I-NEG
loins I-NEG
and I-NEG
knees I-NEG
, O
spitting B-NEG
of I-NEG
blood I-NEG
, O
epistaxis B-NEG
, O
hematuria B-NEG
and O
diarrhea B-NEG
with O
bloody B-NEG
stools I-NEG
due O
to O
heat B-NEG
in I-NEG
the I-NEG
blood I-NEG
, O
abnormal B-NEG
uterine I-NEG
bleeding I-NEG
, O
traumatic B-NEG
bleeding I-NEG
. O

-DOCSTART- O

endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
eldery O
, O
endocrine B-DNP
system I-DNP
, O
intelligence B-POS
, O
others O
, O
memory B-DNP
, O
mental B-DNP
state I-DNP
and I-DNP
performance I-DNP

-DOCSTART- O

fluticasone O
, O
a O
synthetic O
trifluorinated O
glucocorticoid O
receptor O
agonist O
with O
antiallergic O
, O
anti-inflammatory O
and O
antipruritic O
effects O
. O

prazosin O
acts O
by O
inhibiting O
the O
postsynaptic O
alpha(1)-adrenoceptors O
on O
vascular B-DNP
smooth I-DNP
muscle I-DNP
. O

this O
inhibits O
the O
vasoconstrictor B-NEU
effect I-NEU
of O
circulating O
and O
locally O
released O
catecholamines B-DNP
, O
resulting O
in O
peripheral B-NEU
vasodilation I-NEU
. O

oxymetazoline O
is O
a O
direct O
acting O
sympathomimetic O
amine O
, O
which O
acts O
on O
alpha-adrenergic O
receptors O
in O
the O
arterioles O
of O
the O
conjunctiva O
and O
nasal O
mucosa O
. O

-DOCSTART- O

endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
motivation O
, O
mood O
, O
endocrine B-DNP
system I-DNP
, O
effort O
, O
mental B-DNP
state I-DNP
and I-DNP
performance I-DNP

-DOCSTART- O

for O
treatment O
and O
management O
of O
epilepsy B-NEG
and O
seizures B-NEG
associated O
with O
lennox-gastaut B-NEG
syndrome I-NEG
, O
a O
difficult-to-treat O
form O
of O
childhood B-NEG
epilepsy I-NEG
. O

-DOCSTART- O

impotence B-NEG

-DOCSTART- O

in O
countries O
with O
high O
rates O
of O
hepatitis B-NEG
b I-NEG
infection I-NEG
, O
vaccination O
of O
newborns O
has O
not O
only O
reduced O
the O
risk O
of O
infection B-NEG
, O
but O
has O
also O
led O
to O
marked O
reduction O
in O
liver B-NEG
cancer I-NEG
. O

-DOCSTART- O

dirty B-NEG
face I-NEG
; O

dirty B-NEG
complexion I-NEG
; O

grimy B-NEG
facial I-NEG
complexion I-NEG
a O
face O
appearing O
as O
if O
covered O
with O
dirt O
, O
as O
often O
seen O
in O
hepatic B-NEG
disease I-NEG
, O
disease O
due O
to O
damp-heat B-NEG
. O

-DOCSTART- O

nausea B-NEG
without O
vomiting B-NEG
. O

-DOCSTART- O

treatment O
haematemesis B-NEG
, O
epistaxis B-NEG
and O
hematuria B-NEG
due O
to O
heat B-NEU
in O
the O
blood B-DNP
, O
febrile B-NEG
diseases I-NEG
with O
thirst B-NEG
, O
jaundice B-NEG
, O
urinary B-NEG
infection I-NEG
with O
difficult O
painful B-NEG
urination I-NEG
, O
edema B-NEG
in O
acute B-NEG
nephritis I-NEG
. O

-DOCSTART- O

chinese O
herbal O
medicine O
( O
chm O
) O
, O
either O
in O
single O
herb O
or O
in O
herbal O
formula O
, O
has O
been O
used O
to O
treat O
insomnia B-NEG
for O
more O
than O
2000 O
years O
. O

a O
systematic O
review O
including O
chinese O
and O
english O
literature O
of O
randomized O
controlled O
trials O
was O
conducted O
to O
examine O
the O
efficacy B-POS
, O
safety B-POS
, O
and O
composition O
of O
chm O
for O
insomnia B-NEG
. O

among O
the O
217 O
studies O
we O
have O
reviewed O
, O
only O
eight O
had O
a O
jadad O
score O
>= O
3, O
and O
seven O
out O
of O
these O
eight O
studies O
had O
at O
least O
one O
domain O
with O
high O
risks O
of O
bias O
. O

meta-analyses O
of O
the O
studies O
with O
jadad O
score O
>= O
3 O
found O
that O
chm O
was O
similar O
to O
western O
medication O
( O
three O
studies O
) O
and O
placebo O
( O
three O
studies O
) O
in O
treating O
insomnia B-NEG
. O

due O
to O
the O
poor O
methodological O
quality O
of O
the O
studies O
and O
the O
small O
number O
of O
trials O
included O
in O
meta-analyses O
, O
the O
current O
evidence O
is O
insufficient O
to O
support O
the O
efficacy B-POS
of O
chm O
for O
insomnia B-NEG
. O

the O
frequency O
of O
adverse O
events O
associated O
with O
chm O
was O
similar O
to O
that O
of O
placebo O
, O
but O
lower O
than O
with O
western O
medication O
. O

gui O
pi O
tang O
was O
the O
most O
commonly O
used O
standardized O
formula O
, O
while O
suan O
zao O
ren O
( O
ziziphus O
jujuba O
) O
was O
the O
most O
frequently O
used O
single O
herb O
. O

further O
studies O
with O
a O
double-blind O
placebo-controlled O
design O
are O
needed O
to O
accurately O
determine O
the O
benefits O
and O
risks O
of O
chm O
for O
insomnia B-NEG
. O

-DOCSTART- O

metrorrhagia B-NEG
and O
metrostaxis B-NEG

-DOCSTART- O

abdominal B-NEG
mass I-NEG
; O
mass B-NEG
in I-NEG
the I-NEG
abdomen I-NEG

-DOCSTART- O

free O
the O
kidney B-DNP
and O
water O

-DOCSTART- O

its O
decoction O
inhibits O
the O
development O
of O
egg-white O
induced O
arthritis B-NEG
in O
mice O
. O

-DOCSTART- O

edema B-NEG
, O
pathogenesis O
of O
which O
is O
associated O
with O
dysfunction B-NEG
of I-NEG
the I-NEG
lung I-NEG
, I-NEG
spleen I-NEG
and I-NEG
kidney I-NEG
. O

-DOCSTART- O

1 O
its O
alcoholic O
extract O
exerts O
antipyretic O
and O
analgesic O
effect O
. O

2 O
its O
aqueous O
extract O
is O
a O
cardiotonic O
. O

-DOCSTART- O

non B-NEG
small I-NEG
cell I-NEG
lung I-NEG
carcinoma I-NEG

-DOCSTART- O

intraocular B-NEG
melanoma I-NEG

-DOCSTART- O

sudden O
stroke O
and O
fulminant O
reversal O
, O
pain B-NEG
in O
heart O
and O
abdomen B-NEG
, O
postpartum O
blood B-NEG
dizziness I-NEG
, O
child O
fright B-NEG
epilepsy I-NEG
, O
wind B-NEG
impediment O
and O
lumbago B-NEG
. O

-DOCSTART- O

in O
the O
process O
of O
binding O
, O
the O
receptor O
is O
actually O
activated O
- O
causing O
a O
process O
known O
as O
depolarization B-NEU
. O

-DOCSTART- O

disperse O
accumulation B-NEU
and O
kill O
worm B-NEG

-DOCSTART- O

treatment O
of O
carbuncle O
, O
boil B-NEG
and O
other O
pyogenic B-NEG
infections I-NEG
of O
the O
skin O
, O
sore B-NEG
throat I-NEG
, O
scrofula B-NEG
, O
constipation B-NEG
. O

-DOCSTART- O

eye B-NEG
pain I-NEG
, O
eye B-NEG
swelling I-NEG
, O
red B-NEG
eyes I-NEG
and O
tearing B-NEU
. O

-DOCSTART- O

locally O
acting O
as O
an O
irritant O
for O
skin O
and O
mucosa O
; O
orally O
as O
a O
potent O
purgative O
. O

-DOCSTART- O

stomachache B-NEG

-DOCSTART- O

1 O
interrupting O
pregnancy B-NEU
. O
2 O
its O
active O
component O
, O
trichosanthin O
, O
is O
effective O
on O
placental B-NEG
trophocytic I-NEG
tumor I-NEG
. O
3 O
. O
bacteriostatic B-POS
. O
-DOCSTART- O

soothe O
the O
sinews B-DNP
and O
the O
network B-DNP
vessels I-DNP

-DOCSTART- O

urinary B-DNP
system I-DNP
health I-DNP
, O
endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
urinary B-DNP
systems I-DNP
, O
reproductive B-DNP
systems I-DNP

-DOCSTART- O

its O
biochemical O
mechanism O
of O
action O
is O
unknown O
, O
although O
data O
are O
available O
to O
suggest O
that O
the O
drug O
modifies O
the O
peripheral B-NEU
metabolism I-NEU
of O
steroids O
as O
well O
as O
directly O
suppressing O
the O
adrenal B-DNP
cortex I-DNP
. O

-DOCSTART- O

dissipate O
depression B-NEG

-DOCSTART- O

1 O
for O
cases O
of O
malaria B-NEG
with O
splenomegaly B-NEG
, O
epicgastric B-NEG
fullness I-NEG
, O
whitish O
fur O
on O
the O
tongue O
, O
wiry B-NEG
pulse I-NEG
, O
which O
are O
attributive O
to O
dysfunction B-NEG
of I-NEG
spleen I-NEG
and O
stagnation O
of O
vital O
energy O
and O
blood B-DNP
, O
omit O
glycyrrhizae O
and O
add O
ramulus O
cinnamoni O
, O
carapax O
trionycis O
to O
ac O

-DOCSTART- O

pain B-NEG
in O
ear O

-DOCSTART- O

chronic B-NEG
hepatitis I-NEG
b I-NEG

-DOCSTART- O

thioridazine O
blocks O
postsynaptic O
mesolimbic O
dopaminergic O
d1 O
and O
d2 O
receptors O
in O
the O
brain B-DNP
; O
blocks O
alpha-adrenergic O
effect O
, O
depresses O
the O
release O
of O
hypothalamic O
and O
hypophyseal O
hormones O
and O
is O
believed O
to O
depress O
the O
reticular B-DNP
activating I-DNP
system I-DNP
thus O
affecting O
basal O
metabolism B-NEU
, O
body B-NEU
temperature I-NEU
, O
wakefulness B-NEG
, O
vasomotor B-NEU
tone I-NEU
, O
and O
emesis B-NEG
. O

-DOCSTART- O

intelligence B-POS
, O
mental B-DNP
state I-DNP
and I-DNP
performance I-DNP
, O
memory B-POS

-DOCSTART- O

kidney O
transplant O

-DOCSTART- O

paralysis B-NEG
due O
to O
stroke B-NEG

-DOCSTART- O

eliminate O
melasma B-NEG

-DOCSTART- O

japanese O
herbal O
( O
kampo O
) O
medicine O
, O
hochuekkito O
( O
bu-zhong-yi-qi-tang O
in O
chinese O
, O
tj-41 O
) O
and O
juzentaihoto O
( O
shi-quan-da-bu-tang O
in O
chinese O
, O
tj-48 O
) O
are O
well-known O
kampo O
formulas O
used O
as O
tonic O
. O

although O
these O
medicines O
have O
separately O
been O
applied O
to O
the O
patients O
clinically O
depending O
on O
their O
symptoms O
, O
the O
differences O
of O
the O
pharmacological O
activities O
for O
these O
medicines O
have O
not O
been O
fully O
understood O
. O

tj-48 O
and O
tj-41 O
were O
compared O
for O
their O
effects O
on O
antibody B-NEU
response I-NEU
in O
upper O
respiratory B-DNP
mucosal I-DNP
immune I-DNP
system I-DNP
in O
vivo O
. O

oral O
administration O
of O
tj-41 O
( O
100 O
mg O
kg(-1 O
) O
per O
day O
) O
to O
early O
aged O
balb/c O
mice O
, O
which O
were O
nasally O
sensitized O
with O
influenza O
hemagglutinin O
vaccine O
, O
significantly O
enhanced O
influenza O
virus-specific O
iga B-DNP
and I-DNP
igg I-DNP
antibody I-DNP
titers O
in O
nasal O
cavity O
and O
sera O
, O
respectively O
. O

however O
, O
oral O
administration O
of O
tj-48 O
( O
100 O
mg O
kg(-1 O
) O
per O
day O
) O
failed O
to O
show O
the O
enhancing O
activity O
. O

tj-41 O
increased O
not O
only O
influenza O
virus-specific O
iga B-DNP
antibody I-DNP
titer O
but O
also O
total O
iga B-DNP
antibody I-DNP
titer O
in O
nasal O
cavity O
. O

the O
stimulating O
activity O
of O
tj-41 O
disappeared O
after O
treatment O
with O
methotrexate O
. O

the O
present O
study O
strongly O
suggests O
that O
tj-41 O
can O
stimulate O
the O
mucosal B-DNP
immune I-DNP
system I-DNP
of O
upper O
respiratory O
tract O
, O
and O
results O
in O
enhancement O
of O
antigen-specific B-DNP
antibody I-DNP
response I-DNP
in O
upper O
respiratory B-DNP
mucosal I-DNP
and O
systemic B-DNP
immune I-DNP
systems I-DNP
. O

-DOCSTART- O

menopausal B-NEG
syndrome I-NEG
marked O
by O
afternoon O
fever B-NEG
, O
excessive B-NEG
sweating I-NEG
, O
dizziness B-NEG
, O
tinnitus B-NEG
, O
insomnia B-NEG
and O
unsteady B-NEG
blood I-NEG
pressure I-NEG
. O

-DOCSTART- O

untreated O
childhood B-NEG
acute I-NEG
lymphoblastic I-NEG
leukemia I-NEG

-DOCSTART- O

indicated O
in O
the O
treatment O
of O
moderate O
to O
severe O
pain B-NEG
. O
consider O
for O
those O
prone O
to O
constipation B-NEG
or O
respiratory B-NEG
depression I-NEG
. O
tramadol O
is O
used O
to O
treat O
postoperative O
, O
dental O
, O
cancer B-NEG
, O
and O
acute B-NEG
musculosketetal I-NEG
pain I-NEG
and O
as O
an O
adjuvant O
to O
nsaid O
therapy O
in O
patients O
with O
osteoarthritis B-NEG
. O

-DOCSTART- O

alzheimer B-NEG
disease I-NEG

-DOCSTART- O

cerebral B-NEG
thrombosis I-NEG

-DOCSTART- O

moisten O
the O
lung B-DNP
and O
send O
gi(qi O
) O
downward O

-DOCSTART- O

eliminate O
vacuity O
and O
clod O
of O
the O
spleen O
and O
the O
stomach O

-DOCSTART- O

1 O
flaccidity B-NEG
of I-NEG
lower I-NEG
limbs I-NEG
2 O
leg O
gi O
; O
beriberi B-NEG

-DOCSTART- O

hip B-NEG
fracture I-NEG

-DOCSTART- O

migraine B-NEG

-DOCSTART- O

this O
is O
a O
syndrome O
with O
feeling O
like O
vomiting B-NEG
caused O
by O
ascending O
stomach B-DNP
gi O
. O

-DOCSTART- O

mental B-DNP
state I-DNP
and I-DNP
performance I-DNP
, O
mood O

-DOCSTART- O

nourish O
essence-marrow B-NEU

-DOCSTART- O

clarithromycin O
also O
inhibits O
the O
hepatic O
microsomal O
cyp3a4 O
isoenzyme O
and O
p-glycoprotein O
, O
an O
energy-dependent O
drug O
efflux O
pump O
. O

-DOCSTART- O

invigorate O
the O
spleen B-DNP
and O
promote O
the O
stomach B-DNP

-DOCSTART- O

glaucoma B-NEG
, O
open-angle O

-DOCSTART- O

lymphoma B-NEG
, I-NEG
non-hodgkin I-NEG

-DOCSTART- O

complications B-NEG
due O
to O
blood B-NEG
stagnation I-NEG

-DOCSTART- O

follitropin O
alpha O
is O
a O
recombinant O
form O
of O
endogenous O
follicle O
stimulating O
hormone O
( O
fsh O
) O
. O

fsh O
binds O
to O
the O
follicle O
stimulating O
hormone O
receptor O
which O
is O
a O
g-coupled O
transmembrane O
receptor O
. O

binding O
of O
the O
fsh O
to O
its O
receptor O
seems O
to O
induce O
phosphorylation B-DNP
and O
activation B-NEU
of I-NEU
the I-NEU
pi3k I-NEU
( O
phosphatidylinositol-3-kinase O
) O
and O
akt O
signaling O
pathway O
, O
which O
is O
known O
to O
regulate O
many O
other O
metabolic O
and O
related O
survival/maturation O
functions O
in O
cells O
. O

-DOCSTART- O

epiphora B-NEG
; O
lacrimation B-NEG

-DOCSTART- O

urinary B-DNP
system I-DNP
health I-DNP
, O
urinary B-DNP
systems I-DNP

-DOCSTART- O

to O
clear O
away O
heat B-NEU
and O
toxic B-NEG
materials O
, O
remove O
dampness B-NEU
and O
destroy O
trichomonad O
and O
fungus O
, O
remove O
the O
necrotic B-NEG
tissue I-NEG
and O
promote O
granulation O
, O
and O
arrest O
pain B-NEG
by O
removing O
blood B-NEG
stasis I-NEG
. O

-DOCSTART- O

vaccination O
of O
humans O
with O
cyt006-angqb O
has O
been O
shown O
to O
induce O
angiotensin B-DNP
ii I-DNP
specific O
antibodies O
that O
should O
inhibit O
binding O
of O
angiotensin B-DNP
ii I-DNP
to O
its O
receptors O
and O
thus O
reduce O
the O
narrowing B-NEU
of I-NEU
blood I-NEU
vessels I-NEU
. O

-DOCSTART- O

sermorelin O
binds O
to O
the O
growth O
hormone O
releasing O
hormone O
receptor O
and O
mimics O
native O
grf O
in O
its O
ability O
to O
stimulate O
growth O
hormone O
secretion O
. O

-DOCSTART- O

a O
uplc/q-tof-ms/ms O
method O
for O
analyzing O
the O
constituents O
in O
rat O
plasma O
after O
oral O
administration O
of O
yin O
chen O
hao O
tang O
( O
ycht O
) O
, O
a O
traditional O
chinese O
medical O
formula O
, O
has O
been O
established O
. O

the O
uplc/ms O
fingerprints O
of O
the O
samples O
were O
established O
first O
in O
vitro O
and O
in O
vivo O
, O
with O
45 O
compounds O
in O
ycht O
and O
21 O
compounds O
in O
rat O
plasma O
after O
oral O
administration O
of O
ycht O
were O
detected O
. O

of O
the O
45 O
detected O
compounds O
in O
vitro O
, O
30 O
were O
identified O
, O
and O
all O
of O
the O
21 O
compounds O
detected O
in O
rat O
plasma O
were O
identified O
either O
by O
comparing O
the O
retention O
time O
and O
mass O
spectrometry O
data O
with O
that O
of O
reference O
compounds O
or O
by O
mass O
spectrometry O
analysis O
and O
retrieving O
the O
reference O
literatures O
. O

of O
the O
identified O
21 O
compounds O
in O
rat O
plasma O
, O
19 O
were O
the O
original O
form O
of O
compounds O
absorbed O
from O
the O
45 O
detected O
compounds O
in O
vitro O
, O
2 O
were O
the O
metabolites O
of O
the O
compounds O
existed O
in O
ycht O
. O

it O
is O
concluded O
that O
a O
rapid O
and O
validated O
method O
has O
been O
developed O
based O
on O
uplc-ms/ms O
, O
which O
shows O
high O
sensitivity O
and O
resolution O
that O
is O
more O
suitable O
for O
identifying O
the O
bioactive O
constituents O
in O
plasma O
after O
oral O
administration O
of O
chinese O
herbal O
medicines O
, O
and O
provides O
helpful O
chemical O
information O
for O
further O
pharmacology O
and O
active O
mechanism O
research O
on O
the O
chinese O
medical O
formula O
. O

-DOCSTART- O

gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
woman O
, O
eye B-DNP
, O
mood O
, O
physical B-DNP
performance I-DNP
and O
fitness B-POS
, O
quality O
of O
life O
, O
eye B-DNP
health I-DNP
, O
dermatological B-DNP
systems I-DNP
health I-DNP
, O
energy O
supply O
and O
recovery B-POS
, O
mental B-DNP
state I-DNP
and I-DNP
performance I-DNP
, O
general O
woman O
, O
general B-DNP
skin I-DNP
health I-DNP
, O
others O
, O
protective B-NEU
immunity I-NEU
, O
intelligence B-POS
, O
endurance B-NEU

-DOCSTART- O

vaginal B-NEU
atrophy I-NEU

-DOCSTART- O

wind B-NEG
invaded O
chang O
organ O

-DOCSTART- O

papillary B-NEG
serous I-NEG
endometrial I-NEG
cancer I-NEG

-DOCSTART- O

therapeutic O
effects O
of O
saireito O
( O
chai-ling-tang O
) O
, O
a O
traditional O
japanese O
herbal O
medicine O
, O
on O
lymphedema B-NEG
caused O
by O
radiotherapy O
: O
a O
case O
series O
study O
. O

-DOCSTART- O

metformin O
acts O
by O
the O
initial O
activation B-DNP
of I-DNP
amp-activated I-DNP
protein I-DNP
kinase I-DNP
( O
ampk O
) O
, O
a O
liver B-NEU
enzyme I-NEU
that O
plays O
an O
important O
role O
in O
insulin B-NEU
signaling I-NEU
, O
whole B-NEU
body I-NEU
energy I-NEU
balance I-NEU
, O
and O
the O
metabolism B-NEU
of I-NEU
glucose I-NEU
and I-NEU
fats I-NEU
. O

pioglitazone O
activates O
peroxisome B-DNP
proliferator-activated I-DNP
receptor I-DNP
gamma I-DNP
( O
ppar-gamma B-DNP
) O
, O
a O
ligand-activated B-DNP
transcription I-DNP
factor I-DNP
, O
thereby O
inducing O
cell B-NEU
differentiation I-NEU
and O
inhibiting O
cell B-NEU
growth I-NEU
and O
angiogenesis B-NEU
. O

-DOCSTART- O

cataract B-NEG
and O
nebula B-NEG

-DOCSTART- O

food O
accumulation O
, O
stomachache B-NEG
, O
abdomin B-NEG
al I-NEG
pain I-NEG
. O

-DOCSTART- O

1 O
an O
active O
component O
arcitiin O
is O
a O
vasodilator O
and O
hypotensive O
. O
2 O
. O
over O
dosage O
of O
arctiin O
may O
lead O
to O
convulsion B-NEG
and O
respiratory B-NEG
failure I-NEG
. O

-DOCSTART- O

to O
strengthen O
the O
spleen B-DNP
. O

-DOCSTART- O

inhibitory O
effect O
of O
chunghyuldan O
in O
prostaglandin O
e2 O
and O
nitric O
oxide O
biosynthesis O
of O
lipopolysaccharide-induced O
raw O
264.7 O
cells O
. O

-DOCSTART- O

airway O
reflexes O
, O
protective O

-DOCSTART- O

it O
may O
also O
bind O
to O
bacterial B-DNP
potassium I-DNP
transporters I-DNP
, O
thereby O
inhibiting O
their O
function O
. O

-DOCSTART- O

sp-01a O
is O
an O
hiv B-NEG
oral O
entry O
inhibitor O
drug O
. O
in O
order O
for O
viruses B-NEG
to O
reproduce O
, O
they O
must O
infect O
or O
hi-jack O
a O
cell O
, O
and O
use O
it O
to O
make O
new O
viruses B-NEG
. O
just O
as O
your O
body O
is O
constantly O
making O
new O
skin B-DNP
cells I-DNP
, O
or O
new O
blood B-DNP
cells I-DNP
, O
each O
cell O
often O
makes O
new O
proteins O
in O
order O
to O
stay O
alive O
and O
to O
reproduce O
itself O
. O
viruses B-NEG
hide O
their O
own O
dna O
in O
the O
dna O
of O
the O
cell O
, O
and O
then O
, O
when O
the O
cell O
tries O
to O
make O
new O
proteins O
, O
it O
accidentally O
makes O
new O
viruses B-NEG
as O
well O
. O
hiv B-NEG
mostly O
infects O
cells O
in O
the O
immune B-NEU
system I-NEU
. O

-DOCSTART- O

angina B-NEG
pectoris I-NEG
, O
cerebral B-NEG
atherosclerosis I-NEG
, O
diffusive O
intravascular B-NEG
clotting I-NEG
, O
thrombophlebitis B-NEG
, O
hepatitis B-NEG
, O
acute B-NEG
surgical I-NEG
infection I-NEG
, O
mastitis B-NEG
, O
erysipelas B-NEG
, O
otitis B-NEG
media I-NEG
, O
tonsillitis B-NEG
, O
bone B-NEG
marrow I-NEG
infection I-NEG
, O
menstrual B-NEG
disorder I-NEG
, O
dysmenorrhea O
, O
amenorrhea B-NEG
, O
postpartum B-NEG
stasis I-NEG
stagnation I-NEG
abdominal I-NEG
pain I-NEG
, O
pain B-NEG
in O
heart O
and O
abdomen O
, O
concretion B-NEG
conglomeration I-NEG
accumulation I-NEG
and O
gathering O
, O
heat B-NEU
impediment O
swelling B-NEG
and O
pain B-NEG
, O
knocks B-NEG
and O
falls B-NEG
, O
heat B-NEU
entering O
construction-blood B-NEG
, O
vexation B-NEG
and O
agitation B-NEG
, O
insomnia B-NEG
and O
vexation B-NEG
, O
swelling B-NEG
toxin O
of O
welling O
abscess B-NEG
and O
sore B-NEG
, O
zoster B-NEG
, O
neurodermatitis B-NEG
, O
psoriasis B-NEG
. O

-DOCSTART- O

dermatological B-DNP
systems I-DNP
health I-DNP
, O
general O
skin B-DNP
health I-DNP
, O
others O

-DOCSTART- O

swelling B-NEG
of I-NEG
carbuncle I-NEG
is O
lumped O
at O
the O
neck O

-DOCSTART- O

stop O
thirst B-NEG

-DOCSTART- O

a O
symptom O
that O
the O
chest O
is O
heavy O
and O
full O
. O

-DOCSTART- O

imipenem O
acts O
as O
an O
antimicrobial O
through O
the O
inhibition O
of O
cell B-DNP
wall I-DNP
synthesis I-DNP
which O
leads O
to O
rapid O
cell B-DNP
lysis I-DNP
and O
death O
without O
filament B-DNP
formation I-DNP
. O

cilastatin O
helps O
imipenem O
work O
more O
effectively O
by O
preventing O
the O
breakdown O
of O
the O
antibiotic O
in O
the O
kidneys O
. O

-DOCSTART- O

disperse O
goiter B-NEG
core O

-DOCSTART- O

investigated O
for O
use O
/ O
treatment O
in O
diabetes B-NEG
mellitus I-NEG
( O
type O
2 O
) O
. O

-DOCSTART- O

sabarubicin O
blocking O
of O
dna B-NEU
replication I-NEU
reduced O
the O
counteractive B-NEU
activity I-NEU
of I-NEU
mutagenic I-NEU
translesional I-NEU
bypass I-NEU
replication I-NEU
across O
cisplatin-dna O
adducts O
. O

-DOCSTART- O

investigated O
for O
use/treatment O
in O
psoriasis B-NEG
and O
psoriatic B-NEG
disorders I-NEG
. O

-DOCSTART- O

to O
reinforce O
qi O
and O
invigorate O
the O
function O
of O
the O
spleen B-DNP
and O
the O
lung B-DNP
. O

-DOCSTART- O

these O
cross-links O
result O
in O
apoptosis B-POS
and O
cell B-NEU
growth I-NEU
inhibition I-NEU
. O

-DOCSTART- O

redness B-NEG
, I-NEG
swelling I-NEG
and I-NEG
pain I-NEG
of I-NEG
the I-NEG
eyes I-NEG

-DOCSTART- O

to O
promote O
diuresis B-NEU
, O
treat O
stranguria B-NEG
, O
remove O
urinary B-NEG
calculus I-NEG
. O

-DOCSTART- O

bacterial B-NEG
infections I-NEG
of I-NEG
the I-NEG
eyes I-NEG
. O

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
body B-NEU
weight I-NEU
regulation I-NEU
, O
physical B-DNP
performance I-DNP
and O
fitness B-POS
, O
body B-NEG
fat I-NEG
deposition I-NEG
( O
total O
amount O

-DOCSTART- O

release O
the O
exterior O
and O
dispel O
wind B-NEG

-DOCSTART- O

fever B-NEG
with O
dysphoria B-NEG
; O
dysphoria B-NEG
with O
smothery O
sensation O
; O
smothery O
fever B-NEG

-DOCSTART- O

treatment O
of O
dry B-NEG
cough I-NEG
caused O
by O
heat B-NEU
in O
the O
lung O
, O
bloody B-NEG
sputum I-NEG
in O
phthisis B-NEG
, O
thirst B-NEU
in O
febrile B-NEG
diseases I-NEG
. O

-DOCSTART- O

treatment O
of O
cough B-NEG
with O
profuse O
expectoration B-NEG
, O
indigestion B-NEG
, O
stagnancy B-NEG
of I-NEG
food I-NEG
with O
abdominal O
pain B-NEG
, O
traumatic O
swelling B-NEG
and O
ecchymoses B-NEG
, O
amenorrhea B-NEG
due O
to O
blood B-NEG
stasis I-NEG
. O

-DOCSTART- O

polythiazide O
is O
a O
thiazide O
diuretic O
used O
to O
decrease O
edema B-NEG
and O
decrease O
blood B-NEU
pressure I-NEU
. O

-DOCSTART- O

for O
cases O
of O
collapse O
due O
to O
massive O
hemorrhage B-NEG
manifested O
as O
cold B-NEG
limbs I-NEG
, O
oily B-NEG
sweat I-NEG
, O
pale B-NEG
complexion I-NEG
, O
spiritlessness B-NEG
, O
small B-NEG
and I-NEG
indistinct I-NEG
pulse I-NEG
, O
use O
high O
grade O
of O
radix O
ginseng O
( O
such O
as O
ginseng O
korea O
or O
ginseng O
jilin O
) O
instead O
of O
codonopsis O
pilosulae O
. O

-DOCSTART- O

benzodiazepines O
, O
in O
this O
way O
, O
block O
the O
cortical B-NEU
and I-NEU
limbic I-NEU
arousal I-NEU
that O
occurs O
following O
stimulation O
of O
the O
reticular O
pathways O
. O

-DOCSTART- O

cosolidate O
sinews B-DNP
and O
bones B-DNP

-DOCSTART- O

absorption B-NEU
, O
gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
digestion B-NEU
, O
motility B-NEU
, O
others O

-DOCSTART- O

( O
1 O
) O
/ O
morbid B-NEG
leukorrhea I-NEG
; O
( O
2 O
) O
gynecological B-NEG
diseases I-NEG
( O
in O
a O
broad O
sense O
) O

-DOCSTART- O

1 O
inhibiting O
the O
growth O
of O
leukemia615 B-NEG
, O
sarcoma180 B-NEG
and O
cervial B-NEG
carcinoma14 I-NEG
in O
mice O
. O
2 O
relieving O
iodine B-NEG
deficiency I-NEG
and O
goiter B-NEG
in O
experimental O
animals O
. O

-DOCSTART- O

gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
digestion B-NEU
, O
absorption O
, O
lipid O
profile O
, O
liver B-DNP
health I-DNP
, O
dietnarelated O
cardiovascular B-NEG
disease I-NEG
, O
motility O
, O
liver B-DNP
, O
others O
, O
hemostatic B-NEU
function I-NEU

-DOCSTART- O

follicular B-NEG
lymphoma I-NEG

-DOCSTART- O

gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
mood O
, O
physical B-DNP
performance I-DNP
and O
fitness O
, O
intelligence O
, O
neurological B-DNP
systems I-DNP
health I-DNP
, O
strength O
and O
power O
, O
neurological B-DNP
systems I-DNP
, O
protective B-NEU
immunity I-NEU
, O
mental B-DNP
state I-DNP
and I-DNP
performance I-DNP

-DOCSTART- O

bloody B-NEG
stool I-NEG
; O
hematochezia B-NEG

-DOCSTART- O

portal B-NEG
hypertension I-NEG

-DOCSTART- O

not O
discarded O
retention B-NEG
of I-NEG
undigested I-NEG
food I-NEG

-DOCSTART- O

used O
to O
provide O
skeletal B-POS
muscle I-POS
relaxation I-POS
as O
an O
adjunct O
to O
general B-NEU
anesthesia I-NEU
, O
for O
endotracheal O
intubation O
or O
to O
facilitate O
mechanical O
ventilation O
. O

-DOCSTART- O

dilating O
the O
coronary B-DNP
artery I-DNP
and O
blood B-DNP
vessels I-DNP
of O
hind O
legs O
in O
dogs O
. O

lowering O
blood B-NEU
pressure I-NEU
transiently O
. O

inhibiting O
the O
intestines B-DNP
in O
rabbits O
in O
vitro O
. O

its O
component O
paeoniflorin O
inhibits O
the O
central B-DNP
nervous I-DNP
systems I-DNP
. O

-DOCSTART- O

rapamycin O
binds O
to O
the O
immunophilin B-DNP
fk I-DNP
binding I-DNP
protein-12 I-DNP
( O
fkbp-12 B-DNP
) O
to O
generate O
an O
immunosuppressive B-DNP
complex I-DNP
that O
binds O
to O
and O
inhibits O
the O
activation B-NEU
of I-NEU
the I-NEU
mammalian I-NEU
target I-NEU
of I-NEU
rapamycin I-NEU
( O
mtor B-DNP
) O
, O
a O
key O
regulatory O
kinase B-DNP
. O

this O
results O
in O
inhibition O
of O
t B-DNP
lymphocyte I-DNP
activation I-DNP
and I-DNP
proliferation I-DNP
that O
occurs O
in O
response O
to O
antigenic O
and O
cytokine B-DNP
( O
il-2 B-DNP
, O
il-4 B-DNP
, O
and O
il-15 B-DNP
) O
stimulation O
and O
inhibition O
of O
antibody B-NEU
production I-NEU
. O

imatinib O
binds O
to O
an O
intracellular O
pocket O
located O
within O
tyrosine B-DNP
kinases I-DNP
( O
tk B-DNP
) O
, O
thereby O
inhibiting O
atp B-NEU
binding I-NEU
and O
preventing O
phosphorylation B-NEU
and O
the O
subsequent O
activation O
of O
growth O
receptors O
and O
their O
downstream O
signal B-DNP
transduction I-DNP
pathways I-DNP
. O

this O
agent O
inhibits O
tk B-DNP
encoded O
by O
the O
bcr-abl O
oncogene O
as O
well O
as O
receptor O
tks O
encoded O
by O
the O
c-kit O
and O
platelet-derived O
growth O
factor O
receptor O
( O
pdgfr O
) O
oncogenes O
. O

biochemical O
analyses O
raise O
the O
possibility O
that O
inhibition O
of O
4e-bp1 B-NEU
phosphorylation I-NEU
may O
be O
particularly O
important O
for O
the O
synergistic O
effects O
of O
ptk O
inhibitor O
/ O
rapamycin O
combinations O
. O

-DOCSTART- O

urinary B-NEG
bladder I-NEG
overactive I-NEG

-DOCSTART- O

this O
is O
a O
symptom O
with O
a O
cold B-NEG
, O
weak O
waist O
and O
knee O
. O

-DOCSTART- O

difficulty B-NEG
in I-NEG
feces I-NEG
and I-NEG
urine I-NEG

-DOCSTART- O

1 O
to O
remove O
blood B-NEG
stasis I-NEG
and O
alleviate O
pain B-NEG
. O
for O
stomachache B-NEG
, O
headache B-NEG
, O
toothache B-NEG
, O
trauma B-NEG
and O
rheumatism O
. B-NEG

2 O
to O
clear O
heat B-NEU
and O
toxic O
material O
. O
for O
sorethroat B-NEG
, O
aphthae B-NEG
, O
carbuncle B-NEG
, O
burn B-NEG
, O
snake B-NEG
bite I-NEG
, O
dysentery B-NEG
and O
diarrhea B-NEG
. O
3 O
to O
relax O
the O
muscles O
. O
as O
a O
muscle O
relaxant O
for O
restoration O
of O
fracture B-NEG
and O
surgical O
operation O
. O

-DOCSTART- O

deficiency B-NEG
of I-NEG
the I-NEG
heart I-NEG
; O
deficiency B-NEG
syndrome I-NEG
of I-NEG
the I-NEG
heart I-NEG
including O
deficiency B-NEG
of I-NEG
blood I-NEG
and O
eum O
, O
and O
insufficiency O
of O
gi O
and O
yang O
of O
the O
heart O

-DOCSTART- O

fructus O
crataegi O
( O
charred O
) O
: O
has O
more O
digestant O
action O
and O
is O
particularly O
useful O
for O
stagnation B-NEG
of I-NEG
undigested I-NEG
meat I-NEG
and O
diarrhea B-NEG
with O
inadequate B-NEG
discharge I-NEG
from I-NEG
the I-NEG
bowels I-NEG
. O

-DOCSTART- O

treatment O
of O
stagnation O
of O
qi O
of O
the O
liver B-DNP
and O
stomach B-DNP
marked O
by O
distension B-NEG
and O
pain B-NEG
in O
the O
chest O
and O
hypochondriac O
regions O
, O
stuffiness B-NEG
feeling O
in O
the O
stomach O
, O
anorexia B-NEG
and O
vomiting B-NEG
. O

-DOCSTART- O

esophageal B-NEG
bleeding I-NEG

-DOCSTART- O

this O
is O
a O
symptom O
with O
a O
fever B-NEG
, O
shortness B-NEG
of I-NEG
breath I-NEG
, O
irritability B-NEG
and O
restlessness B-NEG
, O
mania B-NEG
derange I-NEG
due O
to O
blocked B-NEG
chest I-NEG
and O
diaphragm B-NEG
. O

it O
has O
a O
sever O
pain B-NEG
when O
pushing O
. O

-DOCSTART- O

its O
alcoholic O
extract O
inhibits O
the O
heart B-DNP
and O
lowers O
blood B-NEU
pressure I-NEU
in O
anesthetized O
cats O
. O

-DOCSTART- O

to O
dissipate O
wind-cold B-NEG
, O
quicken O
network O
vessels B-DNP
and O
relieve O
pain B-NEG
. O

-DOCSTART- O

105ad7 O
vaccine O
is O
a O
human O
anti-idiotype O
which O
mimics O
the O
antigen B-DNP
791tgp72 I-DNP
. O

the O
mechanism O
of O
action O
of O
the O
vaccine O
has O
recently O
been O
clarified O
. O

the O
anti-idiotype O
is O
rapidly O
internalized O
on O
antigen B-DNP
presenting O
cells O
by O
fc O
mediated O
endocytosis O
as O
both O
fab O
and O
ab O
complexed O
to O
alum O
are O
processed O
1000 O
fold O
less O
efficiently O
than O
whole O
ab O
. O

sequencing O
of O
the O
ab O
have O
revealed O
that O
the O
cdr-h3 B-DNP
is O
hypermutated O
and O
contains O
hla B-DNP
a1 I-DNP
, I-DNP
a3 I-DNP
and I-DNP
a24 I-DNP
, O
and O
hla-dr1 B-DNP
, I-DNP
3 I-DNP
and I-DNP
7 I-DNP
mhc O
binding O
motifs O
. O

105ad7 O
is O
an O
antibody-based O
vaccine O
that O
mimics O
a O
target O
( O
cd55 B-DNP
) O
which O
is O
over-expressed O
in O
numerous O
cancers B-NEG
including O
those O
of O
the O
prostate B-DNP
, O
colon B-DNP
and O
pancreas B-DNP
. O

-DOCSTART- O

ankylosing B-NEG
spondylitis I-NEG

-DOCSTART- O

oppressed B-NEG
feeling I-NEG
and O
fullness B-NEG
in O
the O
chest O
and O
diaphragm O

-DOCSTART- O

to O
dissipate O
stasis B-NEG
and O
quicken O
blood B-DNP
, O
relieve O
pain B-NEG
. O

-DOCSTART- O

dalbavancin O
has O
a O
spectrum O
and O
mechanism O
of O
action O
similar O
to O
vancomycin B-DNP
, O
a O
naturally O
formed O
glycopeptide B-DNP
antimicrobial I-DNP
. O

-DOCSTART- O

unspecified O
adult O
solid B-NEG
tumor I-NEG
, O
protocol O
specific O

-DOCSTART- O

to O
stop O
bleeding B-NEG
and O
promote O
the O
healing B-POS
of I-POS
wounds I-POS
. O

-DOCSTART- O

to O
remove O
heat B-NEG
, O
to O
promote O
the O
production O
of O
body B-NEU
fluid I-NEU
, O
and O
to O
facilitate O
the O
drainage O
of O
pus O
and O
the O
subsidence O
of O
swelling B-NEG
. O

-DOCSTART- O

vomiting B-NEG
and O
diarrhea B-NEG
due O
to O
visceral O
cold B-NEG

-DOCSTART- O

to O
relieve O
cough B-NEG
and O
promote O
expectoration B-NEG
, O
to O
promote O
digestion B-NEU
and O
remove O
stagnancy B-NEG
of I-NEG
food I-NEG
, O
and O
to O
promote O
blood B-NEU
circulation I-NEU
and O
remove O
blood B-NEG
stasis I-NEG
. O

-DOCSTART- O

wind-damp B-NEG
impediment O
pain B-NEG
, O
flooding B-NEG
, O
vaginal B-NEG
discharge I-NEG
, O
pharyngolaryngitis B-NEG
, O
mammary B-NEG
welling I-NEG
abscess I-NEG
, O
knocks B-NEG
and O
falls B-NEG
, O
poisonous B-NEG
snake I-NEG
bite I-NEG
. O

-DOCSTART- O

calm O
five B-DNP
viscera I-DNP

-DOCSTART- O

nonalcoholic B-NEG
steatohepatitis I-NEG

-DOCSTART- O

invigorate O
waist B-DNP
and O
limbs B-DNP

-DOCSTART- O

bloody B-NEG
dysentery I-NEG

-DOCSTART- O

rosuvastatin O
is O
a O
competitive O
inhibitor O
of O
hmg-coa O
reductase O
, O
which O
reductase O
catalyzes O
the O
conversion O
of O
hmg-coa O
to O
mevalonate O
, O
an O
early O
rate-limiting O
step O
in O
cholesterol O
biosynthesis O
. O

lapaquistat O
acetate O
is O
a O
squalene O
synthase O
inhibitor O
investigated O
for O
the O
treatment O
of O
hypercholesterolemia B-NEG
. O

-DOCSTART- O

shortness B-NEG
of I-NEG
breath I-NEG
short O
, O
rapid B-NEG
and I-NEG
interrupted I-NEG
breathing I-NEG
, O
and O
anguish B-NEG
with O
chest B-NEG
congestion I-NEG

-DOCSTART- O

gumiganghwaltang O
( O
gmght O
) O
is O
an O
oriental O
herbal O
prescription O
, O
which O
has O
been O
commonly O
used O
to O
treat O
a O
cold B-NEG
and O
inflammatory B-NEG
diseases I-NEG
in O
korea O
. O

however O
, O
the O
mechanism O
of O
gmght O
is O
not O
clear O
. O

in O
this O
study O
, O
we O
investigated O
the O
anti-inflammatory B-POS
mechanism I-POS
of O
gmght O
in O
mouse O
peritoneal O
macrophages O
. O

gmght O
exerted O
an O
anti-inflammatory B-POS
action I-POS
through O
inhibiting O
lipopolysaccaride O
( O
lps)-induced O
tumor O
necrosis O
factor O
( O
tnf O
) O
- O
alpha O
and O
interleukin O
( O
il)-6 O
production O
in O
mouse O
peritoneal O
macrophages O
. O

the O
maximal O
inhibition O
rate O
of O
tnf-alpha O
, O
and O
il-6 O
production O
by O
gmght O
(1 O
mg/ml O
) O
was O
52.31+/-2.8% O
and O
56.31+/-3.1% O
, O
respectively O
. O

in O
the O
inflammatory B-NEG
process I-NEG
, O
cyclooxygenase B-DNP
2 I-DNP
( O
cox-2 B-DNP
) O
and O
inducible O
nitric B-DNP
oxide I-DNP
synthase I-DNP
( O
inos B-DNP
) O
increased O
in O
peritoneal O
macrophages O
. O

gmght O
decreased O
the O
protein O
level O
of O
cox-2 B-DNP
and O
inos B-DNP
in O
lps-stimulated O
mouse O
peritoneal O
macrophages O
. O

in O
addition O
, O
gmght O
inhibited O
nuclear B-NEU
factor-kappab I-NEU
activation I-NEU
and O
ikappab-alpha B-NEU
degradation I-NEU
. O

our O
study O
suggests O
that O
an O
important O
molecular O
mechanism O
by O
gmkht O
reduce O
inflammation B-NEG
, O
which O
might O
explain O
its O
beneficial B-POS
effect I-POS
in O
the O
regulation O
of O
inflammatory B-NEU
reactions I-NEU
. O

-DOCSTART- O

the O
itching B-NEG
sensation I-NEG
due O
to O
eczema B-NEG

-DOCSTART- O

pain B-NEG
in O
the O
supraorbital O
bone O

-DOCSTART- O

the O
powder O
of O
croton O
seed O
( O
badou O
) O
is O
blown O
into O
the O
throat B-DNP
to O
cause O
vomiting B-NEG
. O

-DOCSTART- O

to O
quicken O
blood B-DNP
and O
free O
menstruation B-NEU
( O
raw O
) O
, O
transform O
stasis B-NEG
and O
stanch O
bleeding B-NEG
( O
scorch-fry O
) O
. O

-DOCSTART- O

native O
americans O
residing O
in O
a O
broad O
region O
downwind O
from O
the O
nevada O
test O
site O
during O
the O
1950s O
and O
1960s O
received O
significant O
radiation O
exposures O
from O
nuclear O
weapons O
testing O
. O

because O
of O
differences O
in O
diet O
, O
activities O
, O
and O
housing O
, O
their O
radiation O
exposures O
are O
only O
very O
imperfectly O
represented O
in O
the O
department O
of O
energy O
dose O
reconstructions O
. O

there O
are O
important O
missing O
pathways O
, O
including O
exposures O
to O
radioactive O
iodine O
from O
eating O
small O
game O
. O

the O
dose O
reconstruction O
model O
assumptions O
about O
cattle O
feeding O
practices O
across O
a O
year O
are O
unlikely O
to O
apply O
to O
the O
native O
communities O
as O
are O
other O
model O
assumptions O
about O
diet O
. O

thus O
exposures O
from O
drinking O
milk O
and O
eating O
vegetables O
have O
not O
yet O
been O
properly O
estimated O
for O
these O
communities O
. O

through O
consultations O
with O
members O
of O
the O
affected O
communities O
, O
these O
deficiencies O
could O
be O
corrected O
and O
the O
dose O
reconstruction O
extended O
to O
native O
americans O
. O

an O
illustration O
of O
the O
feasibility O
of O
extending O
the O
dose O
reconstruction O
is O
provided O
by O
a O
sample O
calculation O
to O
estimate O
radiation O
exposures O
to O
the O
thyroid B-DNP
from O
eating O
radio-iodine-contaminated O
rabbit O
thyroids B-DNP
after O
the O
sedan O
test O
. O

the O
illustration O
is O
continued O
with O
a O
discussion O
of O
how O
the O
calculation O
results O
may O
be O
used O
to O
make O
estimates O
for O
other O
tests O
and O
other O
locations O
. O

-DOCSTART- O

its O
decoction O
promotes O
the O
secretion B-NEU
of I-NEU
pepsin I-NEU
and I-NEU
gastric I-NEU
juice I-NEU
. O

-DOCSTART- O

to O
resolve O
exterior O
, O
eliminate O
damp B-NEU
, O
relieve O
cough B-NEG
and O
calm O
asthma B-NEG
. O

-DOCSTART- O

stranguria B-NEG
due O
to O
urinary B-NEG
stone I-NEG
; O
dysuria B-NEG
caused O
by O
urinary B-NEG
stone I-NEG
; O
stranguria B-NEG
due O
to O
urolithiasis B-NEG
; O
stony B-NEG
dysuria I-NEG
; O
dysuria B-NEG
caused O
by O
calculi B-NEG

-DOCSTART- O

this O
is O
pectoral B-NEG
pain I-NEG
with O
stuffiness B-NEG
and O
pain B-NEG
in O
the O
heart O
. O

-DOCSTART- O

the O
large O
hydrophilic O
molecule O
is O
able O
to O
form O
hydrogen O
bond O
interactions O
with O
the O
terminal O
d-alanyl-d-alanine O
moieties O
of O
the O
nam/nag-peptides O
, O
which O
is O
normally O
a O
five-point O
interaction O
. O

-DOCSTART- O

pneumonia B-NEG
, I-NEG
pneumocystis I-NEG
carinii I-NEG

-DOCSTART- O

treament O
of O
chronic B-NEG
bronchitis I-NEG
. O

-DOCSTART- O

1 O
since O
the O
prescription O
possesses O
a O
hemostatic O
action O
, O
it O
is O
also O
indicated O
for O
incised B-NEG
wounds I-NEG
with O
hemorrhage B-NEG
( O
topical O
use O
) O
. O

2 O
applicable O
to O
cases O
of O
angina B-NEG
pectoris I-NEG
which O
are O
attributive O
to O
retention O
of O
blood B-NEG
stasis I-NEG
. O
3 O
also O
applicable O
orally O
or O
topi O

-DOCSTART- O

eye B-DNP
, O
mood O
, O
physical B-DNP
performance I-DNP
and O
fitness O
, O
eye B-DNP
health I-DNP
, O
eye B-DNP
health I-DNP
, O
others O
, O
diet O
related O
cardiovascular B-NEG
disease I-NEG
, O
strength O
and O
power O
, O
intelligence B-POS
, O
hemostatic B-POS
function I-POS
, O
mental B-DNP
state I-DNP
and I-DNP
performance I-DNP

-DOCSTART- O

for O
prophylaxis O
of O
respiratory B-NEG
diseases I-NEG
casued O
by O
respiratory B-NEG
syncytial I-NEG
virus I-NEG
. O

-DOCSTART- O

its O
active O
component O
, O
triterpenic O
acid O
, O
increases O
cornary O
flow O
and O
improve O
systemic B-NEU
circulation. I-NEU
. O

-DOCSTART- O

yang O
poison B-NEG
; O
extreme O
heat B-NEU
; O
symptoms O
due O
to O
extreme O
heat B-NEU

-DOCSTART- O

carcinoma B-NEG
of I-NEG
mammary I-NEG
glands I-NEG
, O
nasopharyngeal B-NEG
carcinoma I-NEG
, O
carcinoma B-NEG
of I-NEG
salivary I-NEG
gland I-NEG
, O
scrofula B-NEG
, O
swelling B-NEG
of I-NEG
skin I-NEG
, O
pain B-NEG
wind I-NEG
. O

-DOCSTART- O

uncomfortable O
of O
the O
heart B-DNP
and O
gallbladder B-DNP

-DOCSTART- O

epigastric O
fullness O
; O
stuffiness B-NEG
in O
the O
gastric O
region O

-DOCSTART- O

glomerulonephritis O

-DOCSTART- O

1 O
analgeic O
. O
2 O
sedative O
. O
3 O
antispasmodic O

-DOCSTART- O

a O
disease O
of O
periumbilical B-NEG
sharp I-NEG
pain I-NEG
and O
cold B-NEG
hand I-NEG
and I-NEG
foot I-NEG

-DOCSTART- O

lack O
of O
gi O
; O

asthenic B-NEG
breathing I-NEG
a O
morbid B-NEG
condition I-NEG
chiefly O
manifested O
as O
disinclination B-NEG
ta1k O
, O
low B-NEU
voice I-NEU
, O
listlessness B-NEG
and O
asthenia B-NEG
, O
lack B-NEG
of I-NEG
strength I-NEG
in O
speaking O
, O
weak O
pulse B-DNP

-DOCSTART- O

strength B-POS
and O
power B-POS
, O
mental B-DNP
state I-DNP
and I-DNP
performance I-DNP
, O
physical B-DNP
performance B-DNP
and O
fitness B-POS
, O
mood O

-DOCSTART- O

( O
1) O
wind-warm B-NEG
; O
wind-warm B-NEG
pathogen I-NEG
( O
1 O
) O
wind B-NEG
and O
warm O
blended O
as O
a O
pathogenic O
factor O
. O

( O
2 O
) O
wind-warm B-NEG
syndrome I-NEG
acute O
febrile B-NEG
diseases I-NEG
caused O
by O
wind-warm B-NEG
pathogene I-NEG
occurring O
in O
winter O
and O
spring O
, O
characterized O
by O
chills B-NEG
and O
fever B-NEG
, O
thirst B-NEG
sweating I-NEG
, O
cough B-NEG
and O
headache B-NEG
in O
the O
initial O
stage O
, O
and O
then O
, O
delirium B-NEG
and O
maculation B-NEG
in O
the O
following O
stage O
. O

-DOCSTART- O

to O
reduce O
swelling B-NEG
and O
promote O
healing B-POS
. O
